Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2020-07-13
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate
## 5S_rRNA 2.6287595 3.1729765 0.4023900
## A1BG 1.0745665 0.4203060 0.8276224
## A1CF -0.6138023 -0.7100788 -0.1176536
## A2M -0.3233384 0.7954409 -1.9577707
## A3GALT2 1.0054503 -1.2495566 0.6904985
## A4GALT -0.5863825 -2.0417950 -0.6623122
## spleen_ctrl_vs_hifibre
## 5S_rRNA -0.3821782
## A1BG -0.2928114
## A1CF 0.5821008
## A2M -1.4404703
## A3GALT2 2.2664941
## A4GALT 0.8781088Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genes_in_profile | 13629 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 7317 |
| num_profile_genes_not_in_sets | 6312 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes. 
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2400 |
| num_genesets_excluded | 1081 |
| num_genesets_included | 1319 |
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | Count | |
|---|---|---|---|---|---|
| 1 | -1 | -1 | -1 | -1 | 1668 |
| 2 | 1 | -1 | -1 | -1 | 1385 |
| 3 | -1 | 1 | -1 | -1 | 338 |
| 4 | 1 | 1 | -1 | -1 | 917 |
| 5 | 1 | -1 | 0 | -1 | 1 |
| 6 | -1 | -1 | 1 | -1 | 939 |
| 7 | 1 | -1 | 1 | -1 | 516 |
| 8 | 1 | 0 | 1 | -1 | 1 |
| 9 | -1 | 1 | 1 | -1 | 287 |
| 10 | 0 | 1 | 1 | -1 | 1 |
| 11 | 1 | 1 | 1 | -1 | 847 |
| 12 | -1 | -1 | -1 | 0 | 1 |
| 13 | -1 | -1 | -1 | 1 | 941 |
| 14 | 1 | -1 | -1 | 1 | 841 |
| 15 | -1 | 1 | -1 | 1 | 190 |
| 16 | 1 | 1 | -1 | 1 | 458 |
| 17 | -1 | -1 | 1 | 1 | 1527 |
| 18 | 1 | -1 | 1 | 1 | 1001 |
| 19 | -1 | 1 | 1 | 1 | 515 |
| 20 | 1 | 1 | 1 | 1 | 1255 |
Gene sets by sector
| s.heart_ctrl_vs_acetate | s.heart_ctrl_vs_hifibre | s.spleen_ctrl_vs_acetate | s.spleen_ctrl_vs_hifibre | Count | |
|---|---|---|---|---|---|
| 1 | -1 | -1 | -1 | -1 | 1 |
| 2 | 1 | 1 | 1 | -1 | 10 |
| 3 | 1 | 1 | -1 | 1 | 4 |
| 4 | -1 | -1 | 1 | 1 | 1 |
| 5 | 1 | 1 | 1 | 1 | 1 |
Interactive enrichment scatterplot
All sets with FDR<0.05. Try hovering over the points.
A heatmap of S values for top results
A plot of effect size versus significance
Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.
Results table
Top N= 50 gene sets
| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.heart_ctrl_vs_acetate | s.heart_ctrl_vs_hifibre | s.spleen_ctrl_vs_acetate | s.spleen_ctrl_vs_hifibre | p.heart_ctrl_vs_acetate | p.heart_ctrl_vs_hifibre | p.spleen_ctrl_vs_acetate | p.spleen_ctrl_vs_hifibre |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRAF6 mediated IRF7 activation | 27 | 1.29e-20 | 8.51e-18 | 1.070 | 0.5200 | 0.551000 | 0.52600 | -0.5340 | 2.90e-06 | 7.20e-07 | 2.23e-06 | 1.54e-06 |
| Regulation of IFNA signaling | 23 | 1.50e-13 | 4.95e-11 | 0.968 | 0.5880 | 0.469000 | 0.47200 | -0.3850 | 1.07e-06 | 9.84e-05 | 8.95e-05 | 1.38e-03 |
| Glucuronidation | 16 | 2.90e-04 | 2.47e-02 | 0.750 | 0.3720 | 0.633000 | 0.08510 | 0.1240 | 9.94e-03 | 1.17e-05 | 5.56e-01 | 3.91e-01 |
| Glutathione synthesis and recycling | 11 | 3.58e-02 | 4.22e-01 | 0.671 | -0.3450 | -0.414000 | -0.24800 | -0.3140 | 4.76e-02 | 1.73e-02 | 1.55e-01 | 7.16e-02 |
| Regulation of TLR by endogenous ligand | 13 | 1.02e-02 | 2.63e-01 | 0.661 | 0.3430 | 0.343000 | -0.26200 | -0.3640 | 3.23e-02 | 3.23e-02 | 1.02e-01 | 2.31e-02 |
| SHC1 events in EGFR signaling | 10 | 1.80e-02 | 3.48e-01 | 0.629 | 0.0746 | 0.446000 | -0.17800 | -0.4000 | 6.83e-01 | 1.47e-02 | 3.30e-01 | 2.84e-02 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 10 | 3.19e-03 | 1.62e-01 | 0.610 | -0.1880 | 0.289000 | 0.32300 | -0.3850 | 3.04e-01 | 1.13e-01 | 7.69e-02 | 3.49e-02 |
| Nucleotide-like (purinergic) receptors | 11 | 7.40e-03 | 2.12e-01 | 0.598 | 0.4460 | 0.148000 | -0.32000 | 0.1860 | 1.05e-02 | 3.95e-01 | 6.60e-02 | 2.84e-01 |
| HIV elongation arrest and recovery | 15 | 7.05e-03 | 2.07e-01 | 0.596 | -0.1410 | -0.443000 | -0.16100 | -0.3370 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Pausing and recovery of HIV elongation | 15 | 7.05e-03 | 2.07e-01 | 0.596 | -0.1410 | -0.443000 | -0.16100 | -0.3370 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Pausing and recovery of Tat-mediated HIV elongation | 15 | 7.05e-03 | 2.07e-01 | 0.596 | -0.1410 | -0.443000 | -0.16100 | -0.3370 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Tat-mediated HIV elongation arrest and recovery | 15 | 7.05e-03 | 2.07e-01 | 0.596 | -0.1410 | -0.443000 | -0.16100 | -0.3370 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Olfactory Signaling Pathway | 142 | 2.23e-27 | 2.95e-24 | 0.596 | 0.2930 | 0.515000 | -0.05230 | 0.0287 | 1.66e-09 | 3.13e-26 | 2.83e-01 | 5.55e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 4.63e-02 | 4.38e-01 | 0.596 | -0.4550 | -0.196000 | 0.27200 | 0.1880 | 8.93e-03 | 2.61e-01 | 1.19e-01 | 2.81e-01 |
| Platelet Adhesion to exposed collagen | 11 | 5.96e-02 | 4.98e-01 | 0.585 | 0.4420 | 0.199000 | 0.22300 | 0.2390 | 1.11e-02 | 2.53e-01 | 2.00e-01 | 1.70e-01 |
| FOXO-mediated transcription of cell death genes | 13 | 3.69e-02 | 4.30e-01 | 0.585 | 0.3260 | 0.157000 | 0.34700 | 0.3010 | 4.20e-02 | 3.26e-01 | 3.02e-02 | 6.05e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 13 | 3.08e-02 | 4.13e-01 | 0.584 | -0.1170 | -0.345000 | -0.22500 | -0.3970 | 4.64e-01 | 3.15e-02 | 1.60e-01 | 1.32e-02 |
| CLEC7A (Dectin-1) induces NFAT activation | 10 | 1.26e-01 | 6.24e-01 | 0.582 | 0.4380 | 0.358000 | 0.12900 | 0.0495 | 1.64e-02 | 5.01e-02 | 4.81e-01 | 7.86e-01 |
| Regulation of PTEN mRNA translation | 11 | 1.15e-01 | 6.22e-01 | 0.581 | 0.2120 | 0.272000 | 0.37800 | 0.2760 | 2.23e-01 | 1.18e-01 | 3.00e-02 | 1.13e-01 |
| Classical antibody-mediated complement activation | 10 | 3.12e-02 | 4.13e-01 | 0.580 | -0.4320 | -0.091000 | -0.01870 | -0.3750 | 1.79e-02 | 6.18e-01 | 9.19e-01 | 3.99e-02 |
| eNOS activation | 10 | 8.56e-02 | 5.76e-01 | 0.579 | 0.0472 | 0.061500 | -0.26300 | -0.5100 | 7.96e-01 | 7.37e-01 | 1.51e-01 | 5.20e-03 |
| Passive transport by Aquaporins | 12 | 1.48e-02 | 3.25e-01 | 0.561 | -0.0866 | -0.392000 | -0.14600 | 0.3630 | 6.03e-01 | 1.88e-02 | 3.82e-01 | 2.93e-02 |
| E2F mediated regulation of DNA replication | 18 | 2.06e-04 | 2.09e-02 | 0.555 | 0.2000 | 0.160000 | 0.45700 | -0.1830 | 1.41e-01 | 2.40e-01 | 7.83e-04 | 1.79e-01 |
| Activation of RAC1 | 10 | 1.26e-01 | 6.24e-01 | 0.548 | 0.2090 | 0.448000 | 0.22400 | -0.0729 | 2.52e-01 | 1.42e-02 | 2.20e-01 | 6.90e-01 |
| Condensation of Prophase Chromosomes | 10 | 4.00e-02 | 4.38e-01 | 0.544 | 0.1790 | 0.063500 | 0.50700 | 0.0572 | 3.27e-01 | 7.28e-01 | 5.52e-03 | 7.54e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 14 | 2.34e-02 | 3.96e-01 | 0.541 | 0.1370 | 0.000451 | -0.16300 | -0.4970 | 3.74e-01 | 9.98e-01 | 2.91e-01 | 1.29e-03 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 58 | 5.14e-12 | 1.36e-09 | 0.540 | 0.2590 | 0.232000 | 0.20400 | -0.3600 | 6.55e-04 | 2.30e-03 | 7.19e-03 | 2.11e-06 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 9.15e-03 | 2.47e-01 | 0.539 | -0.2030 | -0.150000 | 0.46200 | -0.1170 | 2.45e-01 | 3.90e-01 | 7.94e-03 | 5.02e-01 |
| Retrograde neurotrophin signalling | 12 | 4.65e-03 | 1.82e-01 | 0.533 | 0.2130 | -0.052300 | 0.09990 | -0.4760 | 2.01e-01 | 7.54e-01 | 5.49e-01 | 4.33e-03 |
| PINK1-PRKN Mediated Mitophagy | 14 | 2.57e-02 | 4.02e-01 | 0.529 | -0.4090 | -0.165000 | -0.02470 | -0.2910 | 8.11e-03 | 2.84e-01 | 8.73e-01 | 5.96e-02 |
| Presynaptic nicotinic acetylcholine receptors | 11 | 3.38e-02 | 4.13e-01 | 0.524 | -0.5060 | -0.018100 | -0.06220 | -0.1220 | 3.69e-03 | 9.17e-01 | 7.21e-01 | 4.85e-01 |
| Heme degradation | 15 | 1.43e-02 | 3.25e-01 | 0.523 | -0.1220 | 0.198000 | 0.46600 | 0.0433 | 4.15e-01 | 1.85e-01 | 1.76e-03 | 7.71e-01 |
| Mitophagy | 18 | 5.69e-03 | 1.92e-01 | 0.520 | -0.4260 | -0.168000 | 0.05770 | -0.2410 | 1.77e-03 | 2.16e-01 | 6.72e-01 | 7.71e-02 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 10 | 5.26e-02 | 4.71e-01 | 0.518 | 0.1960 | 0.438000 | -0.17200 | 0.0912 | 2.83e-01 | 1.66e-02 | 3.45e-01 | 6.17e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 19 | 5.10e-03 | 1.82e-01 | 0.512 | 0.1620 | -0.132000 | -0.16900 | -0.4360 | 2.22e-01 | 3.19e-01 | 2.01e-01 | 1.00e-03 |
| Interleukin-35 Signalling | 11 | 1.40e-01 | 6.41e-01 | 0.508 | -0.0877 | 0.029600 | 0.23100 | 0.4440 | 6.15e-01 | 8.65e-01 | 1.86e-01 | 1.09e-02 |
| CD209 (DC-SIGN) signaling | 17 | 5.45e-02 | 4.72e-01 | 0.505 | 0.2930 | 0.384000 | 0.10300 | 0.1050 | 3.65e-02 | 6.07e-03 | 4.63e-01 | 4.54e-01 |
| Acetylcholine binding and downstream events | 12 | 4.47e-02 | 4.38e-01 | 0.500 | -0.4700 | -0.045100 | -0.08680 | -0.1380 | 4.82e-03 | 7.87e-01 | 6.03e-01 | 4.08e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 12 | 4.47e-02 | 4.38e-01 | 0.500 | -0.4700 | -0.045100 | -0.08680 | -0.1380 | 4.82e-03 | 7.87e-01 | 6.03e-01 | 4.08e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 11 | 9.06e-02 | 5.78e-01 | 0.499 | -0.2470 | 0.197000 | 0.34800 | 0.1690 | 1.56e-01 | 2.59e-01 | 4.57e-02 | 3.33e-01 |
| ERBB2 Activates PTK6 Signaling | 10 | 2.02e-01 | 6.73e-01 | 0.493 | 0.2920 | 0.263000 | -0.04900 | -0.2940 | 1.10e-01 | 1.50e-01 | 7.88e-01 | 1.07e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 14 | 6.42e-02 | 5.07e-01 | 0.492 | 0.1900 | 0.391000 | 0.07150 | 0.2200 | 2.18e-01 | 1.14e-02 | 6.43e-01 | 1.55e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 12 | 5.95e-02 | 4.98e-01 | 0.491 | 0.2620 | 0.255000 | 0.22400 | -0.2400 | 1.17e-01 | 1.26e-01 | 1.79e-01 | 1.49e-01 |
| GRB2 events in ERBB2 signaling | 11 | 9.51e-02 | 5.93e-01 | 0.490 | 0.0984 | 0.423000 | -0.00988 | -0.2270 | 5.72e-01 | 1.50e-02 | 9.55e-01 | 1.93e-01 |
| Apoptotic cleavage of cell adhesion proteins | 10 | 1.79e-01 | 6.71e-01 | 0.490 | 0.2010 | 0.444000 | 0.02420 | 0.0510 | 2.72e-01 | 1.52e-02 | 8.95e-01 | 7.80e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 12 | 1.41e-01 | 6.41e-01 | 0.490 | -0.3880 | -0.220000 | -0.19800 | -0.0447 | 1.99e-02 | 1.88e-01 | 2.35e-01 | 7.89e-01 |
| Class I peroxisomal membrane protein import | 11 | 1.76e-01 | 6.71e-01 | 0.487 | 0.3090 | 0.186000 | -0.12100 | -0.3040 | 7.64e-02 | 2.86e-01 | 4.87e-01 | 8.10e-02 |
| Insulin receptor recycling | 15 | 3.38e-02 | 4.13e-01 | 0.484 | -0.3860 | -0.067700 | 0.28100 | 0.0487 | 9.73e-03 | 6.50e-01 | 5.95e-02 | 7.44e-01 |
| ERBB2 Regulates Cell Motility | 11 | 2.16e-01 | 6.84e-01 | 0.481 | 0.3130 | 0.300000 | -0.06330 | -0.1980 | 7.27e-02 | 8.51e-02 | 7.16e-01 | 2.54e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 12 | 8.30e-02 | 5.67e-01 | 0.478 | 0.1550 | -0.143000 | -0.42400 | -0.0635 | 3.53e-01 | 3.92e-01 | 1.10e-02 | 7.03e-01 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.heart_ctrl_vs_acetate | s.heart_ctrl_vs_hifibre | s.spleen_ctrl_vs_acetate | s.spleen_ctrl_vs_hifibre | p.heart_ctrl_vs_acetate | p.heart_ctrl_vs_hifibre | p.spleen_ctrl_vs_acetate | p.spleen_ctrl_vs_hifibre |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRAF6 mediated IRF7 activation | 27 | 1.29e-20 | 8.51e-18 | 1.0700 | 5.20e-01 | 0.551000 | 5.26e-01 | -5.34e-01 | 2.90e-06 | 7.20e-07 | 2.23e-06 | 1.54e-06 |
| Regulation of IFNA signaling | 23 | 1.50e-13 | 4.95e-11 | 0.9680 | 5.88e-01 | 0.469000 | 4.72e-01 | -3.85e-01 | 1.07e-06 | 9.84e-05 | 8.95e-05 | 1.38e-03 |
| Glucuronidation | 16 | 2.90e-04 | 2.47e-02 | 0.7500 | 3.72e-01 | 0.633000 | 8.51e-02 | 1.24e-01 | 9.94e-03 | 1.17e-05 | 5.56e-01 | 3.91e-01 |
| Glutathione synthesis and recycling | 11 | 3.58e-02 | 4.22e-01 | 0.6710 | -3.45e-01 | -0.414000 | -2.48e-01 | -3.14e-01 | 4.76e-02 | 1.73e-02 | 1.55e-01 | 7.16e-02 |
| Regulation of TLR by endogenous ligand | 13 | 1.02e-02 | 2.63e-01 | 0.6610 | 3.43e-01 | 0.343000 | -2.62e-01 | -3.64e-01 | 3.23e-02 | 3.23e-02 | 1.02e-01 | 2.31e-02 |
| SHC1 events in EGFR signaling | 10 | 1.80e-02 | 3.48e-01 | 0.6290 | 7.46e-02 | 0.446000 | -1.78e-01 | -4.00e-01 | 6.83e-01 | 1.47e-02 | 3.30e-01 | 2.84e-02 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 10 | 3.19e-03 | 1.62e-01 | 0.6100 | -1.88e-01 | 0.289000 | 3.23e-01 | -3.85e-01 | 3.04e-01 | 1.13e-01 | 7.69e-02 | 3.49e-02 |
| Nucleotide-like (purinergic) receptors | 11 | 7.40e-03 | 2.12e-01 | 0.5980 | 4.46e-01 | 0.148000 | -3.20e-01 | 1.86e-01 | 1.05e-02 | 3.95e-01 | 6.60e-02 | 2.84e-01 |
| HIV elongation arrest and recovery | 15 | 7.05e-03 | 2.07e-01 | 0.5960 | -1.41e-01 | -0.443000 | -1.61e-01 | -3.37e-01 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Pausing and recovery of HIV elongation | 15 | 7.05e-03 | 2.07e-01 | 0.5960 | -1.41e-01 | -0.443000 | -1.61e-01 | -3.37e-01 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Pausing and recovery of Tat-mediated HIV elongation | 15 | 7.05e-03 | 2.07e-01 | 0.5960 | -1.41e-01 | -0.443000 | -1.61e-01 | -3.37e-01 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Tat-mediated HIV elongation arrest and recovery | 15 | 7.05e-03 | 2.07e-01 | 0.5960 | -1.41e-01 | -0.443000 | -1.61e-01 | -3.37e-01 | 3.45e-01 | 2.96e-03 | 2.81e-01 | 2.39e-02 |
| Olfactory Signaling Pathway | 142 | 2.23e-27 | 2.95e-24 | 0.5960 | 2.93e-01 | 0.515000 | -5.23e-02 | 2.87e-02 | 1.66e-09 | 3.13e-26 | 2.83e-01 | 5.55e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 4.63e-02 | 4.38e-01 | 0.5960 | -4.55e-01 | -0.196000 | 2.72e-01 | 1.88e-01 | 8.93e-03 | 2.61e-01 | 1.19e-01 | 2.81e-01 |
| Platelet Adhesion to exposed collagen | 11 | 5.96e-02 | 4.98e-01 | 0.5850 | 4.42e-01 | 0.199000 | 2.23e-01 | 2.39e-01 | 1.11e-02 | 2.53e-01 | 2.00e-01 | 1.70e-01 |
| FOXO-mediated transcription of cell death genes | 13 | 3.69e-02 | 4.30e-01 | 0.5850 | 3.26e-01 | 0.157000 | 3.47e-01 | 3.01e-01 | 4.20e-02 | 3.26e-01 | 3.02e-02 | 6.05e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 13 | 3.08e-02 | 4.13e-01 | 0.5840 | -1.17e-01 | -0.345000 | -2.25e-01 | -3.97e-01 | 4.64e-01 | 3.15e-02 | 1.60e-01 | 1.32e-02 |
| CLEC7A (Dectin-1) induces NFAT activation | 10 | 1.26e-01 | 6.24e-01 | 0.5820 | 4.38e-01 | 0.358000 | 1.29e-01 | 4.95e-02 | 1.64e-02 | 5.01e-02 | 4.81e-01 | 7.86e-01 |
| Regulation of PTEN mRNA translation | 11 | 1.15e-01 | 6.22e-01 | 0.5810 | 2.12e-01 | 0.272000 | 3.78e-01 | 2.76e-01 | 2.23e-01 | 1.18e-01 | 3.00e-02 | 1.13e-01 |
| Classical antibody-mediated complement activation | 10 | 3.12e-02 | 4.13e-01 | 0.5800 | -4.32e-01 | -0.091000 | -1.87e-02 | -3.75e-01 | 1.79e-02 | 6.18e-01 | 9.19e-01 | 3.99e-02 |
| eNOS activation | 10 | 8.56e-02 | 5.76e-01 | 0.5790 | 4.72e-02 | 0.061500 | -2.63e-01 | -5.10e-01 | 7.96e-01 | 7.37e-01 | 1.51e-01 | 5.20e-03 |
| Passive transport by Aquaporins | 12 | 1.48e-02 | 3.25e-01 | 0.5610 | -8.66e-02 | -0.392000 | -1.46e-01 | 3.63e-01 | 6.03e-01 | 1.88e-02 | 3.82e-01 | 2.93e-02 |
| E2F mediated regulation of DNA replication | 18 | 2.06e-04 | 2.09e-02 | 0.5550 | 2.00e-01 | 0.160000 | 4.57e-01 | -1.83e-01 | 1.41e-01 | 2.40e-01 | 7.83e-04 | 1.79e-01 |
| Activation of RAC1 | 10 | 1.26e-01 | 6.24e-01 | 0.5480 | 2.09e-01 | 0.448000 | 2.24e-01 | -7.29e-02 | 2.52e-01 | 1.42e-02 | 2.20e-01 | 6.90e-01 |
| Condensation of Prophase Chromosomes | 10 | 4.00e-02 | 4.38e-01 | 0.5440 | 1.79e-01 | 0.063500 | 5.07e-01 | 5.72e-02 | 3.27e-01 | 7.28e-01 | 5.52e-03 | 7.54e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 14 | 2.34e-02 | 3.96e-01 | 0.5410 | 1.37e-01 | 0.000451 | -1.63e-01 | -4.97e-01 | 3.74e-01 | 9.98e-01 | 2.91e-01 | 1.29e-03 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 58 | 5.14e-12 | 1.36e-09 | 0.5400 | 2.59e-01 | 0.232000 | 2.04e-01 | -3.60e-01 | 6.55e-04 | 2.30e-03 | 7.19e-03 | 2.11e-06 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 9.15e-03 | 2.47e-01 | 0.5390 | -2.03e-01 | -0.150000 | 4.62e-01 | -1.17e-01 | 2.45e-01 | 3.90e-01 | 7.94e-03 | 5.02e-01 |
| Retrograde neurotrophin signalling | 12 | 4.65e-03 | 1.82e-01 | 0.5330 | 2.13e-01 | -0.052300 | 9.99e-02 | -4.76e-01 | 2.01e-01 | 7.54e-01 | 5.49e-01 | 4.33e-03 |
| PINK1-PRKN Mediated Mitophagy | 14 | 2.57e-02 | 4.02e-01 | 0.5290 | -4.09e-01 | -0.165000 | -2.47e-02 | -2.91e-01 | 8.11e-03 | 2.84e-01 | 8.73e-01 | 5.96e-02 |
| Presynaptic nicotinic acetylcholine receptors | 11 | 3.38e-02 | 4.13e-01 | 0.5240 | -5.06e-01 | -0.018100 | -6.22e-02 | -1.22e-01 | 3.69e-03 | 9.17e-01 | 7.21e-01 | 4.85e-01 |
| Heme degradation | 15 | 1.43e-02 | 3.25e-01 | 0.5230 | -1.22e-01 | 0.198000 | 4.66e-01 | 4.33e-02 | 4.15e-01 | 1.85e-01 | 1.76e-03 | 7.71e-01 |
| Mitophagy | 18 | 5.69e-03 | 1.92e-01 | 0.5200 | -4.26e-01 | -0.168000 | 5.77e-02 | -2.41e-01 | 1.77e-03 | 2.16e-01 | 6.72e-01 | 7.71e-02 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 10 | 5.26e-02 | 4.71e-01 | 0.5180 | 1.96e-01 | 0.438000 | -1.72e-01 | 9.12e-02 | 2.83e-01 | 1.66e-02 | 3.45e-01 | 6.17e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 19 | 5.10e-03 | 1.82e-01 | 0.5120 | 1.62e-01 | -0.132000 | -1.69e-01 | -4.36e-01 | 2.22e-01 | 3.19e-01 | 2.01e-01 | 1.00e-03 |
| Interleukin-35 Signalling | 11 | 1.40e-01 | 6.41e-01 | 0.5080 | -8.77e-02 | 0.029600 | 2.31e-01 | 4.44e-01 | 6.15e-01 | 8.65e-01 | 1.86e-01 | 1.09e-02 |
| CD209 (DC-SIGN) signaling | 17 | 5.45e-02 | 4.72e-01 | 0.5050 | 2.93e-01 | 0.384000 | 1.03e-01 | 1.05e-01 | 3.65e-02 | 6.07e-03 | 4.63e-01 | 4.54e-01 |
| Acetylcholine binding and downstream events | 12 | 4.47e-02 | 4.38e-01 | 0.5000 | -4.70e-01 | -0.045100 | -8.68e-02 | -1.38e-01 | 4.82e-03 | 7.87e-01 | 6.03e-01 | 4.08e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 12 | 4.47e-02 | 4.38e-01 | 0.5000 | -4.70e-01 | -0.045100 | -8.68e-02 | -1.38e-01 | 4.82e-03 | 7.87e-01 | 6.03e-01 | 4.08e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 11 | 9.06e-02 | 5.78e-01 | 0.4990 | -2.47e-01 | 0.197000 | 3.48e-01 | 1.69e-01 | 1.56e-01 | 2.59e-01 | 4.57e-02 | 3.33e-01 |
| ERBB2 Activates PTK6 Signaling | 10 | 2.02e-01 | 6.73e-01 | 0.4930 | 2.92e-01 | 0.263000 | -4.90e-02 | -2.94e-01 | 1.10e-01 | 1.50e-01 | 7.88e-01 | 1.07e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 14 | 6.42e-02 | 5.07e-01 | 0.4920 | 1.90e-01 | 0.391000 | 7.15e-02 | 2.20e-01 | 2.18e-01 | 1.14e-02 | 6.43e-01 | 1.55e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 12 | 5.95e-02 | 4.98e-01 | 0.4910 | 2.62e-01 | 0.255000 | 2.24e-01 | -2.40e-01 | 1.17e-01 | 1.26e-01 | 1.79e-01 | 1.49e-01 |
| GRB2 events in ERBB2 signaling | 11 | 9.51e-02 | 5.93e-01 | 0.4900 | 9.84e-02 | 0.423000 | -9.88e-03 | -2.27e-01 | 5.72e-01 | 1.50e-02 | 9.55e-01 | 1.93e-01 |
| Apoptotic cleavage of cell adhesion proteins | 10 | 1.79e-01 | 6.71e-01 | 0.4900 | 2.01e-01 | 0.444000 | 2.42e-02 | 5.10e-02 | 2.72e-01 | 1.52e-02 | 8.95e-01 | 7.80e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 12 | 1.41e-01 | 6.41e-01 | 0.4900 | -3.88e-01 | -0.220000 | -1.98e-01 | -4.47e-02 | 1.99e-02 | 1.88e-01 | 2.35e-01 | 7.89e-01 |
| Class I peroxisomal membrane protein import | 11 | 1.76e-01 | 6.71e-01 | 0.4870 | 3.09e-01 | 0.186000 | -1.21e-01 | -3.04e-01 | 7.64e-02 | 2.86e-01 | 4.87e-01 | 8.10e-02 |
| Insulin receptor recycling | 15 | 3.38e-02 | 4.13e-01 | 0.4840 | -3.86e-01 | -0.067700 | 2.81e-01 | 4.87e-02 | 9.73e-03 | 6.50e-01 | 5.95e-02 | 7.44e-01 |
| ERBB2 Regulates Cell Motility | 11 | 2.16e-01 | 6.84e-01 | 0.4810 | 3.13e-01 | 0.300000 | -6.33e-02 | -1.98e-01 | 7.27e-02 | 8.51e-02 | 7.16e-01 | 2.54e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 12 | 8.30e-02 | 5.67e-01 | 0.4780 | 1.55e-01 | -0.143000 | -4.24e-01 | -6.35e-02 | 3.53e-01 | 3.92e-01 | 1.10e-02 | 7.03e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 22 | 2.36e-03 | 1.24e-01 | 0.4770 | 1.67e-01 | -0.235000 | -1.62e-01 | -3.44e-01 | 1.76e-01 | 5.64e-02 | 1.89e-01 | 5.20e-03 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 10 | 1.12e-01 | 6.20e-01 | 0.4770 | 2.28e-01 | 0.080000 | -5.65e-03 | -4.11e-01 | 2.13e-01 | 6.61e-01 | 9.75e-01 | 2.43e-02 |
| Signaling by EGFR in Cancer | 17 | 2.63e-02 | 4.02e-01 | 0.4760 | 1.56e-01 | 0.405000 | -1.18e-01 | -1.56e-01 | 2.64e-01 | 3.84e-03 | 4.00e-01 | 2.67e-01 |
| Resolution of D-Loop Structures | 23 | 1.79e-03 | 1.03e-01 | 0.4720 | 1.77e-01 | -0.206000 | -1.45e-01 | -3.57e-01 | 1.42e-01 | 8.73e-02 | 2.30e-01 | 3.00e-03 |
| Fertilization | 19 | 7.58e-02 | 5.61e-01 | 0.4700 | -2.76e-01 | -0.324000 | -1.79e-01 | -9.07e-02 | 3.76e-02 | 1.46e-02 | 1.78e-01 | 4.94e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 1.93e-02 | 3.63e-01 | 0.4690 | 1.46e-01 | 0.102000 | 3.71e-01 | -2.26e-01 | 3.81e-01 | 5.40e-01 | 2.62e-02 | 1.76e-01 |
| ROS and RNS production in phagocytes | 26 | 3.51e-03 | 1.65e-01 | 0.4660 | -2.88e-01 | -0.318000 | 6.08e-02 | -1.69e-01 | 1.09e-02 | 4.99e-03 | 5.91e-01 | 1.35e-01 |
| Other interleukin signaling | 17 | 5.27e-03 | 1.83e-01 | 0.4630 | 1.44e-01 | -0.269000 | -9.47e-02 | 3.35e-01 | 3.03e-01 | 5.51e-02 | 4.99e-01 | 1.68e-02 |
| TNFR1-induced proapoptotic signaling | 12 | 3.28e-02 | 4.13e-01 | 0.4630 | 1.08e-01 | -0.020900 | 6.21e-02 | -4.45e-01 | 5.16e-01 | 9.00e-01 | 7.10e-01 | 7.62e-03 |
| Receptor-type tyrosine-protein phosphatases | 14 | 1.15e-01 | 6.22e-01 | 0.4630 | 2.82e-01 | 0.219000 | -2.51e-01 | -1.53e-01 | 6.78e-02 | 1.56e-01 | 1.05e-01 | 3.20e-01 |
| Regulation of TP53 Activity through Methylation | 11 | 9.79e-02 | 5.99e-01 | 0.4610 | 1.77e-01 | -0.302000 | -2.95e-01 | -5.62e-02 | 3.08e-01 | 8.31e-02 | 9.06e-02 | 7.47e-01 |
| Constitutive Signaling by EGFRvIII | 12 | 1.03e-01 | 5.99e-01 | 0.4600 | 5.88e-02 | 0.425000 | 1.19e-01 | -1.12e-01 | 7.25e-01 | 1.08e-02 | 4.74e-01 | 5.01e-01 |
| Signaling by EGFRvIII in Cancer | 12 | 1.03e-01 | 5.99e-01 | 0.4600 | 5.88e-02 | 0.425000 | 1.19e-01 | -1.12e-01 | 7.25e-01 | 1.08e-02 | 4.74e-01 | 5.01e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 13 | 1.00e-01 | 5.99e-01 | 0.4590 | 1.19e-01 | 0.432000 | 4.28e-02 | -8.79e-02 | 4.57e-01 | 6.96e-03 | 7.89e-01 | 5.83e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 13 | 1.00e-01 | 5.99e-01 | 0.4590 | 1.19e-01 | 0.432000 | 4.28e-02 | -8.79e-02 | 4.57e-01 | 6.96e-03 | 7.89e-01 | 5.83e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 11 | 2.50e-02 | 4.02e-01 | 0.4570 | 4.24e-02 | -0.193000 | 1.15e-01 | -3.96e-01 | 8.08e-01 | 2.67e-01 | 5.09e-01 | 2.30e-02 |
| Tandem pore domain potassium channels | 10 | 8.02e-02 | 5.61e-01 | 0.4570 | -1.98e-01 | 0.199000 | 3.33e-01 | -1.39e-01 | 2.79e-01 | 2.76e-01 | 6.80e-02 | 4.48e-01 |
| Adherens junctions interactions | 17 | 6.76e-02 | 5.22e-01 | 0.4560 | 2.28e-01 | 0.315000 | -1.59e-01 | -1.78e-01 | 1.03e-01 | 2.45e-02 | 2.57e-01 | 2.05e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 18 | 4.07e-02 | 4.38e-01 | 0.4560 | -3.44e-02 | 0.336000 | 2.75e-01 | 1.36e-01 | 8.00e-01 | 1.36e-02 | 4.33e-02 | 3.19e-01 |
| Regulation of TP53 Activity through Acetylation | 22 | 1.52e-02 | 3.26e-01 | 0.4550 | -6.95e-02 | -0.316000 | -1.39e-01 | -2.88e-01 | 5.73e-01 | 1.02e-02 | 2.59e-01 | 1.93e-02 |
| Defective GALNT12 causes colorectal cancer 1 (CRCS1) | 11 | 3.31e-01 | 7.66e-01 | 0.4520 | -2.42e-01 | -0.294000 | -2.31e-01 | -7.80e-02 | 1.65e-01 | 9.16e-02 | 1.85e-01 | 6.54e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 20 | 3.46e-02 | 4.18e-01 | 0.4480 | 1.78e-01 | -0.123000 | -3.49e-01 | -1.80e-01 | 1.67e-01 | 3.42e-01 | 6.93e-03 | 1.65e-01 |
| Glyoxylate metabolism and glycine degradation | 23 | 2.68e-02 | 4.02e-01 | 0.4470 | -2.39e-01 | -0.304000 | -2.11e-01 | 7.47e-02 | 4.75e-02 | 1.15e-02 | 7.97e-02 | 5.35e-01 |
| HS-GAG biosynthesis | 22 | 2.21e-02 | 3.85e-01 | 0.4460 | 2.21e-01 | 0.185000 | -3.01e-01 | -1.57e-01 | 7.33e-02 | 1.33e-01 | 1.44e-02 | 2.01e-01 |
| Other semaphorin interactions | 18 | 9.70e-02 | 5.98e-01 | 0.4450 | 2.67e-01 | 0.264000 | 1.13e-01 | 2.11e-01 | 5.01e-02 | 5.24e-02 | 4.07e-01 | 1.21e-01 |
| Prolonged ERK activation events | 12 | 7.66e-02 | 5.61e-01 | 0.4450 | -2.04e-01 | 0.300000 | 2.19e-01 | 1.37e-01 | 2.22e-01 | 7.21e-02 | 1.89e-01 | 4.11e-01 |
| EGFR downregulation | 22 | 1.85e-02 | 3.54e-01 | 0.4440 | 1.22e-01 | 0.318000 | -8.56e-02 | -2.71e-01 | 3.21e-01 | 9.79e-03 | 4.87e-01 | 2.80e-02 |
| Regulation of necroptotic cell death | 12 | 1.68e-01 | 6.67e-01 | 0.4430 | 1.41e-01 | 0.351000 | 1.72e-01 | -1.53e-01 | 3.96e-01 | 3.52e-02 | 3.01e-01 | 3.59e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 10 | 1.17e-01 | 6.22e-01 | 0.4390 | -8.55e-02 | -0.094000 | 4.20e-01 | 1.24e-02 | 6.40e-01 | 6.07e-01 | 2.13e-02 | 9.46e-01 |
| alpha-linolenic acid (ALA) metabolism | 10 | 1.17e-01 | 6.22e-01 | 0.4390 | -8.55e-02 | -0.094000 | 4.20e-01 | 1.24e-02 | 6.40e-01 | 6.07e-01 | 2.13e-02 | 9.46e-01 |
| Organic cation/anion/zwitterion transport | 13 | 9.54e-02 | 5.93e-01 | 0.4380 | 2.70e-01 | -0.043600 | 2.28e-01 | 2.55e-01 | 9.25e-02 | 7.85e-01 | 1.54e-01 | 1.12e-01 |
| Transport of vitamins, nucleosides, and related molecules | 36 | 4.48e-04 | 3.48e-02 | 0.4370 | -3.40e-01 | -0.038300 | 2.64e-01 | 6.59e-02 | 4.13e-04 | 6.91e-01 | 6.24e-03 | 4.94e-01 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 10 | 2.58e-01 | 7.20e-01 | 0.4370 | 3.68e-01 | 0.152000 | -5.01e-03 | 1.80e-01 | 4.40e-02 | 4.06e-01 | 9.78e-01 | 3.23e-01 |
| Interferon alpha/beta signaling | 50 | 6.36e-09 | 1.40e-06 | 0.4360 | 2.63e-01 | 0.031200 | 2.89e-01 | -1.91e-01 | 1.32e-03 | 7.03e-01 | 4.06e-04 | 1.96e-02 |
| Signal regulatory protein family interactions | 11 | 1.23e-01 | 6.22e-01 | 0.4340 | -7.27e-03 | 0.202000 | 3.23e-02 | -3.83e-01 | 9.67e-01 | 2.46e-01 | 8.53e-01 | 2.80e-02 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 12 | 2.20e-01 | 6.85e-01 | 0.4340 | -2.28e-01 | 0.059100 | 2.88e-01 | 2.23e-01 | 1.72e-01 | 7.23e-01 | 8.44e-02 | 1.80e-01 |
| Aflatoxin activation and detoxification | 15 | 1.49e-01 | 6.51e-01 | 0.4320 | -2.56e-01 | -0.301000 | -3.59e-02 | -1.72e-01 | 8.65e-02 | 4.37e-02 | 8.10e-01 | 2.48e-01 |
| Deadenylation of mRNA | 16 | 1.93e-01 | 6.71e-01 | 0.4320 | 1.77e-01 | 0.281000 | 2.53e-01 | 1.10e-01 | 2.21e-01 | 5.13e-02 | 7.97e-02 | 4.48e-01 |
| PI3K events in ERBB2 signaling | 13 | 1.94e-01 | 6.71e-01 | 0.4320 | 1.81e-01 | 0.369000 | 1.84e-02 | -1.30e-01 | 2.57e-01 | 2.13e-02 | 9.08e-01 | 4.17e-01 |
| Xenobiotics | 22 | 2.39e-02 | 3.99e-01 | 0.4300 | 1.06e-01 | 0.328000 | 2.39e-01 | -9.52e-02 | 3.90e-01 | 7.71e-03 | 5.20e-02 | 4.40e-01 |
| RUNX3 regulates NOTCH signaling | 13 | 1.87e-01 | 6.71e-01 | 0.4270 | 2.75e-01 | 0.227000 | 3.68e-02 | -2.33e-01 | 8.63e-02 | 1.57e-01 | 8.18e-01 | 1.46e-01 |
| Interleukin-20 family signaling | 20 | 1.61e-02 | 3.26e-01 | 0.4270 | -2.22e-02 | -0.331000 | -5.43e-02 | 2.64e-01 | 8.64e-01 | 1.04e-02 | 6.74e-01 | 4.11e-02 |
| ER Quality Control Compartment (ERQC) | 11 | 2.88e-01 | 7.37e-01 | 0.4250 | 1.25e-01 | -0.111000 | -2.20e-01 | -3.23e-01 | 4.73e-01 | 5.24e-01 | 2.06e-01 | 6.36e-02 |
| Mitochondrial tRNA aminoacylation | 12 | 3.17e-01 | 7.52e-01 | 0.4240 | -3.14e-01 | -0.227000 | -1.63e-01 | -5.44e-02 | 5.97e-02 | 1.74e-01 | 3.28e-01 | 7.44e-01 |
| Termination of O-glycan biosynthesis | 17 | 1.23e-01 | 6.22e-01 | 0.4230 | -1.49e-01 | -0.355000 | -1.73e-01 | 2.92e-02 | 2.88e-01 | 1.13e-02 | 2.16e-01 | 8.35e-01 |
| Eicosanoid ligand-binding receptors | 10 | 2.88e-01 | 7.37e-01 | 0.4220 | 2.46e-01 | -0.068200 | -3.07e-01 | -1.37e-01 | 1.78e-01 | 7.09e-01 | 9.27e-02 | 4.52e-01 |
| Acyl chain remodelling of PS | 16 | 8.65e-02 | 5.77e-01 | 0.4200 | -7.52e-02 | -0.373000 | -1.43e-01 | 1.06e-01 | 6.03e-01 | 9.80e-03 | 3.22e-01 | 4.61e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 14 | 1.50e-01 | 6.51e-01 | 0.4190 | 1.31e-01 | 0.366000 | 5.61e-04 | -1.58e-01 | 3.97e-01 | 1.78e-02 | 9.97e-01 | 3.06e-01 |
| Transport of organic anions | 11 | 2.85e-01 | 7.37e-01 | 0.4190 | 1.41e-01 | 0.303000 | 2.42e-01 | -7.18e-02 | 4.18e-01 | 8.23e-02 | 1.64e-01 | 6.80e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 11 | 2.56e-01 | 7.17e-01 | 0.4180 | -2.68e-01 | 0.060300 | 2.51e-01 | 1.91e-01 | 1.24e-01 | 7.29e-01 | 1.49e-01 | 2.72e-01 |
| Signaling by Activin | 12 | 2.84e-01 | 7.37e-01 | 0.4170 | 1.24e-01 | 0.330000 | 1.30e-01 | 1.80e-01 | 4.57e-01 | 4.77e-02 | 4.35e-01 | 2.82e-01 |
| Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) | 11 | 3.80e-01 | 7.68e-01 | 0.4160 | -2.49e-01 | -0.247000 | -2.22e-01 | -2.70e-02 | 1.52e-01 | 1.56e-01 | 2.02e-01 | 8.77e-01 |
| CASP8 activity is inhibited | 10 | 2.70e-01 | 7.26e-01 | 0.4140 | 1.14e-01 | 0.303000 | 1.30e-01 | -2.24e-01 | 5.34e-01 | 9.76e-02 | 4.78e-01 | 2.19e-01 |
| Dimerization of procaspase-8 | 10 | 2.70e-01 | 7.26e-01 | 0.4140 | 1.14e-01 | 0.303000 | 1.30e-01 | -2.24e-01 | 5.34e-01 | 9.76e-02 | 4.78e-01 | 2.19e-01 |
| Regulation by c-FLIP | 10 | 2.70e-01 | 7.26e-01 | 0.4140 | 1.14e-01 | 0.303000 | 1.30e-01 | -2.24e-01 | 5.34e-01 | 9.76e-02 | 4.78e-01 | 2.19e-01 |
| Citric acid cycle (TCA cycle) | 13 | 1.42e-01 | 6.41e-01 | 0.4130 | 4.95e-02 | 0.288000 | 2.71e-01 | -1.09e-01 | 7.57e-01 | 7.24e-02 | 9.11e-02 | 4.95e-01 |
| Role of phospholipids in phagocytosis | 25 | 4.82e-02 | 4.47e-01 | 0.4120 | -1.79e-01 | -0.107000 | -2.02e-01 | -2.93e-01 | 1.21e-01 | 3.55e-01 | 8.09e-02 | 1.14e-02 |
| Regulation of FZD by ubiquitination | 13 | 8.19e-02 | 5.63e-01 | 0.4110 | -3.91e-02 | 0.110000 | 9.03e-03 | 3.94e-01 | 8.07e-01 | 4.93e-01 | 9.55e-01 | 1.38e-02 |
| Signaling by BMP | 25 | 3.02e-02 | 4.13e-01 | 0.4090 | 1.71e-01 | 0.242000 | -2.09e-01 | -1.90e-01 | 1.40e-01 | 3.59e-02 | 7.08e-02 | 1.00e-01 |
| Removal of the Flap Intermediate from the C-strand | 11 | 3.67e-01 | 7.67e-01 | 0.4080 | -2.22e-01 | -0.341000 | 4.89e-03 | 3.74e-02 | 2.03e-01 | 5.05e-02 | 9.78e-01 | 8.30e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 17 | 1.55e-01 | 6.51e-01 | 0.4070 | 1.35e-01 | -0.047100 | -2.26e-01 | -3.07e-01 | 3.36e-01 | 7.37e-01 | 1.06e-01 | 2.85e-02 |
| Elevation of cytosolic Ca2+ levels | 11 | 4.34e-01 | 8.01e-01 | 0.4060 | -2.22e-01 | -0.181000 | -2.38e-01 | -1.62e-01 | 2.02e-01 | 2.99e-01 | 1.72e-01 | 3.51e-01 |
| Signaling by ERBB2 in Cancer | 20 | 8.20e-02 | 5.63e-01 | 0.4050 | 1.63e-01 | 0.345000 | 5.36e-02 | -1.27e-01 | 2.08e-01 | 7.62e-03 | 6.79e-01 | 3.25e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 18 | 5.97e-03 | 1.92e-01 | 0.4050 | 3.14e-01 | -0.240000 | -8.33e-03 | 8.61e-02 | 2.11e-02 | 7.76e-02 | 9.51e-01 | 5.27e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 10 | 2.81e-01 | 7.34e-01 | 0.4050 | 5.82e-02 | 0.328000 | -7.53e-02 | -2.17e-01 | 7.50e-01 | 7.27e-02 | 6.80e-01 | 2.34e-01 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 12 | 1.49e-01 | 6.51e-01 | 0.4050 | -8.98e-02 | -0.336000 | 3.10e-03 | -2.07e-01 | 5.90e-01 | 4.41e-02 | 9.85e-01 | 2.14e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 13 | 1.70e-01 | 6.68e-01 | 0.4040 | -3.50e-01 | -0.004920 | 1.54e-01 | 1.29e-01 | 2.88e-02 | 9.76e-01 | 3.37e-01 | 4.22e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 11 | 2.87e-01 | 7.37e-01 | 0.4030 | -4.28e-02 | -0.044000 | 3.68e-01 | 1.54e-01 | 8.06e-01 | 8.00e-01 | 3.47e-02 | 3.77e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 11 | 1.43e-01 | 6.41e-01 | 0.4030 | 9.29e-02 | 0.358000 | -8.68e-02 | 1.34e-01 | 5.94e-01 | 4.00e-02 | 6.18e-01 | 4.40e-01 |
| CD28 dependent PI3K/Akt signaling | 19 | 1.31e-01 | 6.32e-01 | 0.4020 | 1.27e-01 | 0.023500 | -2.12e-01 | -3.16e-01 | 3.37e-01 | 8.60e-01 | 1.09e-01 | 1.71e-02 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 16 | 6.94e-02 | 5.27e-01 | 0.4020 | 2.74e-02 | 0.149000 | 8.09e-03 | -3.72e-01 | 8.49e-01 | 3.03e-01 | 9.55e-01 | 9.93e-03 |
| Nucleosome assembly | 16 | 6.94e-02 | 5.27e-01 | 0.4020 | 2.74e-02 | 0.149000 | 8.09e-03 | -3.72e-01 | 8.49e-01 | 3.03e-01 | 9.55e-01 | 9.93e-03 |
| Sema4D induced cell migration and growth-cone collapse | 16 | 2.14e-01 | 6.84e-01 | 0.4000 | -1.80e-01 | -0.341000 | -9.30e-02 | -4.84e-02 | 2.12e-01 | 1.81e-02 | 5.20e-01 | 7.38e-01 |
| Organic cation transport | 10 | 2.74e-01 | 7.29e-01 | 0.3990 | 3.67e-01 | 0.037000 | 9.45e-02 | 1.22e-01 | 4.48e-02 | 8.40e-01 | 6.05e-01 | 5.05e-01 |
| Synthesis of PIPs at the early endosome membrane | 14 | 3.13e-01 | 7.52e-01 | 0.3990 | 3.03e-01 | 0.236000 | 1.00e-01 | 4.45e-02 | 4.99e-02 | 1.27e-01 | 5.16e-01 | 7.73e-01 |
| Negative regulation of MET activity | 14 | 2.03e-01 | 6.73e-01 | 0.3980 | 1.36e-01 | 0.349000 | 1.58e-03 | -1.35e-01 | 3.77e-01 | 2.38e-02 | 9.92e-01 | 3.81e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 11 | 1.23e-01 | 6.22e-01 | 0.3970 | 1.83e-01 | -0.198000 | -2.34e-01 | 1.72e-01 | 2.93e-01 | 2.56e-01 | 1.79e-01 | 3.22e-01 |
| Diseases associated with the TLR signaling cascade | 18 | 1.56e-01 | 6.51e-01 | 0.3970 | 4.59e-02 | 0.041400 | -3.12e-01 | -2.37e-01 | 7.36e-01 | 7.61e-01 | 2.21e-02 | 8.14e-02 |
| Diseases of Immune System | 18 | 1.56e-01 | 6.51e-01 | 0.3970 | 4.59e-02 | 0.041400 | -3.12e-01 | -2.37e-01 | 7.36e-01 | 7.61e-01 | 2.21e-02 | 8.14e-02 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 11 | 2.11e-01 | 6.82e-01 | 0.3960 | 2.59e-01 | -0.047800 | -2.97e-01 | -1.46e-03 | 1.38e-01 | 7.84e-01 | 8.84e-02 | 9.93e-01 |
| Defective EXT2 causes exostoses 2 | 11 | 2.11e-01 | 6.82e-01 | 0.3960 | 2.59e-01 | -0.047800 | -2.97e-01 | -1.46e-03 | 1.38e-01 | 7.84e-01 | 8.84e-02 | 9.93e-01 |
| Metalloprotease DUBs | 16 | 2.24e-01 | 6.87e-01 | 0.3960 | 1.84e-01 | 0.284000 | 2.05e-01 | -1.65e-02 | 2.04e-01 | 4.93e-02 | 1.56e-01 | 9.09e-01 |
| WNT5A-dependent internalization of FZD4 | 11 | 1.41e-01 | 6.41e-01 | 0.3950 | -1.38e-01 | -0.276000 | 1.29e-01 | -2.09e-01 | 4.29e-01 | 1.13e-01 | 4.57e-01 | 2.29e-01 |
| VLDLR internalisation and degradation | 11 | 1.18e-01 | 6.22e-01 | 0.3940 | -3.96e-02 | -0.190000 | 6.86e-02 | -3.36e-01 | 8.20e-01 | 2.76e-01 | 6.94e-01 | 5.34e-02 |
| Signal transduction by L1 | 15 | 2.36e-01 | 6.96e-01 | 0.3920 | -2.16e-01 | -0.048500 | 1.87e-01 | 2.64e-01 | 1.48e-01 | 7.45e-01 | 2.09e-01 | 7.71e-02 |
| Degradation of cysteine and homocysteine | 11 | 4.10e-01 | 7.90e-01 | 0.3910 | -3.08e-01 | -0.213000 | 9.95e-02 | 5.53e-02 | 7.73e-02 | 2.22e-01 | 5.68e-01 | 7.51e-01 |
| Cleavage of the damaged pyrimidine | 13 | 2.27e-01 | 6.87e-01 | 0.3910 | -3.02e-01 | -0.155000 | 2.36e-02 | -1.92e-01 | 5.91e-02 | 3.33e-01 | 8.83e-01 | 2.32e-01 |
| Depyrimidination | 13 | 2.27e-01 | 6.87e-01 | 0.3910 | -3.02e-01 | -0.155000 | 2.36e-02 | -1.92e-01 | 5.91e-02 | 3.33e-01 | 8.83e-01 | 2.32e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 13 | 2.27e-01 | 6.87e-01 | 0.3910 | -3.02e-01 | -0.155000 | 2.36e-02 | -1.92e-01 | 5.91e-02 | 3.33e-01 | 8.83e-01 | 2.32e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 15 | 3.55e-02 | 4.21e-01 | 0.3910 | 4.27e-02 | -0.374000 | 1.03e-01 | 2.84e-02 | 7.74e-01 | 1.23e-02 | 4.91e-01 | 8.49e-01 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 13 | 1.28e-01 | 6.25e-01 | 0.3900 | -6.25e-02 | -0.323000 | 1.87e-01 | 9.23e-02 | 6.97e-01 | 4.39e-02 | 2.43e-01 | 5.65e-01 |
| Diseases of hemostasis | 13 | 1.28e-01 | 6.25e-01 | 0.3900 | -6.25e-02 | -0.323000 | 1.87e-01 | 9.23e-02 | 6.97e-01 | 4.39e-02 | 2.43e-01 | 5.65e-01 |
| VEGFR2 mediated vascular permeability | 24 | 6.75e-02 | 5.22e-01 | 0.3890 | 1.44e-01 | 0.024000 | -1.79e-01 | -3.13e-01 | 2.21e-01 | 8.39e-01 | 1.29e-01 | 7.98e-03 |
| Signaling by ERBB2 KD Mutants | 19 | 1.20e-01 | 6.22e-01 | 0.3890 | 1.56e-01 | 0.342000 | 1.02e-02 | -9.91e-02 | 2.38e-01 | 9.97e-03 | 9.39e-01 | 4.54e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 11 | 4.76e-01 | 8.26e-01 | 0.3860 | 9.88e-02 | 0.198000 | 1.88e-01 | 2.55e-01 | 5.70e-01 | 2.55e-01 | 2.82e-01 | 1.44e-01 |
| Surfactant metabolism | 19 | 4.26e-02 | 4.38e-01 | 0.3860 | -3.59e-01 | -0.015400 | -1.20e-01 | -7.22e-02 | 6.73e-03 | 9.08e-01 | 3.65e-01 | 5.86e-01 |
| Scavenging of heme from plasma | 10 | 2.70e-01 | 7.26e-01 | 0.3850 | -6.63e-02 | -0.141000 | -3.46e-01 | 6.53e-02 | 7.17e-01 | 4.40e-01 | 5.79e-02 | 7.21e-01 |
| Regulation of signaling by NODAL | 10 | 2.65e-01 | 7.26e-01 | 0.3850 | 7.61e-02 | -0.107000 | -3.60e-01 | 3.48e-02 | 6.77e-01 | 5.57e-01 | 4.86e-02 | 8.49e-01 |
| Signaling by EGFR | 37 | 9.18e-03 | 2.47e-01 | 0.3850 | 1.77e-01 | 0.272000 | -1.05e-01 | -1.78e-01 | 6.25e-02 | 4.25e-03 | 2.71e-01 | 6.07e-02 |
| IRE1alpha activates chaperones | 39 | 1.53e-02 | 3.26e-01 | 0.3840 | -2.09e-01 | -0.306000 | -1.01e-01 | 1.48e-03 | 2.40e-02 | 9.58e-04 | 2.76e-01 | 9.87e-01 |
| Kinesins | 34 | 3.44e-03 | 1.65e-01 | 0.3830 | 1.33e-01 | -0.197000 | -1.56e-01 | -2.57e-01 | 1.79e-01 | 4.72e-02 | 1.15e-01 | 9.48e-03 |
| Synthesis of PC | 20 | 1.53e-01 | 6.51e-01 | 0.3810 | -8.11e-02 | -0.024700 | 3.01e-01 | 2.18e-01 | 5.30e-01 | 8.49e-01 | 1.99e-02 | 9.23e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 23 | 6.13e-02 | 4.99e-01 | 0.3790 | -1.31e-01 | -0.271000 | -6.10e-02 | -2.23e-01 | 2.75e-01 | 2.47e-02 | 6.13e-01 | 6.45e-02 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 23 | 6.13e-02 | 4.99e-01 | 0.3790 | -1.31e-01 | -0.271000 | -6.10e-02 | -2.23e-01 | 2.75e-01 | 2.47e-02 | 6.13e-01 | 6.45e-02 |
| HIV Transcription Elongation | 23 | 6.13e-02 | 4.99e-01 | 0.3790 | -1.31e-01 | -0.271000 | -6.10e-02 | -2.23e-01 | 2.75e-01 | 2.47e-02 | 6.13e-01 | 6.45e-02 |
| Tat-mediated elongation of the HIV-1 transcript | 23 | 6.13e-02 | 4.99e-01 | 0.3790 | -1.31e-01 | -0.271000 | -6.10e-02 | -2.23e-01 | 2.75e-01 | 2.47e-02 | 6.13e-01 | 6.45e-02 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 32 | 3.85e-03 | 1.69e-01 | 0.3790 | 3.10e-01 | 0.011300 | -2.15e-01 | 2.77e-02 | 2.40e-03 | 9.12e-01 | 3.50e-02 | 7.86e-01 |
| RHO GTPases activate CIT | 16 | 2.55e-01 | 7.17e-01 | 0.3780 | -2.57e-01 | -0.221000 | 1.25e-01 | 1.13e-01 | 7.52e-02 | 1.26e-01 | 3.88e-01 | 4.33e-01 |
| DCC mediated attractive signaling | 12 | 3.87e-01 | 7.75e-01 | 0.3780 | 3.12e-01 | 0.170000 | 4.36e-02 | 1.21e-01 | 6.15e-02 | 3.09e-01 | 7.94e-01 | 4.69e-01 |
| XBP1(S) activates chaperone genes | 38 | 2.02e-02 | 3.76e-01 | 0.3760 | -1.89e-01 | -0.306000 | -1.12e-01 | -4.48e-03 | 4.44e-02 | 1.11e-03 | 2.33e-01 | 9.62e-01 |
| Phase 4 - resting membrane potential | 16 | 1.03e-01 | 5.99e-01 | 0.3750 | -2.04e-01 | 0.017600 | 3.14e-01 | -7.69e-03 | 1.58e-01 | 9.03e-01 | 2.96e-02 | 9.58e-01 |
| GAB1 signalosome | 14 | 3.21e-01 | 7.56e-01 | 0.3750 | 1.48e-01 | 0.178000 | -1.79e-01 | -2.34e-01 | 3.39e-01 | 2.49e-01 | 2.45e-01 | 1.29e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 16 | 2.27e-01 | 6.87e-01 | 0.3740 | 1.57e-01 | 0.314000 | 4.20e-03 | -1.30e-01 | 2.76e-01 | 2.98e-02 | 9.77e-01 | 3.67e-01 |
| O-glycosylation of TSR domain-containing proteins | 33 | 3.74e-03 | 1.69e-01 | 0.3740 | 2.97e-01 | 0.011400 | -2.25e-01 | 2.58e-02 | 3.16e-03 | 9.10e-01 | 2.52e-02 | 7.98e-01 |
| p75NTR signals via NF-kB | 10 | 4.68e-01 | 8.26e-01 | 0.3710 | 2.69e-01 | 0.092500 | -9.71e-02 | -2.18e-01 | 1.40e-01 | 6.13e-01 | 5.95e-01 | 2.34e-01 |
| Depolymerisation of the Nuclear Lamina | 12 | 3.78e-01 | 7.68e-01 | 0.3710 | -1.34e-01 | -0.151000 | 2.54e-01 | 1.80e-01 | 4.22e-01 | 3.67e-01 | 1.27e-01 | 2.80e-01 |
| Processing of Capped Intronless Pre-mRNA | 17 | 1.96e-01 | 6.71e-01 | 0.3710 | 1.45e-01 | 0.267000 | 1.97e-01 | -7.98e-02 | 3.00e-01 | 5.64e-02 | 1.60e-01 | 5.69e-01 |
| Initial triggering of complement | 23 | 1.31e-01 | 6.32e-01 | 0.3700 | -2.99e-01 | -0.191000 | -6.68e-02 | -8.34e-02 | 1.32e-02 | 1.14e-01 | 5.79e-01 | 4.89e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 19 | 5.12e-02 | 4.69e-01 | 0.3700 | -3.12e-02 | 0.304000 | 5.41e-02 | -2.01e-01 | 8.14e-01 | 2.18e-02 | 6.83e-01 | 1.30e-01 |
| Budding and maturation of HIV virion | 17 | 2.11e-01 | 6.82e-01 | 0.3690 | 1.11e-01 | -0.035400 | -1.64e-01 | -3.10e-01 | 4.29e-01 | 8.01e-01 | 2.41e-01 | 2.70e-02 |
| PKA-mediated phosphorylation of CREB | 16 | 2.39e-01 | 7.00e-01 | 0.3690 | 5.62e-02 | 0.241000 | 1.36e-01 | 2.38e-01 | 6.97e-01 | 9.51e-02 | 3.45e-01 | 9.98e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE | 15 | 1.74e-01 | 6.71e-01 | 0.3690 | -3.98e-02 | -0.096600 | -6.15e-02 | -3.49e-01 | 7.89e-01 | 5.17e-01 | 6.80e-01 | 1.94e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 15 | 1.74e-01 | 6.71e-01 | 0.3690 | -3.98e-02 | -0.096600 | -6.15e-02 | -3.49e-01 | 7.89e-01 | 5.17e-01 | 6.80e-01 | 1.94e-02 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 10 | 4.19e-01 | 7.91e-01 | 0.3680 | 1.13e-01 | 0.225000 | -2.23e-01 | -1.51e-01 | 5.35e-01 | 2.18e-01 | 2.23e-01 | 4.08e-01 |
| G1/S-Specific Transcription | 24 | 3.95e-02 | 4.38e-01 | 0.3680 | 2.86e-01 | 0.036300 | 1.95e-01 | 1.18e-01 | 1.53e-02 | 7.58e-01 | 9.79e-02 | 3.19e-01 |
| PKA activation | 15 | 2.16e-01 | 6.84e-01 | 0.3660 | 3.15e-02 | 0.205000 | 9.84e-02 | 2.84e-01 | 8.33e-01 | 1.69e-01 | 5.09e-01 | 5.65e-02 |
| HDR through Single Strand Annealing (SSA) | 26 | 1.09e-01 | 6.12e-01 | 0.3650 | -1.94e-02 | -0.134000 | -2.03e-01 | -2.71e-01 | 8.64e-01 | 2.36e-01 | 7.36e-02 | 1.67e-02 |
| Dissolution of Fibrin Clot | 12 | 4.29e-01 | 7.95e-01 | 0.3650 | 2.92e-01 | 0.185000 | 2.17e-02 | -1.13e-01 | 7.95e-02 | 2.68e-01 | 8.97e-01 | 4.97e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 15 | 4.53e-02 | 4.38e-01 | 0.3640 | -5.42e-02 | -0.204000 | 2.84e-01 | -8.62e-02 | 7.16e-01 | 1.72e-01 | 5.66e-02 | 5.63e-01 |
| mRNA decay by 3' to 5' exoribonuclease | 10 | 2.76e-01 | 7.32e-01 | 0.3630 | -3.16e-01 | 0.090200 | 1.52e-01 | -2.66e-02 | 8.34e-02 | 6.21e-01 | 4.05e-01 | 8.84e-01 |
| Activation of SMO | 10 | 3.05e-01 | 7.49e-01 | 0.3630 | 2.07e-01 | -0.128000 | -2.67e-01 | 3.20e-02 | 2.56e-01 | 4.83e-01 | 1.43e-01 | 8.61e-01 |
| Cell recruitment (pro-inflammatory response) | 18 | 1.50e-01 | 6.51e-01 | 0.3620 | 1.05e-01 | -0.215000 | -2.03e-01 | -1.81e-01 | 4.41e-01 | 1.15e-01 | 1.36e-01 | 1.84e-01 |
| Purinergic signaling in leishmaniasis infection | 18 | 1.50e-01 | 6.51e-01 | 0.3620 | 1.05e-01 | -0.215000 | -2.03e-01 | -1.81e-01 | 4.41e-01 | 1.15e-01 | 1.36e-01 | 1.84e-01 |
| Beta defensins | 19 | 3.16e-02 | 4.13e-01 | 0.3620 | -2.93e-01 | -0.006790 | -2.00e-01 | 6.93e-02 | 2.69e-02 | 9.59e-01 | 1.31e-01 | 6.01e-01 |
| Metabolism of porphyrins | 24 | 4.34e-02 | 4.38e-01 | 0.3620 | -1.10e-01 | 0.067100 | 3.36e-01 | 3.55e-02 | 3.52e-01 | 5.70e-01 | 4.39e-03 | 7.63e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 12 | 1.84e-01 | 6.71e-01 | 0.3610 | 7.69e-02 | -0.170000 | -2.77e-01 | 1.39e-01 | 6.45e-01 | 3.09e-01 | 9.66e-02 | 4.05e-01 |
| CRMPs in Sema3A signaling | 14 | 1.96e-01 | 6.71e-01 | 0.3610 | 3.56e-01 | 0.030600 | -2.01e-02 | 4.76e-02 | 2.11e-02 | 8.43e-01 | 8.96e-01 | 7.58e-01 |
| Insulin processing | 17 | 2.96e-01 | 7.47e-01 | 0.3610 | 1.79e-01 | 0.111000 | 1.77e-01 | 2.34e-01 | 2.01e-01 | 4.26e-01 | 2.07e-01 | 9.54e-02 |
| FGFRL1 modulation of FGFR1 signaling | 12 | 3.53e-01 | 7.67e-01 | 0.3610 | 1.15e-01 | 0.272000 | 1.55e-01 | -1.38e-01 | 4.91e-01 | 1.03e-01 | 3.53e-01 | 4.08e-01 |
| RIPK1-mediated regulated necrosis | 14 | 3.63e-01 | 7.67e-01 | 0.3610 | 1.33e-01 | 0.291000 | 1.64e-01 | -3.23e-02 | 3.88e-01 | 5.99e-02 | 2.87e-01 | 8.34e-01 |
| Regulated Necrosis | 14 | 3.63e-01 | 7.67e-01 | 0.3610 | 1.33e-01 | 0.291000 | 1.64e-01 | -3.23e-02 | 3.88e-01 | 5.99e-02 | 2.87e-01 | 8.34e-01 |
| Signaling by ERBB2 ECD mutants | 13 | 3.16e-01 | 7.52e-01 | 0.3610 | 7.33e-02 | 0.338000 | 9.60e-02 | -3.94e-02 | 6.47e-01 | 3.51e-02 | 5.49e-01 | 8.06e-01 |
| Removal of the Flap Intermediate | 11 | 2.95e-01 | 7.46e-01 | 0.3600 | -6.43e-02 | -0.345000 | 1.01e-02 | -8.01e-02 | 7.12e-01 | 4.77e-02 | 9.54e-01 | 6.46e-01 |
| Frs2-mediated activation | 10 | 3.00e-01 | 7.48e-01 | 0.3600 | -1.61e-01 | 0.266000 | 1.64e-01 | 7.41e-02 | 3.77e-01 | 1.45e-01 | 3.69e-01 | 6.85e-01 |
| Nucleobase biosynthesis | 13 | 3.02e-01 | 7.49e-01 | 0.3600 | -2.19e-01 | -0.224000 | 3.85e-02 | -1.73e-01 | 1.72e-01 | 1.63e-01 | 8.10e-01 | 2.81e-01 |
| Creation of C4 and C2 activators | 17 | 1.03e-01 | 5.99e-01 | 0.3580 | -3.42e-01 | -0.001550 | 2.78e-02 | -1.03e-01 | 1.46e-02 | 9.91e-01 | 8.43e-01 | 4.64e-01 |
| Telomere Extension By Telomerase | 15 | 3.94e-01 | 7.86e-01 | 0.3580 | -2.16e-02 | 0.082200 | 2.75e-01 | 2.12e-01 | 8.85e-01 | 5.82e-01 | 6.49e-02 | 1.55e-01 |
| Translesion Synthesis by POLH | 11 | 5.02e-01 | 8.33e-01 | 0.3570 | -4.98e-02 | 0.032300 | 1.71e-01 | 3.08e-01 | 7.75e-01 | 8.53e-01 | 3.26e-01 | 7.71e-02 |
| Cyclin A/B1/B2 associated events during G2/M transition | 13 | 2.08e-01 | 6.80e-01 | 0.3570 | 5.86e-02 | 0.085800 | 3.40e-01 | -2.90e-02 | 7.15e-01 | 5.92e-01 | 3.37e-02 | 8.56e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 13 | 4.30e-01 | 7.95e-01 | 0.3570 | 1.85e-01 | 0.298000 | 3.91e-02 | 4.88e-02 | 2.49e-01 | 6.25e-02 | 8.07e-01 | 7.61e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 25 | 1.39e-01 | 6.41e-01 | 0.3550 | -3.00e-02 | 0.120000 | 2.82e-01 | 1.76e-01 | 7.95e-01 | 2.99e-01 | 1.45e-02 | 1.27e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 13 | 1.03e-01 | 5.99e-01 | 0.3540 | 7.07e-02 | 0.009700 | 3.25e-01 | -1.20e-01 | 6.59e-01 | 9.52e-01 | 4.26e-02 | 4.55e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 13 | 1.03e-01 | 5.99e-01 | 0.3540 | 7.07e-02 | 0.009700 | 3.25e-01 | -1.20e-01 | 6.59e-01 | 9.52e-01 | 4.26e-02 | 4.55e-01 |
| G alpha (s) signalling events | 255 | 1.17e-18 | 5.13e-16 | 0.3520 | 1.50e-01 | 0.313000 | -5.17e-02 | 2.84e-02 | 3.81e-05 | 8.74e-18 | 1.57e-01 | 4.36e-01 |
| Metabolism of folate and pterines | 13 | 1.96e-01 | 6.71e-01 | 0.3520 | 6.10e-02 | -0.302000 | -1.13e-01 | 1.26e-01 | 7.03e-01 | 5.93e-02 | 4.83e-01 | 4.31e-01 |
| Aspartate and asparagine metabolism | 10 | 5.41e-01 | 8.56e-01 | 0.3510 | 2.02e-01 | -0.015600 | -2.11e-01 | -1.95e-01 | 2.70e-01 | 9.32e-01 | 2.48e-01 | 2.85e-01 |
| FCGR activation | 15 | 2.30e-01 | 6.91e-01 | 0.3510 | -2.29e-01 | -0.013700 | -8.43e-02 | -2.52e-01 | 1.24e-01 | 9.27e-01 | 5.72e-01 | 9.16e-02 |
| Antimicrobial peptides | 45 | 1.21e-03 | 7.23e-02 | 0.3510 | -2.92e-01 | -0.083000 | -1.73e-01 | 2.98e-02 | 7.02e-04 | 3.36e-01 | 4.50e-02 | 7.29e-01 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 11 | 3.72e-01 | 7.67e-01 | 0.3510 | 2.15e-01 | 0.209000 | -1.78e-01 | 3.79e-02 | 2.17e-01 | 2.31e-01 | 3.06e-01 | 8.28e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 11 | 3.17e-01 | 7.52e-01 | 0.3510 | 2.55e-01 | 0.089700 | -9.20e-02 | 2.03e-01 | 1.43e-01 | 6.06e-01 | 5.97e-01 | 2.44e-01 |
| Downregulation of ERBB2 signaling | 18 | 2.00e-01 | 6.73e-01 | 0.3490 | 6.72e-02 | 0.123000 | -8.67e-02 | -3.07e-01 | 6.22e-01 | 3.65e-01 | 5.25e-01 | 2.40e-02 |
| Pyruvate metabolism | 23 | 1.43e-01 | 6.41e-01 | 0.3480 | -2.61e-01 | -0.127000 | -1.76e-01 | -7.76e-02 | 3.06e-02 | 2.92e-01 | 1.43e-01 | 5.20e-01 |
| Homologous DNA Pairing and Strand Exchange | 28 | 8.35e-02 | 5.67e-01 | 0.3480 | 3.22e-03 | -0.118000 | -1.57e-01 | -2.87e-01 | 9.76e-01 | 2.79e-01 | 1.52e-01 | 8.63e-03 |
| Myogenesis | 27 | 2.65e-02 | 4.02e-01 | 0.3460 | 9.69e-02 | 0.207000 | -2.49e-01 | -7.56e-02 | 3.83e-01 | 6.29e-02 | 2.52e-02 | 4.97e-01 |
| Fatty acids | 11 | 3.56e-01 | 7.67e-01 | 0.3460 | 6.61e-03 | 0.219000 | 5.31e-03 | -2.68e-01 | 9.70e-01 | 2.08e-01 | 9.76e-01 | 1.25e-01 |
| Pentose phosphate pathway | 10 | 5.02e-01 | 8.33e-01 | 0.3460 | -2.09e-01 | -0.151000 | -2.29e-01 | 2.45e-02 | 2.52e-01 | 4.07e-01 | 2.11e-01 | 8.94e-01 |
| Reduction of cytosolic Ca++ levels | 11 | 5.52e-01 | 8.64e-01 | 0.3450 | 1.33e-01 | 0.256000 | 1.00e-01 | 1.61e-01 | 4.44e-01 | 1.42e-01 | 5.64e-01 | 3.56e-01 |
| RHO GTPases activate IQGAPs | 10 | 6.08e-01 | 8.75e-01 | 0.3440 | 2.54e-01 | 0.166000 | 7.79e-02 | 1.42e-01 | 1.65e-01 | 3.63e-01 | 6.70e-01 | 4.37e-01 |
| Protein ubiquitination | 37 | 1.61e-02 | 3.26e-01 | 0.3440 | -3.03e-02 | 0.267000 | 1.88e-01 | 1.05e-01 | 7.50e-01 | 5.04e-03 | 4.82e-02 | 2.69e-01 |
| Chondroitin sulfate biosynthesis | 18 | 1.97e-01 | 6.73e-01 | 0.3420 | -1.48e-02 | 0.205000 | 2.73e-01 | 9.28e-03 | 9.14e-01 | 1.32e-01 | 4.49e-02 | 9.46e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 11 | 3.34e-01 | 7.67e-01 | 0.3420 | -2.49e-01 | -0.090200 | 1.11e-01 | -1.85e-01 | 1.53e-01 | 6.05e-01 | 5.23e-01 | 2.88e-01 |
| mRNA Capping | 16 | 1.71e-01 | 6.68e-01 | 0.3420 | 2.27e-02 | -0.069100 | -3.36e-02 | -3.32e-01 | 8.75e-01 | 6.33e-01 | 8.16e-01 | 2.14e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 21 | 1.75e-01 | 6.71e-01 | 0.3400 | -2.01e-01 | 0.009050 | 2.39e-01 | 1.34e-01 | 1.12e-01 | 9.43e-01 | 5.76e-02 | 2.88e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 15 | 3.06e-01 | 7.49e-01 | 0.3400 | 2.11e-01 | 0.222000 | -3.42e-02 | 1.43e-01 | 1.56e-01 | 1.37e-01 | 8.18e-01 | 3.38e-01 |
| Synthesis of PA | 29 | 3.94e-02 | 4.38e-01 | 0.3400 | -3.68e-02 | -0.323000 | -9.47e-02 | 2.37e-02 | 7.32e-01 | 2.60e-03 | 3.78e-01 | 8.25e-01 |
| Rap1 signalling | 14 | 3.36e-01 | 7.67e-01 | 0.3390 | -3.46e-03 | 0.142000 | 1.06e-01 | 2.89e-01 | 9.82e-01 | 3.58e-01 | 4.91e-01 | 6.10e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 12 | 2.47e-01 | 7.09e-01 | 0.3390 | 1.93e-01 | -0.143000 | 8.35e-02 | 2.24e-01 | 2.47e-01 | 3.92e-01 | 6.17e-01 | 1.79e-01 |
| Interleukin-6 family signaling | 20 | 1.87e-01 | 6.71e-01 | 0.3380 | -1.19e-01 | -0.253000 | -1.15e-02 | 1.90e-01 | 3.57e-01 | 4.99e-02 | 9.29e-01 | 1.42e-01 |
| mTORC1-mediated signalling | 17 | 3.43e-01 | 7.67e-01 | 0.3380 | -1.55e-02 | 0.145000 | 2.78e-01 | 1.27e-01 | 9.12e-01 | 3.01e-01 | 4.74e-02 | 3.66e-01 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 5.37e-01 | 8.53e-01 | 0.3380 | -7.07e-02 | -0.187000 | -2.72e-01 | 5.49e-03 | 6.99e-01 | 3.05e-01 | 1.36e-01 | 9.76e-01 |
| Gluconeogenesis | 27 | 7.28e-02 | 5.46e-01 | 0.3370 | -6.20e-02 | -0.271000 | -1.80e-01 | 6.39e-02 | 5.77e-01 | 1.49e-02 | 1.06e-01 | 5.65e-01 |
| Biosynthesis of DHA-derived SPMs | 14 | 3.08e-01 | 7.52e-01 | 0.3370 | 2.63e-01 | 0.096900 | 1.87e-01 | -8.76e-04 | 8.84e-02 | 5.30e-01 | 2.26e-01 | 9.95e-01 |
| PERK regulates gene expression | 19 | 3.57e-01 | 7.67e-01 | 0.3370 | 1.98e-01 | 0.177000 | 1.57e-01 | 1.36e-01 | 1.36e-01 | 1.82e-01 | 2.37e-01 | 3.07e-01 |
| p38MAPK events | 11 | 5.33e-01 | 8.52e-01 | 0.3370 | -1.15e-01 | -0.189000 | 9.80e-02 | 2.33e-01 | 5.09e-01 | 2.77e-01 | 5.74e-01 | 1.80e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 15 | 2.88e-01 | 7.37e-01 | 0.3360 | 1.44e-01 | 0.083200 | -2.81e-01 | -7.84e-02 | 3.34e-01 | 5.77e-01 | 5.94e-02 | 5.99e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 10 | 3.51e-01 | 7.67e-01 | 0.3360 | 2.99e-01 | -0.025300 | 1.41e-01 | 5.55e-02 | 1.02e-01 | 8.90e-01 | 4.42e-01 | 7.61e-01 |
| Defensins | 20 | 6.32e-02 | 5.07e-01 | 0.3340 | -2.69e-01 | -0.041000 | -1.66e-01 | 1.00e-01 | 3.72e-02 | 7.51e-01 | 1.98e-01 | 4.39e-01 |
| Pre-NOTCH Processing in Golgi | 14 | 1.36e-01 | 6.41e-01 | 0.3330 | 1.40e-01 | -0.264000 | -4.89e-02 | -1.38e-01 | 3.64e-01 | 8.68e-02 | 7.51e-01 | 3.73e-01 |
| Regulation of gene expression by Hypoxia-inducible Factor | 11 | 5.83e-01 | 8.70e-01 | 0.3330 | 1.09e-01 | 0.233000 | 1.09e-01 | 1.81e-01 | 5.32e-01 | 1.81e-01 | 5.30e-01 | 2.99e-01 |
| Selective autophagy | 47 | 2.92e-02 | 4.13e-01 | 0.3330 | -1.47e-01 | -0.139000 | -1.71e-01 | -2.02e-01 | 8.14e-02 | 1.00e-01 | 4.25e-02 | 1.67e-02 |
| Sema4D in semaphorin signaling | 19 | 3.51e-01 | 7.67e-01 | 0.3320 | -1.83e-01 | -0.248000 | -1.25e-01 | -3.79e-03 | 1.67e-01 | 6.16e-02 | 3.47e-01 | 9.77e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 14 | 3.13e-01 | 7.52e-01 | 0.3320 | 2.16e-01 | 0.091900 | -2.35e-01 | -1.66e-02 | 1.63e-01 | 5.52e-01 | 1.29e-01 | 9.14e-01 |
| Signaling by Hippo | 17 | 2.52e-01 | 7.17e-01 | 0.3320 | 1.40e-01 | 0.181000 | 3.19e-02 | 2.38e-01 | 3.19e-01 | 1.97e-01 | 8.20e-01 | 8.91e-02 |
| Metabolism of amine-derived hormones | 15 | 4.44e-01 | 8.13e-01 | 0.3320 | -2.52e-01 | -0.179000 | -1.21e-01 | -9.55e-03 | 9.16e-02 | 2.31e-01 | 4.17e-01 | 9.49e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 16 | 4.25e-01 | 7.93e-01 | 0.3320 | 7.80e-02 | 0.107000 | 1.65e-01 | 2.55e-01 | 5.89e-01 | 4.59e-01 | 2.53e-01 | 7.71e-02 |
| Apoptotic cleavage of cellular proteins | 31 | 7.15e-02 | 5.39e-01 | 0.3310 | 1.54e-01 | 0.183000 | 2.29e-01 | -9.82e-03 | 1.39e-01 | 7.78e-02 | 2.76e-02 | 9.25e-01 |
| Transferrin endocytosis and recycling | 20 | 2.27e-01 | 6.87e-01 | 0.3310 | -2.38e-01 | -0.075900 | 1.92e-01 | 1.00e-01 | 6.59e-02 | 5.57e-01 | 1.36e-01 | 4.39e-01 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 22 | 1.23e-01 | 6.22e-01 | 0.3300 | 9.54e-03 | -0.103000 | 2.71e-01 | 1.57e-01 | 9.38e-01 | 4.01e-01 | 2.77e-02 | 2.04e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 12 | 4.78e-01 | 8.26e-01 | 0.3300 | -2.07e-01 | -0.139000 | -2.16e-01 | -2.31e-03 | 2.15e-01 | 4.05e-01 | 1.96e-01 | 9.89e-01 |
| Signaling by NOTCH2 | 21 | 2.53e-01 | 7.17e-01 | 0.3280 | 1.47e-01 | 0.125000 | -1.99e-01 | -1.75e-01 | 2.45e-01 | 3.20e-01 | 1.15e-01 | 1.64e-01 |
| RNA Polymerase I Transcription Initiation | 30 | 1.22e-01 | 6.22e-01 | 0.3270 | -3.43e-02 | -0.205000 | -1.72e-01 | -1.85e-01 | 7.45e-01 | 5.22e-02 | 1.04e-01 | 7.90e-02 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 10 | 5.20e-01 | 8.49e-01 | 0.3270 | -1.43e-02 | -0.187000 | -2.66e-01 | 2.99e-02 | 9.38e-01 | 3.05e-01 | 1.46e-01 | 8.70e-01 |
| Spry regulation of FGF signaling | 11 | 5.41e-01 | 8.56e-01 | 0.3270 | 1.00e-01 | 0.259000 | 1.54e-01 | -7.62e-02 | 5.64e-01 | 1.37e-01 | 3.78e-01 | 6.62e-01 |
| Nephrin family interactions | 19 | 3.70e-01 | 7.67e-01 | 0.3270 | 1.63e-01 | 0.256000 | 1.17e-01 | 2.71e-02 | 2.19e-01 | 5.30e-02 | 3.79e-01 | 8.38e-01 |
| IKK complex recruitment mediated by RIP1 | 16 | 3.03e-01 | 7.49e-01 | 0.3260 | 1.61e-01 | 0.273000 | -5.33e-02 | 5.56e-02 | 2.66e-01 | 5.90e-02 | 7.12e-01 | 7.00e-01 |
| Chaperone Mediated Autophagy | 15 | 4.28e-01 | 7.93e-01 | 0.3260 | 3.47e-02 | -0.022800 | -2.87e-01 | -1.49e-01 | 8.16e-01 | 8.79e-01 | 5.47e-02 | 3.18e-01 |
| Glutamate and glutamine metabolism | 13 | 4.26e-01 | 7.93e-01 | 0.3250 | -7.21e-02 | -0.283000 | -1.15e-01 | 8.68e-02 | 6.53e-01 | 7.76e-02 | 4.73e-01 | 5.88e-01 |
| Mitochondrial calcium ion transport | 17 | 3.87e-01 | 7.75e-01 | 0.3250 | -1.45e-01 | -0.055300 | 2.17e-01 | 1.87e-01 | 3.02e-01 | 6.93e-01 | 1.22e-01 | 1.83e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 11 | 5.99e-01 | 8.75e-01 | 0.3240 | -1.60e-01 | -0.177000 | 1.45e-01 | 1.64e-01 | 3.59e-01 | 3.09e-01 | 4.04e-01 | 3.46e-01 |
| GP1b-IX-V activation signalling | 10 | 6.61e-01 | 8.91e-01 | 0.3240 | 2.43e-01 | 0.145000 | 8.81e-02 | 1.31e-01 | 1.83e-01 | 4.28e-01 | 6.29e-01 | 4.75e-01 |
| RNA Polymerase II Transcription Termination | 44 | 1.12e-02 | 2.75e-01 | 0.3230 | 1.46e-01 | 0.211000 | 1.46e-01 | -1.33e-01 | 9.42e-02 | 1.56e-02 | 9.43e-02 | 1.28e-01 |
| Glycogen storage diseases | 11 | 3.71e-01 | 7.67e-01 | 0.3230 | -2.21e-01 | -0.064500 | -2.20e-01 | 5.49e-02 | 2.04e-01 | 7.11e-01 | 2.07e-01 | 7.52e-01 |
| Listeria monocytogenes entry into host cells | 14 | 4.13e-01 | 7.90e-01 | 0.3230 | 1.04e-01 | 0.272000 | 2.73e-02 | -1.36e-01 | 4.99e-01 | 7.82e-02 | 8.59e-01 | 3.77e-01 |
| Processive synthesis on the C-strand of the telomere | 12 | 5.30e-01 | 8.51e-01 | 0.3220 | -1.49e-01 | -0.250000 | 8.11e-02 | 1.13e-01 | 3.72e-01 | 1.34e-01 | 6.27e-01 | 4.98e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 14 | 2.17e-01 | 6.84e-01 | 0.3220 | -1.33e-01 | -0.021700 | 2.87e-01 | -5.89e-02 | 3.90e-01 | 8.88e-01 | 6.31e-02 | 7.03e-01 |
| Regulation of gene expression in beta cells | 13 | 3.40e-01 | 7.67e-01 | 0.3220 | -8.71e-02 | 0.108000 | -2.38e-01 | -1.67e-01 | 5.86e-01 | 5.01e-01 | 1.38e-01 | 2.96e-01 |
| Ribosomal scanning and start codon recognition | 20 | 2.41e-01 | 7.01e-01 | 0.3200 | -1.97e-01 | -0.004090 | 2.28e-01 | 1.08e-01 | 1.27e-01 | 9.75e-01 | 7.76e-02 | 4.01e-01 |
| Translation initiation complex formation | 20 | 2.41e-01 | 7.01e-01 | 0.3200 | -1.97e-01 | -0.004090 | 2.28e-01 | 1.08e-01 | 1.27e-01 | 9.75e-01 | 7.76e-02 | 4.01e-01 |
| Interleukin-7 signaling | 13 | 2.25e-01 | 6.87e-01 | 0.3200 | 2.14e-01 | -0.195000 | -1.36e-01 | 2.27e-02 | 1.82e-01 | 2.25e-01 | 3.96e-01 | 8.87e-01 |
| Formation of the cornified envelope | 30 | 1.41e-01 | 6.41e-01 | 0.3200 | -6.34e-02 | -0.075000 | -1.59e-01 | -2.60e-01 | 5.48e-01 | 4.77e-01 | 1.31e-01 | 1.39e-02 |
| Lewis blood group biosynthesis | 10 | 4.77e-01 | 8.26e-01 | 0.3200 | 2.80e-01 | -0.045800 | -1.16e-01 | -9.17e-02 | 1.25e-01 | 8.02e-01 | 5.26e-01 | 6.16e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 38 | 1.25e-02 | 2.95e-01 | 0.3200 | -1.36e-01 | -0.204000 | 2.67e-02 | -2.04e-01 | 1.46e-01 | 2.98e-02 | 7.76e-01 | 2.98e-02 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 25 | 2.20e-01 | 6.85e-01 | 0.3200 | 3.03e-02 | -0.073600 | -1.81e-01 | -2.51e-01 | 7.93e-01 | 5.24e-01 | 1.18e-01 | 2.96e-02 |
| The canonical retinoid cycle in rods (twilight vision) | 19 | 1.93e-01 | 6.71e-01 | 0.3200 | -1.75e-01 | -0.152000 | -1.95e-01 | 1.02e-01 | 1.87e-01 | 2.50e-01 | 1.41e-01 | 4.43e-01 |
| The NLRP3 inflammasome | 11 | 4.87e-01 | 8.26e-01 | 0.3190 | -1.07e-02 | -0.292000 | -9.80e-02 | -8.34e-02 | 9.51e-01 | 9.35e-02 | 5.74e-01 | 6.32e-01 |
| FOXO-mediated transcription of cell cycle genes | 14 | 3.59e-01 | 7.67e-01 | 0.3180 | 1.72e-01 | 0.201000 | -3.75e-02 | 1.72e-01 | 2.65e-01 | 1.92e-01 | 8.08e-01 | 2.65e-01 |
| PKA activation in glucagon signalling | 15 | 3.85e-01 | 7.73e-01 | 0.3170 | -6.85e-03 | 0.122000 | 1.07e-01 | 2.73e-01 | 9.63e-01 | 4.15e-01 | 4.72e-01 | 6.74e-02 |
| N-Glycan antennae elongation | 12 | 2.52e-01 | 7.17e-01 | 0.3170 | 1.59e-01 | 0.021700 | -1.75e-01 | 2.11e-01 | 3.42e-01 | 8.97e-01 | 2.94e-01 | 2.06e-01 |
| RNA Polymerase I Transcription Termination | 17 | 4.84e-01 | 8.26e-01 | 0.3160 | -4.16e-02 | -0.135000 | -2.12e-01 | -1.88e-01 | 7.66e-01 | 3.36e-01 | 1.30e-01 | 1.80e-01 |
| MECP2 regulates neuronal receptors and channels | 14 | 1.98e-01 | 6.73e-01 | 0.3160 | 8.87e-02 | 0.225000 | -1.13e-01 | 1.70e-01 | 5.66e-01 | 1.46e-01 | 4.65e-01 | 2.72e-01 |
| Regulation of signaling by CBL | 15 | 4.66e-01 | 8.26e-01 | 0.3150 | -4.39e-02 | 0.038800 | 1.49e-01 | 2.71e-01 | 7.68e-01 | 7.95e-01 | 3.17e-01 | 6.90e-02 |
| Apoptotic execution phase | 36 | 3.31e-02 | 4.13e-01 | 0.3150 | 1.00e-01 | 0.154000 | 2.53e-01 | -3.18e-02 | 2.99e-01 | 1.09e-01 | 8.63e-03 | 7.41e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 10 | 4.11e-01 | 7.90e-01 | 0.3140 | 1.17e-01 | -0.175000 | -2.61e-02 | 2.32e-01 | 5.20e-01 | 3.39e-01 | 8.86e-01 | 2.05e-01 |
| FGFR2 alternative splicing | 14 | 4.87e-01 | 8.26e-01 | 0.3130 | 1.82e-01 | 0.206000 | 8.12e-02 | -1.26e-01 | 2.39e-01 | 1.83e-01 | 5.99e-01 | 4.16e-01 |
| Heme biosynthesis | 11 | 6.18e-01 | 8.78e-01 | 0.3120 | -1.50e-01 | 0.027500 | 2.30e-01 | 1.46e-01 | 3.91e-01 | 8.74e-01 | 1.88e-01 | 4.01e-01 |
| Repression of WNT target genes | 11 | 4.83e-01 | 8.26e-01 | 0.3110 | 2.08e-02 | -0.178000 | 5.66e-02 | 2.48e-01 | 9.05e-01 | 3.06e-01 | 7.45e-01 | 1.54e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 17 | 1.87e-01 | 6.71e-01 | 0.3100 | 2.95e-02 | 0.173000 | 1.74e-01 | -1.87e-01 | 8.33e-01 | 2.16e-01 | 2.13e-01 | 1.83e-01 |
| Regulation of TNFR1 signaling | 25 | 1.15e-01 | 6.22e-01 | 0.3100 | 8.94e-02 | -0.012400 | -6.03e-02 | -2.90e-01 | 4.39e-01 | 9.14e-01 | 6.02e-01 | 1.20e-02 |
| RHO GTPases Activate NADPH Oxidases | 20 | 2.97e-01 | 7.47e-01 | 0.3090 | -1.59e-01 | -0.263000 | 2.44e-02 | -2.21e-02 | 2.20e-01 | 4.20e-02 | 8.50e-01 | 8.64e-01 |
| Late endosomal microautophagy | 21 | 3.71e-01 | 7.67e-01 | 0.3080 | 1.48e-02 | -0.040500 | -2.36e-01 | -1.93e-01 | 9.06e-01 | 7.48e-01 | 6.09e-02 | 1.27e-01 |
| RNA Polymerase III Chain Elongation | 11 | 6.08e-01 | 8.75e-01 | 0.3070 | -2.83e-01 | -0.107000 | 2.19e-02 | 4.63e-02 | 1.04e-01 | 5.37e-01 | 9.00e-01 | 7.90e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 5.24e-01 | 8.49e-01 | 0.3060 | -9.19e-03 | 0.227000 | 1.56e-01 | 1.34e-01 | 9.54e-01 | 1.57e-01 | 3.31e-01 | 4.01e-01 |
| Regulation of Complement cascade | 37 | 9.37e-02 | 5.89e-01 | 0.3060 | -1.56e-01 | -0.070300 | -1.73e-01 | -1.85e-01 | 1.00e-01 | 4.59e-01 | 6.87e-02 | 5.12e-02 |
| Transcription of E2F targets under negative control by DREAM complex | 16 | 4.28e-01 | 7.93e-01 | 0.3050 | 1.08e-01 | -0.012100 | 1.95e-01 | 2.09e-01 | 4.56e-01 | 9.34e-01 | 1.78e-01 | 1.48e-01 |
| FCERI mediated MAPK activation | 24 | 2.62e-01 | 7.24e-01 | 0.3040 | -4.57e-03 | 0.186000 | 2.18e-01 | 1.00e-01 | 9.69e-01 | 1.14e-01 | 6.41e-02 | 3.96e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 17 | 3.96e-01 | 7.86e-01 | 0.3040 | -2.38e-01 | -0.065500 | 1.49e-01 | 9.49e-02 | 8.94e-02 | 6.40e-01 | 2.86e-01 | 4.98e-01 |
| TRAF6 mediated NF-kB activation | 19 | 2.28e-01 | 6.88e-01 | 0.3030 | 5.95e-02 | -0.033700 | -4.80e-02 | -2.91e-01 | 6.54e-01 | 7.99e-01 | 7.17e-01 | 2.82e-02 |
| Diseases of programmed cell death | 18 | 2.61e-01 | 7.23e-01 | 0.3020 | 4.23e-02 | -0.130000 | 2.06e-01 | 1.74e-01 | 7.56e-01 | 3.40e-01 | 1.31e-01 | 2.01e-01 |
| Netrin-1 signaling | 41 | 7.85e-02 | 5.61e-01 | 0.3020 | 2.22e-01 | 0.199000 | 5.48e-03 | 4.65e-02 | 1.38e-02 | 2.76e-02 | 9.52e-01 | 6.07e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 19 | 2.68e-01 | 7.26e-01 | 0.3020 | -3.08e-02 | 0.044500 | -6.41e-02 | -2.90e-01 | 8.16e-01 | 7.37e-01 | 6.29e-01 | 2.86e-02 |
| DARPP-32 events | 20 | 3.71e-01 | 7.67e-01 | 0.3020 | 2.07e-01 | 0.124000 | 1.66e-01 | 7.12e-02 | 1.08e-01 | 3.38e-01 | 1.98e-01 | 5.81e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 11 | 4.65e-01 | 8.26e-01 | 0.3020 | 4.21e-02 | 0.282000 | -3.28e-03 | 9.68e-02 | 8.09e-01 | 1.05e-01 | 9.85e-01 | 5.78e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 17 | 3.07e-01 | 7.49e-01 | 0.3010 | 3.98e-02 | -0.136000 | 1.83e-01 | 1.93e-01 | 7.76e-01 | 3.31e-01 | 1.92e-01 | 1.68e-01 |
| Neurodegenerative Diseases | 17 | 3.07e-01 | 7.49e-01 | 0.3010 | 3.98e-02 | -0.136000 | 1.83e-01 | 1.93e-01 | 7.76e-01 | 3.31e-01 | 1.92e-01 | 1.68e-01 |
| Smooth Muscle Contraction | 29 | 8.18e-02 | 5.63e-01 | 0.3010 | 1.48e-02 | 0.022000 | 2.95e-01 | 5.43e-02 | 8.90e-01 | 8.37e-01 | 5.99e-03 | 6.13e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 20 | 1.21e-01 | 6.22e-01 | 0.3010 | -2.22e-01 | 0.112000 | 1.60e-01 | -5.68e-02 | 8.63e-02 | 3.86e-01 | 2.15e-01 | 6.60e-01 |
| Activation of Ca-permeable Kainate Receptor | 10 | 6.38e-01 | 8.80e-01 | 0.3010 | 1.75e-01 | 0.224000 | -9.56e-02 | 1.72e-02 | 3.38e-01 | 2.20e-01 | 6.01e-01 | 9.25e-01 |
| Ionotropic activity of kainate receptors | 10 | 6.38e-01 | 8.80e-01 | 0.3010 | 1.75e-01 | 0.224000 | -9.56e-02 | 1.72e-02 | 3.38e-01 | 2.20e-01 | 6.01e-01 | 9.25e-01 |
| Hyaluronan metabolism | 11 | 4.20e-01 | 7.91e-01 | 0.3000 | 1.18e-01 | -0.142000 | -2.20e-01 | 8.74e-02 | 4.97e-01 | 4.13e-01 | 2.07e-01 | 6.16e-01 |
| Glucagon-type ligand receptors | 25 | 1.55e-01 | 6.51e-01 | 0.3000 | -2.37e-01 | -0.021100 | 1.76e-01 | 4.72e-02 | 3.99e-02 | 8.55e-01 | 1.28e-01 | 6.83e-01 |
| FCERI mediated Ca+2 mobilization | 24 | 2.83e-01 | 7.37e-01 | 0.2990 | 1.17e-01 | 0.192000 | 1.97e-01 | 7.60e-03 | 3.21e-01 | 1.03e-01 | 9.52e-02 | 9.49e-01 |
| RNA Polymerase I Transcription | 34 | 1.10e-01 | 6.12e-01 | 0.2990 | -8.12e-02 | -0.198000 | -9.21e-02 | -1.88e-01 | 4.13e-01 | 4.60e-02 | 3.53e-01 | 5.81e-02 |
| Signaling by FGFR1 | 39 | 8.91e-02 | 5.78e-01 | 0.2990 | 1.32e-01 | 0.256000 | 7.31e-02 | -2.91e-02 | 1.53e-01 | 5.66e-03 | 4.30e-01 | 7.54e-01 |
| Assembly of active LPL and LIPC lipase complexes | 16 | 5.09e-01 | 8.39e-01 | 0.2990 | -1.52e-01 | -0.132000 | -9.57e-02 | -1.99e-01 | 2.92e-01 | 3.60e-01 | 5.08e-01 | 1.69e-01 |
| NCAM1 interactions | 29 | 8.03e-02 | 5.61e-01 | 0.2980 | -4.65e-02 | -0.208000 | -1.68e-01 | 1.22e-01 | 6.65e-01 | 5.21e-02 | 1.16e-01 | 2.58e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 15 | 2.67e-01 | 7.26e-01 | 0.2980 | -6.90e-02 | 0.235000 | 1.03e-01 | -1.35e-01 | 6.44e-01 | 1.16e-01 | 4.90e-01 | 3.66e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 16 | 8.99e-02 | 5.78e-01 | 0.2980 | 1.32e-01 | -0.244000 | 9.85e-02 | -3.98e-02 | 3.60e-01 | 9.06e-02 | 4.95e-01 | 7.83e-01 |
| Signaling by FGFR3 in disease | 17 | 2.17e-01 | 6.84e-01 | 0.2970 | -3.61e-02 | 0.283000 | 4.70e-02 | 6.64e-02 | 7.97e-01 | 4.33e-02 | 7.37e-01 | 6.35e-01 |
| Signaling by FGFR3 point mutants in cancer | 17 | 2.17e-01 | 6.84e-01 | 0.2970 | -3.61e-02 | 0.283000 | 4.70e-02 | 6.64e-02 | 7.97e-01 | 4.33e-02 | 7.37e-01 | 6.35e-01 |
| Creatine metabolism | 10 | 6.89e-01 | 8.99e-01 | 0.2970 | -2.52e-01 | -0.096600 | 5.58e-02 | 1.10e-01 | 1.68e-01 | 5.97e-01 | 7.60e-01 | 5.46e-01 |
| Signalling to ERKs | 29 | 1.40e-01 | 6.41e-01 | 0.2960 | -1.19e-01 | 0.117000 | 1.71e-01 | 1.75e-01 | 2.67e-01 | 2.77e-01 | 1.11e-01 | 1.03e-01 |
| Cell surface interactions at the vascular wall | 113 | 3.00e-04 | 2.47e-02 | 0.2950 | -1.65e-01 | -0.109000 | -1.70e-01 | -1.38e-01 | 2.50e-03 | 4.54e-02 | 1.80e-03 | 1.16e-02 |
| Mitochondrial protein import | 44 | 5.82e-02 | 4.95e-01 | 0.2930 | -1.21e-01 | -0.033400 | -1.50e-01 | -2.19e-01 | 1.66e-01 | 7.02e-01 | 8.46e-02 | 1.22e-02 |
| Base-Excision Repair, AP Site Formation | 15 | 4.89e-01 | 8.26e-01 | 0.2930 | -2.35e-01 | -0.151000 | 7.78e-02 | -4.38e-02 | 1.16e-01 | 3.10e-01 | 6.02e-01 | 7.69e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 13 | 5.23e-01 | 8.49e-01 | 0.2930 | 1.86e-01 | 0.045900 | 2.02e-01 | 8.98e-02 | 2.45e-01 | 7.74e-01 | 2.07e-01 | 5.75e-01 |
| Factors involved in megakaryocyte development and platelet production | 99 | 1.34e-05 | 1.48e-03 | 0.2930 | 2.09e-01 | 0.101000 | 9.60e-02 | -1.50e-01 | 3.22e-04 | 8.26e-02 | 9.92e-02 | 1.02e-02 |
| RNA Polymerase I Promoter Clearance | 33 | 1.40e-01 | 6.41e-01 | 0.2930 | -5.55e-02 | -0.201000 | -1.10e-01 | -1.74e-01 | 5.81e-01 | 4.62e-02 | 2.74e-01 | 8.39e-02 |
| Caspase activation via extrinsic apoptotic signalling pathway | 21 | 3.51e-01 | 7.67e-01 | 0.2930 | 1.36e-01 | 0.224000 | -4.95e-02 | -1.21e-01 | 2.80e-01 | 7.62e-02 | 6.95e-01 | 3.37e-01 |
| Activation of AMPK downstream of NMDARs | 10 | 6.79e-01 | 8.99e-01 | 0.2920 | 4.79e-02 | -0.183000 | -2.12e-01 | -7.03e-02 | 7.93e-01 | 3.18e-01 | 2.46e-01 | 7.00e-01 |
| Formation of the Early Elongation Complex | 19 | 3.05e-01 | 7.49e-01 | 0.2920 | -1.55e-01 | -0.208000 | 3.48e-02 | -1.30e-01 | 2.42e-01 | 1.17e-01 | 7.93e-01 | 3.27e-01 |
| Formation of the HIV-1 Early Elongation Complex | 19 | 3.05e-01 | 7.49e-01 | 0.2920 | -1.55e-01 | -0.208000 | 3.48e-02 | -1.30e-01 | 2.42e-01 | 1.17e-01 | 7.93e-01 | 3.27e-01 |
| Mismatch Repair | 13 | 2.73e-01 | 7.28e-01 | 0.2920 | 9.77e-02 | -0.149000 | 2.23e-01 | 6.28e-02 | 5.42e-01 | 3.53e-01 | 1.64e-01 | 6.95e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 23 | 2.06e-01 | 6.78e-01 | 0.2920 | -4.90e-02 | -0.276000 | -5.08e-02 | -6.26e-02 | 6.84e-01 | 2.18e-02 | 6.73e-01 | 6.04e-01 |
| Inhibition of DNA recombination at telomere | 11 | 4.14e-01 | 7.90e-01 | 0.2910 | -3.29e-02 | -0.202000 | 4.31e-02 | -2.03e-01 | 8.50e-01 | 2.45e-01 | 8.04e-01 | 2.45e-01 |
| TNFs bind their physiological receptors | 20 | 1.68e-01 | 6.67e-01 | 0.2910 | -1.59e-01 | -0.065500 | 2.28e-01 | -5.65e-02 | 2.19e-01 | 6.12e-01 | 7.78e-02 | 6.62e-01 |
| Interleukin-12 family signaling | 41 | 1.09e-01 | 6.12e-01 | 0.2900 | -5.50e-02 | 0.070600 | 2.01e-01 | 1.89e-01 | 5.42e-01 | 4.34e-01 | 2.59e-02 | 3.66e-02 |
| Phase 2 - plateau phase | 20 | 1.72e-01 | 6.68e-01 | 0.2900 | 1.12e-01 | -0.064800 | -2.54e-01 | 5.27e-02 | 3.88e-01 | 6.16e-01 | 4.91e-02 | 6.83e-01 |
| Plasma lipoprotein remodeling | 23 | 3.79e-01 | 7.68e-01 | 0.2900 | -2.14e-01 | -0.146000 | -1.11e-01 | -6.72e-02 | 7.61e-02 | 2.25e-01 | 3.55e-01 | 5.77e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 16 | 3.89e-01 | 7.79e-01 | 0.2890 | 2.37e-01 | 0.069600 | 1.50e-01 | 1.15e-02 | 1.00e-01 | 6.30e-01 | 3.00e-01 | 9.36e-01 |
| IL-6-type cytokine receptor ligand interactions | 15 | 5.06e-01 | 8.35e-01 | 0.2890 | -1.01e-01 | -0.238000 | -7.17e-02 | 1.07e-01 | 4.96e-01 | 1.11e-01 | 6.31e-01 | 4.72e-01 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 17 | 5.14e-01 | 8.44e-01 | 0.2890 | 1.50e-01 | 0.112000 | 1.02e-01 | 1.94e-01 | 2.84e-01 | 4.23e-01 | 4.68e-01 | 1.65e-01 |
| MicroRNA (miRNA) biogenesis | 13 | 5.03e-01 | 8.34e-01 | 0.2880 | 1.01e-01 | -0.183000 | -1.63e-01 | -1.13e-01 | 5.27e-01 | 2.53e-01 | 3.08e-01 | 4.81e-01 |
| Adenylate cyclase inhibitory pathway | 13 | 2.03e-01 | 6.73e-01 | 0.2880 | -1.39e-01 | 0.234000 | -4.44e-02 | 8.48e-02 | 3.85e-01 | 1.45e-01 | 7.82e-01 | 5.97e-01 |
| Serotonin Neurotransmitter Release Cycle | 11 | 4.38e-01 | 8.05e-01 | 0.2880 | 1.95e-01 | -0.013000 | -1.44e-01 | 1.55e-01 | 2.63e-01 | 9.41e-01 | 4.07e-01 | 3.73e-01 |
| STING mediated induction of host immune responses | 11 | 4.23e-01 | 7.93e-01 | 0.2880 | -3.33e-02 | -0.266000 | 8.69e-02 | -5.72e-02 | 8.48e-01 | 1.27e-01 | 6.18e-01 | 7.42e-01 |
| SHC1 events in ERBB2 signaling | 17 | 3.79e-01 | 7.68e-01 | 0.2880 | 5.40e-02 | 0.164000 | -1.54e-02 | -2.29e-01 | 7.00e-01 | 2.41e-01 | 9.12e-01 | 1.02e-01 |
| Interleukin-12 signaling | 32 | 2.23e-01 | 6.87e-01 | 0.2860 | -1.52e-02 | 0.113000 | 1.86e-01 | 1.86e-01 | 8.82e-01 | 2.68e-01 | 6.91e-02 | 6.89e-02 |
| Adenylate cyclase activating pathway | 10 | 4.76e-01 | 8.26e-01 | 0.2860 | -1.21e-01 | 0.105000 | 2.69e-03 | 2.37e-01 | 5.09e-01 | 5.64e-01 | 9.88e-01 | 1.94e-01 |
| AKT phosphorylates targets in the cytosol | 12 | 6.82e-01 | 8.99e-01 | 0.2850 | -2.36e-01 | -0.146000 | -6.02e-02 | 2.65e-02 | 1.57e-01 | 3.81e-01 | 7.18e-01 | 8.74e-01 |
| Signaling by FGFR2 | 49 | 4.11e-02 | 4.38e-01 | 0.2840 | 1.10e-01 | 0.259000 | 3.50e-02 | -2.76e-02 | 1.85e-01 | 1.75e-03 | 6.72e-01 | 7.39e-01 |
| Positive epigenetic regulation of rRNA expression | 32 | 1.41e-01 | 6.41e-01 | 0.2830 | 1.86e-02 | -0.170000 | -1.23e-01 | -1.90e-01 | 8.56e-01 | 9.69e-02 | 2.30e-01 | 6.34e-02 |
| FRS-mediated FGFR4 signaling | 16 | 1.22e-01 | 6.22e-01 | 0.2830 | -1.96e-01 | 0.104000 | -1.28e-01 | 1.20e-01 | 1.74e-01 | 4.72e-01 | 3.75e-01 | 4.07e-01 |
| G0 and Early G1 | 22 | 2.68e-01 | 7.26e-01 | 0.2830 | 1.86e-01 | 0.009220 | 1.60e-01 | 1.39e-01 | 1.30e-01 | 9.40e-01 | 1.93e-01 | 2.59e-01 |
| Ethanol oxidation | 10 | 7.00e-01 | 9.02e-01 | 0.2820 | 2.41e-01 | 0.109000 | 7.89e-02 | -5.51e-02 | 1.86e-01 | 5.50e-01 | 6.66e-01 | 7.63e-01 |
| Signaling by FGFR3 | 29 | 1.60e-01 | 6.58e-01 | 0.2820 | 6.80e-02 | 0.270000 | 3.69e-02 | -1.61e-02 | 5.26e-01 | 1.17e-02 | 7.31e-01 | 8.81e-01 |
| Syndecan interactions | 16 | 3.57e-01 | 7.67e-01 | 0.2790 | -4.34e-02 | -0.147000 | -2.12e-01 | 9.79e-02 | 7.64e-01 | 3.10e-01 | 1.42e-01 | 4.98e-01 |
| Leading Strand Synthesis | 12 | 3.45e-01 | 7.67e-01 | 0.2790 | -3.49e-02 | -0.202000 | 1.04e-01 | -1.58e-01 | 8.34e-01 | 2.26e-01 | 5.31e-01 | 3.42e-01 |
| Polymerase switching | 12 | 3.45e-01 | 7.67e-01 | 0.2790 | -3.49e-02 | -0.202000 | 1.04e-01 | -1.58e-01 | 8.34e-01 | 2.26e-01 | 5.31e-01 | 3.42e-01 |
| RHO GTPases activate PKNs | 27 | 1.39e-01 | 6.41e-01 | 0.2790 | -1.83e-01 | 0.020300 | 2.09e-01 | 6.67e-03 | 1.00e-01 | 8.55e-01 | 5.99e-02 | 9.52e-01 |
| CD28 dependent Vav1 pathway | 11 | 6.97e-01 | 9.01e-01 | 0.2780 | 7.48e-02 | 0.211000 | 1.62e-01 | -3.48e-02 | 6.68e-01 | 2.26e-01 | 3.54e-01 | 8.41e-01 |
| WNT ligand biogenesis and trafficking | 19 | 1.31e-01 | 6.32e-01 | 0.2780 | -2.34e-01 | 0.087200 | -3.26e-02 | 1.17e-01 | 7.72e-02 | 5.11e-01 | 8.06e-01 | 3.76e-01 |
| Regulation of KIT signaling | 10 | 5.73e-01 | 8.67e-01 | 0.2780 | 2.24e-01 | -0.014400 | 1.51e-01 | 6.05e-02 | 2.19e-01 | 9.37e-01 | 4.08e-01 | 7.41e-01 |
| Pre-NOTCH Transcription and Translation | 31 | 3.21e-02 | 4.13e-01 | 0.2770 | 1.21e-01 | -0.021000 | 5.87e-02 | -2.41e-01 | 2.43e-01 | 8.40e-01 | 5.72e-01 | 2.01e-02 |
| tRNA Aminoacylation | 17 | 5.76e-01 | 8.67e-01 | 0.2770 | -1.82e-01 | -0.112000 | -1.42e-01 | -1.04e-01 | 1.93e-01 | 4.24e-01 | 3.11e-01 | 4.59e-01 |
| Activation of Matrix Metalloproteinases | 23 | 4.41e-01 | 8.10e-01 | 0.2770 | -1.39e-01 | -0.097800 | -1.52e-01 | -1.56e-01 | 2.47e-01 | 4.17e-01 | 2.07e-01 | 1.95e-01 |
| Transcriptional Regulation by MECP2 | 48 | 8.01e-02 | 5.61e-01 | 0.2760 | 1.52e-01 | 0.218000 | 3.31e-02 | 6.46e-02 | 6.78e-02 | 8.97e-03 | 6.91e-01 | 4.39e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 17 | 4.78e-01 | 8.26e-01 | 0.2760 | 6.19e-02 | -0.040000 | 2.05e-01 | 1.69e-01 | 6.59e-01 | 7.75e-01 | 1.43e-01 | 2.27e-01 |
| Glucagon signaling in metabolic regulation | 25 | 2.04e-01 | 6.73e-01 | 0.2760 | -1.09e-01 | 0.132000 | 1.18e-01 | 1.81e-01 | 3.45e-01 | 2.53e-01 | 3.06e-01 | 1.18e-01 |
| Diseases of carbohydrate metabolism | 25 | 3.49e-01 | 7.67e-01 | 0.2760 | -1.61e-01 | -0.198000 | 5.92e-02 | 8.59e-02 | 1.63e-01 | 8.70e-02 | 6.09e-01 | 4.57e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 21 | 2.95e-01 | 7.46e-01 | 0.2750 | 6.53e-02 | -0.059800 | 2.23e-01 | 1.34e-01 | 6.04e-01 | 6.35e-01 | 7.71e-02 | 2.89e-01 |
| Physiological factors | 10 | 5.83e-01 | 8.70e-01 | 0.2750 | -1.21e-01 | 0.129000 | -5.51e-02 | -2.03e-01 | 5.07e-01 | 4.81e-01 | 7.63e-01 | 2.67e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 19 | 1.80e-01 | 6.71e-01 | 0.2750 | 7.89e-02 | -0.098000 | -1.85e-01 | 1.59e-01 | 5.51e-01 | 4.60e-01 | 1.63e-01 | 2.30e-01 |
| Endogenous sterols | 23 | 7.62e-02 | 5.61e-01 | 0.2740 | 7.00e-02 | 0.102000 | -2.15e-01 | 1.15e-01 | 5.61e-01 | 3.99e-01 | 7.38e-02 | 3.38e-01 |
| Cellular hexose transport | 19 | 5.05e-01 | 8.35e-01 | 0.2730 | -1.43e-01 | -0.210000 | -5.80e-02 | 8.01e-02 | 2.79e-01 | 1.13e-01 | 6.62e-01 | 5.46e-01 |
| Digestion and absorption | 21 | 2.56e-01 | 7.17e-01 | 0.2730 | 2.26e-01 | -0.044700 | -1.42e-01 | -3.51e-02 | 7.27e-02 | 7.23e-01 | 2.61e-01 | 7.81e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 12 | 3.78e-01 | 7.68e-01 | 0.2730 | 9.07e-02 | -0.150000 | 2.00e-01 | 5.88e-02 | 5.86e-01 | 3.67e-01 | 2.29e-01 | 7.25e-01 |
| Na+/Cl- dependent neurotransmitter transporters | 14 | 6.11e-01 | 8.75e-01 | 0.2730 | -2.97e-02 | -0.003050 | 2.46e-01 | 1.15e-01 | 8.47e-01 | 9.84e-01 | 1.11e-01 | 4.58e-01 |
| Formation of Incision Complex in GG-NER | 28 | 1.82e-01 | 6.71e-01 | 0.2730 | -2.04e-01 | -0.036300 | 4.16e-02 | 1.73e-01 | 6.22e-02 | 7.40e-01 | 7.04e-01 | 1.13e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 12 | 3.54e-01 | 7.67e-01 | 0.2720 | 5.41e-02 | -0.183000 | 1.92e-01 | 2.70e-02 | 7.45e-01 | 2.72e-01 | 2.49e-01 | 8.71e-01 |
| Glycosphingolipid metabolism | 30 | 1.43e-01 | 6.41e-01 | 0.2710 | -1.46e-01 | -0.182000 | 4.27e-02 | -1.32e-01 | 1.67e-01 | 8.48e-02 | 6.86e-01 | 2.12e-01 |
| Downstream signaling of activated FGFR2 | 24 | 7.83e-02 | 5.61e-01 | 0.2710 | -1.57e-02 | 0.251000 | -6.97e-02 | 7.30e-02 | 8.94e-01 | 3.34e-02 | 5.55e-01 | 5.36e-01 |
| RHO GTPases Activate ROCKs | 13 | 6.19e-01 | 8.78e-01 | 0.2710 | -1.24e-01 | -0.237000 | 3.44e-02 | -2.09e-02 | 4.37e-01 | 1.39e-01 | 8.30e-01 | 8.96e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 14 | 5.99e-01 | 8.75e-01 | 0.2700 | 1.69e-01 | 0.132000 | 1.69e-02 | 1.64e-01 | 2.74e-01 | 3.93e-01 | 9.13e-01 | 2.88e-01 |
| Retrograde transport at the Trans-Golgi-Network | 36 | 1.69e-01 | 6.67e-01 | 0.2700 | 1.26e-01 | 0.195000 | -3.33e-02 | -1.35e-01 | 1.90e-01 | 4.33e-02 | 7.29e-01 | 1.62e-01 |
| MET activates PTK2 signaling | 16 | 3.80e-01 | 7.68e-01 | 0.2700 | -2.43e-01 | -0.037500 | -1.01e-01 | 4.50e-02 | 9.21e-02 | 7.95e-01 | 4.82e-01 | 7.55e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 31 | 9.01e-02 | 5.78e-01 | 0.2690 | 1.37e-01 | -0.092400 | 8.06e-02 | 1.97e-01 | 1.88e-01 | 3.74e-01 | 4.38e-01 | 5.79e-02 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 40 | 8.44e-02 | 5.71e-01 | 0.2680 | 3.66e-02 | 0.094700 | -2.14e-01 | -1.26e-01 | 6.89e-01 | 3.00e-01 | 1.93e-02 | 1.67e-01 |
| PECAM1 interactions | 10 | 6.75e-01 | 8.96e-01 | 0.2680 | 8.32e-02 | -0.096000 | 1.60e-01 | 1.74e-01 | 6.49e-01 | 5.99e-01 | 3.81e-01 | 3.41e-01 |
| Extra-nuclear estrogen signaling | 60 | 5.90e-03 | 1.92e-01 | 0.2680 | -3.14e-02 | 0.168000 | -7.34e-02 | -1.93e-01 | 6.74e-01 | 2.46e-02 | 3.26e-01 | 9.67e-03 |
| Processive synthesis on the lagging strand | 12 | 4.48e-01 | 8.18e-01 | 0.2680 | -4.65e-03 | -0.254000 | 8.59e-02 | 5.42e-03 | 9.78e-01 | 1.28e-01 | 6.06e-01 | 9.74e-01 |
| Recycling of bile acids and salts | 13 | 4.84e-01 | 8.26e-01 | 0.2680 | -6.15e-02 | 0.238000 | 1.04e-01 | -2.41e-02 | 7.01e-01 | 1.37e-01 | 5.18e-01 | 8.81e-01 |
| HDR through Homologous Recombination (HRR) | 43 | 3.29e-02 | 4.13e-01 | 0.2680 | 7.82e-02 | -0.130000 | -7.25e-02 | -2.08e-01 | 3.75e-01 | 1.41e-01 | 4.11e-01 | 1.81e-02 |
| Miscellaneous transport and binding events | 16 | 4.51e-01 | 8.19e-01 | 0.2680 | -6.86e-02 | 0.072700 | -5.42e-02 | -2.42e-01 | 6.35e-01 | 6.15e-01 | 7.07e-01 | 9.35e-02 |
| mRNA 3'-end processing | 38 | 1.03e-01 | 5.99e-01 | 0.2680 | 1.11e-01 | 0.179000 | 1.28e-01 | -1.04e-01 | 2.37e-01 | 5.61e-02 | 1.72e-01 | 2.68e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 12 | 2.79e-01 | 7.33e-01 | 0.2670 | 1.38e-01 | -0.190000 | 1.20e-01 | -4.38e-02 | 4.08e-01 | 2.53e-01 | 4.73e-01 | 7.93e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 40 | 1.86e-01 | 6.71e-01 | 0.2670 | 1.10e-01 | 0.196000 | 9.30e-02 | 1.11e-01 | 2.31e-01 | 3.18e-02 | 3.09e-01 | 2.27e-01 |
| Signaling by PTK6 | 40 | 1.86e-01 | 6.71e-01 | 0.2670 | 1.10e-01 | 0.196000 | 9.30e-02 | 1.11e-01 | 2.31e-01 | 3.18e-02 | 3.09e-01 | 2.27e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 23 | 3.10e-01 | 7.52e-01 | 0.2670 | 5.17e-02 | 0.248000 | 4.94e-02 | -6.81e-02 | 6.68e-01 | 3.97e-02 | 6.82e-01 | 5.72e-01 |
| Regulation of innate immune responses to cytosolic DNA | 11 | 7.09e-01 | 9.05e-01 | 0.2670 | 6.12e-02 | -0.095900 | -1.12e-01 | -2.13e-01 | 7.25e-01 | 5.82e-01 | 5.19e-01 | 2.20e-01 |
| Zinc transporters | 12 | 5.37e-01 | 8.53e-01 | 0.2660 | 1.47e-02 | -0.149000 | -2.71e-02 | -2.19e-01 | 9.30e-01 | 3.71e-01 | 8.71e-01 | 1.90e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 17 | 6.54e-01 | 8.87e-01 | 0.2660 | 1.16e-01 | 0.126000 | 1.73e-01 | 1.06e-01 | 4.07e-01 | 3.69e-01 | 2.16e-01 | 4.50e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 19 | 4.55e-01 | 8.20e-01 | 0.2650 | 1.62e-01 | 0.140000 | 1.48e-01 | -5.37e-02 | 2.21e-01 | 2.92e-01 | 2.65e-01 | 6.85e-01 |
| Signaling by FGFR | 61 | 5.28e-02 | 4.71e-01 | 0.2650 | 1.60e-01 | 0.210000 | 2.51e-02 | -1.34e-02 | 3.12e-02 | 4.60e-03 | 7.35e-01 | 8.56e-01 |
| Cholesterol biosynthesis | 15 | 7.12e-01 | 9.05e-01 | 0.2650 | -1.05e-01 | -0.166000 | -1.59e-01 | -7.88e-02 | 4.83e-01 | 2.65e-01 | 2.86e-01 | 5.97e-01 |
| Signaling by NODAL | 18 | 3.68e-01 | 7.67e-01 | 0.2640 | 5.42e-02 | -0.185000 | -1.76e-01 | 3.88e-02 | 6.91e-01 | 1.74e-01 | 1.97e-01 | 7.76e-01 |
| Interleukin-27 signaling | 10 | 8.04e-01 | 9.36e-01 | 0.2640 | -1.24e-01 | -0.126000 | 1.12e-01 | 1.61e-01 | 4.99e-01 | 4.91e-01 | 5.40e-01 | 3.78e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 3.46e-01 | 7.67e-01 | 0.2630 | 8.60e-02 | 0.015400 | 1.55e-01 | -1.94e-01 | 5.91e-01 | 9.23e-01 | 3.33e-01 | 2.26e-01 |
| Acyl chain remodelling of PG | 15 | 5.69e-01 | 8.67e-01 | 0.2630 | -8.94e-02 | -0.187000 | -3.85e-02 | 1.57e-01 | 5.49e-01 | 2.10e-01 | 7.96e-01 | 2.92e-01 |
| Cyclin D associated events in G1 | 32 | 1.67e-01 | 6.67e-01 | 0.2630 | 9.15e-02 | 0.148000 | 1.90e-01 | -5.11e-02 | 3.70e-01 | 1.47e-01 | 6.31e-02 | 6.17e-01 |
| G1 Phase | 32 | 1.67e-01 | 6.67e-01 | 0.2630 | 9.15e-02 | 0.148000 | 1.90e-01 | -5.11e-02 | 3.70e-01 | 1.47e-01 | 6.31e-02 | 6.17e-01 |
| Activation of BAD and translocation to mitochondria | 13 | 6.26e-01 | 8.78e-01 | 0.2630 | -7.45e-02 | 0.153000 | 1.91e-01 | 5.83e-02 | 6.42e-01 | 3.38e-01 | 2.33e-01 | 7.16e-01 |
| Amino acid transport across the plasma membrane | 28 | 3.99e-01 | 7.86e-01 | 0.2630 | -1.35e-01 | -0.201000 | -7.82e-02 | -6.38e-02 | 2.16e-01 | 6.55e-02 | 4.74e-01 | 5.59e-01 |
| Complement cascade | 47 | 7.59e-02 | 5.61e-01 | 0.2620 | -1.91e-01 | -0.058700 | -1.33e-01 | -1.04e-01 | 2.34e-02 | 4.86e-01 | 1.14e-01 | 2.16e-01 |
| RHO GTPases Activate WASPs and WAVEs | 30 | 9.89e-02 | 5.99e-01 | 0.2620 | 1.39e-01 | 0.062600 | 2.04e-01 | -5.97e-02 | 1.88e-01 | 5.53e-01 | 5.29e-02 | 5.72e-01 |
| Signaling by FGFR1 in disease | 31 | 2.41e-01 | 7.01e-01 | 0.2610 | 2.11e-02 | 0.143000 | 9.75e-02 | 1.95e-01 | 8.39e-01 | 1.67e-01 | 3.48e-01 | 6.09e-02 |
| PCNA-Dependent Long Patch Base Excision Repair | 15 | 5.69e-01 | 8.67e-01 | 0.2610 | -3.35e-02 | -0.092700 | 2.09e-01 | 1.22e-01 | 8.22e-01 | 5.34e-01 | 1.62e-01 | 4.13e-01 |
| HS-GAG degradation | 16 | 4.89e-01 | 8.26e-01 | 0.2600 | 7.78e-02 | -0.137000 | -2.07e-01 | -1.24e-02 | 5.90e-01 | 3.43e-01 | 1.52e-01 | 9.32e-01 |
| Lysine catabolism | 10 | 8.01e-01 | 9.36e-01 | 0.2600 | -8.97e-02 | -0.041600 | 1.08e-01 | 2.15e-01 | 6.23e-01 | 8.20e-01 | 5.55e-01 | 2.39e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 36 | 2.24e-01 | 6.87e-01 | 0.2600 | 1.97e-01 | 0.125000 | 4.54e-02 | 1.05e-01 | 4.11e-02 | 1.94e-01 | 6.37e-01 | 2.76e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 32 | 2.99e-01 | 7.48e-01 | 0.2590 | -5.70e-02 | -0.200000 | -1.45e-01 | -5.53e-02 | 5.77e-01 | 5.08e-02 | 1.55e-01 | 5.88e-01 |
| EPHA-mediated growth cone collapse | 12 | 4.66e-01 | 8.26e-01 | 0.2590 | 9.69e-03 | -0.220000 | 1.31e-01 | 3.39e-02 | 9.54e-01 | 1.87e-01 | 4.32e-01 | 8.39e-01 |
| Carnitine metabolism | 11 | 7.59e-01 | 9.16e-01 | 0.2590 | -1.72e-01 | -0.074200 | -1.60e-01 | -7.87e-02 | 3.23e-01 | 6.70e-01 | 3.59e-01 | 6.51e-01 |
| RIP-mediated NFkB activation via ZBP1 | 15 | 5.66e-01 | 8.67e-01 | 0.2590 | -1.02e-02 | 0.039300 | -5.77e-02 | -2.49e-01 | 9.45e-01 | 7.92e-01 | 6.99e-01 | 9.54e-02 |
| Downstream signaling of activated FGFR3 | 19 | 2.77e-01 | 7.32e-01 | 0.2590 | -5.54e-03 | 0.257000 | -1.29e-02 | 2.25e-02 | 9.67e-01 | 5.24e-02 | 9.23e-01 | 8.65e-01 |
| PI-3K cascade:FGFR4 | 17 | 1.54e-01 | 6.51e-01 | 0.2580 | -1.37e-01 | 0.117000 | -1.17e-01 | 1.43e-01 | 3.30e-01 | 4.05e-01 | 4.05e-01 | 3.07e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 24 | 2.87e-01 | 7.37e-01 | 0.2570 | -6.50e-02 | -0.241000 | 4.36e-02 | 4.31e-02 | 5.82e-01 | 4.11e-02 | 7.12e-01 | 7.15e-01 |
| Lysosome Vesicle Biogenesis | 26 | 4.53e-02 | 4.38e-01 | 0.2560 | 1.06e-01 | -0.175000 | 7.20e-02 | -1.37e-01 | 3.50e-01 | 1.23e-01 | 5.25e-01 | 2.28e-01 |
| Cargo concentration in the ER | 21 | 5.58e-01 | 8.67e-01 | 0.2560 | -1.53e-01 | -0.116000 | -1.52e-01 | -7.54e-02 | 2.26e-01 | 3.56e-01 | 2.28e-01 | 5.50e-01 |
| Pre-NOTCH Expression and Processing | 44 | 5.07e-03 | 1.82e-01 | 0.2560 | 8.84e-02 | -0.089100 | 7.26e-02 | -2.11e-01 | 3.11e-01 | 3.07e-01 | 4.05e-01 | 1.56e-02 |
| Notch-HLH transcription pathway | 22 | 1.90e-01 | 6.71e-01 | 0.2560 | 1.94e-01 | -0.107000 | -4.68e-02 | -1.20e-01 | 1.16e-01 | 3.84e-01 | 7.04e-01 | 3.32e-01 |
| Processing of Intronless Pre-mRNAs | 11 | 7.81e-01 | 9.29e-01 | 0.2560 | 2.44e-02 | 0.189000 | 1.64e-01 | 4.72e-02 | 8.89e-01 | 2.78e-01 | 3.48e-01 | 7.87e-01 |
| DAP12 signaling | 20 | 3.31e-01 | 7.66e-01 | 0.2560 | 7.92e-03 | 0.245000 | -2.36e-03 | -7.25e-02 | 9.51e-01 | 5.80e-02 | 9.85e-01 | 5.75e-01 |
| Meiotic recombination | 19 | 1.83e-01 | 6.71e-01 | 0.2560 | -7.71e-03 | -0.156000 | 8.97e-02 | -1.81e-01 | 9.54e-01 | 2.40e-01 | 4.99e-01 | 1.71e-01 |
| Blood group systems biosynthesis | 12 | 4.85e-01 | 8.26e-01 | 0.2550 | 1.75e-01 | -0.156000 | -9.34e-02 | 3.83e-02 | 2.93e-01 | 3.49e-01 | 5.75e-01 | 8.18e-01 |
| Recycling pathway of L1 | 24 | 1.22e-01 | 6.22e-01 | 0.2550 | 1.04e-01 | 0.035300 | 1.42e-01 | -1.82e-01 | 3.80e-01 | 7.65e-01 | 2.30e-01 | 1.22e-01 |
| RUNX2 regulates bone development | 24 | 5.23e-01 | 8.49e-01 | 0.2550 | 1.57e-01 | 0.184000 | 6.78e-02 | 4.38e-02 | 1.83e-01 | 1.19e-01 | 5.66e-01 | 7.10e-01 |
| Translocation of ZAP-70 to Immunological synapse | 11 | 4.60e-01 | 8.25e-01 | 0.2550 | 7.80e-02 | -0.188000 | 1.48e-01 | 3.87e-02 | 6.54e-01 | 2.80e-01 | 3.94e-01 | 8.24e-01 |
| Non-integrin membrane-ECM interactions | 35 | 1.40e-01 | 6.41e-01 | 0.2550 | -1.84e-01 | -0.098200 | -1.36e-01 | 5.52e-02 | 5.98e-02 | 3.15e-01 | 1.65e-01 | 5.72e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 10 | 7.16e-01 | 9.06e-01 | 0.2550 | 1.70e-01 | 0.044500 | 2.94e-05 | -1.85e-01 | 3.52e-01 | 8.07e-01 | 1.00e+00 | 3.12e-01 |
| Regulation of beta-cell development | 28 | 2.47e-01 | 7.09e-01 | 0.2550 | 5.62e-02 | 0.204000 | 5.96e-02 | -1.29e-01 | 6.07e-01 | 6.23e-02 | 5.85e-01 | 2.37e-01 |
| DAP12 interactions | 25 | 2.89e-01 | 7.37e-01 | 0.2540 | 3.97e-02 | 0.226000 | 1.35e-02 | -1.09e-01 | 7.31e-01 | 5.05e-02 | 9.07e-01 | 3.47e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 6.97e-01 | 9.01e-01 | 0.2540 | -6.17e-02 | -0.118000 | 6.88e-02 | 2.04e-01 | 7.00e-01 | 4.60e-01 | 6.68e-01 | 2.02e-01 |
| Iron uptake and transport | 41 | 1.17e-01 | 6.22e-01 | 0.2530 | -1.48e-01 | 0.059800 | 1.45e-01 | 1.33e-01 | 1.01e-01 | 5.08e-01 | 1.07e-01 | 1.42e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic | 62 | 4.27e-02 | 4.38e-01 | 0.2530 | -1.17e-03 | -0.138000 | -1.15e-01 | -1.78e-01 | 9.87e-01 | 5.97e-02 | 1.18e-01 | 1.57e-02 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 6.25e-01 | 8.78e-01 | 0.2520 | -1.97e-01 | 0.086700 | 1.30e-01 | 1.83e-02 | 2.58e-01 | 6.19e-01 | 4.56e-01 | 9.16e-01 |
| Formation of RNA Pol II elongation complex | 33 | 1.42e-01 | 6.41e-01 | 0.2520 | -1.49e-01 | -0.129000 | 4.92e-02 | -1.49e-01 | 1.39e-01 | 2.02e-01 | 6.25e-01 | 1.40e-01 |
| RNA Polymerase II Transcription Elongation | 33 | 1.42e-01 | 6.41e-01 | 0.2520 | -1.49e-01 | -0.129000 | 4.92e-02 | -1.49e-01 | 1.39e-01 | 2.02e-01 | 6.25e-01 | 1.40e-01 |
| HDMs demethylate histones | 15 | 5.88e-01 | 8.71e-01 | 0.2510 | 2.91e-02 | 0.069500 | 2.38e-01 | 2.75e-02 | 8.46e-01 | 6.41e-01 | 1.10e-01 | 8.54e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 26 | 2.71e-01 | 7.27e-01 | 0.2510 | -2.18e-02 | 0.192000 | 1.59e-01 | -2.40e-02 | 8.47e-01 | 9.04e-02 | 1.60e-01 | 8.33e-01 |
| Oncogene Induced Senescence | 25 | 3.81e-01 | 7.68e-01 | 0.2510 | 1.67e-01 | 0.107000 | 1.55e-01 | 5.67e-04 | 1.49e-01 | 3.54e-01 | 1.81e-01 | 9.96e-01 |
| Meiotic synapsis | 27 | 1.58e-01 | 6.51e-01 | 0.2510 | -9.71e-02 | -0.127000 | 1.92e-01 | -2.05e-02 | 3.83e-01 | 2.52e-01 | 8.39e-02 | 8.53e-01 |
| Diseases associated with O-glycosylation of proteins | 53 | 3.21e-02 | 4.13e-01 | 0.2510 | 1.20e-01 | -0.067700 | -2.09e-01 | -2.55e-02 | 1.32e-01 | 3.94e-01 | 8.68e-03 | 7.48e-01 |
| Prolactin receptor signaling | 11 | 7.16e-01 | 9.06e-01 | 0.2510 | -1.91e-01 | -0.082700 | -3.56e-02 | 1.36e-01 | 2.73e-01 | 6.35e-01 | 8.38e-01 | 4.35e-01 |
| Lagging Strand Synthesis | 16 | 4.48e-01 | 8.18e-01 | 0.2510 | -7.59e-02 | -0.217000 | 9.96e-02 | -1.85e-02 | 5.99e-01 | 1.34e-01 | 4.90e-01 | 8.98e-01 |
| PI-3K cascade:FGFR2 | 20 | 1.62e-01 | 6.61e-01 | 0.2510 | -3.39e-02 | 0.208000 | -7.17e-02 | 1.15e-01 | 7.93e-01 | 1.07e-01 | 5.79e-01 | 3.72e-01 |
| Apoptotic factor-mediated response | 11 | 8.00e-01 | 9.36e-01 | 0.2500 | -2.04e-01 | -0.135000 | 5.01e-02 | 8.81e-03 | 2.40e-01 | 4.37e-01 | 7.74e-01 | 9.60e-01 |
| Glycogen breakdown (glycogenolysis) | 11 | 5.80e-01 | 8.69e-01 | 0.2500 | 1.13e-01 | -0.150000 | -2.06e-03 | 1.65e-01 | 5.16e-01 | 3.88e-01 | 9.91e-01 | 3.44e-01 |
| Voltage gated Potassium channels | 31 | 2.61e-01 | 7.23e-01 | 0.2500 | 2.24e-01 | 0.074800 | -1.86e-02 | -7.99e-02 | 3.08e-02 | 4.71e-01 | 8.58e-01 | 4.42e-01 |
| Circadian Clock | 56 | 6.39e-02 | 5.07e-01 | 0.2500 | -1.38e-02 | 0.160000 | 1.29e-01 | 1.42e-01 | 8.58e-01 | 3.85e-02 | 9.61e-02 | 6.59e-02 |
| Tie2 Signaling | 15 | 3.06e-01 | 7.49e-01 | 0.2500 | 3.85e-02 | 0.108000 | -1.35e-01 | 1.77e-01 | 7.96e-01 | 4.70e-01 | 3.66e-01 | 2.36e-01 |
| Negative epigenetic regulation of rRNA expression | 29 | 3.99e-01 | 7.86e-01 | 0.2500 | 5.91e-02 | 0.027400 | -1.49e-01 | -1.90e-01 | 5.82e-01 | 7.98e-01 | 1.65e-01 | 7.72e-02 |
| Sulfur amino acid metabolism | 21 | 6.08e-01 | 8.75e-01 | 0.2500 | -1.17e-01 | -0.135000 | -1.07e-01 | -1.37e-01 | 3.53e-01 | 2.84e-01 | 3.98e-01 | 2.76e-01 |
| FRS-mediated FGFR2 signaling | 19 | 1.55e-01 | 6.51e-01 | 0.2490 | -7.88e-02 | 0.202000 | -7.89e-02 | 9.44e-02 | 5.52e-01 | 1.27e-01 | 5.52e-01 | 4.77e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 52 | 4.57e-02 | 4.38e-01 | 0.2490 | 1.20e-01 | 0.144000 | 1.23e-01 | -1.09e-01 | 1.36e-01 | 7.19e-02 | 1.24e-01 | 1.76e-01 |
| Downstream signaling of activated FGFR4 | 21 | 1.02e-01 | 5.99e-01 | 0.2490 | -9.62e-02 | 0.183000 | -1.06e-01 | 8.94e-02 | 4.45e-01 | 1.47e-01 | 4.01e-01 | 4.78e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 10 | 6.62e-01 | 8.91e-01 | 0.2490 | -8.49e-02 | 0.096100 | 2.42e-02 | -2.12e-01 | 6.42e-01 | 5.99e-01 | 8.95e-01 | 2.46e-01 |
| Response of Mtb to phagocytosis | 18 | 4.71e-01 | 8.26e-01 | 0.2490 | -7.36e-02 | 0.180000 | 1.31e-01 | 8.40e-02 | 5.89e-01 | 1.87e-01 | 3.37e-01 | 5.37e-01 |
| Signaling by NTRK2 (TRKB) | 20 | 4.06e-01 | 7.89e-01 | 0.2490 | -5.71e-03 | 0.221000 | 7.00e-02 | 8.96e-02 | 9.65e-01 | 8.73e-02 | 5.88e-01 | 4.88e-01 |
| Interferon gamma signaling | 55 | 2.14e-02 | 3.85e-01 | 0.2480 | -2.52e-02 | -0.131000 | -2.43e-02 | -2.08e-01 | 7.46e-01 | 9.23e-02 | 7.56e-01 | 7.67e-03 |
| SUMOylation of transcription factors | 13 | 6.30e-01 | 8.78e-01 | 0.2470 | -2.95e-02 | -0.244000 | -2.19e-02 | 1.59e-02 | 8.54e-01 | 1.28e-01 | 8.91e-01 | 9.21e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 23 | 2.94e-01 | 7.46e-01 | 0.2470 | -3.19e-02 | 0.227000 | 7.29e-02 | 5.55e-02 | 7.91e-01 | 5.96e-02 | 5.45e-01 | 6.45e-01 |
| Interconversion of nucleotide di- and triphosphates | 22 | 3.12e-01 | 7.52e-01 | 0.2470 | -2.18e-01 | 0.046100 | 9.30e-02 | 4.94e-02 | 7.64e-02 | 7.08e-01 | 4.50e-01 | 6.88e-01 |
| Methylation | 10 | 7.15e-01 | 9.06e-01 | 0.2460 | -3.87e-02 | 0.123000 | -1.66e-01 | -1.28e-01 | 8.32e-01 | 4.99e-01 | 3.64e-01 | 4.82e-01 |
| Deactivation of the beta-catenin transactivating complex | 28 | 1.11e-01 | 6.19e-01 | 0.2460 | 8.91e-02 | -0.064200 | -1.75e-01 | 1.34e-01 | 4.15e-01 | 5.56e-01 | 1.09e-01 | 2.21e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 16 | 5.21e-01 | 8.49e-01 | 0.2460 | -2.27e-01 | -0.026200 | 7.14e-02 | -5.65e-02 | 1.16e-01 | 8.56e-01 | 6.21e-01 | 6.96e-01 |
| Branched-chain amino acid catabolism | 18 | 3.16e-01 | 7.52e-01 | 0.2450 | -4.17e-02 | 0.017700 | 8.11e-02 | -2.27e-01 | 7.59e-01 | 8.97e-01 | 5.51e-01 | 9.53e-02 |
| Trafficking of GluR2-containing AMPA receptors | 13 | 4.65e-01 | 8.26e-01 | 0.2450 | 3.25e-02 | -0.235000 | 6.00e-02 | 9.11e-03 | 8.39e-01 | 1.42e-01 | 7.08e-01 | 9.55e-01 |
| Synaptic adhesion-like molecules | 18 | 5.67e-01 | 8.67e-01 | 0.2450 | -9.31e-03 | -0.208000 | -1.19e-01 | -4.88e-02 | 9.45e-01 | 1.26e-01 | 3.83e-01 | 7.20e-01 |
| Aggrephagy | 18 | 5.33e-01 | 8.52e-01 | 0.2450 | 1.27e-01 | 0.038200 | -2.00e-01 | -4.97e-02 | 3.49e-01 | 7.79e-01 | 1.43e-01 | 7.15e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 17 | 4.88e-01 | 8.26e-01 | 0.2450 | -2.01e-01 | -0.053800 | 1.07e-01 | -7.07e-02 | 1.50e-01 | 7.01e-01 | 4.44e-01 | 6.14e-01 |
| Glycogen synthesis | 11 | 4.41e-01 | 8.10e-01 | 0.2440 | -2.50e-02 | 0.164000 | -1.44e-01 | 1.07e-01 | 8.86e-01 | 3.47e-01 | 4.08e-01 | 5.39e-01 |
| Acyl chain remodelling of PI | 14 | 6.69e-01 | 8.93e-01 | 0.2440 | -6.59e-02 | -0.219000 | -8.89e-03 | 8.65e-02 | 6.70e-01 | 1.57e-01 | 9.54e-01 | 5.75e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 29 | 1.28e-01 | 6.25e-01 | 0.2440 | 1.24e-01 | -0.088700 | -4.90e-02 | 1.84e-01 | 2.48e-01 | 4.09e-01 | 6.48e-01 | 8.61e-02 |
| Polymerase switching on the C-strand of the telomere | 20 | 3.54e-01 | 7.67e-01 | 0.2440 | -3.81e-02 | -0.237000 | 3.52e-02 | -2.85e-02 | 7.68e-01 | 6.68e-02 | 7.85e-01 | 8.25e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 7.61e-01 | 9.17e-01 | 0.2440 | 1.11e-01 | 0.167000 | 1.25e-01 | -6.25e-02 | 5.06e-01 | 3.18e-01 | 4.55e-01 | 7.08e-01 |
| TNFR1-induced NFkappaB signaling pathway | 22 | 4.78e-01 | 8.26e-01 | 0.2440 | 9.45e-02 | 0.037800 | -6.87e-02 | -2.11e-01 | 4.43e-01 | 7.59e-01 | 5.77e-01 | 8.72e-02 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 33 | 4.65e-02 | 4.38e-01 | 0.2430 | -2.22e-02 | -0.127000 | 9.26e-02 | -1.85e-01 | 8.26e-01 | 2.08e-01 | 3.58e-01 | 6.65e-02 |
| DNA Double Strand Break Response | 34 | 5.91e-02 | 4.98e-01 | 0.2430 | -2.26e-02 | -0.109000 | 6.05e-02 | -2.07e-01 | 8.20e-01 | 2.74e-01 | 5.42e-01 | 3.67e-02 |
| Signaling by KIT in disease | 16 | 5.48e-01 | 8.61e-01 | 0.2410 | 2.10e-01 | 0.010200 | 4.39e-02 | 1.10e-01 | 1.46e-01 | 9.44e-01 | 7.61e-01 | 4.45e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 16 | 5.48e-01 | 8.61e-01 | 0.2410 | 2.10e-01 | 0.010200 | 4.39e-02 | 1.10e-01 | 1.46e-01 | 9.44e-01 | 7.61e-01 | 4.45e-01 |
| TNF signaling | 32 | 2.67e-01 | 7.26e-01 | 0.2410 | 1.16e-01 | 0.079500 | -2.61e-02 | -1.94e-01 | 2.57e-01 | 4.36e-01 | 7.98e-01 | 5.75e-02 |
| Cytochrome P450 - arranged by substrate type | 53 | 1.39e-01 | 6.41e-01 | 0.2410 | 1.53e-01 | 0.184000 | -1.34e-02 | -2.15e-02 | 5.41e-02 | 2.03e-02 | 8.67e-01 | 7.87e-01 |
| Triglyceride catabolism | 18 | 3.30e-01 | 7.66e-01 | 0.2400 | 1.04e-01 | 0.082100 | -1.74e-01 | 9.93e-02 | 4.46e-01 | 5.46e-01 | 2.01e-01 | 4.66e-01 |
| MET promotes cell motility | 26 | 1.88e-01 | 6.71e-01 | 0.2390 | -2.06e-01 | 0.080700 | 5.01e-02 | 7.56e-02 | 6.91e-02 | 4.76e-01 | 6.59e-01 | 5.05e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 30 | 1.57e-01 | 6.51e-01 | 0.2390 | -6.13e-02 | 0.124000 | 2.89e-02 | -1.93e-01 | 5.61e-01 | 2.39e-01 | 7.84e-01 | 6.80e-02 |
| Negative regulators of DDX58/IFIH1 signaling | 21 | 5.52e-01 | 8.64e-01 | 0.2390 | -1.09e-01 | -0.050700 | -8.24e-02 | -1.89e-01 | 3.86e-01 | 6.88e-01 | 5.13e-01 | 1.33e-01 |
| RAF activation | 27 | 2.83e-01 | 7.37e-01 | 0.2390 | -2.36e-01 | -0.020900 | 2.63e-02 | -1.52e-02 | 3.40e-02 | 8.51e-01 | 8.13e-01 | 8.91e-01 |
| Activation of gene expression by SREBF (SREBP) | 35 | 5.01e-02 | 4.63e-01 | 0.2380 | -7.77e-02 | -0.080300 | 1.78e-01 | -1.11e-01 | 4.26e-01 | 4.11e-01 | 6.80e-02 | 2.54e-01 |
| Incretin synthesis, secretion, and inactivation | 16 | 4.84e-01 | 8.26e-01 | 0.2380 | 5.19e-02 | 0.154000 | -1.71e-01 | -2.99e-02 | 7.19e-01 | 2.85e-01 | 2.36e-01 | 8.36e-01 |
| Signaling by ERBB4 | 41 | 2.26e-01 | 6.87e-01 | 0.2380 | 9.31e-02 | 0.133000 | -9.12e-02 | -1.48e-01 | 3.02e-01 | 1.41e-01 | 3.12e-01 | 1.01e-01 |
| Purine salvage | 11 | 6.19e-01 | 8.78e-01 | 0.2370 | -1.45e-01 | 0.045800 | 1.37e-01 | -1.20e-01 | 4.04e-01 | 7.92e-01 | 4.32e-01 | 4.90e-01 |
| Nucleotide salvage | 17 | 4.77e-01 | 8.26e-01 | 0.2370 | -1.71e-01 | -0.063300 | 1.10e-01 | -1.05e-01 | 2.23e-01 | 6.52e-01 | 4.32e-01 | 4.55e-01 |
| Striated Muscle Contraction | 32 | 2.35e-01 | 6.96e-01 | 0.2370 | -7.95e-02 | -0.106000 | -1.94e-01 | 3.05e-02 | 4.36e-01 | 2.99e-01 | 5.76e-02 | 7.66e-01 |
| MHC class II antigen presentation | 84 | 2.20e-02 | 3.85e-01 | 0.2370 | 5.93e-02 | -0.084100 | -1.38e-01 | -1.63e-01 | 3.48e-01 | 1.83e-01 | 2.95e-02 | 9.90e-03 |
| FGFR4 ligand binding and activation | 11 | 6.23e-01 | 8.78e-01 | 0.2370 | -1.48e-01 | -0.036800 | -1.57e-01 | 9.04e-02 | 3.96e-01 | 8.33e-01 | 3.68e-01 | 6.04e-01 |
| Digestion | 16 | 6.49e-01 | 8.84e-01 | 0.2370 | 2.18e-01 | 0.077300 | -3.48e-02 | 3.34e-02 | 1.30e-01 | 5.92e-01 | 8.09e-01 | 8.17e-01 |
| Glutamate Neurotransmitter Release Cycle | 19 | 3.23e-01 | 7.57e-01 | 0.2350 | 3.68e-02 | -0.058300 | -1.08e-01 | 1.97e-01 | 7.81e-01 | 6.60e-01 | 4.14e-01 | 1.37e-01 |
| ADP signalling through P2Y purinoceptor 12 | 15 | 3.96e-01 | 7.86e-01 | 0.2350 | -1.03e-01 | 0.207000 | -1.80e-02 | -3.73e-02 | 4.91e-01 | 1.65e-01 | 9.04e-01 | 8.03e-01 |
| Beta-catenin phosphorylation cascade | 15 | 7.06e-01 | 9.05e-01 | 0.2340 | 5.76e-02 | 0.174000 | 6.25e-02 | 1.31e-01 | 6.99e-01 | 2.43e-01 | 6.75e-01 | 3.78e-01 |
| Metabolism of non-coding RNA | 34 | 3.17e-01 | 7.52e-01 | 0.2340 | 1.97e-02 | 0.169000 | 1.58e-01 | 2.39e-02 | 8.43e-01 | 8.78e-02 | 1.10e-01 | 8.10e-01 |
| snRNP Assembly | 34 | 3.17e-01 | 7.52e-01 | 0.2340 | 1.97e-02 | 0.169000 | 1.58e-01 | 2.39e-02 | 8.43e-01 | 8.78e-02 | 1.10e-01 | 8.10e-01 |
| Defective B3GAT3 causes JDSSDHD | 15 | 6.36e-01 | 8.80e-01 | 0.2340 | 1.36e-01 | 0.093900 | -1.64e-01 | -1.43e-02 | 3.60e-01 | 5.29e-01 | 2.71e-01 | 9.24e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 22 | 3.71e-01 | 7.67e-01 | 0.2340 | 7.88e-03 | 0.157000 | 1.30e-01 | -1.13e-01 | 9.49e-01 | 2.01e-01 | 2.90e-01 | 3.59e-01 |
| Class B/2 (Secretin family receptors) | 67 | 1.39e-02 | 3.21e-01 | 0.2330 | -1.85e-01 | 0.062300 | 1.12e-01 | 6.09e-02 | 8.99e-03 | 3.79e-01 | 1.13e-01 | 3.89e-01 |
| PRC2 methylates histones and DNA | 11 | 6.68e-01 | 8.93e-01 | 0.2330 | -7.02e-02 | 0.156000 | 1.24e-01 | -9.68e-02 | 6.87e-01 | 3.70e-01 | 4.77e-01 | 5.78e-01 |
| Mitotic Prophase | 61 | 6.44e-02 | 5.07e-01 | 0.2320 | 3.63e-02 | 0.090100 | 2.09e-01 | 3.19e-02 | 6.24e-01 | 2.24e-01 | 4.84e-03 | 6.67e-01 |
| RAF-independent MAPK1/3 activation | 18 | 6.80e-01 | 8.99e-01 | 0.2320 | -1.27e-01 | -0.023300 | 1.26e-01 | 1.47e-01 | 3.53e-01 | 8.64e-01 | 3.56e-01 | 2.81e-01 |
| Abacavir transport and metabolism | 10 | 7.59e-01 | 9.16e-01 | 0.2320 | -1.55e-02 | 0.056100 | 2.16e-02 | 2.24e-01 | 9.32e-01 | 7.59e-01 | 9.06e-01 | 2.21e-01 |
| Sema3A PAK dependent Axon repulsion | 12 | 5.64e-01 | 8.67e-01 | 0.2320 | 1.00e-01 | -0.126000 | 1.51e-01 | 7.18e-02 | 5.48e-01 | 4.51e-01 | 3.66e-01 | 6.67e-01 |
| Signaling by NOTCH3 | 37 | 2.35e-01 | 6.96e-01 | 0.2320 | 1.32e-01 | 0.012100 | -6.81e-02 | -1.77e-01 | 1.64e-01 | 8.98e-01 | 4.73e-01 | 6.23e-02 |
| CS/DS degradation | 11 | 8.21e-01 | 9.36e-01 | 0.2320 | 1.15e-01 | 0.172000 | -8.17e-02 | -6.57e-02 | 5.09e-01 | 3.24e-01 | 6.39e-01 | 7.06e-01 |
| SHC-mediated cascade:FGFR4 | 15 | 3.72e-01 | 7.67e-01 | 0.2310 | -1.67e-01 | 0.094000 | -1.29e-01 | -6.86e-05 | 2.62e-01 | 5.29e-01 | 3.86e-01 | 1.00e+00 |
| Inositol phosphate metabolism | 38 | 2.99e-01 | 7.48e-01 | 0.2310 | -6.09e-02 | -0.089500 | 1.24e-01 | 1.62e-01 | 5.16e-01 | 3.40e-01 | 1.85e-01 | 8.38e-02 |
| Signalling to RAS | 16 | 7.35e-01 | 9.06e-01 | 0.2300 | -4.21e-02 | -0.062400 | 1.39e-01 | 1.68e-01 | 7.71e-01 | 6.66e-01 | 3.36e-01 | 2.46e-01 |
| Plasma lipoprotein assembly | 12 | 8.02e-01 | 9.36e-01 | 0.2300 | -1.38e-01 | -0.047500 | -1.52e-01 | -9.34e-02 | 4.08e-01 | 7.76e-01 | 3.63e-01 | 5.75e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 32 | 4.10e-01 | 7.90e-01 | 0.2300 | 1.56e-01 | 0.163000 | -4.13e-02 | -1.38e-02 | 1.27e-01 | 1.11e-01 | 6.86e-01 | 8.92e-01 |
| Intra-Golgi traffic | 34 | 3.59e-01 | 7.67e-01 | 0.2300 | 1.16e-01 | 0.169000 | 1.34e-02 | -1.03e-01 | 2.42e-01 | 8.90e-02 | 8.92e-01 | 2.98e-01 |
| Reproduction | 63 | 4.02e-02 | 4.38e-01 | 0.2290 | -1.06e-01 | -0.188000 | 3.54e-02 | -6.76e-02 | 1.45e-01 | 9.89e-03 | 6.27e-01 | 3.54e-01 |
| Signaling by WNT in cancer | 27 | 1.60e-01 | 6.58e-01 | 0.2290 | 7.12e-02 | 0.108000 | -1.11e-01 | 1.52e-01 | 5.22e-01 | 3.33e-01 | 3.17e-01 | 1.71e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 21 | 3.29e-01 | 7.66e-01 | 0.2280 | 1.78e-01 | -0.006210 | 1.42e-01 | -1.06e-02 | 1.57e-01 | 9.61e-01 | 2.61e-01 | 9.33e-01 |
| Carboxyterminal post-translational modifications of tubulin | 32 | 2.43e-01 | 7.03e-01 | 0.2270 | -2.32e-02 | -0.222000 | -1.34e-02 | 4.02e-02 | 8.21e-01 | 2.97e-02 | 8.96e-01 | 6.94e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 27 | 1.52e-01 | 6.51e-01 | 0.2270 | -9.41e-02 | 0.040500 | -6.01e-02 | 1.94e-01 | 3.98e-01 | 7.16e-01 | 5.89e-01 | 8.14e-02 |
| G beta:gamma signalling through PI3Kgamma | 17 | 6.05e-01 | 8.75e-01 | 0.2270 | -2.15e-01 | -0.035500 | 5.78e-02 | -2.18e-02 | 1.24e-01 | 8.00e-01 | 6.80e-01 | 8.76e-01 |
| Neurexins and neuroligins | 49 | 3.10e-02 | 4.13e-01 | 0.2270 | 8.69e-02 | 0.056100 | -1.94e-01 | 5.38e-02 | 2.93e-01 | 4.97e-01 | 1.86e-02 | 5.15e-01 |
| Cell-cell junction organization | 45 | 1.79e-01 | 6.71e-01 | 0.2260 | 1.85e-01 | 0.046900 | -1.13e-01 | -4.62e-02 | 3.22e-02 | 5.87e-01 | 1.90e-01 | 5.92e-01 |
| RMTs methylate histone arginines | 26 | 3.40e-01 | 7.67e-01 | 0.2260 | -4.37e-02 | -0.208000 | 6.18e-02 | 4.74e-02 | 7.00e-01 | 6.67e-02 | 5.86e-01 | 6.76e-01 |
| Formation of a pool of free 40S subunits | 38 | 2.64e-01 | 7.26e-01 | 0.2260 | -1.89e-01 | -0.051300 | 1.03e-01 | 4.56e-02 | 4.39e-02 | 5.85e-01 | 2.74e-01 | 6.27e-01 |
| FGFR2 ligand binding and activation | 16 | 6.27e-01 | 8.78e-01 | 0.2250 | 8.53e-02 | 0.200000 | -4.21e-02 | 4.10e-02 | 5.55e-01 | 1.66e-01 | 7.70e-01 | 7.76e-01 |
| Selenocysteine synthesis | 35 | 2.94e-01 | 7.46e-01 | 0.2250 | -1.70e-01 | -0.006560 | 1.27e-01 | 7.46e-02 | 8.13e-02 | 9.47e-01 | 1.94e-01 | 4.45e-01 |
| Dectin-2 family | 15 | 6.53e-01 | 8.86e-01 | 0.2250 | -2.21e-01 | -0.026900 | 6.21e-03 | 3.39e-02 | 1.39e-01 | 8.57e-01 | 9.67e-01 | 8.20e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 41 | 2.17e-01 | 6.84e-01 | 0.2250 | -1.25e-01 | -0.004650 | -9.25e-02 | -1.62e-01 | 1.67e-01 | 9.59e-01 | 3.06e-01 | 7.21e-02 |
| Growth hormone receptor signaling | 18 | 5.02e-01 | 8.33e-01 | 0.2240 | 2.41e-02 | -0.178000 | 5.43e-02 | 1.23e-01 | 8.60e-01 | 1.91e-01 | 6.90e-01 | 3.65e-01 |
| Tight junction interactions | 26 | 2.37e-01 | 6.97e-01 | 0.2240 | 1.53e-01 | -0.127000 | -1.01e-01 | 2.82e-02 | 1.78e-01 | 2.64e-01 | 3.72e-01 | 8.04e-01 |
| Sialic acid metabolism | 27 | 3.40e-01 | 7.67e-01 | 0.2240 | -5.04e-03 | -0.180000 | -1.01e-01 | 8.71e-02 | 9.64e-01 | 1.06e-01 | 3.63e-01 | 4.33e-01 |
| SHC-mediated cascade:FGFR3 | 13 | 6.31e-01 | 8.78e-01 | 0.2240 | -4.59e-02 | 0.189000 | 3.12e-03 | -1.11e-01 | 7.74e-01 | 2.39e-01 | 9.84e-01 | 4.87e-01 |
| Fanconi Anemia Pathway | 23 | 3.65e-01 | 7.67e-01 | 0.2240 | 2.43e-02 | -0.214000 | -3.56e-02 | 4.83e-02 | 8.40e-01 | 7.53e-02 | 7.68e-01 | 6.89e-01 |
| VxPx cargo-targeting to cilium | 15 | 5.17e-01 | 8.47e-01 | 0.2240 | 2.17e-01 | -0.042900 | 3.05e-02 | -8.07e-03 | 1.45e-01 | 7.74e-01 | 8.38e-01 | 9.57e-01 |
| Transcription of the HIV genome | 44 | 2.03e-01 | 6.73e-01 | 0.2230 | 5.36e-02 | -0.064200 | -9.16e-02 | -1.86e-01 | 5.39e-01 | 4.62e-01 | 2.93e-01 | 3.31e-02 |
| G beta:gamma signalling through CDC42 | 13 | 6.59e-01 | 8.91e-01 | 0.2230 | -1.70e-02 | 0.210000 | 1.07e-02 | -7.07e-02 | 9.15e-01 | 1.89e-01 | 9.47e-01 | 6.59e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 10 | 8.41e-01 | 9.43e-01 | 0.2220 | 2.95e-02 | -0.039400 | 1.86e-01 | 1.12e-01 | 8.72e-01 | 8.29e-01 | 3.08e-01 | 5.41e-01 |
| Ovarian tumor domain proteases | 26 | 4.51e-01 | 8.19e-01 | 0.2220 | 7.86e-02 | 0.160000 | 7.32e-02 | -1.11e-01 | 4.88e-01 | 1.58e-01 | 5.18e-01 | 3.29e-01 |
| Basigin interactions | 23 | 6.62e-01 | 8.91e-01 | 0.2220 | 3.22e-03 | -0.093300 | -1.54e-01 | -1.30e-01 | 9.79e-01 | 4.39e-01 | 2.02e-01 | 2.82e-01 |
| NoRC negatively regulates rRNA expression | 26 | 5.83e-01 | 8.70e-01 | 0.2220 | 7.03e-02 | -0.001320 | -1.39e-01 | -1.58e-01 | 5.35e-01 | 9.91e-01 | 2.21e-01 | 1.64e-01 |
| Gap junction assembly | 15 | 6.81e-01 | 8.99e-01 | 0.2210 | -3.60e-02 | -0.106000 | -3.31e-02 | -1.88e-01 | 8.09e-01 | 4.79e-01 | 8.25e-01 | 2.06e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 19 | 3.98e-01 | 7.86e-01 | 0.2210 | 9.70e-02 | 0.044100 | 1.67e-01 | -9.83e-02 | 4.64e-01 | 7.40e-01 | 2.07e-01 | 4.58e-01 |
| Vpr-mediated nuclear import of PICs | 23 | 4.74e-01 | 8.26e-01 | 0.2210 | 9.01e-02 | 0.122000 | 1.42e-01 | -7.68e-02 | 4.55e-01 | 3.12e-01 | 2.40e-01 | 5.24e-01 |
| Phosphorylation of CD3 and TCR zeta chains | 13 | 7.10e-01 | 9.05e-01 | 0.2210 | 1.90e-01 | 0.001850 | -2.93e-02 | -1.10e-01 | 2.36e-01 | 9.91e-01 | 8.55e-01 | 4.94e-01 |
| Sphingolipid de novo biosynthesis | 32 | 2.44e-01 | 7.03e-01 | 0.2210 | -1.73e-01 | 0.018400 | 1.35e-01 | -1.46e-02 | 9.02e-02 | 8.57e-01 | 1.86e-01 | 8.87e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 24 | 3.43e-01 | 7.67e-01 | 0.2210 | 1.63e-01 | 0.011800 | 1.49e-01 | 1.91e-03 | 1.68e-01 | 9.21e-01 | 2.08e-01 | 9.87e-01 |
| Downstream signaling of activated FGFR1 | 26 | 3.67e-01 | 7.67e-01 | 0.2210 | 5.93e-02 | 0.200000 | -1.87e-02 | 7.00e-02 | 6.01e-01 | 7.80e-02 | 8.69e-01 | 5.37e-01 |
| Regulation of IFNG signaling | 10 | 6.97e-01 | 9.01e-01 | 0.2200 | 9.95e-02 | -0.178000 | -3.59e-02 | -7.56e-02 | 5.86e-01 | 3.30e-01 | 8.44e-01 | 6.79e-01 |
| Transport of Mature Transcript to Cytoplasm | 58 | 4.36e-02 | 4.38e-01 | 0.2200 | 7.84e-02 | 0.112000 | 1.35e-01 | -1.08e-01 | 3.02e-01 | 1.41e-01 | 7.57e-02 | 1.54e-01 |
| RNA Polymerase III Transcription Initiation | 23 | 3.97e-01 | 7.86e-01 | 0.2200 | -1.97e-01 | 0.010400 | 8.53e-02 | -4.72e-02 | 1.01e-01 | 9.31e-01 | 4.79e-01 | 6.96e-01 |
| Peptide chain elongation | 33 | 3.90e-01 | 7.79e-01 | 0.2190 | -1.29e-01 | 0.021200 | 1.28e-01 | 1.21e-01 | 2.00e-01 | 8.33e-01 | 2.04e-01 | 2.28e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 20 | 2.86e-01 | 7.37e-01 | 0.2190 | -2.28e-02 | -0.051100 | 1.28e-01 | -1.69e-01 | 8.60e-01 | 6.92e-01 | 3.23e-01 | 1.90e-01 |
| NIK-->noncanonical NF-kB signaling | 38 | 2.37e-01 | 6.96e-01 | 0.2190 | -1.22e-01 | 0.016900 | -7.89e-02 | -1.63e-01 | 1.93e-01 | 8.57e-01 | 4.00e-01 | 8.17e-02 |
| SHC-mediated cascade:FGFR2 | 18 | 3.64e-01 | 7.67e-01 | 0.2190 | -4.82e-02 | 0.199000 | -7.70e-02 | -6.97e-03 | 7.23e-01 | 1.43e-01 | 5.72e-01 | 9.59e-01 |
| Nuclear Envelope (NE) Reassembly | 56 | 2.43e-02 | 4.01e-01 | 0.2190 | -6.58e-02 | 0.000492 | 2.02e-01 | -5.30e-02 | 3.94e-01 | 9.95e-01 | 8.91e-03 | 4.93e-01 |
| Synthesis of PE | 10 | 7.25e-01 | 9.06e-01 | 0.2190 | 7.31e-02 | -0.168000 | 5.43e-02 | 1.07e-01 | 6.89e-01 | 3.58e-01 | 7.66e-01 | 5.59e-01 |
| Downstream signal transduction | 25 | 5.65e-01 | 8.67e-01 | 0.2190 | 4.54e-02 | 0.040400 | 8.63e-02 | 1.92e-01 | 6.94e-01 | 7.27e-01 | 4.55e-01 | 9.70e-02 |
| Acyl chain remodelling of PC | 21 | 6.66e-01 | 8.93e-01 | 0.2180 | -1.10e-01 | -0.185000 | -4.41e-04 | 3.61e-02 | 3.82e-01 | 1.42e-01 | 9.97e-01 | 7.75e-01 |
| NGF-stimulated transcription | 30 | 2.39e-01 | 7.00e-01 | 0.2180 | 1.90e-01 | -0.002710 | 1.06e-01 | 1.88e-02 | 7.23e-02 | 9.80e-01 | 3.14e-01 | 8.58e-01 |
| Processing of SMDT1 | 11 | 8.05e-01 | 9.36e-01 | 0.2180 | -1.79e-02 | -0.139000 | 1.14e-01 | 1.22e-01 | 9.18e-01 | 4.25e-01 | 5.13e-01 | 4.83e-01 |
| NS1 Mediated Effects on Host Pathways | 26 | 3.61e-01 | 7.67e-01 | 0.2180 | 4.81e-05 | 0.153000 | 4.83e-02 | -1.47e-01 | 1.00e+00 | 1.78e-01 | 6.70e-01 | 1.93e-01 |
| Glutathione conjugation | 29 | 3.51e-01 | 7.67e-01 | 0.2170 | -1.92e-01 | -0.014500 | -6.94e-02 | -7.32e-02 | 7.40e-02 | 8.92e-01 | 5.18e-01 | 4.95e-01 |
| CD28 co-stimulation | 28 | 5.13e-01 | 8.43e-01 | 0.2160 | 8.47e-02 | 0.058200 | -7.10e-02 | -1.77e-01 | 4.38e-01 | 5.94e-01 | 5.15e-01 | 1.06e-01 |
| Interferon Signaling | 131 | 8.07e-06 | 1.06e-03 | 0.2160 | 7.17e-02 | 0.030500 | 1.35e-01 | -1.50e-01 | 1.57e-01 | 5.48e-01 | 7.91e-03 | 3.01e-03 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 30 | 4.76e-01 | 8.26e-01 | 0.2160 | 1.98e-01 | 0.087100 | -3.46e-03 | -7.41e-03 | 6.13e-02 | 4.09e-01 | 9.74e-01 | 9.44e-01 |
| Interaction between L1 and Ankyrins | 27 | 4.35e-01 | 8.02e-01 | 0.2160 | 1.89e-01 | 0.031700 | 3.98e-02 | 9.00e-02 | 8.89e-02 | 7.76e-01 | 7.21e-01 | 4.19e-01 |
| Peroxisomal lipid metabolism | 23 | 6.11e-01 | 8.75e-01 | 0.2160 | -1.01e-01 | -0.157000 | -2.88e-02 | -1.03e-01 | 4.02e-01 | 1.92e-01 | 8.11e-01 | 3.91e-01 |
| Nonhomologous End-Joining (NHEJ) | 24 | 2.33e-01 | 6.96e-01 | 0.2150 | -2.17e-02 | -0.067400 | 9.88e-02 | -1.77e-01 | 8.54e-01 | 5.68e-01 | 4.02e-01 | 1.33e-01 |
| FRS-mediated FGFR3 signaling | 14 | 5.20e-01 | 8.49e-01 | 0.2150 | -8.76e-02 | 0.193000 | -5.18e-03 | 3.35e-02 | 5.71e-01 | 2.11e-01 | 9.73e-01 | 8.28e-01 |
| RNA polymerase II transcribes snRNA genes | 46 | 1.95e-01 | 6.71e-01 | 0.2150 | 7.09e-02 | 0.090300 | -1.76e-02 | -1.80e-01 | 4.05e-01 | 2.90e-01 | 8.36e-01 | 3.44e-02 |
| LGI-ADAM interactions | 13 | 7.11e-01 | 9.05e-01 | 0.2150 | 3.57e-03 | -0.158000 | -6.08e-02 | 1.32e-01 | 9.82e-01 | 3.25e-01 | 7.04e-01 | 4.10e-01 |
| Aquaporin-mediated transport | 42 | 1.91e-01 | 6.71e-01 | 0.2140 | -7.30e-02 | -0.049400 | 9.03e-03 | 1.95e-01 | 4.13e-01 | 5.80e-01 | 9.19e-01 | 2.86e-02 |
| Regulation of TP53 Activity | 120 | 4.00e-03 | 1.70e-01 | 0.2140 | 8.09e-03 | -0.131000 | -8.01e-02 | -1.49e-01 | 8.79e-01 | 1.33e-02 | 1.30e-01 | 4.84e-03 |
| PI-3K cascade:FGFR3 | 15 | 5.64e-01 | 8.67e-01 | 0.2140 | -2.71e-02 | 0.202000 | -4.11e-04 | 6.55e-02 | 8.56e-01 | 1.76e-01 | 9.98e-01 | 6.60e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 17 | 5.79e-01 | 8.69e-01 | 0.2140 | 1.59e-02 | 0.022900 | 1.58e-02 | -2.12e-01 | 9.09e-01 | 8.70e-01 | 9.10e-01 | 1.31e-01 |
| Ca-dependent events | 30 | 3.94e-01 | 7.86e-01 | 0.2130 | 1.33e-02 | 0.157000 | 5.66e-02 | 1.32e-01 | 9.00e-01 | 1.36e-01 | 5.92e-01 | 2.13e-01 |
| Acyl chain remodelling of PE | 19 | 6.69e-01 | 8.93e-01 | 0.2130 | -6.58e-02 | -0.188000 | -7.77e-03 | 7.50e-02 | 6.20e-01 | 1.56e-01 | 9.53e-01 | 5.71e-01 |
| mRNA decay by 5' to 3' exoribonuclease | 12 | 6.72e-01 | 8.94e-01 | 0.2130 | 1.07e-01 | -0.081700 | -1.22e-01 | 1.12e-01 | 5.22e-01 | 6.24e-01 | 4.66e-01 | 5.03e-01 |
| Sphingolipid metabolism | 62 | 5.45e-02 | 4.72e-01 | 0.2130 | -1.60e-01 | -0.078700 | 9.06e-02 | -7.15e-02 | 2.92e-02 | 2.84e-01 | 2.18e-01 | 3.31e-01 |
| DAG and IP3 signaling | 34 | 2.97e-01 | 7.47e-01 | 0.2120 | 8.69e-03 | 0.124000 | 4.11e-02 | 1.67e-01 | 9.30e-01 | 2.10e-01 | 6.79e-01 | 9.21e-02 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 24 | 6.39e-01 | 8.81e-01 | 0.2120 | 1.13e-01 | 0.135000 | 4.24e-02 | 1.10e-01 | 3.36e-01 | 2.51e-01 | 7.19e-01 | 3.52e-01 |
| PD-1 signaling | 12 | 7.79e-01 | 9.29e-01 | 0.2110 | -2.40e-02 | -0.201000 | -2.44e-02 | -5.38e-02 | 8.85e-01 | 2.28e-01 | 8.84e-01 | 7.47e-01 |
| Chemokine receptors bind chemokines | 37 | 3.12e-01 | 7.52e-01 | 0.2110 | 2.58e-02 | 0.129000 | -5.17e-02 | -1.57e-01 | 7.86e-01 | 1.75e-01 | 5.86e-01 | 9.94e-02 |
| Protein-protein interactions at synapses | 72 | 3.09e-02 | 4.13e-01 | 0.2100 | 1.12e-01 | 0.053800 | -1.70e-01 | -3.50e-03 | 1.01e-01 | 4.31e-01 | 1.28e-02 | 9.59e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 30 | 5.59e-01 | 8.67e-01 | 0.2100 | -1.26e-01 | -0.158000 | 5.36e-03 | 5.68e-02 | 2.31e-01 | 1.34e-01 | 9.60e-01 | 5.90e-01 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 42 | 2.67e-01 | 7.26e-01 | 0.2100 | -1.46e-01 | -0.005950 | 1.41e-01 | 5.43e-02 | 1.03e-01 | 9.47e-01 | 1.14e-01 | 5.43e-01 |
| Extension of Telomeres | 35 | 3.14e-01 | 7.52e-01 | 0.2100 | -2.22e-02 | -0.126000 | 1.26e-01 | 1.08e-01 | 8.20e-01 | 1.96e-01 | 1.98e-01 | 2.68e-01 |
| FOXO-mediated transcription | 54 | 1.89e-01 | 6.71e-01 | 0.2090 | 6.69e-02 | 0.173000 | 4.29e-02 | 8.62e-02 | 3.95e-01 | 2.78e-02 | 5.86e-01 | 2.74e-01 |
| Interactions of Rev with host cellular proteins | 25 | 3.65e-01 | 7.67e-01 | 0.2090 | -4.42e-02 | 0.122000 | 1.32e-01 | -9.62e-02 | 7.02e-01 | 2.90e-01 | 2.53e-01 | 4.05e-01 |
| Signaling by ERBB2 | 35 | 4.08e-01 | 7.90e-01 | 0.2090 | 2.58e-02 | 0.088600 | -8.85e-02 | -1.65e-01 | 7.92e-01 | 3.65e-01 | 3.65e-01 | 9.13e-02 |
| Phospholipase C-mediated cascade; FGFR4 | 12 | 6.06e-01 | 8.75e-01 | 0.2080 | -1.10e-01 | 0.017200 | -1.16e-01 | 1.32e-01 | 5.09e-01 | 9.18e-01 | 4.86e-01 | 4.27e-01 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 49 | 2.56e-01 | 7.17e-01 | 0.2080 | 6.52e-03 | 0.091000 | 1.81e-01 | 4.70e-02 | 9.37e-01 | 2.71e-01 | 2.83e-02 | 5.70e-01 |
| Nonsense-Mediated Decay (NMD) | 49 | 2.56e-01 | 7.17e-01 | 0.2080 | 6.52e-03 | 0.091000 | 1.81e-01 | 4.70e-02 | 9.37e-01 | 2.71e-01 | 2.83e-02 | 5.70e-01 |
| Loss of Nlp from mitotic centrosomes | 55 | 1.07e-01 | 6.04e-01 | 0.2080 | 1.71e-01 | 0.048400 | 1.08e-01 | -4.63e-03 | 2.79e-02 | 5.35e-01 | 1.68e-01 | 9.53e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 55 | 1.07e-01 | 6.04e-01 | 0.2080 | 1.71e-01 | 0.048400 | 1.08e-01 | -4.63e-03 | 2.79e-02 | 5.35e-01 | 1.68e-01 | 9.53e-01 |
| SUMOylation of DNA methylation proteins | 15 | 6.30e-01 | 8.78e-01 | 0.2080 | 5.26e-02 | -0.137000 | 1.03e-01 | 1.05e-01 | 7.24e-01 | 3.57e-01 | 4.90e-01 | 4.80e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 23 | 6.71e-01 | 8.94e-01 | 0.2080 | 1.68e-01 | 0.111000 | -4.67e-02 | -2.13e-02 | 1.62e-01 | 3.58e-01 | 6.98e-01 | 8.60e-01 |
| G alpha (z) signalling events | 36 | 3.27e-01 | 7.66e-01 | 0.2080 | -1.28e-01 | 0.042600 | 9.03e-02 | 1.29e-01 | 1.83e-01 | 6.59e-01 | 3.49e-01 | 1.79e-01 |
| Signaling by FGFR4 | 30 | 2.55e-01 | 7.17e-01 | 0.2080 | -6.10e-03 | 0.205000 | -1.61e-02 | 2.51e-02 | 9.54e-01 | 5.16e-02 | 8.79e-01 | 8.12e-01 |
| Synthesis of substrates in N-glycan biosythesis | 50 | 7.96e-02 | 5.61e-01 | 0.2070 | 2.16e-02 | -0.199000 | -3.57e-03 | 5.28e-02 | 7.91e-01 | 1.49e-02 | 9.65e-01 | 5.19e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 24 | 2.18e-01 | 6.84e-01 | 0.2070 | 7.15e-02 | -0.067400 | 1.72e-01 | -6.09e-02 | 5.44e-01 | 5.68e-01 | 1.46e-01 | 6.06e-01 |
| Fatty acyl-CoA biosynthesis | 27 | 4.71e-01 | 8.26e-01 | 0.2070 | 5.75e-02 | 0.010400 | 1.90e-01 | 5.62e-02 | 6.05e-01 | 9.25e-01 | 8.75e-02 | 6.14e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 18 | 5.49e-01 | 8.61e-01 | 0.2060 | -4.18e-02 | -0.080300 | 1.85e-01 | 5.38e-03 | 7.59e-01 | 5.56e-01 | 1.74e-01 | 9.68e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 60 | 6.50e-02 | 5.07e-01 | 0.2060 | -1.96e-01 | -0.005290 | 3.97e-02 | -4.89e-02 | 8.65e-03 | 9.44e-01 | 5.96e-01 | 5.13e-01 |
| FGFR1 mutant receptor activation | 26 | 6.32e-01 | 8.80e-01 | 0.2060 | 3.56e-02 | 0.059400 | 9.19e-02 | 1.71e-01 | 7.53e-01 | 6.00e-01 | 4.18e-01 | 1.32e-01 |
| Negative regulation of FGFR3 signaling | 21 | 6.71e-01 | 8.94e-01 | 0.2060 | 4.66e-02 | 0.185000 | 7.67e-02 | -1.63e-02 | 7.12e-01 | 1.43e-01 | 5.43e-01 | 8.97e-01 |
| Gap junction trafficking | 23 | 2.81e-01 | 7.34e-01 | 0.2060 | 5.42e-02 | -0.064300 | 7.08e-02 | -1.74e-01 | 6.53e-01 | 5.94e-01 | 5.57e-01 | 1.49e-01 |
| Activation of the pre-replicative complex | 23 | 3.77e-01 | 7.68e-01 | 0.2060 | 1.53e-01 | 0.011600 | 8.08e-02 | -1.10e-01 | 2.04e-01 | 9.23e-01 | 5.03e-01 | 3.59e-01 |
| Termination of translesion DNA synthesis | 21 | 5.26e-01 | 8.49e-01 | 0.2060 | -7.15e-03 | -0.202000 | 5.63e-03 | 3.96e-02 | 9.55e-01 | 1.10e-01 | 9.64e-01 | 7.54e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 30 | 6.27e-01 | 8.78e-01 | 0.2050 | 7.82e-02 | 0.145000 | 1.13e-01 | 4.70e-02 | 4.59e-01 | 1.71e-01 | 2.86e-01 | 6.56e-01 |
| CYP2E1 reactions | 10 | 7.89e-01 | 9.32e-01 | 0.2050 | -5.11e-02 | 0.122000 | 9.22e-02 | -1.26e-01 | 7.80e-01 | 5.03e-01 | 6.14e-01 | 4.92e-01 |
| Effects of PIP2 hydrolysis | 20 | 7.36e-01 | 9.06e-01 | 0.2040 | 4.41e-02 | -0.090000 | -1.38e-01 | -1.13e-01 | 7.33e-01 | 4.86e-01 | 2.87e-01 | 3.82e-01 |
| Calnexin/calreticulin cycle | 14 | 7.45e-01 | 9.09e-01 | 0.2040 | 9.04e-02 | -0.034000 | -4.05e-02 | -1.75e-01 | 5.58e-01 | 8.26e-01 | 7.93e-01 | 2.56e-01 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 35 | 4.76e-01 | 8.26e-01 | 0.2040 | -1.24e-01 | -0.063600 | -6.98e-02 | -1.32e-01 | 2.04e-01 | 5.15e-01 | 4.75e-01 | 1.78e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 23 | 5.97e-01 | 8.75e-01 | 0.2030 | 3.50e-02 | 0.149000 | 1.26e-01 | -4.55e-02 | 7.71e-01 | 2.15e-01 | 2.97e-01 | 7.06e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 20 | 6.08e-01 | 8.75e-01 | 0.2030 | -1.98e-02 | 0.022200 | -1.93e-01 | -5.62e-02 | 8.78e-01 | 8.63e-01 | 1.35e-01 | 6.63e-01 |
| rRNA modification in the nucleus and cytosol | 43 | 3.42e-01 | 7.67e-01 | 0.2030 | -1.86e-01 | -0.079400 | -1.90e-02 | 3.90e-03 | 3.51e-02 | 3.68e-01 | 8.29e-01 | 9.65e-01 |
| AURKA Activation by TPX2 | 57 | 8.99e-02 | 5.78e-01 | 0.2030 | 1.59e-01 | 0.032900 | 1.22e-01 | 2.17e-03 | 3.84e-02 | 6.68e-01 | 1.11e-01 | 9.77e-01 |
| Keratinization | 93 | 2.16e-03 | 1.19e-01 | 0.2030 | 8.50e-02 | -0.178000 | -4.61e-02 | 7.43e-03 | 1.57e-01 | 3.02e-03 | 4.43e-01 | 9.02e-01 |
| Metabolic disorders of biological oxidation enzymes | 29 | 4.25e-01 | 7.93e-01 | 0.2030 | 8.30e-02 | 0.009450 | -1.84e-01 | -1.94e-02 | 4.39e-01 | 9.30e-01 | 8.69e-02 | 8.57e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 40 | 1.95e-01 | 6.71e-01 | 0.2030 | -1.19e-01 | -0.104000 | 9.21e-02 | -8.78e-02 | 1.94e-01 | 2.55e-01 | 3.14e-01 | 3.37e-01 |
| tRNA modification in the nucleus and cytosol | 28 | 5.35e-01 | 8.53e-01 | 0.2030 | -1.34e-01 | -0.121000 | 9.08e-02 | 9.56e-03 | 2.19e-01 | 2.66e-01 | 4.06e-01 | 9.30e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 68 | 9.74e-03 | 2.57e-01 | 0.2020 | -1.07e-02 | -0.126000 | 5.90e-02 | -1.46e-01 | 8.79e-01 | 7.16e-02 | 4.01e-01 | 3.72e-02 |
| G beta:gamma signalling through BTK | 11 | 7.81e-01 | 9.29e-01 | 0.2020 | -1.37e-01 | 0.108000 | 9.63e-02 | 3.29e-02 | 4.30e-01 | 5.33e-01 | 5.80e-01 | 8.50e-01 |
| Signaling by SCF-KIT | 34 | 1.99e-01 | 6.73e-01 | 0.2020 | 1.51e-01 | -0.081100 | 4.95e-02 | 9.46e-02 | 1.27e-01 | 4.13e-01 | 6.17e-01 | 3.40e-01 |
| Nuclear signaling by ERBB4 | 25 | 6.62e-01 | 8.91e-01 | 0.2020 | 9.79e-02 | 0.005290 | -1.17e-01 | -1.33e-01 | 3.97e-01 | 9.63e-01 | 3.13e-01 | 2.51e-01 |
| Generation of second messenger molecules | 22 | 3.59e-01 | 7.67e-01 | 0.2020 | 1.54e-03 | -0.020400 | 1.90e-01 | -6.59e-02 | 9.90e-01 | 8.69e-01 | 1.24e-01 | 5.93e-01 |
| Synthesis of PIPs at the Golgi membrane | 14 | 8.10e-01 | 9.36e-01 | 0.2010 | 5.66e-02 | 0.184000 | 1.14e-02 | -5.74e-02 | 7.14e-01 | 2.33e-01 | 9.41e-01 | 7.10e-01 |
| Triglyceride biosynthesis | 10 | 8.10e-01 | 9.36e-01 | 0.2010 | -1.43e-01 | -0.001350 | 6.85e-02 | -1.24e-01 | 4.34e-01 | 9.94e-01 | 7.07e-01 | 4.98e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 44 | 1.31e-01 | 6.32e-01 | 0.2010 | 5.37e-02 | 0.046100 | -1.88e-01 | 1.37e-02 | 5.38e-01 | 5.97e-01 | 3.14e-02 | 8.76e-01 |
| Regulation of MECP2 expression and activity | 23 | 7.32e-01 | 9.06e-01 | 0.2010 | 4.78e-02 | 0.145000 | 1.20e-01 | 5.36e-02 | 6.92e-01 | 2.30e-01 | 3.21e-01 | 6.57e-01 |
| RNA Polymerase I Promoter Escape | 17 | 8.08e-01 | 9.36e-01 | 0.2010 | -4.32e-06 | -0.128000 | -1.21e-01 | -9.51e-02 | 1.00e+00 | 3.60e-01 | 3.86e-01 | 4.97e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 29 | 1.95e-01 | 6.71e-01 | 0.2000 | 1.02e-02 | -0.009360 | 1.29e-01 | -1.52e-01 | 9.24e-01 | 9.30e-01 | 2.28e-01 | 1.56e-01 |
| Diseases of mitotic cell cycle | 29 | 1.95e-01 | 6.71e-01 | 0.2000 | 1.02e-02 | -0.009360 | 1.29e-01 | -1.52e-01 | 9.24e-01 | 9.30e-01 | 2.28e-01 | 1.56e-01 |
| Complex I biogenesis | 34 | 1.72e-01 | 6.68e-01 | 0.2000 | -1.73e-01 | 0.097700 | 2.56e-02 | 5.40e-03 | 8.14e-02 | 3.25e-01 | 7.96e-01 | 9.57e-01 |
| RA biosynthesis pathway | 18 | 6.88e-01 | 8.99e-01 | 0.2000 | 1.22e-01 | -0.019900 | 1.02e-01 | 1.20e-01 | 3.72e-01 | 8.84e-01 | 4.53e-01 | 3.77e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 63 | 2.03e-01 | 6.73e-01 | 0.2000 | 1.06e-01 | 0.086000 | 1.41e-01 | 3.86e-02 | 1.46e-01 | 2.38e-01 | 5.38e-02 | 5.97e-01 |
| Dopamine Neurotransmitter Release Cycle | 15 | 7.54e-01 | 9.13e-01 | 0.2000 | 8.96e-02 | 0.163000 | -7.10e-02 | 1.28e-02 | 5.48e-01 | 2.74e-01 | 6.34e-01 | 9.32e-01 |
| ERKs are inactivated | 11 | 8.61e-01 | 9.46e-01 | 0.2000 | -1.05e-01 | -0.083500 | 1.44e-01 | 3.40e-02 | 5.47e-01 | 6.31e-01 | 4.08e-01 | 8.45e-01 |
| Post-chaperonin tubulin folding pathway | 20 | 4.99e-01 | 8.33e-01 | 0.1990 | -3.55e-02 | -0.107000 | 1.64e-01 | -1.91e-04 | 7.84e-01 | 4.07e-01 | 2.03e-01 | 9.99e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 44 | 3.46e-01 | 7.67e-01 | 0.1990 | -1.02e-01 | -0.077000 | -4.45e-02 | -1.46e-01 | 2.42e-01 | 3.77e-01 | 6.10e-01 | 9.40e-02 |
| Degradation of AXIN | 36 | 4.04e-01 | 7.89e-01 | 0.1990 | -1.26e-01 | -0.048300 | -3.23e-02 | -1.43e-01 | 1.92e-01 | 6.16e-01 | 7.38e-01 | 1.38e-01 |
| Phase II - Conjugation of compounds | 79 | 3.38e-02 | 4.13e-01 | 0.1990 | 3.19e-02 | 0.195000 | -1.14e-02 | -1.63e-02 | 6.24e-01 | 2.72e-03 | 8.61e-01 | 8.03e-01 |
| PI3K Cascade | 37 | 1.86e-01 | 6.71e-01 | 0.1990 | 2.38e-02 | -0.009190 | -1.92e-01 | 4.46e-02 | 8.02e-01 | 9.23e-01 | 4.34e-02 | 6.39e-01 |
| HDACs deacetylate histones | 22 | 4.61e-01 | 8.26e-01 | 0.1990 | 4.27e-03 | -0.192000 | 4.75e-02 | 2.08e-02 | 9.72e-01 | 1.20e-01 | 7.00e-01 | 8.66e-01 |
| Negative regulation of FGFR2 signaling | 26 | 4.79e-01 | 8.26e-01 | 0.1990 | 2.72e-02 | 0.193000 | 7.03e-03 | 3.78e-02 | 8.10e-01 | 8.87e-02 | 9.51e-01 | 7.39e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 18 | 6.16e-01 | 8.78e-01 | 0.1980 | -2.92e-02 | -0.106000 | -1.00e-01 | 1.31e-01 | 8.30e-01 | 4.36e-01 | 4.63e-01 | 3.36e-01 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 35 | 4.96e-01 | 8.31e-01 | 0.1980 | -6.39e-02 | 0.070700 | 1.41e-01 | 1.01e-01 | 5.13e-01 | 4.69e-01 | 1.48e-01 | 3.00e-01 |
| Eukaryotic Translation Elongation | 36 | 4.94e-01 | 8.31e-01 | 0.1980 | -8.99e-02 | 0.024700 | 1.33e-01 | 1.13e-01 | 3.51e-01 | 7.98e-01 | 1.69e-01 | 2.41e-01 |
| PLC beta mediated events | 45 | 2.44e-01 | 7.03e-01 | 0.1980 | 9.25e-02 | 0.125000 | -1.08e-02 | 1.21e-01 | 2.83e-01 | 1.47e-01 | 9.00e-01 | 1.59e-01 |
| GABA receptor activation | 43 | 6.95e-02 | 5.27e-01 | 0.1970 | -3.95e-02 | 0.172000 | -4.68e-02 | 7.42e-02 | 6.54e-01 | 5.05e-02 | 5.95e-01 | 4.00e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 13 | 6.98e-01 | 9.01e-01 | 0.1970 | 4.02e-03 | 0.095100 | -1.72e-01 | -1.38e-02 | 9.80e-01 | 5.53e-01 | 2.82e-01 | 9.31e-01 |
| G-protein mediated events | 46 | 2.18e-01 | 6.84e-01 | 0.1970 | 1.00e-01 | 0.121000 | -2.55e-02 | 1.17e-01 | 2.40e-01 | 1.57e-01 | 7.65e-01 | 1.71e-01 |
| Diseases associated with visual transduction | 11 | 8.70e-01 | 9.50e-01 | 0.1970 | -5.09e-02 | 0.131000 | 1.25e-01 | 5.78e-02 | 7.70e-01 | 4.51e-01 | 4.73e-01 | 7.40e-01 |
| Diseases of the neuronal system | 11 | 8.70e-01 | 9.50e-01 | 0.1970 | -5.09e-02 | 0.131000 | 1.25e-01 | 5.78e-02 | 7.70e-01 | 4.51e-01 | 4.73e-01 | 7.40e-01 |
| Retinoid cycle disease events | 11 | 8.70e-01 | 9.50e-01 | 0.1970 | -5.09e-02 | 0.131000 | 1.25e-01 | 5.78e-02 | 7.70e-01 | 4.51e-01 | 4.73e-01 | 7.40e-01 |
| Reversible hydration of carbon dioxide | 10 | 9.15e-01 | 9.68e-01 | 0.1970 | 6.91e-02 | 0.107000 | -9.28e-02 | -1.18e-01 | 7.05e-01 | 5.57e-01 | 6.11e-01 | 5.20e-01 |
| PKMTs methylate histone lysines | 32 | 1.69e-01 | 6.67e-01 | 0.1970 | 1.68e-01 | -0.095700 | 3.17e-02 | -1.66e-02 | 1.00e-01 | 3.49e-01 | 7.57e-01 | 8.71e-01 |
| Transport of the SLBP Dependant Mature mRNA | 24 | 4.90e-01 | 8.26e-01 | 0.1970 | 3.70e-02 | 0.107000 | 1.07e-01 | -1.20e-01 | 7.54e-01 | 3.66e-01 | 3.65e-01 | 3.08e-01 |
| MAP kinase activation | 49 | 1.98e-01 | 6.73e-01 | 0.1970 | -8.12e-03 | 0.180000 | 6.75e-02 | 4.18e-02 | 9.22e-01 | 2.98e-02 | 4.14e-01 | 6.13e-01 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 43 | 3.47e-01 | 7.67e-01 | 0.1960 | -1.26e-01 | 0.004500 | 1.33e-01 | 7.00e-02 | 1.53e-01 | 9.59e-01 | 1.31e-01 | 4.28e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 22 | 6.46e-01 | 8.84e-01 | 0.1960 | -7.77e-03 | 0.128000 | 1.48e-01 | -6.28e-03 | 9.50e-01 | 2.97e-01 | 2.30e-01 | 9.59e-01 |
| Phospholipase C-mediated cascade; FGFR2 | 15 | 6.23e-01 | 8.78e-01 | 0.1960 | 2.15e-02 | 0.159000 | -5.60e-02 | 9.76e-02 | 8.86e-01 | 2.87e-01 | 7.07e-01 | 5.13e-01 |
| PCP/CE pathway | 65 | 8.71e-02 | 5.77e-01 | 0.1960 | -1.32e-01 | -0.096100 | 1.00e-01 | -4.07e-02 | 6.61e-02 | 1.81e-01 | 1.62e-01 | 5.71e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 37 | 2.89e-01 | 7.37e-01 | 0.1960 | -1.56e-01 | 0.016900 | -3.16e-02 | -1.13e-01 | 1.02e-01 | 8.59e-01 | 7.39e-01 | 2.34e-01 |
| Signaling by TGFB family members | 76 | 1.21e-01 | 6.22e-01 | 0.1950 | 1.10e-01 | 0.126000 | -8.48e-02 | -5.67e-02 | 9.89e-02 | 5.85e-02 | 2.02e-01 | 3.93e-01 |
| IGF1R signaling cascade | 43 | 1.57e-01 | 6.51e-01 | 0.1950 | 3.97e-02 | 0.048300 | -1.85e-01 | 8.31e-03 | 6.53e-01 | 5.84e-01 | 3.61e-02 | 9.25e-01 |
| Purine catabolism | 14 | 7.33e-01 | 9.06e-01 | 0.1950 | -1.32e-01 | 0.011500 | -1.38e-01 | -4.09e-02 | 3.94e-01 | 9.41e-01 | 3.72e-01 | 7.91e-01 |
| NR1H2 and NR1H3-mediated signaling | 40 | 4.04e-01 | 7.89e-01 | 0.1950 | -7.67e-02 | -0.153000 | 5.15e-02 | 7.83e-02 | 4.01e-01 | 9.43e-02 | 5.73e-01 | 3.92e-01 |
| BBSome-mediated cargo-targeting to cilium | 18 | 5.63e-01 | 8.67e-01 | 0.1950 | -9.30e-02 | 0.161000 | 5.56e-02 | 1.86e-02 | 4.95e-01 | 2.38e-01 | 6.83e-01 | 8.91e-01 |
| activated TAK1 mediates p38 MAPK activation | 14 | 5.67e-01 | 8.67e-01 | 0.1950 | -1.13e-01 | 0.095400 | -5.01e-02 | 1.17e-01 | 4.65e-01 | 5.37e-01 | 7.46e-01 | 4.50e-01 |
| Meiosis | 44 | 9.16e-02 | 5.78e-01 | 0.1930 | -3.28e-02 | -0.129000 | 1.28e-01 | -5.74e-02 | 7.06e-01 | 1.39e-01 | 1.42e-01 | 5.10e-01 |
| Viral mRNA Translation | 33 | 4.15e-01 | 7.90e-01 | 0.1930 | -1.51e-01 | 0.034700 | 8.87e-02 | 7.42e-02 | 1.34e-01 | 7.30e-01 | 3.78e-01 | 4.61e-01 |
| Assembly of collagen fibrils and other multimeric structures | 44 | 2.79e-01 | 7.33e-01 | 0.1930 | -3.26e-02 | -0.100000 | -1.59e-01 | 2.92e-02 | 7.08e-01 | 2.50e-01 | 6.90e-02 | 7.38e-01 |
| DNA Damage Recognition in GG-NER | 25 | 3.79e-01 | 7.68e-01 | 0.1920 | 3.56e-02 | 0.058400 | -6.39e-02 | 1.67e-01 | 7.58e-01 | 6.13e-01 | 5.81e-01 | 1.48e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 15 | 6.22e-01 | 8.78e-01 | 0.1920 | 1.23e-01 | -0.065400 | 1.72e-02 | -1.31e-01 | 4.10e-01 | 6.61e-01 | 9.08e-01 | 3.81e-01 |
| Metabolism of steroid hormones | 29 | 4.73e-01 | 8.26e-01 | 0.1910 | 3.64e-02 | -0.059500 | -1.78e-01 | 4.86e-03 | 7.34e-01 | 5.79e-01 | 9.70e-02 | 9.64e-01 |
| Rev-mediated nuclear export of HIV RNA | 24 | 5.32e-01 | 8.52e-01 | 0.1910 | -1.31e-02 | 0.109000 | 1.44e-01 | -6.07e-02 | 9.12e-01 | 3.54e-01 | 2.21e-01 | 6.07e-01 |
| SRP-dependent cotranslational protein targeting to membrane | 48 | 3.75e-01 | 7.68e-01 | 0.1910 | -1.22e-01 | -0.031600 | 1.06e-01 | 9.69e-02 | 1.43e-01 | 7.05e-01 | 2.05e-01 | 2.46e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 19 | 5.84e-01 | 8.70e-01 | 0.1910 | -1.81e-01 | 0.041300 | 1.76e-02 | 3.87e-02 | 1.71e-01 | 7.55e-01 | 8.94e-01 | 7.70e-01 |
| Selenoamino acid metabolism | 47 | 2.69e-01 | 7.26e-01 | 0.1910 | -1.67e-01 | -0.010100 | 8.60e-02 | 3.11e-02 | 4.77e-02 | 9.04e-01 | 3.08e-01 | 7.13e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 25 | 7.38e-01 | 9.06e-01 | 0.1910 | 6.34e-02 | 0.141000 | 1.09e-01 | 2.56e-02 | 5.83e-01 | 2.23e-01 | 3.47e-01 | 8.25e-01 |
| Signaling by NOTCH1 | 54 | 2.17e-01 | 6.84e-01 | 0.1910 | 1.70e-01 | 0.043100 | -7.50e-02 | 3.39e-03 | 3.11e-02 | 5.84e-01 | 3.41e-01 | 9.66e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 13 | 7.75e-01 | 9.27e-01 | 0.1910 | 5.75e-02 | 0.055600 | 4.77e-02 | -1.66e-01 | 7.20e-01 | 7.29e-01 | 7.66e-01 | 3.00e-01 |
| PPARA activates gene expression | 95 | 3.49e-02 | 4.19e-01 | 0.1900 | 6.24e-02 | 0.129000 | 9.21e-02 | -8.53e-02 | 2.94e-01 | 3.03e-02 | 1.21e-01 | 1.51e-01 |
| Arachidonic acid metabolism | 43 | 4.25e-01 | 7.93e-01 | 0.1900 | 9.97e-03 | -0.034700 | 1.35e-01 | 1.29e-01 | 9.10e-01 | 6.94e-01 | 1.27e-01 | 1.43e-01 |
| Transcriptional regulation of pluripotent stem cells | 22 | 4.82e-01 | 8.26e-01 | 0.1900 | 9.88e-02 | -0.120000 | -3.25e-02 | 1.05e-01 | 4.22e-01 | 3.32e-01 | 7.92e-01 | 3.95e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 49 | 3.62e-01 | 7.67e-01 | 0.1900 | -4.38e-02 | -0.078800 | -6.76e-02 | -1.53e-01 | 5.96e-01 | 3.40e-01 | 4.13e-01 | 6.42e-02 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 20 | 6.44e-01 | 8.83e-01 | 0.1900 | -8.00e-02 | -0.073400 | -4.75e-02 | 1.48e-01 | 5.36e-01 | 5.70e-01 | 7.13e-01 | 2.51e-01 |
| Late Phase of HIV Life Cycle | 86 | 5.36e-02 | 4.71e-01 | 0.1900 | 3.92e-02 | -0.019000 | -4.34e-02 | -1.80e-01 | 5.30e-01 | 7.61e-01 | 4.87e-01 | 4.04e-03 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 25 | 5.40e-01 | 8.56e-01 | 0.1900 | -2.30e-02 | 0.084400 | 1.66e-01 | -2.85e-02 | 8.42e-01 | 4.65e-01 | 1.51e-01 | 8.05e-01 |
| Platelet sensitization by LDL | 15 | 8.95e-01 | 9.63e-01 | 0.1890 | -9.22e-02 | -0.111000 | -1.12e-01 | -4.83e-02 | 5.37e-01 | 4.56e-01 | 4.52e-01 | 7.46e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 65 | 1.01e-01 | 5.99e-01 | 0.1890 | 1.01e-01 | -0.015500 | 1.42e-01 | 7.22e-02 | 1.61e-01 | 8.29e-01 | 4.80e-02 | 3.15e-01 |
| RORA activates gene expression | 16 | 6.65e-01 | 8.93e-01 | 0.1880 | -4.34e-02 | 0.066000 | 1.48e-01 | -8.49e-02 | 7.64e-01 | 6.47e-01 | 3.06e-01 | 5.56e-01 |
| Regulation of TP53 Activity through Phosphorylation | 66 | 2.67e-01 | 7.26e-01 | 0.1880 | -1.28e-03 | -0.109000 | -1.26e-01 | -8.63e-02 | 9.86e-01 | 1.26e-01 | 7.62e-02 | 2.26e-01 |
| Golgi Associated Vesicle Biogenesis | 37 | 2.14e-01 | 6.84e-01 | 0.1870 | 1.19e-01 | 0.019700 | 1.09e-01 | -9.26e-02 | 2.09e-01 | 8.36e-01 | 2.52e-01 | 3.30e-01 |
| Signaling by PDGF | 46 | 1.81e-01 | 6.71e-01 | 0.1870 | 1.23e-01 | 0.002400 | -4.88e-02 | 1.32e-01 | 1.50e-01 | 9.78e-01 | 5.67e-01 | 1.21e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 19 | 7.68e-01 | 9.21e-01 | 0.1870 | -9.56e-03 | -0.087100 | -5.98e-02 | -1.54e-01 | 9.43e-01 | 5.11e-01 | 6.52e-01 | 2.46e-01 |
| RUNX2 regulates osteoblast differentiation | 18 | 8.36e-01 | 9.40e-01 | 0.1870 | 4.42e-02 | 0.104000 | 1.44e-01 | 3.57e-02 | 7.46e-01 | 4.47e-01 | 2.89e-01 | 7.93e-01 |
| Keratan sulfate biosynthesis | 21 | 6.57e-01 | 8.90e-01 | 0.1860 | -4.95e-02 | -0.084700 | 1.52e-01 | 4.20e-02 | 6.94e-01 | 5.02e-01 | 2.27e-01 | 7.39e-01 |
| Recruitment of NuMA to mitotic centrosomes | 64 | 6.45e-02 | 5.07e-01 | 0.1860 | 1.40e-01 | 0.029500 | 8.94e-02 | -7.88e-02 | 5.36e-02 | 6.83e-01 | 2.16e-01 | 2.76e-01 |
| Regulation of lipid metabolism by PPARalpha | 97 | 4.34e-02 | 4.38e-01 | 0.1860 | 5.89e-02 | 0.133000 | 7.35e-02 | -8.90e-02 | 3.17e-01 | 2.40e-02 | 2.12e-01 | 1.30e-01 |
| Ca2+ pathway | 52 | 4.00e-01 | 7.87e-01 | 0.1860 | -1.22e-02 | 0.076100 | 1.08e-01 | 1.30e-01 | 8.79e-01 | 3.43e-01 | 1.78e-01 | 1.06e-01 |
| Telomere Maintenance | 42 | 1.83e-01 | 6.71e-01 | 0.1850 | -8.32e-04 | -0.155000 | 9.76e-02 | 2.65e-02 | 9.93e-01 | 8.14e-02 | 2.74e-01 | 7.66e-01 |
| IRS-mediated signalling | 39 | 2.03e-01 | 6.73e-01 | 0.1850 | 1.31e-02 | 0.020600 | -1.81e-01 | 3.42e-02 | 8.87e-01 | 8.24e-01 | 5.11e-02 | 7.12e-01 |
| IRS-related events triggered by IGF1R | 42 | 1.74e-01 | 6.71e-01 | 0.1850 | 3.20e-02 | 0.047000 | -1.74e-01 | 2.84e-02 | 7.20e-01 | 5.98e-01 | 5.09e-02 | 7.50e-01 |
| Interactions of Vpr with host cellular proteins | 25 | 6.28e-01 | 8.78e-01 | 0.1850 | 3.34e-02 | 0.147000 | 7.92e-02 | -7.17e-02 | 7.73e-01 | 2.02e-01 | 4.93e-01 | 5.35e-01 |
| The phototransduction cascade | 24 | 7.00e-01 | 9.02e-01 | 0.1850 | -6.47e-02 | -0.154000 | 1.76e-02 | 7.69e-02 | 5.83e-01 | 1.91e-01 | 8.81e-01 | 5.15e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 22 | 5.96e-01 | 8.75e-01 | 0.1840 | -5.39e-02 | 0.139000 | 5.27e-02 | 9.40e-02 | 6.62e-01 | 2.60e-01 | 6.69e-01 | 4.45e-01 |
| Antigen processing-Cross presentation | 66 | 3.12e-01 | 7.52e-01 | 0.1840 | 2.07e-02 | -0.017200 | -1.36e-01 | -1.20e-01 | 7.71e-01 | 8.09e-01 | 5.60e-02 | 9.15e-02 |
| Homology Directed Repair | 72 | 1.58e-02 | 3.26e-01 | 0.1830 | 1.11e-02 | -0.094400 | 5.75e-02 | -1.46e-01 | 8.70e-01 | 1.67e-01 | 4.00e-01 | 3.23e-02 |
| RHO GTPases activate PAKs | 18 | 8.09e-01 | 9.36e-01 | 0.1830 | -4.00e-02 | -0.095800 | 9.98e-02 | 1.14e-01 | 7.69e-01 | 4.82e-01 | 4.64e-01 | 4.03e-01 |
| Phase I - Functionalization of compounds | 83 | 2.03e-01 | 6.73e-01 | 0.1830 | 6.49e-02 | 0.131000 | 1.06e-01 | 2.86e-02 | 3.07e-01 | 3.90e-02 | 9.49e-02 | 6.53e-01 |
| G2/M DNA damage checkpoint | 43 | 1.79e-01 | 6.71e-01 | 0.1830 | -5.25e-02 | -0.002130 | 6.41e-02 | -1.63e-01 | 5.52e-01 | 9.81e-01 | 4.67e-01 | 6.49e-02 |
| Stabilization of p53 | 38 | 4.70e-01 | 8.26e-01 | 0.1820 | -6.89e-02 | -0.060900 | -3.33e-02 | -1.54e-01 | 4.63e-01 | 5.16e-01 | 7.22e-01 | 1.01e-01 |
| Activation of NMDA receptors and postsynaptic events | 61 | 1.17e-01 | 6.22e-01 | 0.1820 | 4.66e-02 | 0.166000 | -5.75e-02 | 1.28e-02 | 5.30e-01 | 2.54e-02 | 4.38e-01 | 8.63e-01 |
| Chaperonin-mediated protein folding | 71 | 3.00e-01 | 7.48e-01 | 0.1820 | 8.51e-02 | 0.067600 | 1.11e-01 | 9.47e-02 | 2.16e-01 | 3.25e-01 | 1.07e-01 | 1.68e-01 |
| mRNA Splicing - Minor Pathway | 30 | 6.23e-01 | 8.78e-01 | 0.1820 | -2.91e-02 | -0.082700 | -5.63e-02 | -1.49e-01 | 7.83e-01 | 4.33e-01 | 5.94e-01 | 1.58e-01 |
| Peroxisomal protein import | 48 | 4.14e-01 | 7.90e-01 | 0.1820 | -1.49e-01 | -0.096100 | 2.76e-02 | -2.68e-02 | 7.41e-02 | 2.50e-01 | 7.41e-01 | 7.48e-01 |
| Regulation of RUNX3 expression and activity | 37 | 6.49e-01 | 8.84e-01 | 0.1820 | -6.03e-02 | -0.084900 | -9.79e-02 | -1.12e-01 | 5.25e-01 | 3.72e-01 | 3.03e-01 | 2.39e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 8.51e-01 | 9.45e-01 | 0.1820 | 1.38e-01 | -0.008300 | -1.08e-01 | 4.53e-02 | 4.27e-01 | 9.62e-01 | 5.34e-01 | 7.95e-01 |
| TGF-beta receptor signaling activates SMADs | 19 | 7.24e-01 | 9.06e-01 | 0.1810 | -4.22e-02 | 0.067300 | -1.29e-01 | -9.96e-02 | 7.50e-01 | 6.12e-01 | 3.30e-01 | 4.52e-01 |
| Common Pathway of Fibrin Clot Formation | 18 | 5.73e-01 | 8.67e-01 | 0.1810 | 3.89e-02 | 0.088700 | -9.21e-02 | 1.22e-01 | 7.75e-01 | 5.15e-01 | 4.99e-01 | 3.71e-01 |
| Transport of the SLBP independent Mature mRNA | 23 | 6.08e-01 | 8.75e-01 | 0.1810 | 4.44e-02 | 0.096900 | 1.11e-01 | -9.53e-02 | 7.13e-01 | 4.21e-01 | 3.58e-01 | 4.29e-01 |
| Metabolism of cofactors | 18 | 7.19e-01 | 9.06e-01 | 0.1800 | -2.89e-03 | 0.072400 | 1.85e-02 | -1.64e-01 | 9.83e-01 | 5.95e-01 | 8.92e-01 | 2.29e-01 |
| Glycogen metabolism | 20 | 5.97e-01 | 8.75e-01 | 0.1800 | -1.00e-02 | -0.054400 | -7.97e-02 | 1.51e-01 | 9.38e-01 | 6.74e-01 | 5.37e-01 | 2.41e-01 |
| Respiratory electron transport | 57 | 4.60e-02 | 4.38e-01 | 0.1800 | -1.34e-01 | 0.094400 | -7.03e-02 | -1.98e-02 | 7.99e-02 | 2.18e-01 | 3.59e-01 | 7.96e-01 |
| FCGR3A-mediated IL10 synthesis | 37 | 3.66e-01 | 7.67e-01 | 0.1790 | -5.17e-02 | 0.147000 | 6.54e-02 | 5.92e-02 | 5.86e-01 | 1.22e-01 | 4.92e-01 | 5.34e-01 |
| SARS-CoV-1 Infection | 32 | 4.12e-01 | 7.90e-01 | 0.1780 | 4.67e-02 | -0.017100 | 1.70e-01 | 1.89e-02 | 6.48e-01 | 8.67e-01 | 9.61e-02 | 8.53e-01 |
| Vif-mediated degradation of APOBEC3G | 33 | 4.96e-01 | 8.31e-01 | 0.1780 | -1.10e-01 | -0.027400 | -3.73e-03 | -1.37e-01 | 2.74e-01 | 7.85e-01 | 9.70e-01 | 1.73e-01 |
| Cytosolic sulfonation of small molecules | 17 | 6.45e-01 | 8.83e-01 | 0.1780 | 1.03e-01 | -0.132000 | -3.39e-02 | -4.83e-02 | 4.61e-01 | 3.45e-01 | 8.09e-01 | 7.30e-01 |
| Telomere C-strand synthesis initiation | 10 | 8.15e-01 | 9.36e-01 | 0.1780 | 3.55e-02 | -0.160000 | 6.83e-02 | 8.80e-03 | 8.46e-01 | 3.81e-01 | 7.08e-01 | 9.62e-01 |
| Deadenylation-dependent mRNA decay | 38 | 6.27e-01 | 8.78e-01 | 0.1780 | 2.49e-02 | 0.117000 | 1.08e-01 | 7.45e-02 | 7.91e-01 | 2.14e-01 | 2.48e-01 | 4.27e-01 |
| HIV Life Cycle | 94 | 3.75e-02 | 4.32e-01 | 0.1770 | 4.61e-02 | -0.012500 | -1.39e-02 | -1.70e-01 | 4.41e-01 | 8.34e-01 | 8.16e-01 | 4.41e-03 |
| TNFR2 non-canonical NF-kB pathway | 68 | 1.05e-01 | 6.00e-01 | 0.1770 | -1.33e-01 | -0.018000 | 3.62e-02 | -1.10e-01 | 5.88e-02 | 7.97e-01 | 6.06e-01 | 1.17e-01 |
| Golgi-to-ER retrograde transport | 89 | 1.72e-01 | 6.68e-01 | 0.1760 | 1.79e-02 | -0.073300 | -1.02e-01 | -1.23e-01 | 7.70e-01 | 2.32e-01 | 9.71e-02 | 4.55e-02 |
| SUMOylation of DNA replication proteins | 32 | 3.51e-01 | 7.67e-01 | 0.1760 | 1.71e-02 | 0.002100 | 1.71e-01 | -3.93e-02 | 8.67e-01 | 9.84e-01 | 9.39e-02 | 7.01e-01 |
| DNA Double-Strand Break Repair | 93 | 9.16e-03 | 2.47e-01 | 0.1760 | 2.28e-02 | -0.097900 | 2.62e-02 | -1.43e-01 | 7.04e-01 | 1.03e-01 | 6.63e-01 | 1.76e-02 |
| Cap-dependent Translation Initiation | 49 | 4.14e-01 | 7.90e-01 | 0.1760 | -1.25e-01 | -0.047600 | 1.04e-01 | 4.94e-02 | 1.31e-01 | 5.64e-01 | 2.07e-01 | 5.50e-01 |
| Eukaryotic Translation Initiation | 49 | 4.14e-01 | 7.90e-01 | 0.1760 | -1.25e-01 | -0.047600 | 1.04e-01 | 4.94e-02 | 1.31e-01 | 5.64e-01 | 2.07e-01 | 5.50e-01 |
| Signaling by PDGFR in disease | 17 | 8.84e-01 | 9.58e-01 | 0.1760 | 1.19e-01 | 0.075900 | 6.94e-02 | 7.93e-02 | 3.94e-01 | 5.88e-01 | 6.21e-01 | 5.72e-01 |
| Assembly and cell surface presentation of NMDA receptors | 20 | 5.68e-01 | 8.67e-01 | 0.1760 | -8.34e-02 | 0.123000 | -6.79e-02 | -6.65e-02 | 5.19e-01 | 3.42e-01 | 5.99e-01 | 6.07e-01 |
| NOD1/2 Signaling Pathway | 24 | 7.32e-01 | 9.06e-01 | 0.1760 | 5.03e-02 | 0.158000 | 3.21e-02 | 5.12e-02 | 6.70e-01 | 1.81e-01 | 7.86e-01 | 6.64e-01 |
| Nicotinamide salvaging | 11 | 9.28e-01 | 9.73e-01 | 0.1760 | -1.13e-01 | -0.073100 | -2.76e-02 | -1.10e-01 | 5.16e-01 | 6.75e-01 | 8.74e-01 | 5.27e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 33 | 6.52e-01 | 8.86e-01 | 0.1760 | -4.19e-02 | -0.064900 | 9.89e-02 | 1.23e-01 | 6.77e-01 | 5.19e-01 | 3.26e-01 | 2.21e-01 |
| Metabolism of polyamines | 41 | 4.22e-01 | 7.93e-01 | 0.1750 | -1.61e-01 | -0.037700 | 3.71e-02 | -4.38e-02 | 7.44e-02 | 6.77e-01 | 6.81e-01 | 6.28e-01 |
| Interleukin receptor SHC signaling | 19 | 8.51e-01 | 9.45e-01 | 0.1750 | -9.42e-02 | -0.135000 | -8.36e-03 | 5.95e-02 | 4.77e-01 | 3.09e-01 | 9.50e-01 | 6.54e-01 |
| Metabolism of nucleotides | 76 | 1.43e-01 | 6.41e-01 | 0.1750 | -1.53e-01 | -0.054100 | 5.72e-02 | -3.11e-02 | 2.11e-02 | 4.15e-01 | 3.89e-01 | 6.40e-01 |
| Negative regulation of NOTCH4 signaling | 36 | 4.84e-01 | 8.26e-01 | 0.1750 | -1.10e-01 | -0.024000 | -1.28e-02 | -1.33e-01 | 2.55e-01 | 8.03e-01 | 8.94e-01 | 1.66e-01 |
| Infection with Mycobacterium tuberculosis | 21 | 5.35e-01 | 8.53e-01 | 0.1750 | -5.58e-02 | 0.157000 | -6.87e-03 | 5.27e-02 | 6.58e-01 | 2.14e-01 | 9.57e-01 | 6.76e-01 |
| Laminin interactions | 22 | 5.86e-01 | 8.71e-01 | 0.1740 | -1.10e-01 | -0.022900 | -6.99e-02 | 1.14e-01 | 3.73e-01 | 8.52e-01 | 5.70e-01 | 3.57e-01 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 29 | 4.06e-01 | 7.89e-01 | 0.1740 | -2.24e-02 | 0.041500 | 1.37e-01 | -9.72e-02 | 8.35e-01 | 6.99e-01 | 2.03e-01 | 3.65e-01 |
| Uptake and actions of bacterial toxins | 27 | 5.68e-01 | 8.67e-01 | 0.1740 | 5.74e-02 | -0.141000 | -7.97e-02 | -2.85e-02 | 6.06e-01 | 2.06e-01 | 4.73e-01 | 7.98e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 36 | 4.86e-01 | 8.26e-01 | 0.1740 | -8.06e-02 | -0.012300 | -1.97e-02 | -1.52e-01 | 4.03e-01 | 8.98e-01 | 8.38e-01 | 1.14e-01 |
| HSF1 activation | 19 | 8.24e-01 | 9.37e-01 | 0.1730 | -7.32e-02 | -0.110000 | 8.88e-02 | 6.70e-02 | 5.81e-01 | 4.06e-01 | 5.03e-01 | 6.13e-01 |
| Regulation of PTEN stability and activity | 45 | 3.41e-01 | 7.67e-01 | 0.1730 | -7.19e-02 | -0.015700 | -4.70e-03 | -1.56e-01 | 4.05e-01 | 8.56e-01 | 9.56e-01 | 7.01e-02 |
| Base Excision Repair | 35 | 5.30e-01 | 8.51e-01 | 0.1720 | -6.70e-02 | -0.061200 | 1.41e-01 | 4.01e-02 | 4.93e-01 | 5.31e-01 | 1.49e-01 | 6.82e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 62 | 1.21e-01 | 6.22e-01 | 0.1720 | 3.36e-02 | -0.159000 | -2.34e-02 | 5.32e-02 | 6.47e-01 | 3.09e-02 | 7.50e-01 | 4.69e-01 |
| RNA Polymerase III Transcription Termination | 15 | 8.28e-01 | 9.37e-01 | 0.1720 | -8.42e-02 | -0.083500 | -8.66e-02 | 9.01e-02 | 5.72e-01 | 5.75e-01 | 5.61e-01 | 5.46e-01 |
| Phase 0 - rapid depolarisation | 37 | 3.58e-01 | 7.67e-01 | 0.1720 | 1.19e-01 | 0.009110 | -7.29e-02 | 1.00e-01 | 2.09e-01 | 9.24e-01 | 4.43e-01 | 2.92e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 23 | 7.12e-01 | 9.05e-01 | 0.1720 | -2.75e-02 | -0.155000 | 1.16e-02 | 6.79e-02 | 8.19e-01 | 1.98e-01 | 9.23e-01 | 5.73e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 26 | 6.00e-01 | 8.75e-01 | 0.1720 | 5.56e-02 | -0.137000 | -8.78e-02 | -6.98e-03 | 6.24e-01 | 2.28e-01 | 4.39e-01 | 9.51e-01 |
| Trafficking of AMPA receptors | 26 | 6.00e-01 | 8.75e-01 | 0.1720 | 5.56e-02 | -0.137000 | -8.78e-02 | -6.98e-03 | 6.24e-01 | 2.28e-01 | 4.39e-01 | 9.51e-01 |
| ADP signalling through P2Y purinoceptor 1 | 19 | 8.16e-01 | 9.36e-01 | 0.1720 | -6.83e-02 | 0.022900 | 6.36e-02 | 1.42e-01 | 6.07e-01 | 8.63e-01 | 6.31e-01 | 2.83e-01 |
| Resolution of Sister Chromatid Cohesion | 77 | 8.66e-02 | 5.77e-01 | 0.1710 | 3.80e-02 | 0.090500 | 1.14e-01 | -8.25e-02 | 5.65e-01 | 1.70e-01 | 8.46e-02 | 2.11e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 53 | 2.25e-01 | 6.87e-01 | 0.1710 | -3.65e-02 | -0.055200 | 6.52e-03 | -1.58e-01 | 6.46e-01 | 4.87e-01 | 9.35e-01 | 4.68e-02 |
| Activation of BH3-only proteins | 26 | 6.80e-01 | 8.99e-01 | 0.1710 | 3.42e-02 | 0.129000 | 8.28e-02 | -6.62e-02 | 7.63e-01 | 2.54e-01 | 4.65e-01 | 5.59e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 48 | 3.83e-01 | 7.72e-01 | 0.1700 | -8.10e-02 | -0.044200 | -1.85e-02 | -1.42e-01 | 3.32e-01 | 5.97e-01 | 8.24e-01 | 8.88e-02 |
| CaM pathway | 28 | 5.26e-01 | 8.49e-01 | 0.1700 | 7.19e-04 | 0.109000 | 7.61e-04 | 1.31e-01 | 9.95e-01 | 3.19e-01 | 9.94e-01 | 2.31e-01 |
| Calmodulin induced events | 28 | 5.26e-01 | 8.49e-01 | 0.1700 | 7.19e-04 | 0.109000 | 7.61e-04 | 1.31e-01 | 9.95e-01 | 3.19e-01 | 9.94e-01 | 2.31e-01 |
| Interleukin-37 signaling | 15 | 8.46e-01 | 9.44e-01 | 0.1700 | -2.00e-02 | -0.139000 | 4.83e-02 | 8.29e-02 | 8.94e-01 | 3.53e-01 | 7.46e-01 | 5.78e-01 |
| RET signaling | 33 | 3.53e-01 | 7.67e-01 | 0.1700 | -4.18e-02 | -0.029100 | -9.48e-02 | 1.31e-01 | 6.78e-01 | 7.73e-01 | 3.46e-01 | 1.92e-01 |
| Centrosome maturation | 65 | 9.12e-02 | 5.78e-01 | 0.1690 | 1.14e-01 | 0.022200 | 8.95e-02 | -8.44e-02 | 1.11e-01 | 7.57e-01 | 2.12e-01 | 2.40e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 65 | 9.12e-02 | 5.78e-01 | 0.1690 | 1.14e-01 | 0.022200 | 8.95e-02 | -8.44e-02 | 1.11e-01 | 7.57e-01 | 2.12e-01 | 2.40e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 17 | 6.97e-01 | 9.01e-01 | 0.1690 | -6.88e-03 | -0.034800 | 4.78e-02 | -1.58e-01 | 9.61e-01 | 8.04e-01 | 7.33e-01 | 2.59e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 17 | 6.97e-01 | 9.01e-01 | 0.1690 | -6.88e-03 | -0.034800 | 4.78e-02 | -1.58e-01 | 9.61e-01 | 8.04e-01 | 7.33e-01 | 2.59e-01 |
| FGFR2c ligand binding and activation | 10 | 8.28e-01 | 9.37e-01 | 0.1690 | 2.47e-02 | 0.080000 | -1.05e-01 | 1.02e-01 | 8.92e-01 | 6.61e-01 | 5.66e-01 | 5.76e-01 |
| Cell junction organization | 67 | 2.29e-01 | 6.91e-01 | 0.1680 | 1.24e-01 | -0.012900 | -1.05e-01 | -4.34e-02 | 8.07e-02 | 8.55e-01 | 1.37e-01 | 5.39e-01 |
| Gap junction trafficking and regulation | 25 | 4.33e-01 | 8.01e-01 | 0.1680 | 7.04e-02 | -0.061400 | 5.42e-02 | -1.29e-01 | 5.43e-01 | 5.95e-01 | 6.39e-01 | 2.63e-01 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 13 | 8.21e-01 | 9.36e-01 | 0.1680 | 2.08e-02 | 0.157000 | -4.49e-02 | 3.57e-02 | 8.96e-01 | 3.28e-01 | 7.79e-01 | 8.24e-01 |
| S33 mutants of beta-catenin aren't phosphorylated | 13 | 8.21e-01 | 9.36e-01 | 0.1680 | 2.08e-02 | 0.157000 | -4.49e-02 | 3.57e-02 | 8.96e-01 | 3.28e-01 | 7.79e-01 | 8.24e-01 |
| S37 mutants of beta-catenin aren't phosphorylated | 13 | 8.21e-01 | 9.36e-01 | 0.1680 | 2.08e-02 | 0.157000 | -4.49e-02 | 3.57e-02 | 8.96e-01 | 3.28e-01 | 7.79e-01 | 8.24e-01 |
| S45 mutants of beta-catenin aren't phosphorylated | 13 | 8.21e-01 | 9.36e-01 | 0.1680 | 2.08e-02 | 0.157000 | -4.49e-02 | 3.57e-02 | 8.96e-01 | 3.28e-01 | 7.79e-01 | 8.24e-01 |
| T41 mutants of beta-catenin aren't phosphorylated | 13 | 8.21e-01 | 9.36e-01 | 0.1680 | 2.08e-02 | 0.157000 | -4.49e-02 | 3.57e-02 | 8.96e-01 | 3.28e-01 | 7.79e-01 | 8.24e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 13 | 8.21e-01 | 9.36e-01 | 0.1680 | 2.08e-02 | 0.157000 | -4.49e-02 | 3.57e-02 | 8.96e-01 | 3.28e-01 | 7.79e-01 | 8.24e-01 |
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | 35 | 5.71e-01 | 8.67e-01 | 0.1680 | -9.31e-02 | -0.072600 | -3.89e-03 | -1.20e-01 | 3.41e-01 | 4.58e-01 | 9.68e-01 | 2.21e-01 |
| mRNA Splicing - Major Pathway | 115 | 3.34e-02 | 4.13e-01 | 0.1680 | 6.68e-02 | 0.089500 | 5.40e-02 | -1.13e-01 | 2.17e-01 | 9.77e-02 | 3.18e-01 | 3.65e-02 |
| Processing of DNA double-strand break ends | 43 | 2.20e-01 | 6.85e-01 | 0.1680 | -5.17e-02 | -0.014800 | 9.12e-02 | -1.30e-01 | 5.58e-01 | 8.66e-01 | 3.01e-01 | 1.40e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 19 | 8.16e-01 | 9.36e-01 | 0.1670 | 5.54e-02 | 0.000619 | -3.96e-02 | -1.53e-01 | 6.76e-01 | 9.96e-01 | 7.65e-01 | 2.50e-01 |
| Activation of HOX genes during differentiation | 39 | 6.49e-01 | 8.84e-01 | 0.1670 | 2.09e-02 | 0.120000 | 1.00e-01 | 5.47e-02 | 8.21e-01 | 1.96e-01 | 2.79e-01 | 5.55e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 39 | 6.49e-01 | 8.84e-01 | 0.1670 | 2.09e-02 | 0.120000 | 1.00e-01 | 5.47e-02 | 8.21e-01 | 1.96e-01 | 2.79e-01 | 5.55e-01 |
| Uptake and function of anthrax toxins | 11 | 9.06e-01 | 9.64e-01 | 0.1670 | 1.33e-01 | 0.034900 | 2.32e-02 | -9.15e-02 | 4.46e-01 | 8.41e-01 | 8.94e-01 | 5.99e-01 |
| The citric acid (TCA) cycle and respiratory electron transport | 98 | 1.69e-02 | 3.34e-01 | 0.1670 | -1.35e-01 | 0.053600 | -6.46e-02 | -4.86e-02 | 2.07e-02 | 3.60e-01 | 2.70e-01 | 4.07e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 33 | 5.97e-01 | 8.75e-01 | 0.1660 | -1.25e-01 | -0.060900 | 1.88e-02 | -9.02e-02 | 2.16e-01 | 5.45e-01 | 8.52e-01 | 3.70e-01 |
| Cell-Cell communication | 96 | 1.83e-01 | 6.71e-01 | 0.1660 | 1.20e-01 | 0.065000 | -5.40e-02 | -7.84e-02 | 4.25e-02 | 2.72e-01 | 3.61e-01 | 1.85e-01 |
| PI-3K cascade:FGFR1 | 19 | 6.11e-01 | 8.75e-01 | 0.1660 | -3.37e-02 | 0.105000 | -3.68e-02 | 1.19e-01 | 7.99e-01 | 4.29e-01 | 7.81e-01 | 3.69e-01 |
| Synthesis of PIPs at the plasma membrane | 48 | 6.11e-01 | 8.75e-01 | 0.1660 | 4.77e-02 | 0.065400 | 1.19e-01 | 8.28e-02 | 5.68e-01 | 4.33e-01 | 1.55e-01 | 3.21e-01 |
| SUMOylation of SUMOylation proteins | 22 | 6.85e-01 | 8.99e-01 | 0.1660 | -6.48e-03 | 0.063000 | 1.46e-01 | -4.49e-02 | 9.58e-01 | 6.09e-01 | 2.35e-01 | 7.16e-01 |
| G2/M Checkpoints | 90 | 2.67e-02 | 4.02e-01 | 0.1660 | -1.52e-02 | -0.006500 | 5.30e-02 | -1.56e-01 | 8.04e-01 | 9.15e-01 | 3.86e-01 | 1.06e-02 |
| Opioid Signalling | 73 | 3.14e-01 | 7.52e-01 | 0.1660 | 7.55e-02 | 0.109000 | 3.77e-02 | 9.18e-02 | 2.65e-01 | 1.08e-01 | 5.78e-01 | 1.76e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 39 | 2.77e-01 | 7.32e-01 | 0.1650 | 1.26e-01 | -0.069800 | 6.94e-02 | 4.13e-02 | 1.73e-01 | 4.51e-01 | 4.53e-01 | 6.56e-01 |
| HIV Transcription Initiation | 31 | 7.38e-01 | 9.06e-01 | 0.1650 | 5.67e-02 | 0.015200 | -8.00e-02 | -1.32e-01 | 5.85e-01 | 8.84e-01 | 4.41e-01 | 2.04e-01 |
| RNA Polymerase II HIV Promoter Escape | 31 | 7.38e-01 | 9.06e-01 | 0.1650 | 5.67e-02 | 0.015200 | -8.00e-02 | -1.32e-01 | 5.85e-01 | 8.84e-01 | 4.41e-01 | 2.04e-01 |
| RNA Polymerase II Promoter Escape | 31 | 7.38e-01 | 9.06e-01 | 0.1650 | 5.67e-02 | 0.015200 | -8.00e-02 | -1.32e-01 | 5.85e-01 | 8.84e-01 | 4.41e-01 | 2.04e-01 |
| RNA Polymerase II Transcription Initiation | 31 | 7.38e-01 | 9.06e-01 | 0.1650 | 5.67e-02 | 0.015200 | -8.00e-02 | -1.32e-01 | 5.85e-01 | 8.84e-01 | 4.41e-01 | 2.04e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 31 | 7.38e-01 | 9.06e-01 | 0.1650 | 5.67e-02 | 0.015200 | -8.00e-02 | -1.32e-01 | 5.85e-01 | 8.84e-01 | 4.41e-01 | 2.04e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 31 | 7.38e-01 | 9.06e-01 | 0.1650 | 5.67e-02 | 0.015200 | -8.00e-02 | -1.32e-01 | 5.85e-01 | 8.84e-01 | 4.41e-01 | 2.04e-01 |
| Degradation of the extracellular matrix | 84 | 2.77e-01 | 7.32e-01 | 0.1650 | -8.65e-02 | -0.103000 | -9.54e-02 | -5.70e-03 | 1.71e-01 | 1.03e-01 | 1.31e-01 | 9.28e-01 |
| Dual Incision in GG-NER | 31 | 7.51e-01 | 9.11e-01 | 0.1650 | -1.01e-01 | -0.119000 | 2.07e-02 | 4.83e-02 | 3.30e-01 | 2.51e-01 | 8.42e-01 | 6.42e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 24 | 6.16e-01 | 8.78e-01 | 0.1640 | -4.76e-02 | 0.092900 | 9.61e-02 | -8.32e-02 | 6.87e-01 | 4.31e-01 | 4.15e-01 | 4.80e-01 |
| Transcriptional Regulation by E2F6 | 27 | 5.34e-01 | 8.53e-01 | 0.1640 | -1.55e-03 | 0.042800 | 1.42e-01 | -6.98e-02 | 9.89e-01 | 7.00e-01 | 2.01e-01 | 5.30e-01 |
| Activated point mutants of FGFR2 | 14 | 7.40e-01 | 9.07e-01 | 0.1640 | 1.12e-03 | 0.127000 | -8.39e-02 | 6.22e-02 | 9.94e-01 | 4.12e-01 | 5.87e-01 | 6.87e-01 |
| Costimulation by the CD28 family | 49 | 5.37e-01 | 8.53e-01 | 0.1640 | 4.36e-02 | -0.007760 | -8.16e-02 | -1.35e-01 | 5.98e-01 | 9.25e-01 | 3.23e-01 | 1.02e-01 |
| Regulation of PTEN gene transcription | 48 | 1.66e-01 | 6.67e-01 | 0.1640 | 8.51e-02 | -0.090000 | 1.03e-01 | 3.24e-02 | 3.08e-01 | 2.81e-01 | 2.19e-01 | 6.98e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 28 | 4.94e-01 | 8.31e-01 | 0.1640 | -1.84e-02 | 0.031200 | 1.41e-01 | -7.58e-02 | 8.66e-01 | 7.75e-01 | 1.97e-01 | 4.88e-01 |
| Collagen formation | 69 | 1.14e-01 | 6.22e-01 | 0.1640 | 5.34e-02 | -0.064400 | -1.28e-01 | 5.81e-02 | 4.44e-01 | 3.55e-01 | 6.54e-02 | 4.05e-01 |
| CTLA4 inhibitory signaling | 18 | 9.08e-01 | 9.64e-01 | 0.1630 | -6.81e-02 | -0.057800 | -1.12e-01 | -7.86e-02 | 6.17e-01 | 6.71e-01 | 4.12e-01 | 5.64e-01 |
| Signaling by NTRK3 (TRKC) | 14 | 7.45e-01 | 9.09e-01 | 0.1630 | -5.67e-02 | 0.146000 | -4.47e-02 | -1.78e-03 | 7.13e-01 | 3.43e-01 | 7.72e-01 | 9.91e-01 |
| Nuclear import of Rev protein | 23 | 6.43e-01 | 8.83e-01 | 0.1630 | -4.19e-02 | 0.087700 | 9.63e-02 | -8.79e-02 | 7.28e-01 | 4.67e-01 | 4.24e-01 | 4.66e-01 |
| FRS-mediated FGFR1 signaling | 18 | 6.14e-01 | 8.78e-01 | 0.1620 | -8.11e-02 | 0.092500 | -4.25e-02 | 9.72e-02 | 5.51e-01 | 4.97e-01 | 7.55e-01 | 4.75e-01 |
| Visual phototransduction | 74 | 3.06e-01 | 7.49e-01 | 0.1620 | -8.03e-02 | -0.121000 | -3.64e-02 | 6.31e-02 | 2.33e-01 | 7.21e-02 | 5.89e-01 | 3.49e-01 |
| Cell-extracellular matrix interactions | 14 | 8.74e-01 | 9.52e-01 | 0.1620 | 3.18e-02 | 0.061800 | 1.02e-02 | -1.46e-01 | 8.37e-01 | 6.89e-01 | 9.47e-01 | 3.43e-01 |
| Signaling by Retinoic Acid | 38 | 6.07e-01 | 8.75e-01 | 0.1620 | -1.01e-01 | -0.086000 | -2.64e-02 | 9.01e-02 | 2.84e-01 | 3.59e-01 | 7.79e-01 | 3.37e-01 |
| Integrin cell surface interactions | 56 | 3.72e-01 | 7.67e-01 | 0.1620 | -5.05e-02 | -0.110000 | -9.53e-02 | 5.00e-02 | 5.13e-01 | 1.54e-01 | 2.18e-01 | 5.18e-01 |
| Ion homeostasis | 41 | 6.40e-01 | 8.81e-01 | 0.1620 | 1.01e-02 | 0.106000 | 1.14e-01 | 4.25e-02 | 9.11e-01 | 2.40e-01 | 2.06e-01 | 6.38e-01 |
| Amine ligand-binding receptors | 33 | 4.13e-01 | 7.90e-01 | 0.1620 | 4.32e-04 | 0.068500 | -3.48e-02 | 1.42e-01 | 9.97e-01 | 4.96e-01 | 7.30e-01 | 1.57e-01 |
| ECM proteoglycans | 47 | 3.46e-01 | 7.67e-01 | 0.1620 | -6.01e-02 | 0.018400 | -1.44e-01 | -3.96e-02 | 4.76e-01 | 8.27e-01 | 8.82e-02 | 6.39e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 97 | 1.88e-01 | 6.71e-01 | 0.1620 | -1.07e-01 | -0.036900 | 6.45e-02 | 9.63e-02 | 7.01e-02 | 5.31e-01 | 2.73e-01 | 1.02e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 73 | 2.72e-01 | 7.27e-01 | 0.1610 | -1.96e-03 | 0.116000 | 1.11e-01 | 1.35e-02 | 9.77e-01 | 8.65e-02 | 1.01e-01 | 8.42e-01 |
| Regulation of ornithine decarboxylase (ODC) | 35 | 5.66e-01 | 8.67e-01 | 0.1610 | -1.38e-01 | -0.036300 | 4.11e-02 | -6.18e-02 | 1.57e-01 | 7.10e-01 | 6.74e-01 | 5.27e-01 |
| Activation of GABAB receptors | 34 | 4.03e-01 | 7.88e-01 | 0.1610 | -6.66e-02 | 0.097200 | 6.07e-03 | 1.09e-01 | 5.02e-01 | 3.27e-01 | 9.51e-01 | 2.70e-01 |
| GABA B receptor activation | 34 | 4.03e-01 | 7.88e-01 | 0.1610 | -6.66e-02 | 0.097200 | 6.07e-03 | 1.09e-01 | 5.02e-01 | 3.27e-01 | 9.51e-01 | 2.70e-01 |
| Diseases associated with N-glycosylation of proteins | 14 | 8.51e-01 | 9.45e-01 | 0.1610 | 1.01e-01 | 0.003670 | -2.63e-02 | 1.23e-01 | 5.14e-01 | 9.81e-01 | 8.65e-01 | 4.27e-01 |
| Tryptophan catabolism | 12 | 8.33e-01 | 9.39e-01 | 0.1610 | 1.35e-01 | -0.016700 | 6.56e-02 | -5.60e-02 | 4.19e-01 | 9.20e-01 | 6.94e-01 | 7.37e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 28 | 6.84e-01 | 8.99e-01 | 0.1610 | 1.58e-01 | 0.023400 | 3.49e-03 | 1.82e-02 | 1.48e-01 | 8.30e-01 | 9.75e-01 | 8.68e-01 |
| Nitric oxide stimulates guanylate cyclase | 21 | 8.61e-01 | 9.46e-01 | 0.1610 | 8.09e-02 | 0.083600 | -7.96e-02 | -7.74e-02 | 5.21e-01 | 5.07e-01 | 5.28e-01 | 5.39e-01 |
| Intraflagellar transport | 35 | 4.69e-01 | 8.26e-01 | 0.1610 | -6.11e-02 | 0.049000 | -1.31e-01 | -5.11e-02 | 5.32e-01 | 6.16e-01 | 1.81e-01 | 6.01e-01 |
| NRAGE signals death through JNK | 53 | 1.71e-01 | 6.68e-01 | 0.1600 | 1.16e-01 | -0.099900 | -2.69e-02 | 3.89e-02 | 1.44e-01 | 2.09e-01 | 7.35e-01 | 6.25e-01 |
| TBC/RABGAPs | 32 | 6.10e-01 | 8.75e-01 | 0.1600 | -9.14e-02 | -0.094600 | 3.76e-02 | -8.25e-02 | 3.71e-01 | 3.54e-01 | 7.13e-01 | 4.20e-01 |
| Biological oxidations | 165 | 2.55e-02 | 4.02e-01 | 0.1600 | 3.28e-02 | 0.147000 | 5.18e-02 | 1.08e-02 | 4.68e-01 | 1.14e-03 | 2.52e-01 | 8.12e-01 |
| Diseases of glycosylation | 114 | 4.33e-02 | 4.38e-01 | 0.1600 | 9.57e-02 | -0.067200 | -1.07e-01 | -2.17e-02 | 7.80e-02 | 2.16e-01 | 4.95e-02 | 6.90e-01 |
| Transcriptional regulation of white adipocyte differentiation | 66 | 1.84e-01 | 6.71e-01 | 0.1600 | 6.48e-02 | 0.057700 | 1.22e-01 | -5.48e-02 | 3.63e-01 | 4.18e-01 | 8.63e-02 | 4.42e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 39 | 4.17e-01 | 7.90e-01 | 0.1590 | -4.24e-02 | -0.015000 | 2.87e-02 | -1.49e-01 | 6.47e-01 | 8.71e-01 | 7.57e-01 | 1.07e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 68 | 1.67e-01 | 6.67e-01 | 0.1580 | 1.78e-02 | 0.085600 | 8.12e-02 | -1.04e-01 | 8.00e-01 | 2.23e-01 | 2.47e-01 | 1.38e-01 |
| Amplification of signal from the kinetochores | 68 | 1.67e-01 | 6.67e-01 | 0.1580 | 1.78e-02 | 0.085600 | 8.12e-02 | -1.04e-01 | 8.00e-01 | 2.23e-01 | 2.47e-01 | 1.38e-01 |
| Interleukin-17 signaling | 55 | 3.48e-01 | 7.67e-01 | 0.1580 | -3.17e-03 | 0.138000 | 4.34e-02 | 6.43e-02 | 9.68e-01 | 7.70e-02 | 5.78e-01 | 4.10e-01 |
| Signaling by ROBO receptors | 121 | 5.29e-02 | 4.71e-01 | 0.1580 | 3.90e-02 | 0.109000 | 8.37e-02 | -6.74e-02 | 4.59e-01 | 3.88e-02 | 1.13e-01 | 2.01e-01 |
| ISG15 antiviral mechanism | 48 | 3.38e-01 | 7.67e-01 | 0.1580 | -1.67e-02 | 0.083800 | 1.17e-01 | -6.13e-02 | 8.41e-01 | 3.15e-01 | 1.60e-01 | 4.63e-01 |
| Collagen biosynthesis and modifying enzymes | 53 | 2.56e-01 | 7.17e-01 | 0.1580 | 1.09e-01 | -0.027700 | -9.38e-02 | 5.74e-02 | 1.69e-01 | 7.28e-01 | 2.38e-01 | 4.70e-01 |
| SUMOylation of DNA damage response and repair proteins | 49 | 1.93e-01 | 6.71e-01 | 0.1570 | 2.46e-02 | -0.009930 | 1.44e-01 | -5.87e-02 | 7.66e-01 | 9.04e-01 | 8.20e-02 | 4.77e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 64 | 1.94e-01 | 6.71e-01 | 0.1570 | 1.52e-01 | -0.017600 | -6.94e-03 | 3.45e-02 | 3.51e-02 | 8.08e-01 | 9.24e-01 | 6.33e-01 |
| MyD88 dependent cascade initiated on endosome | 68 | 3.56e-01 | 7.67e-01 | 0.1570 | 1.08e-02 | 0.131000 | 7.59e-02 | 4.25e-02 | 8.78e-01 | 6.26e-02 | 2.79e-01 | 5.45e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 68 | 3.56e-01 | 7.67e-01 | 0.1570 | 1.08e-02 | 0.131000 | 7.59e-02 | 4.25e-02 | 8.78e-01 | 6.26e-02 | 2.79e-01 | 5.45e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 5.28e-01 | 8.51e-01 | 0.1570 | -1.99e-02 | 0.062600 | 9.52e-03 | 1.42e-01 | 8.41e-01 | 5.28e-01 | 9.23e-01 | 1.51e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 159 | 2.26e-02 | 3.87e-01 | 0.1570 | 6.38e-02 | 0.104000 | 5.77e-02 | -8.10e-02 | 1.66e-01 | 2.44e-02 | 2.10e-01 | 7.85e-02 |
| Downstream signaling events of B Cell Receptor (BCR) | 55 | 4.17e-01 | 7.90e-01 | 0.1570 | 1.37e-02 | 0.088900 | -4.51e-02 | -1.21e-01 | 8.61e-01 | 2.54e-01 | 5.63e-01 | 1.22e-01 |
| Platelet Aggregation (Plug Formation) | 33 | 6.58e-01 | 8.90e-01 | 0.1570 | -1.59e-02 | -0.072000 | 1.15e-01 | 7.74e-02 | 8.75e-01 | 4.74e-01 | 2.53e-01 | 4.42e-01 |
| LDL clearance | 16 | 6.88e-01 | 8.99e-01 | 0.1570 | 6.24e-02 | -0.041200 | 9.52e-02 | -9.95e-02 | 6.66e-01 | 7.76e-01 | 5.10e-01 | 4.91e-01 |
| Protein localization | 113 | 1.54e-01 | 6.51e-01 | 0.1560 | -7.92e-02 | -0.042600 | -5.66e-02 | -1.15e-01 | 1.46e-01 | 4.34e-01 | 2.99e-01 | 3.52e-02 |
| Degradation of DVL | 37 | 6.27e-01 | 8.78e-01 | 0.1560 | -1.13e-01 | -0.060700 | 3.94e-03 | -8.96e-02 | 2.36e-01 | 5.23e-01 | 9.67e-01 | 3.46e-01 |
| trans-Golgi Network Vesicle Budding | 49 | 1.62e-01 | 6.61e-01 | 0.1560 | 8.03e-02 | -0.051100 | 5.84e-02 | -1.09e-01 | 3.31e-01 | 5.36e-01 | 4.80e-01 | 1.87e-01 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 63 | 7.71e-02 | 5.61e-01 | 0.1560 | -9.88e-02 | 0.096900 | -7.13e-02 | -1.13e-02 | 1.75e-01 | 1.84e-01 | 3.28e-01 | 8.77e-01 |
| Autophagy | 94 | 1.54e-01 | 6.51e-01 | 0.1560 | -7.55e-02 | -0.085700 | -4.47e-03 | -1.06e-01 | 2.07e-01 | 1.52e-01 | 9.40e-01 | 7.57e-02 |
| Post NMDA receptor activation events | 52 | 3.22e-01 | 7.57e-01 | 0.1560 | 4.98e-02 | 0.131000 | -3.88e-02 | 5.65e-02 | 5.34e-01 | 1.03e-01 | 6.29e-01 | 4.81e-01 |
| EML4 and NUDC in mitotic spindle formation | 71 | 2.23e-01 | 6.87e-01 | 0.1560 | 2.92e-02 | 0.106000 | 6.31e-02 | -9.05e-02 | 6.71e-01 | 1.23e-01 | 3.58e-01 | 1.88e-01 |
| MyD88 cascade initiated on plasma membrane | 63 | 3.65e-01 | 7.67e-01 | 0.1560 | -1.59e-02 | 0.122000 | 8.70e-02 | 3.94e-02 | 8.27e-01 | 9.51e-02 | 2.33e-01 | 5.88e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 63 | 3.65e-01 | 7.67e-01 | 0.1560 | -1.59e-02 | 0.122000 | 8.70e-02 | 3.94e-02 | 8.27e-01 | 9.51e-02 | 2.33e-01 | 5.88e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 63 | 3.65e-01 | 7.67e-01 | 0.1560 | -1.59e-02 | 0.122000 | 8.70e-02 | 3.94e-02 | 8.27e-01 | 9.51e-02 | 2.33e-01 | 5.88e-01 |
| ERK/MAPK targets | 19 | 7.88e-01 | 9.32e-01 | 0.1560 | -7.76e-02 | 0.058000 | 1.19e-01 | -2.32e-02 | 5.58e-01 | 6.62e-01 | 3.68e-01 | 8.61e-01 |
| Downregulation of TGF-beta receptor signaling | 17 | 7.79e-01 | 9.29e-01 | 0.1550 | -5.32e-02 | 0.102000 | -7.92e-02 | -6.83e-02 | 7.04e-01 | 4.67e-01 | 5.72e-01 | 6.26e-01 |
| Mitochondrial translation initiation | 55 | 4.73e-01 | 8.26e-01 | 0.1550 | -1.34e-01 | -0.059100 | 5.05e-02 | 2.42e-04 | 8.51e-02 | 4.49e-01 | 5.18e-01 | 9.98e-01 |
| Inflammasomes | 16 | 8.78e-01 | 9.53e-01 | 0.1550 | 8.95e-02 | 0.001810 | 1.12e-01 | 5.85e-02 | 5.36e-01 | 9.90e-01 | 4.38e-01 | 6.85e-01 |
| Unfolded Protein Response (UPR) | 66 | 4.55e-01 | 8.20e-01 | 0.1540 | -8.15e-02 | -0.119000 | -3.55e-02 | 4.21e-02 | 2.52e-01 | 9.49e-02 | 6.18e-01 | 5.55e-01 |
| ESR-mediated signaling | 128 | 5.48e-02 | 4.72e-01 | 0.1540 | 3.09e-02 | 0.088600 | 2.87e-03 | -1.22e-01 | 5.46e-01 | 8.41e-02 | 9.55e-01 | 1.70e-02 |
| Nicotinate metabolism | 20 | 9.04e-01 | 9.63e-01 | 0.1540 | -9.27e-02 | -0.068300 | -9.10e-02 | -4.64e-02 | 4.73e-01 | 5.97e-01 | 4.81e-01 | 7.19e-01 |
| cGMP effects | 16 | 7.50e-01 | 9.11e-01 | 0.1540 | 2.48e-02 | 0.090500 | -8.15e-02 | 9.08e-02 | 8.64e-01 | 5.31e-01 | 5.73e-01 | 5.30e-01 |
| Regulation of TP53 Expression and Degradation | 30 | 6.18e-01 | 8.78e-01 | 0.1540 | 6.47e-02 | -0.020100 | -6.49e-03 | -1.38e-01 | 5.40e-01 | 8.49e-01 | 9.51e-01 | 1.92e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 35 | 7.01e-01 | 9.02e-01 | 0.1540 | -6.67e-02 | -0.040700 | -3.99e-02 | -1.26e-01 | 4.95e-01 | 6.77e-01 | 6.83e-01 | 1.97e-01 |
| G alpha (12/13) signalling events | 65 | 2.51e-01 | 7.16e-01 | 0.1530 | 3.13e-02 | -0.072300 | -1.29e-01 | 2.64e-02 | 6.63e-01 | 3.14e-01 | 7.27e-02 | 7.13e-01 |
| Regulation of RUNX1 Expression and Activity | 14 | 9.00e-01 | 9.63e-01 | 0.1530 | 5.21e-02 | 0.000923 | 1.38e-01 | 4.09e-02 | 7.36e-01 | 9.95e-01 | 3.71e-01 | 7.91e-01 |
| Mitotic Anaphase | 169 | 1.00e-03 | 6.96e-02 | 0.1520 | -2.88e-02 | 0.018200 | 9.11e-02 | -1.17e-01 | 5.20e-01 | 6.84e-01 | 4.14e-02 | 8.68e-03 |
| Thrombin signalling through proteinase activated receptors (PARs) | 24 | 7.91e-01 | 9.32e-01 | 0.1520 | -1.44e-01 | -0.033500 | -3.46e-02 | 1.00e-03 | 2.21e-01 | 7.76e-01 | 7.69e-01 | 9.93e-01 |
| SUMOylation of RNA binding proteins | 34 | 7.08e-01 | 9.05e-01 | 0.1520 | 3.99e-02 | 0.070100 | 1.29e-01 | 6.48e-03 | 6.87e-01 | 4.80e-01 | 1.93e-01 | 9.48e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 21 | 8.46e-01 | 9.44e-01 | 0.1520 | 1.07e-01 | 0.064100 | 2.28e-02 | -8.39e-02 | 3.97e-01 | 6.11e-01 | 8.56e-01 | 5.06e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 8.55e-01 | 9.45e-01 | 0.1520 | -8.00e-03 | -0.123000 | 5.20e-02 | -7.15e-02 | 9.62e-01 | 4.60e-01 | 7.55e-01 | 6.68e-01 |
| Signaling by FGFR2 in disease | 28 | 5.79e-01 | 8.69e-01 | 0.1520 | -1.42e-02 | 0.144000 | -4.31e-02 | -1.33e-02 | 8.97e-01 | 1.87e-01 | 6.93e-01 | 9.03e-01 |
| Gene Silencing by RNA | 52 | 2.60e-01 | 7.23e-01 | 0.1520 | 1.34e-01 | -0.036300 | 5.40e-02 | 2.66e-02 | 9.38e-02 | 6.51e-01 | 5.01e-01 | 7.40e-01 |
| Mitotic Prometaphase | 140 | 2.13e-02 | 3.85e-01 | 0.1510 | 6.54e-02 | 0.064600 | 9.77e-02 | -7.01e-02 | 1.82e-01 | 1.88e-01 | 4.64e-02 | 1.53e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 62 | 1.66e-01 | 6.67e-01 | 0.1510 | 1.00e-01 | -0.092200 | -2.74e-02 | 5.94e-02 | 1.72e-01 | 2.10e-01 | 7.09e-01 | 4.19e-01 |
| rRNA processing in the nucleus and cytosol | 103 | 1.93e-01 | 6.71e-01 | 0.1510 | -1.17e-01 | -0.030300 | 5.02e-02 | 7.62e-02 | 4.09e-02 | 5.96e-01 | 3.80e-01 | 1.82e-01 |
| Cell Cycle Checkpoints | 183 | 1.20e-03 | 7.23e-02 | 0.1510 | -5.58e-03 | 0.030900 | 5.91e-02 | -1.36e-01 | 8.97e-01 | 4.72e-01 | 1.69e-01 | 1.61e-03 |
| Anchoring of the basal body to the plasma membrane | 75 | 2.12e-01 | 6.82e-01 | 0.1510 | 1.13e-01 | 0.044700 | 7.57e-02 | -4.67e-02 | 8.98e-02 | 5.04e-01 | 2.57e-01 | 4.85e-01 |
| Hh mutants abrogate ligand secretion | 38 | 6.74e-01 | 8.96e-01 | 0.1510 | -8.24e-02 | -0.058400 | -2.30e-02 | -1.10e-01 | 3.79e-01 | 5.33e-01 | 8.06e-01 | 2.42e-01 |
| Phospholipase C-mediated cascade; FGFR3 | 10 | 9.73e-01 | 9.88e-01 | 0.1510 | 5.93e-02 | 0.125000 | 5.86e-02 | 1.41e-02 | 7.46e-01 | 4.94e-01 | 7.48e-01 | 9.39e-01 |
| Mitotic Metaphase and Anaphase | 170 | 1.12e-03 | 7.23e-02 | 0.1510 | -2.42e-02 | 0.021000 | 9.43e-02 | -1.13e-01 | 5.87e-01 | 6.37e-01 | 3.44e-02 | 1.11e-02 |
| O-linked glycosylation of mucins | 48 | 4.08e-01 | 7.90e-01 | 0.1510 | -7.22e-02 | -0.059400 | -9.52e-02 | 7.00e-02 | 3.87e-01 | 4.77e-01 | 2.54e-01 | 4.02e-01 |
| Apoptosis | 128 | 4.67e-02 | 4.38e-01 | 0.1510 | 2.27e-02 | 0.103000 | 8.03e-02 | -7.22e-02 | 6.58e-01 | 4.56e-02 | 1.17e-01 | 1.59e-01 |
| Retinoid metabolism and transport | 30 | 8.01e-01 | 9.36e-01 | 0.1500 | -3.38e-02 | -0.092600 | -1.13e-01 | -1.42e-02 | 7.49e-01 | 3.80e-01 | 2.86e-01 | 8.93e-01 |
| Nuclear Envelope Breakdown | 37 | 7.83e-01 | 9.30e-01 | 0.1500 | 3.32e-02 | 0.075700 | 1.12e-01 | 5.70e-02 | 7.27e-01 | 4.26e-01 | 2.41e-01 | 5.49e-01 |
| Glycerophospholipid biosynthesis | 91 | 2.04e-01 | 6.73e-01 | 0.1500 | -4.94e-02 | -0.133000 | 3.18e-02 | 3.68e-02 | 4.16e-01 | 2.85e-02 | 6.00e-01 | 5.45e-01 |
| Translation of structural proteins | 19 | 9.04e-01 | 9.63e-01 | 0.1500 | 1.17e-02 | 0.034700 | 1.35e-01 | 5.40e-02 | 9.30e-01 | 7.94e-01 | 3.10e-01 | 6.84e-01 |
| Metabolism of amino acids and derivatives | 244 | 2.22e-02 | 3.85e-01 | 0.1500 | -1.09e-01 | -0.101000 | -1.67e-02 | -6.77e-03 | 3.58e-03 | 6.63e-03 | 6.55e-01 | 8.56e-01 |
| Activation of NF-kappaB in B cells | 44 | 5.43e-01 | 8.57e-01 | 0.1500 | -7.48e-02 | 0.023500 | -4.98e-02 | -1.17e-01 | 3.91e-01 | 7.88e-01 | 5.68e-01 | 1.79e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 70 | 4.53e-01 | 8.19e-01 | 0.1490 | 2.54e-02 | 0.119000 | 7.78e-02 | 4.00e-02 | 7.13e-01 | 8.68e-02 | 2.61e-01 | 5.63e-01 |
| Mitotic Spindle Checkpoint | 82 | 1.27e-01 | 6.25e-01 | 0.1490 | 5.58e-03 | 0.069900 | 5.85e-02 | -1.18e-01 | 9.31e-01 | 2.74e-01 | 3.61e-01 | 6.43e-02 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 67 | 3.66e-01 | 7.67e-01 | 0.1490 | 2.14e-03 | 0.132000 | 6.32e-02 | 3.13e-02 | 9.76e-01 | 6.24e-02 | 3.72e-01 | 6.59e-01 |
| Interleukin-2 family signaling | 31 | 7.31e-01 | 9.06e-01 | 0.1490 | -4.11e-02 | -0.109000 | 6.93e-02 | 6.35e-02 | 6.93e-01 | 2.96e-01 | 5.04e-01 | 5.41e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 141 | 9.57e-02 | 5.93e-01 | 0.1490 | 6.04e-02 | 0.046200 | -4.24e-02 | -1.21e-01 | 2.17e-01 | 3.44e-01 | 3.85e-01 | 1.33e-02 |
| Potential therapeutics for SARS | 26 | 5.75e-01 | 8.67e-01 | 0.1490 | -3.87e-02 | -0.040800 | 9.79e-02 | -9.73e-02 | 7.33e-01 | 7.19e-01 | 3.88e-01 | 3.91e-01 |
| Transcriptional regulation of granulopoiesis | 28 | 7.37e-01 | 9.06e-01 | 0.1490 | -1.84e-02 | -0.059800 | 1.24e-01 | 5.34e-02 | 8.66e-01 | 5.84e-01 | 2.56e-01 | 6.25e-01 |
| p75 NTR receptor-mediated signalling | 78 | 1.46e-01 | 6.51e-01 | 0.1490 | 1.09e-01 | -0.061900 | -7.96e-02 | 1.20e-02 | 9.67e-02 | 3.45e-01 | 2.25e-01 | 8.54e-01 |
| Protein folding | 77 | 4.56e-01 | 8.20e-01 | 0.1490 | 5.34e-02 | 0.041400 | 1.05e-01 | 8.05e-02 | 4.18e-01 | 5.31e-01 | 1.10e-01 | 2.23e-01 |
| RAB geranylgeranylation | 39 | 6.93e-01 | 9.01e-01 | 0.1490 | -9.64e-02 | -0.052900 | -2.82e-02 | -9.61e-02 | 2.98e-01 | 5.68e-01 | 7.61e-01 | 2.99e-01 |
| Extracellular matrix organization | 233 | 1.04e-02 | 2.63e-01 | 0.1490 | -2.29e-02 | -0.077600 | -1.24e-01 | -1.35e-02 | 5.48e-01 | 4.19e-02 | 1.16e-03 | 7.23e-01 |
| Translesion synthesis by POLI | 12 | 9.02e-01 | 9.63e-01 | 0.1480 | 4.26e-02 | -0.003130 | -2.61e-02 | 1.40e-01 | 7.98e-01 | 9.85e-01 | 8.76e-01 | 4.02e-01 |
| Macroautophagy | 84 | 2.35e-01 | 6.96e-01 | 0.1480 | -5.41e-02 | -0.077700 | -1.14e-02 | -1.13e-01 | 3.92e-01 | 2.19e-01 | 8.57e-01 | 7.31e-02 |
| Viral Messenger RNA Synthesis | 25 | 6.42e-01 | 8.83e-01 | 0.1470 | 5.29e-03 | -0.001740 | 5.39e-02 | -1.37e-01 | 9.63e-01 | 9.88e-01 | 6.41e-01 | 2.35e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 42 | 5.75e-01 | 8.67e-01 | 0.1470 | 1.40e-01 | 0.021200 | -2.46e-02 | 3.17e-02 | 1.17e-01 | 8.13e-01 | 7.83e-01 | 7.22e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 42 | 5.75e-01 | 8.67e-01 | 0.1470 | 1.40e-01 | 0.021200 | -2.46e-02 | 3.17e-02 | 1.17e-01 | 8.13e-01 | 7.83e-01 | 7.22e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 42 | 5.75e-01 | 8.67e-01 | 0.1470 | 1.40e-01 | 0.021200 | -2.46e-02 | 3.17e-02 | 1.17e-01 | 8.13e-01 | 7.83e-01 | 7.22e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 42 | 5.75e-01 | 8.67e-01 | 0.1470 | 1.40e-01 | 0.021200 | -2.46e-02 | 3.17e-02 | 1.17e-01 | 8.13e-01 | 7.83e-01 | 7.22e-01 |
| Signaling by NOTCH1 in Cancer | 42 | 5.75e-01 | 8.67e-01 | 0.1470 | 1.40e-01 | 0.021200 | -2.46e-02 | 3.17e-02 | 1.17e-01 | 8.13e-01 | 7.83e-01 | 7.22e-01 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 38 | 7.25e-01 | 9.06e-01 | 0.1460 | -3.12e-02 | 0.075100 | 8.89e-02 | 8.33e-02 | 7.40e-01 | 4.23e-01 | 3.43e-01 | 3.75e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 51 | 5.47e-01 | 8.61e-01 | 0.1460 | -5.45e-02 | -0.041400 | -2.97e-02 | -1.26e-01 | 5.01e-01 | 6.09e-01 | 7.14e-01 | 1.20e-01 |
| RAS processing | 12 | 9.31e-01 | 9.73e-01 | 0.1460 | -1.96e-02 | 0.021700 | 1.43e-01 | 7.83e-03 | 9.06e-01 | 8.96e-01 | 3.90e-01 | 9.63e-01 |
| Influenza Infection | 74 | 1.50e-01 | 6.51e-01 | 0.1460 | -6.43e-02 | 0.073200 | 6.12e-02 | -8.97e-02 | 3.39e-01 | 2.77e-01 | 3.63e-01 | 1.83e-01 |
| O-linked glycosylation | 85 | 1.24e-01 | 6.24e-01 | 0.1460 | 6.20e-02 | -0.027800 | -1.23e-01 | 4.00e-02 | 3.23e-01 | 6.58e-01 | 5.08e-02 | 5.25e-01 |
| CLEC7A (Dectin-1) signaling | 70 | 2.95e-01 | 7.46e-01 | 0.1460 | -2.04e-02 | 0.075000 | -2.61e-02 | -1.21e-01 | 7.68e-01 | 2.79e-01 | 7.07e-01 | 8.13e-02 |
| AMER1 mutants destabilize the destruction complex | 12 | 8.59e-01 | 9.45e-01 | 0.1460 | -4.33e-02 | 0.133000 | -2.44e-02 | 3.36e-02 | 7.95e-01 | 4.26e-01 | 8.84e-01 | 8.40e-01 |
| APC truncation mutants have impaired AXIN binding | 12 | 8.59e-01 | 9.45e-01 | 0.1460 | -4.33e-02 | 0.133000 | -2.44e-02 | 3.36e-02 | 7.95e-01 | 4.26e-01 | 8.84e-01 | 8.40e-01 |
| AXIN missense mutants destabilize the destruction complex | 12 | 8.59e-01 | 9.45e-01 | 0.1460 | -4.33e-02 | 0.133000 | -2.44e-02 | 3.36e-02 | 7.95e-01 | 4.26e-01 | 8.84e-01 | 8.40e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 12 | 8.59e-01 | 9.45e-01 | 0.1460 | -4.33e-02 | 0.133000 | -2.44e-02 | 3.36e-02 | 7.95e-01 | 4.26e-01 | 8.84e-01 | 8.40e-01 |
| Truncations of AMER1 destabilize the destruction complex | 12 | 8.59e-01 | 9.45e-01 | 0.1460 | -4.33e-02 | 0.133000 | -2.44e-02 | 3.36e-02 | 7.95e-01 | 4.26e-01 | 8.84e-01 | 8.40e-01 |
| truncated APC mutants destabilize the destruction complex | 12 | 8.59e-01 | 9.45e-01 | 0.1460 | -4.33e-02 | 0.133000 | -2.44e-02 | 3.36e-02 | 7.95e-01 | 4.26e-01 | 8.84e-01 | 8.40e-01 |
| Attenuation phase | 16 | 8.02e-01 | 9.36e-01 | 0.1460 | 4.52e-02 | 0.017200 | 1.09e-01 | -8.32e-02 | 7.54e-01 | 9.05e-01 | 4.50e-01 | 5.65e-01 |
| Translesion synthesis by REV1 | 11 | 9.18e-01 | 9.69e-01 | 0.1450 | -4.23e-03 | -0.004390 | -2.62e-02 | 1.43e-01 | 9.81e-01 | 9.80e-01 | 8.80e-01 | 4.12e-01 |
| Regulation of RUNX2 expression and activity | 47 | 6.29e-01 | 8.78e-01 | 0.1450 | 4.70e-02 | 0.095200 | -3.73e-02 | -9.21e-02 | 5.78e-01 | 2.59e-01 | 6.58e-01 | 2.75e-01 |
| TRP channels | 20 | 7.42e-01 | 9.07e-01 | 0.1450 | -4.91e-02 | 0.014600 | -1.34e-01 | 2.06e-02 | 7.04e-01 | 9.10e-01 | 2.99e-01 | 8.74e-01 |
| rRNA processing | 110 | 2.11e-01 | 6.82e-01 | 0.1450 | -1.03e-01 | -0.023000 | 5.96e-02 | 7.90e-02 | 6.12e-02 | 6.77e-01 | 2.81e-01 | 1.53e-01 |
| SARS-CoV Infections | 58 | 2.06e-01 | 6.78e-01 | 0.1450 | 8.41e-03 | -0.027800 | 1.38e-01 | -3.33e-02 | 9.12e-01 | 7.14e-01 | 6.93e-02 | 6.62e-01 |
| Mitochondrial translation elongation | 55 | 5.87e-01 | 8.71e-01 | 0.1450 | -1.15e-01 | -0.081500 | 3.31e-02 | -4.71e-03 | 1.41e-01 | 2.96e-01 | 6.72e-01 | 9.52e-01 |
| MyD88-independent TLR4 cascade | 76 | 3.77e-01 | 7.68e-01 | 0.1450 | 1.47e-02 | 0.123000 | 7.32e-02 | 1.07e-02 | 8.25e-01 | 6.32e-02 | 2.70e-01 | 8.73e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 76 | 3.77e-01 | 7.68e-01 | 0.1450 | 1.47e-02 | 0.123000 | 7.32e-02 | 1.07e-02 | 8.25e-01 | 6.32e-02 | 2.70e-01 | 8.73e-01 |
| Programmed Cell Death | 131 | 6.45e-02 | 5.07e-01 | 0.1440 | 2.04e-02 | 0.101000 | 8.03e-02 | -6.12e-02 | 6.87e-01 | 4.60e-02 | 1.13e-01 | 2.28e-01 |
| Antiviral mechanism by IFN-stimulated genes | 54 | 3.12e-01 | 7.52e-01 | 0.1440 | -5.34e-02 | 0.022200 | 1.20e-01 | -5.38e-02 | 4.97e-01 | 7.78e-01 | 1.26e-01 | 4.94e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 26 | 7.18e-01 | 9.06e-01 | 0.1440 | 6.37e-02 | -0.070800 | 6.82e-02 | 8.36e-02 | 5.74e-01 | 5.32e-01 | 5.47e-01 | 4.61e-01 |
| Signaling by PDGFRA extracellular domain mutants | 10 | 9.29e-01 | 9.73e-01 | 0.1440 | -6.50e-02 | 0.119000 | 4.85e-02 | 5.84e-03 | 7.22e-01 | 5.16e-01 | 7.90e-01 | 9.74e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 10 | 9.29e-01 | 9.73e-01 | 0.1440 | -6.50e-02 | 0.119000 | 4.85e-02 | 5.84e-03 | 7.22e-01 | 5.16e-01 | 7.90e-01 | 9.74e-01 |
| G-protein beta:gamma signalling | 22 | 8.08e-01 | 9.36e-01 | 0.1440 | -9.64e-02 | 0.018700 | -1.69e-02 | -1.04e-01 | 4.34e-01 | 8.79e-01 | 8.91e-01 | 4.00e-01 |
| tRNA processing in the nucleus | 42 | 5.71e-01 | 8.67e-01 | 0.1440 | 7.23e-02 | 0.065100 | 8.70e-02 | -5.99e-02 | 4.18e-01 | 4.66e-01 | 3.29e-01 | 5.02e-01 |
| Signaling by NOTCH4 | 59 | 3.29e-01 | 7.66e-01 | 0.1440 | -6.72e-02 | 0.034200 | 8.03e-03 | -1.22e-01 | 3.72e-01 | 6.50e-01 | 9.15e-01 | 1.06e-01 |
| Vpu mediated degradation of CD4 | 34 | 7.50e-01 | 9.11e-01 | 0.1430 | -1.07e-01 | -0.047200 | -1.20e-02 | -8.15e-02 | 2.79e-01 | 6.34e-01 | 9.04e-01 | 4.11e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 40 | 8.00e-01 | 9.36e-01 | 0.1430 | 6.60e-02 | 0.095500 | 6.42e-02 | 5.42e-02 | 4.70e-01 | 2.96e-01 | 4.82e-01 | 5.53e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 16 | 8.28e-01 | 9.37e-01 | 0.1430 | -1.20e-01 | 0.023500 | -7.49e-02 | -7.99e-04 | 4.07e-01 | 8.71e-01 | 6.04e-01 | 9.96e-01 |
| Stimuli-sensing channels | 77 | 3.50e-01 | 7.67e-01 | 0.1430 | 5.64e-02 | 0.118000 | -4.45e-02 | -3.69e-02 | 3.92e-01 | 7.30e-02 | 5.00e-01 | 5.76e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 32 | 6.19e-01 | 8.78e-01 | 0.1430 | 8.03e-02 | -0.093300 | -7.20e-02 | 1.07e-02 | 4.32e-01 | 3.61e-01 | 4.81e-01 | 9.17e-01 |
| Semaphorin interactions | 54 | 3.44e-01 | 7.67e-01 | 0.1430 | 1.23e-01 | -0.033100 | -3.41e-02 | 5.47e-02 | 1.18e-01 | 6.74e-01 | 6.65e-01 | 4.87e-01 |
| GPCR downstream signalling | 681 | 2.82e-08 | 4.66e-06 | 0.1430 | 7.18e-02 | 0.113000 | -4.62e-02 | 1.95e-02 | 1.56e-03 | 6.83e-07 | 4.20e-02 | 3.90e-01 |
| Amino acids regulate mTORC1 | 36 | 4.71e-01 | 8.26e-01 | 0.1430 | -1.08e-02 | -0.011300 | 1.31e-01 | -5.39e-02 | 9.11e-01 | 9.07e-01 | 1.73e-01 | 5.76e-01 |
| DNA strand elongation | 23 | 8.42e-01 | 9.43e-01 | 0.1420 | -2.61e-03 | -0.125000 | -4.67e-02 | -4.95e-02 | 9.83e-01 | 2.99e-01 | 6.99e-01 | 6.81e-01 |
| Nuclear Events (kinase and transcription factor activation) | 49 | 4.76e-01 | 8.26e-01 | 0.1420 | 8.61e-02 | 0.020900 | 1.12e-01 | 2.53e-03 | 2.97e-01 | 8.00e-01 | 1.77e-01 | 9.76e-01 |
| Regulation of HSF1-mediated heat shock response | 51 | 5.63e-01 | 8.67e-01 | 0.1420 | 1.48e-02 | 0.125000 | 6.25e-02 | -1.84e-02 | 8.55e-01 | 1.22e-01 | 4.41e-01 | 8.20e-01 |
| Metal ion SLC transporters | 19 | 8.46e-01 | 9.44e-01 | 0.1420 | 2.05e-02 | -0.115000 | -3.11e-02 | -7.43e-02 | 8.77e-01 | 3.87e-01 | 8.14e-01 | 5.75e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 15 | 8.36e-01 | 9.40e-01 | 0.1410 | -2.19e-02 | 0.130000 | -5.10e-02 | -5.53e-03 | 8.83e-01 | 3.84e-01 | 7.32e-01 | 9.70e-01 |
| NCAM signaling for neurite out-growth | 46 | 4.27e-01 | 7.93e-01 | 0.1410 | -4.65e-02 | -0.036800 | -6.41e-02 | 1.11e-01 | 5.86e-01 | 6.66e-01 | 4.52e-01 | 1.95e-01 |
| Nuclear Receptor transcription pathway | 48 | 4.14e-01 | 7.90e-01 | 0.1410 | -4.74e-02 | 0.053000 | 3.41e-03 | 1.21e-01 | 5.70e-01 | 5.25e-01 | 9.67e-01 | 1.46e-01 |
| ER-Phagosome pathway | 53 | 6.67e-01 | 8.93e-01 | 0.1410 | 4.65e-02 | 0.006000 | -8.08e-02 | -1.05e-01 | 5.58e-01 | 9.40e-01 | 3.09e-01 | 1.85e-01 |
| Regulation of TP53 Degradation | 29 | 6.60e-01 | 8.91e-01 | 0.1410 | 5.55e-02 | -0.046900 | -8.52e-04 | -1.20e-01 | 6.05e-01 | 6.62e-01 | 9.94e-01 | 2.62e-01 |
| FGFR3 ligand binding and activation | 10 | 9.68e-01 | 9.85e-01 | 0.1410 | 5.24e-02 | 0.127000 | -1.77e-02 | -2.23e-02 | 7.74e-01 | 4.86e-01 | 9.23e-01 | 9.03e-01 |
| FGFR3c ligand binding and activation | 10 | 9.68e-01 | 9.85e-01 | 0.1410 | 5.24e-02 | 0.127000 | -1.77e-02 | -2.23e-02 | 7.74e-01 | 4.86e-01 | 9.23e-01 | 9.03e-01 |
| Epigenetic regulation of gene expression | 61 | 5.10e-01 | 8.39e-01 | 0.1390 | 5.58e-03 | -0.051500 | -4.60e-02 | -1.21e-01 | 9.40e-01 | 4.87e-01 | 5.34e-01 | 1.02e-01 |
| Negative regulation of FGFR4 signaling | 23 | 6.87e-01 | 8.99e-01 | 0.1390 | -4.08e-02 | 0.123000 | -1.61e-02 | 4.81e-02 | 7.35e-01 | 3.06e-01 | 8.94e-01 | 6.90e-01 |
| Activation of ATR in response to replication stress | 23 | 7.87e-01 | 9.31e-01 | 0.1390 | 8.04e-02 | 0.038800 | 5.98e-02 | -8.85e-02 | 5.05e-01 | 7.47e-01 | 6.20e-01 | 4.62e-01 |
| Regulation of RAS by GAPs | 47 | 4.53e-01 | 8.19e-01 | 0.1390 | -8.71e-03 | 0.047400 | 4.21e-02 | -1.23e-01 | 9.18e-01 | 5.75e-01 | 6.18e-01 | 1.44e-01 |
| Mitotic G2-G2/M phases | 129 | 1.70e-02 | 3.34e-01 | 0.1390 | 1.63e-02 | 0.010200 | 1.19e-01 | -6.86e-02 | 7.49e-01 | 8.42e-01 | 1.97e-02 | 1.79e-01 |
| Insulin receptor signalling cascade | 45 | 3.39e-01 | 7.67e-01 | 0.1380 | -6.52e-03 | 0.071500 | -1.15e-01 | 2.89e-02 | 9.40e-01 | 4.07e-01 | 1.84e-01 | 7.38e-01 |
| Estrogen-dependent gene expression | 72 | 2.35e-01 | 6.96e-01 | 0.1380 | 7.49e-02 | 0.031700 | 5.85e-02 | -9.50e-02 | 2.72e-01 | 6.43e-01 | 3.91e-01 | 1.64e-01 |
| Transcriptional regulation by small RNAs | 29 | 5.88e-01 | 8.71e-01 | 0.1380 | -6.75e-03 | -0.006670 | 1.14e-01 | -7.68e-02 | 9.50e-01 | 9.50e-01 | 2.87e-01 | 4.74e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 33 | 7.32e-01 | 9.06e-01 | 0.1380 | -8.02e-02 | -0.040400 | 4.73e-03 | -1.05e-01 | 4.25e-01 | 6.88e-01 | 9.63e-01 | 2.98e-01 |
| p53-Independent DNA Damage Response | 33 | 7.32e-01 | 9.06e-01 | 0.1380 | -8.02e-02 | -0.040400 | 4.73e-03 | -1.05e-01 | 4.25e-01 | 6.88e-01 | 9.63e-01 | 2.98e-01 |
| p53-Independent G1/S DNA damage checkpoint | 33 | 7.32e-01 | 9.06e-01 | 0.1380 | -8.02e-02 | -0.040400 | 4.73e-03 | -1.05e-01 | 4.25e-01 | 6.88e-01 | 9.63e-01 | 2.98e-01 |
| RHO GTPases Activate Formins | 88 | 3.03e-01 | 7.49e-01 | 0.1380 | 3.35e-02 | 0.104000 | 7.02e-02 | -4.60e-02 | 5.88e-01 | 9.17e-02 | 2.56e-01 | 4.57e-01 |
| SUMOylation of intracellular receptors | 25 | 8.94e-01 | 9.63e-01 | 0.1380 | -1.97e-02 | 0.033100 | 1.17e-01 | 6.17e-02 | 8.64e-01 | 7.75e-01 | 3.11e-01 | 5.94e-01 |
| Degradation of GLI1 by the proteasome | 38 | 5.84e-01 | 8.70e-01 | 0.1380 | -1.15e-01 | 0.030500 | -2.42e-02 | -6.57e-02 | 2.21e-01 | 7.45e-01 | 7.97e-01 | 4.84e-01 |
| Separation of Sister Chromatids | 123 | 4.04e-02 | 4.38e-01 | 0.1380 | -2.22e-02 | 0.036100 | 5.36e-02 | -1.20e-01 | 6.72e-01 | 4.90e-01 | 3.05e-01 | 2.22e-02 |
| Phosphorylation of the APC/C | 16 | 8.57e-01 | 9.45e-01 | 0.1380 | -3.93e-02 | -0.030100 | 4.45e-02 | -1.20e-01 | 7.85e-01 | 8.35e-01 | 7.58e-01 | 4.04e-01 |
| Negative regulation of MAPK pathway | 33 | 5.96e-01 | 8.75e-01 | 0.1380 | -1.24e-01 | 0.031400 | -7.97e-03 | 4.96e-02 | 2.17e-01 | 7.55e-01 | 9.37e-01 | 6.22e-01 |
| ABC transporters in lipid homeostasis | 13 | 9.53e-01 | 9.82e-01 | 0.1370 | 1.14e-01 | 0.042500 | 6.31e-02 | 8.40e-03 | 4.78e-01 | 7.91e-01 | 6.94e-01 | 9.58e-01 |
| p53-Dependent G1 DNA Damage Response | 45 | 5.81e-01 | 8.69e-01 | 0.1370 | -5.51e-02 | -0.040100 | 4.04e-03 | -1.19e-01 | 5.23e-01 | 6.42e-01 | 9.63e-01 | 1.69e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 45 | 5.81e-01 | 8.69e-01 | 0.1370 | -5.51e-02 | -0.040100 | 4.04e-03 | -1.19e-01 | 5.23e-01 | 6.42e-01 | 9.63e-01 | 1.69e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 56 | 2.47e-01 | 7.09e-01 | 0.1370 | 4.58e-02 | -0.045400 | 4.28e-02 | -1.12e-01 | 5.54e-01 | 5.57e-01 | 5.80e-01 | 1.46e-01 |
| HCMV Early Events | 44 | 6.83e-01 | 8.99e-01 | 0.1360 | 4.37e-02 | 0.100000 | 1.37e-02 | -8.02e-02 | 6.16e-01 | 2.51e-01 | 8.75e-01 | 3.58e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 75 | 4.70e-01 | 8.26e-01 | 0.1360 | 5.65e-02 | 0.071400 | -2.07e-02 | -9.86e-02 | 3.98e-01 | 2.85e-01 | 7.57e-01 | 1.40e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 71 | 5.01e-01 | 8.33e-01 | 0.1360 | 2.81e-02 | 0.120000 | 4.72e-02 | 2.97e-02 | 6.83e-01 | 7.95e-02 | 4.92e-01 | 6.66e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 71 | 5.01e-01 | 8.33e-01 | 0.1360 | 2.81e-02 | 0.120000 | 4.72e-02 | 2.97e-02 | 6.83e-01 | 7.95e-02 | 4.92e-01 | 6.66e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 71 | 5.01e-01 | 8.33e-01 | 0.1360 | 2.81e-02 | 0.120000 | 4.72e-02 | 2.97e-02 | 6.83e-01 | 7.95e-02 | 4.92e-01 | 6.66e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 71 | 5.01e-01 | 8.33e-01 | 0.1360 | 2.81e-02 | 0.120000 | 4.72e-02 | 2.97e-02 | 6.83e-01 | 7.95e-02 | 4.92e-01 | 6.66e-01 |
| Hedgehog 'on' state | 55 | 6.64e-01 | 8.92e-01 | 0.1350 | -5.15e-02 | -0.024300 | -1.03e-01 | -6.64e-02 | 5.09e-01 | 7.56e-01 | 1.85e-01 | 3.95e-01 |
| M Phase | 260 | 2.57e-04 | 2.42e-02 | 0.1350 | 2.98e-02 | 0.030900 | 9.71e-02 | -8.39e-02 | 4.10e-01 | 3.93e-01 | 7.22e-03 | 2.03e-02 |
| Transcriptional activation of mitochondrial biogenesis | 45 | 5.26e-01 | 8.49e-01 | 0.1350 | -6.58e-02 | 0.005400 | 1.15e-01 | -2.74e-02 | 4.45e-01 | 9.50e-01 | 1.83e-01 | 7.51e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 60 | 5.64e-01 | 8.67e-01 | 0.1350 | -6.51e-02 | -0.012300 | 4.03e-02 | 1.11e-01 | 3.83e-01 | 8.69e-01 | 5.90e-01 | 1.39e-01 |
| Activation of the phototransduction cascade | 11 | 9.57e-01 | 9.83e-01 | 0.1350 | -2.94e-02 | -0.068700 | -1.67e-02 | 1.11e-01 | 8.66e-01 | 6.93e-01 | 9.24e-01 | 5.24e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 54 | 7.09e-01 | 9.05e-01 | 0.1350 | -6.46e-02 | -0.070400 | -4.75e-02 | -8.21e-02 | 4.12e-01 | 3.71e-01 | 5.47e-01 | 2.97e-01 |
| mRNA Splicing | 122 | 1.56e-01 | 6.51e-01 | 0.1350 | 5.06e-02 | 0.084800 | 4.02e-02 | -8.21e-02 | 3.35e-01 | 1.06e-01 | 4.44e-01 | 1.18e-01 |
| Chromatin modifying enzymes | 150 | 5.03e-03 | 1.82e-01 | 0.1340 | 4.12e-02 | -0.109000 | 6.68e-02 | -8.61e-03 | 3.85e-01 | 2.16e-02 | 1.59e-01 | 8.56e-01 |
| Chromatin organization | 150 | 5.03e-03 | 1.82e-01 | 0.1340 | 4.12e-02 | -0.109000 | 6.68e-02 | -8.61e-03 | 3.85e-01 | 2.16e-02 | 1.59e-01 | 8.56e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 90 | 2.32e-01 | 6.96e-01 | 0.1340 | 8.82e-02 | 0.031300 | -9.52e-02 | 1.60e-02 | 1.49e-01 | 6.08e-01 | 1.19e-01 | 7.93e-01 |
| G-protein activation | 20 | 8.34e-01 | 9.39e-01 | 0.1340 | 4.23e-02 | 0.067700 | -3.12e-02 | 1.03e-01 | 7.43e-01 | 6.00e-01 | 8.09e-01 | 4.25e-01 |
| GABA synthesis, release, reuptake and degradation | 13 | 9.63e-01 | 9.85e-01 | 0.1340 | -9.01e-02 | -0.039800 | -8.38e-02 | -3.53e-02 | 5.74e-01 | 8.04e-01 | 6.01e-01 | 8.26e-01 |
| Defects in vitamin and cofactor metabolism | 14 | 9.11e-01 | 9.66e-01 | 0.1340 | -4.70e-02 | 0.079900 | -5.35e-04 | -9.67e-02 | 7.61e-01 | 6.05e-01 | 9.97e-01 | 5.31e-01 |
| FGFR2 mutant receptor activation | 20 | 9.41e-01 | 9.78e-01 | 0.1340 | 2.52e-02 | -0.007010 | -8.77e-02 | -9.78e-02 | 8.45e-01 | 9.57e-01 | 4.97e-01 | 4.49e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 13 | 8.85e-01 | 9.58e-01 | 0.1340 | 3.37e-02 | 0.044300 | -7.76e-02 | 9.39e-02 | 8.34e-01 | 7.82e-01 | 6.28e-01 | 5.58e-01 |
| G1/S Transition | 92 | 1.84e-01 | 6.71e-01 | 0.1340 | 2.51e-02 | 0.033600 | 1.24e-01 | -2.53e-02 | 6.77e-01 | 5.78e-01 | 3.97e-02 | 6.75e-01 |
| Amyloid fiber formation | 34 | 8.31e-01 | 9.39e-01 | 0.1330 | -6.16e-02 | -0.045900 | 8.95e-02 | 6.22e-02 | 5.35e-01 | 6.44e-01 | 3.67e-01 | 5.31e-01 |
| Switching of origins to a post-replicative state | 63 | 4.18e-01 | 7.91e-01 | 0.1330 | -1.21e-02 | 0.025500 | 1.72e-03 | -1.30e-01 | 8.68e-01 | 7.26e-01 | 9.81e-01 | 7.47e-02 |
| Neutrophil degranulation | 333 | 1.18e-02 | 2.83e-01 | 0.1330 | -6.50e-02 | -0.087700 | -3.58e-02 | -6.68e-02 | 4.23e-02 | 6.15e-03 | 2.63e-01 | 3.71e-02 |
| Plasma lipoprotein clearance | 29 | 5.90e-01 | 8.73e-01 | 0.1330 | 7.53e-03 | -0.085100 | 9.29e-02 | -4.03e-02 | 9.44e-01 | 4.28e-01 | 3.87e-01 | 7.07e-01 |
| Assembly of the pre-replicative complex | 46 | 4.81e-01 | 8.26e-01 | 0.1320 | -5.28e-03 | -0.000967 | 3.53e-02 | -1.27e-01 | 9.51e-01 | 9.91e-01 | 6.79e-01 | 1.35e-01 |
| Activation of G protein gated Potassium channels | 21 | 9.03e-01 | 9.63e-01 | 0.1320 | -2.15e-02 | 0.012500 | 3.73e-02 | 1.24e-01 | 8.64e-01 | 9.21e-01 | 7.67e-01 | 3.24e-01 |
| G protein gated Potassium channels | 21 | 9.03e-01 | 9.63e-01 | 0.1320 | -2.15e-02 | 0.012500 | 3.73e-02 | 1.24e-01 | 8.64e-01 | 9.21e-01 | 7.67e-01 | 3.24e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 21 | 9.03e-01 | 9.63e-01 | 0.1320 | -2.15e-02 | 0.012500 | 3.73e-02 | 1.24e-01 | 8.64e-01 | 9.21e-01 | 7.67e-01 | 3.24e-01 |
| Intrinsic Pathway for Apoptosis | 41 | 5.90e-01 | 8.73e-01 | 0.1320 | -9.43e-03 | 0.069300 | 9.24e-02 | -6.37e-02 | 9.17e-01 | 4.43e-01 | 3.06e-01 | 4.80e-01 |
| Signaling by GPCR | 724 | 2.47e-08 | 4.66e-06 | 0.1320 | 5.49e-02 | 0.107000 | -4.58e-02 | 2.68e-02 | 1.27e-02 | 1.15e-06 | 3.77e-02 | 2.24e-01 |
| Ub-specific processing proteases | 125 | 3.79e-02 | 4.32e-01 | 0.1310 | -9.20e-03 | 0.018000 | 1.07e-01 | -7.27e-02 | 8.59e-01 | 7.28e-01 | 3.87e-02 | 1.61e-01 |
| G2/M Transition | 127 | 2.92e-02 | 4.13e-01 | 0.1310 | 1.10e-02 | 0.005030 | 1.12e-01 | -6.72e-02 | 8.31e-01 | 9.22e-01 | 2.99e-02 | 1.92e-01 |
| Post-translational protein phosphorylation | 79 | 3.29e-01 | 7.66e-01 | 0.1310 | 9.69e-02 | 0.045400 | -5.99e-02 | 4.60e-02 | 1.37e-01 | 4.86e-01 | 3.58e-01 | 4.80e-01 |
| Presynaptic function of Kainate receptors | 15 | 9.13e-01 | 9.67e-01 | 0.1310 | -2.16e-02 | 0.099200 | 4.60e-02 | -6.84e-02 | 8.85e-01 | 5.06e-01 | 7.58e-01 | 6.47e-01 |
| Transcriptional Regulation by TP53 | 256 | 2.56e-02 | 4.02e-01 | 0.1310 | -2.50e-02 | -0.060100 | -4.22e-02 | -1.05e-01 | 4.93e-01 | 9.90e-02 | 2.46e-01 | 3.85e-03 |
| Defective CFTR causes cystic fibrosis | 39 | 6.89e-01 | 8.99e-01 | 0.1300 | -4.09e-02 | -0.023200 | -1.81e-03 | -1.21e-01 | 6.59e-01 | 8.02e-01 | 9.84e-01 | 1.90e-01 |
| Cell Cycle, Mitotic | 359 | 9.06e-06 | 1.09e-03 | 0.1300 | 2.42e-02 | 0.014900 | 1.05e-01 | -7.14e-02 | 4.33e-01 | 6.29e-01 | 7.09e-04 | 2.07e-02 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 17 | 8.94e-01 | 9.63e-01 | 0.1300 | -2.26e-03 | -0.082500 | -2.62e-03 | -1.00e-01 | 9.87e-01 | 5.56e-01 | 9.85e-01 | 4.75e-01 |
| Diseases associated with glycosaminoglycan metabolism | 33 | 8.67e-01 | 9.49e-01 | 0.1290 | 6.62e-02 | 0.048600 | -5.72e-02 | -8.18e-02 | 5.11e-01 | 6.29e-01 | 5.70e-01 | 4.16e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 36 | 7.84e-01 | 9.30e-01 | 0.1290 | -9.72e-02 | -0.039300 | -2.19e-03 | -7.48e-02 | 3.13e-01 | 6.83e-01 | 9.82e-01 | 4.38e-01 |
| Negative regulation of FGFR1 signaling | 25 | 8.97e-01 | 9.63e-01 | 0.1290 | 2.98e-02 | 0.114000 | 3.67e-02 | 3.76e-02 | 7.97e-01 | 3.26e-01 | 7.51e-01 | 7.45e-01 |
| Metabolism of fat-soluble vitamins | 31 | 8.34e-01 | 9.39e-01 | 0.1280 | -1.26e-02 | -0.096600 | -8.21e-02 | 1.55e-02 | 9.03e-01 | 3.52e-01 | 4.29e-01 | 8.81e-01 |
| Fc epsilon receptor (FCERI) signaling | 96 | 3.37e-01 | 7.67e-01 | 0.1280 | -9.02e-03 | 0.106000 | 6.67e-02 | 2.60e-02 | 8.79e-01 | 7.30e-02 | 2.59e-01 | 6.60e-01 |
| HIV Infection | 151 | 4.30e-02 | 4.38e-01 | 0.1280 | -1.90e-02 | -0.015200 | 1.99e-02 | -1.24e-01 | 6.87e-01 | 7.47e-01 | 6.73e-01 | 8.70e-03 |
| Synthesis of bile acids and bile salts | 25 | 8.02e-01 | 9.36e-01 | 0.1280 | 1.85e-02 | -0.055900 | -3.83e-02 | 1.07e-01 | 8.73e-01 | 6.29e-01 | 7.40e-01 | 3.55e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 13 | 9.53e-01 | 9.82e-01 | 0.1270 | -4.78e-03 | -0.095700 | 1.39e-02 | 8.22e-02 | 9.76e-01 | 5.50e-01 | 9.31e-01 | 6.08e-01 |
| Chromosome Maintenance | 56 | 3.14e-01 | 7.52e-01 | 0.1270 | 4.98e-03 | -0.077000 | 5.03e-02 | -8.70e-02 | 9.49e-01 | 3.19e-01 | 5.15e-01 | 2.60e-01 |
| Cell Cycle | 449 | 3.73e-07 | 5.46e-05 | 0.1270 | 2.89e-02 | 0.005870 | 8.51e-02 | -8.90e-02 | 2.98e-01 | 8.32e-01 | 2.13e-03 | 1.32e-03 |
| Translation | 153 | 1.90e-01 | 6.71e-01 | 0.1260 | -1.04e-01 | -0.061600 | 3.79e-02 | 2.54e-03 | 2.71e-02 | 1.90e-01 | 4.20e-01 | 9.57e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 45 | 4.87e-01 | 8.26e-01 | 0.1260 | -4.15e-02 | -0.026300 | 7.45e-02 | -8.93e-02 | 6.30e-01 | 7.60e-01 | 3.88e-01 | 3.01e-01 |
| RNA Polymerase II Pre-transcription Events | 52 | 5.96e-01 | 8.75e-01 | 0.1260 | -1.57e-02 | -0.030700 | -9.97e-03 | -1.21e-01 | 8.45e-01 | 7.02e-01 | 9.01e-01 | 1.32e-01 |
| Signaling by NOTCH | 135 | 1.24e-01 | 6.23e-01 | 0.1260 | 3.35e-02 | -0.022600 | -1.81e-02 | -1.18e-01 | 5.03e-01 | 6.51e-01 | 7.17e-01 | 1.80e-02 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 55 | 4.55e-01 | 8.20e-01 | 0.1260 | -5.62e-02 | -0.037200 | 4.56e-02 | -9.62e-02 | 4.71e-01 | 6.33e-01 | 5.59e-01 | 2.17e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 55 | 4.55e-01 | 8.20e-01 | 0.1260 | -5.62e-02 | -0.037200 | 4.56e-02 | -9.62e-02 | 4.71e-01 | 6.33e-01 | 5.59e-01 | 2.17e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 40 | 6.41e-01 | 8.81e-01 | 0.1260 | -1.01e-01 | 0.014900 | 4.68e-02 | -5.76e-02 | 2.71e-01 | 8.70e-01 | 6.08e-01 | 5.29e-01 |
| Resolution of Abasic Sites (AP sites) | 29 | 7.84e-01 | 9.30e-01 | 0.1260 | -1.44e-02 | -0.076800 | 9.43e-02 | 2.93e-02 | 8.94e-01 | 4.74e-01 | 3.80e-01 | 7.85e-01 |
| Signaling by TGF-beta Receptor Complex | 50 | 6.66e-01 | 8.93e-01 | 0.1250 | 7.21e-02 | 0.039300 | -9.31e-02 | -1.24e-02 | 3.78e-01 | 6.31e-01 | 2.55e-01 | 8.79e-01 |
| Potassium Channels | 78 | 5.74e-01 | 8.67e-01 | 0.1250 | 8.65e-02 | 0.055600 | 6.89e-02 | 1.42e-02 | 1.87e-01 | 3.96e-01 | 2.94e-01 | 8.28e-01 |
| Translesion synthesis by POLK | 12 | 9.55e-01 | 9.83e-01 | 0.1240 | -2.47e-02 | 0.022300 | 7.27e-03 | 1.19e-01 | 8.82e-01 | 8.93e-01 | 9.65e-01 | 4.75e-01 |
| Activation of kainate receptors upon glutamate binding | 24 | 8.66e-01 | 9.49e-01 | 0.1240 | 2.04e-02 | 0.121000 | -1.39e-02 | -3.84e-03 | 8.62e-01 | 3.04e-01 | 9.06e-01 | 9.74e-01 |
| Keratan sulfate/keratin metabolism | 25 | 7.71e-01 | 9.24e-01 | 0.1240 | -1.11e-02 | -0.066100 | 1.03e-01 | -1.34e-02 | 9.23e-01 | 5.68e-01 | 3.73e-01 | 9.08e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 20 | 9.24e-01 | 9.73e-01 | 0.1240 | 1.43e-02 | 0.083700 | -3.94e-02 | -8.06e-02 | 9.12e-01 | 5.17e-01 | 7.60e-01 | 5.33e-01 |
| Signal amplification | 24 | 7.24e-01 | 9.06e-01 | 0.1240 | -4.09e-02 | 0.097900 | -3.71e-02 | 5.13e-02 | 7.29e-01 | 4.07e-01 | 7.53e-01 | 6.64e-01 |
| Signaling by RAF1 mutants | 30 | 7.48e-01 | 9.11e-01 | 0.1240 | 1.17e-03 | 0.007290 | 1.21e-01 | -2.45e-02 | 9.91e-01 | 9.45e-01 | 2.52e-01 | 8.16e-01 |
| Signaling by the B Cell Receptor (BCR) | 79 | 3.60e-01 | 7.67e-01 | 0.1230 | -9.34e-03 | 0.080800 | 1.90e-02 | -9.09e-02 | 8.86e-01 | 2.15e-01 | 7.70e-01 | 1.63e-01 |
| G1/S DNA Damage Checkpoints | 46 | 6.24e-01 | 8.78e-01 | 0.1230 | -4.26e-02 | -0.035700 | 1.51e-02 | -1.09e-01 | 6.18e-01 | 6.75e-01 | 8.60e-01 | 2.01e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 31 | 7.80e-01 | 9.29e-01 | 0.1230 | 2.78e-02 | 0.086000 | -1.08e-02 | 8.29e-02 | 7.89e-01 | 4.07e-01 | 9.17e-01 | 4.25e-01 |
| TP53 Regulates Metabolic Genes | 62 | 4.85e-01 | 8.26e-01 | 0.1230 | -6.08e-03 | 0.009530 | -1.22e-01 | -1.19e-02 | 9.34e-01 | 8.97e-01 | 9.69e-02 | 8.71e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 27 | 9.14e-01 | 9.68e-01 | 0.1230 | 3.82e-02 | 0.107000 | 4.29e-02 | 1.70e-02 | 7.32e-01 | 3.34e-01 | 7.00e-01 | 8.78e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 144 | 2.85e-02 | 4.13e-01 | 0.1220 | -1.95e-03 | 0.103000 | -5.99e-02 | 2.91e-02 | 9.68e-01 | 3.40e-02 | 2.16e-01 | 5.48e-01 |
| Long-term potentiation | 19 | 8.26e-01 | 9.37e-01 | 0.1220 | -2.60e-02 | 0.088700 | -7.95e-02 | 3.02e-03 | 8.45e-01 | 5.03e-01 | 5.49e-01 | 9.82e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 89 | 3.33e-01 | 7.67e-01 | 0.1210 | -3.74e-02 | -0.061000 | -4.45e-02 | 8.74e-02 | 5.43e-01 | 3.21e-01 | 4.68e-01 | 1.55e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 18 | 9.58e-01 | 9.83e-01 | 0.1210 | -7.92e-02 | -0.081200 | 3.80e-02 | 2.03e-02 | 5.61e-01 | 5.51e-01 | 7.80e-01 | 8.81e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 27 | 8.58e-01 | 9.45e-01 | 0.1210 | 6.16e-02 | 0.076400 | -7.11e-02 | 3.83e-03 | 5.80e-01 | 4.92e-01 | 5.23e-01 | 9.73e-01 |
| Deubiquitination | 183 | 5.32e-02 | 4.71e-01 | 0.1210 | 6.19e-03 | 0.040200 | 1.13e-01 | -1.73e-02 | 8.86e-01 | 3.50e-01 | 8.81e-03 | 6.86e-01 |
| Interleukin-15 signaling | 11 | 9.63e-01 | 9.85e-01 | 0.1210 | 6.11e-02 | -0.043400 | 6.64e-02 | 6.77e-02 | 7.26e-01 | 8.03e-01 | 7.03e-01 | 6.98e-01 |
| Transcriptional regulation by RUNX2 | 80 | 5.17e-01 | 8.47e-01 | 0.1210 | 4.24e-02 | 0.078600 | 6.50e-03 | -8.08e-02 | 5.13e-01 | 2.24e-01 | 9.20e-01 | 2.12e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 13 | 9.28e-01 | 9.73e-01 | 0.1210 | -1.22e-02 | 0.099900 | -6.43e-02 | -1.64e-02 | 9.39e-01 | 5.33e-01 | 6.88e-01 | 9.19e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 44 | 8.62e-01 | 9.46e-01 | 0.1200 | 4.15e-02 | 0.055800 | 6.34e-02 | 7.48e-02 | 6.34e-01 | 5.22e-01 | 4.67e-01 | 3.91e-01 |
| Mitochondrial translation termination | 55 | 7.20e-01 | 9.06e-01 | 0.1200 | -9.53e-02 | -0.062800 | 2.18e-02 | -2.91e-02 | 2.22e-01 | 4.21e-01 | 7.79e-01 | 7.09e-01 |
| ABC-family proteins mediated transport | 70 | 5.30e-01 | 8.51e-01 | 0.1200 | -4.59e-02 | -0.063600 | -2.03e-03 | -9.04e-02 | 5.07e-01 | 3.58e-01 | 9.77e-01 | 1.91e-01 |
| SUMO E3 ligases SUMOylate target proteins | 121 | 1.04e-01 | 6.00e-01 | 0.1200 | 6.57e-02 | 0.018500 | 7.15e-02 | -6.74e-02 | 2.13e-01 | 7.26e-01 | 1.75e-01 | 2.01e-01 |
| FCERI mediated NF-kB activation | 54 | 4.90e-01 | 8.26e-01 | 0.1190 | -1.10e-01 | 0.042300 | 9.72e-03 | -1.45e-02 | 1.61e-01 | 5.91e-01 | 9.02e-01 | 8.53e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 17 | 8.56e-01 | 9.45e-01 | 0.1190 | -2.45e-02 | 0.094800 | -6.54e-02 | 1.78e-02 | 8.61e-01 | 4.98e-01 | 6.41e-01 | 8.99e-01 |
| SUMOylation of ubiquitinylation proteins | 25 | 8.25e-01 | 9.37e-01 | 0.1190 | 4.91e-04 | 0.032700 | 1.03e-01 | -4.88e-02 | 9.97e-01 | 7.77e-01 | 3.71e-01 | 6.73e-01 |
| Signaling by VEGF | 88 | 4.52e-01 | 8.19e-01 | 0.1190 | 6.37e-02 | -0.038000 | -5.79e-02 | -7.27e-02 | 3.03e-01 | 5.38e-01 | 3.48e-01 | 2.39e-01 |
| Eukaryotic Translation Termination | 35 | 7.99e-01 | 9.36e-01 | 0.1190 | -8.39e-02 | 0.040000 | 6.65e-02 | 3.20e-02 | 3.91e-01 | 6.83e-01 | 4.96e-01 | 7.43e-01 |
| Collagen chain trimerization | 38 | 7.43e-01 | 9.08e-01 | 0.1190 | 1.00e-01 | -0.002450 | -5.60e-02 | 3.05e-02 | 2.87e-01 | 9.79e-01 | 5.51e-01 | 7.45e-01 |
| Hedgehog ligand biogenesis | 44 | 7.11e-01 | 9.05e-01 | 0.1180 | 6.96e-04 | -0.027800 | -9.41e-03 | -1.15e-01 | 9.94e-01 | 7.50e-01 | 9.14e-01 | 1.88e-01 |
| Regulation of expression of SLITs and ROBOs | 86 | 4.20e-01 | 7.91e-01 | 0.1180 | -2.16e-02 | 0.069800 | 9.23e-02 | -9.89e-03 | 7.29e-01 | 2.64e-01 | 1.39e-01 | 8.74e-01 |
| Inwardly rectifying K+ channels | 27 | 8.04e-01 | 9.36e-01 | 0.1180 | -2.21e-03 | -0.029200 | -4.84e-02 | 1.04e-01 | 9.84e-01 | 7.93e-01 | 6.64e-01 | 3.52e-01 |
| Vitamin B5 (pantothenate) metabolism | 13 | 9.70e-01 | 9.86e-01 | 0.1180 | 1.09e-01 | 0.022400 | 1.98e-02 | 3.23e-02 | 4.95e-01 | 8.89e-01 | 9.02e-01 | 8.40e-01 |
| MAP2K and MAPK activation | 28 | 7.50e-01 | 9.11e-01 | 0.1180 | 7.69e-03 | 0.002570 | 1.03e-01 | -5.58e-02 | 9.44e-01 | 9.81e-01 | 3.44e-01 | 6.09e-01 |
| Peptide hormone metabolism | 62 | 7.10e-01 | 9.05e-01 | 0.1180 | 4.53e-02 | 0.095300 | 2.26e-02 | 4.71e-02 | 5.38e-01 | 1.95e-01 | 7.58e-01 | 5.22e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 18 | 9.29e-01 | 9.73e-01 | 0.1180 | 1.39e-02 | -0.035200 | 1.04e-01 | 4.01e-02 | 9.19e-01 | 7.96e-01 | 4.46e-01 | 7.68e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 22 | 9.45e-01 | 9.79e-01 | 0.1170 | 6.10e-02 | 0.076500 | 6.13e-02 | -2.06e-02 | 6.20e-01 | 5.35e-01 | 6.19e-01 | 8.67e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 22 | 9.45e-01 | 9.79e-01 | 0.1170 | 6.10e-02 | 0.076500 | 6.13e-02 | -2.06e-02 | 6.20e-01 | 5.35e-01 | 6.19e-01 | 8.67e-01 |
| Signaling by MET | 54 | 5.43e-01 | 8.57e-01 | 0.1170 | -6.02e-02 | 0.063400 | -4.24e-02 | -6.55e-02 | 4.44e-01 | 4.21e-01 | 5.90e-01 | 4.05e-01 |
| SLC-mediated transmembrane transport | 205 | 1.61e-01 | 6.59e-01 | 0.1170 | -5.02e-02 | -0.055500 | 5.56e-02 | 7.09e-02 | 2.17e-01 | 1.72e-01 | 1.71e-01 | 8.09e-02 |
| Mitotic G1 phase and G1/S transition | 104 | 1.77e-01 | 6.71e-01 | 0.1170 | 2.65e-02 | 0.006690 | 1.09e-01 | -3.04e-02 | 6.41e-01 | 9.06e-01 | 5.47e-02 | 5.93e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 42 | 6.95e-01 | 9.01e-01 | 0.1160 | -3.52e-02 | 0.025300 | 1.05e-01 | -2.56e-02 | 6.93e-01 | 7.77e-01 | 2.39e-01 | 7.74e-01 |
| C-type lectin receptors (CLRs) | 96 | 2.79e-01 | 7.33e-01 | 0.1160 | -2.20e-02 | 0.097500 | -9.92e-03 | -5.85e-02 | 7.10e-01 | 9.91e-02 | 8.67e-01 | 3.23e-01 |
| SUMOylation of chromatin organization proteins | 39 | 7.32e-01 | 9.06e-01 | 0.1160 | 4.36e-02 | 0.038300 | 9.22e-02 | -4.04e-02 | 6.37e-01 | 6.79e-01 | 3.19e-01 | 6.62e-01 |
| Presynaptic depolarization and calcium channel opening | 11 | 9.54e-01 | 9.83e-01 | 0.1160 | 7.30e-02 | -0.083400 | -3.05e-02 | -1.67e-02 | 6.75e-01 | 6.32e-01 | 8.61e-01 | 9.24e-01 |
| Beta-catenin independent WNT signaling | 111 | 3.55e-01 | 7.67e-01 | 0.1160 | -6.33e-02 | -0.022300 | 9.25e-02 | 1.97e-02 | 2.50e-01 | 6.86e-01 | 9.28e-02 | 7.20e-01 |
| HATs acetylate histones | 57 | 4.03e-01 | 7.88e-01 | 0.1160 | 3.13e-03 | -0.009530 | 7.58e-02 | -8.72e-02 | 9.67e-01 | 9.01e-01 | 3.23e-01 | 2.55e-01 |
| DNA Replication Pre-Initiation | 58 | 4.02e-01 | 7.88e-01 | 0.1160 | 1.03e-02 | -0.021200 | 5.62e-02 | -9.84e-02 | 8.93e-01 | 7.80e-01 | 4.60e-01 | 1.95e-01 |
| p130Cas linkage to MAPK signaling for integrins | 13 | 9.36e-01 | 9.76e-01 | 0.1160 | 1.95e-02 | -0.088100 | 6.91e-02 | 2.14e-02 | 9.03e-01 | 5.83e-01 | 6.66e-01 | 8.94e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 42 | 7.39e-01 | 9.06e-01 | 0.1160 | -9.81e-02 | 0.021500 | 5.67e-02 | 7.34e-03 | 2.72e-01 | 8.09e-01 | 5.25e-01 | 9.34e-01 |
| Cellular Senescence | 101 | 2.48e-01 | 7.09e-01 | 0.1150 | 4.86e-02 | -0.004350 | 1.29e-02 | -1.04e-01 | 3.99e-01 | 9.40e-01 | 8.23e-01 | 7.21e-02 |
| Formation of TC-NER Pre-Incision Complex | 32 | 7.56e-01 | 9.15e-01 | 0.1150 | -7.03e-02 | 0.067200 | 4.14e-03 | -6.17e-02 | 4.92e-01 | 5.11e-01 | 9.68e-01 | 5.46e-01 |
| Interleukin-1 signaling | 71 | 4.15e-01 | 7.90e-01 | 0.1150 | -4.70e-02 | 0.088500 | 3.64e-02 | -4.21e-02 | 4.94e-01 | 1.98e-01 | 5.96e-01 | 5.40e-01 |
| RHO GTPase Effectors | 191 | 1.47e-02 | 3.25e-01 | 0.1140 | -1.53e-02 | -0.010800 | 9.42e-02 | -6.12e-02 | 7.16e-01 | 7.98e-01 | 2.52e-02 | 1.46e-01 |
| Host Interactions of HIV factors | 89 | 2.72e-01 | 7.27e-01 | 0.1140 | -5.46e-02 | -0.002650 | 7.00e-02 | -7.10e-02 | 3.74e-01 | 9.66e-01 | 2.54e-01 | 2.47e-01 |
| APC/C-mediated degradation of cell cycle proteins | 64 | 3.69e-01 | 7.67e-01 | 0.1130 | -1.58e-02 | -0.022000 | 8.69e-02 | -6.77e-02 | 8.27e-01 | 7.61e-01 | 2.30e-01 | 3.49e-01 |
| Regulation of mitotic cell cycle | 64 | 3.69e-01 | 7.67e-01 | 0.1130 | -1.58e-02 | -0.022000 | 8.69e-02 | -6.77e-02 | 8.27e-01 | 7.61e-01 | 2.30e-01 | 3.49e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 38 | 7.60e-01 | 9.16e-01 | 0.1130 | 9.85e-03 | -0.052000 | -5.41e-03 | -1.00e-01 | 9.16e-01 | 5.79e-01 | 9.54e-01 | 2.86e-01 |
| Mitochondrial translation | 61 | 7.51e-01 | 9.11e-01 | 0.1130 | -8.67e-02 | -0.068600 | 1.42e-02 | -2.02e-02 | 2.42e-01 | 3.55e-01 | 8.48e-01 | 7.85e-01 |
| Regulation of insulin secretion | 65 | 5.22e-01 | 8.49e-01 | 0.1130 | 2.74e-02 | 0.032300 | -1.44e-02 | 1.04e-01 | 7.03e-01 | 6.52e-01 | 8.41e-01 | 1.49e-01 |
| TCR signaling | 81 | 3.96e-01 | 7.86e-01 | 0.1130 | -1.13e-02 | 0.065000 | 5.25e-02 | -7.51e-02 | 8.61e-01 | 3.12e-01 | 4.15e-01 | 2.43e-01 |
| G beta:gamma signalling through PLC beta | 14 | 9.45e-01 | 9.79e-01 | 0.1130 | -8.99e-02 | 0.047500 | 4.46e-02 | -1.88e-02 | 5.60e-01 | 7.58e-01 | 7.73e-01 | 9.03e-01 |
| Glucose metabolism | 71 | 7.08e-01 | 9.05e-01 | 0.1120 | -3.67e-02 | -0.099700 | -3.57e-02 | -7.13e-03 | 5.93e-01 | 1.47e-01 | 6.03e-01 | 9.17e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 52 | 5.73e-01 | 8.67e-01 | 0.1120 | -3.70e-02 | -0.029300 | 4.31e-02 | -9.20e-02 | 6.45e-01 | 7.15e-01 | 5.91e-01 | 2.51e-01 |
| S Phase | 116 | 1.52e-01 | 6.51e-01 | 0.1120 | 6.75e-03 | 0.021900 | 6.18e-02 | -9.06e-02 | 9.00e-01 | 6.84e-01 | 2.51e-01 | 9.25e-02 |
| Constitutive Signaling by AKT1 E17K in Cancer | 21 | 9.53e-01 | 9.82e-01 | 0.1120 | -8.40e-02 | -0.044400 | -9.29e-03 | -5.78e-02 | 5.05e-01 | 7.25e-01 | 9.41e-01 | 6.47e-01 |
| DNA Damage Bypass | 30 | 9.03e-01 | 9.63e-01 | 0.1120 | 1.64e-02 | -0.034700 | 6.88e-02 | 7.89e-02 | 8.77e-01 | 7.42e-01 | 5.14e-01 | 4.55e-01 |
| Regulation of Apoptosis | 35 | 8.43e-01 | 9.43e-01 | 0.1110 | -7.26e-02 | -0.015900 | -9.37e-04 | -8.28e-02 | 4.57e-01 | 8.70e-01 | 9.92e-01 | 3.97e-01 |
| TCF dependent signaling in response to WNT | 127 | 1.47e-01 | 6.51e-01 | 0.1110 | -4.00e-02 | 0.011600 | -1.99e-02 | 1.01e-01 | 4.37e-01 | 8.21e-01 | 6.99e-01 | 4.98e-02 |
| Signaling by NTRK1 (TRKA) | 95 | 5.26e-01 | 8.49e-01 | 0.1110 | 4.37e-02 | 0.041900 | 9.24e-02 | 9.79e-03 | 4.62e-01 | 4.81e-01 | 1.20e-01 | 8.69e-01 |
| Orc1 removal from chromatin | 47 | 6.81e-01 | 8.99e-01 | 0.1110 | -1.72e-02 | 0.048000 | 3.15e-02 | -9.30e-02 | 8.38e-01 | 5.70e-01 | 7.09e-01 | 2.70e-01 |
| HSF1-dependent transactivation | 25 | 8.23e-01 | 9.36e-01 | 0.1100 | 8.90e-03 | -0.097400 | 4.97e-02 | -1.25e-02 | 9.39e-01 | 3.99e-01 | 6.67e-01 | 9.14e-01 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 53 | 6.04e-01 | 8.75e-01 | 0.1100 | -3.02e-02 | -0.027100 | 2.94e-02 | -9.82e-02 | 7.04e-01 | 7.33e-01 | 7.12e-01 | 2.17e-01 |
| ABC transporter disorders | 52 | 8.16e-01 | 9.36e-01 | 0.1100 | -9.42e-02 | -0.043500 | -1.85e-02 | -3.20e-02 | 2.40e-01 | 5.88e-01 | 8.17e-01 | 6.90e-01 |
| Free fatty acids regulate insulin secretion | 11 | 9.88e-01 | 9.94e-01 | 0.1100 | -2.99e-03 | -0.016800 | -1.00e-01 | -4.26e-02 | 9.86e-01 | 9.23e-01 | 5.66e-01 | 8.07e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 35 | 8.08e-01 | 9.36e-01 | 0.1100 | -6.72e-02 | -0.012700 | 2.59e-02 | -8.21e-02 | 4.92e-01 | 8.96e-01 | 7.91e-01 | 4.01e-01 |
| SUMOylation | 126 | 1.18e-01 | 6.22e-01 | 0.1100 | 4.91e-02 | 0.005580 | 6.26e-02 | -7.53e-02 | 3.42e-01 | 9.14e-01 | 2.26e-01 | 1.45e-01 |
| Signaling by Erythropoietin | 19 | 9.61e-01 | 9.85e-01 | 0.1100 | 2.72e-02 | -0.016500 | 7.73e-02 | 7.09e-02 | 8.38e-01 | 9.01e-01 | 5.60e-01 | 5.93e-01 |
| Detoxification of Reactive Oxygen Species | 23 | 8.77e-01 | 9.53e-01 | 0.1090 | -6.11e-02 | 0.068400 | 2.61e-02 | -5.22e-02 | 6.12e-01 | 5.71e-01 | 8.29e-01 | 6.65e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 42 | 8.07e-01 | 9.36e-01 | 0.1080 | -7.29e-04 | 0.076400 | 7.06e-02 | -2.90e-02 | 9.93e-01 | 3.92e-01 | 4.29e-01 | 7.45e-01 |
| EPHB-mediated forward signaling | 24 | 9.26e-01 | 9.73e-01 | 0.1080 | 1.03e-01 | 0.020100 | 2.17e-02 | -8.58e-03 | 3.82e-01 | 8.65e-01 | 8.54e-01 | 9.42e-01 |
| Integration of energy metabolism | 93 | 6.06e-01 | 8.75e-01 | 0.1070 | -2.17e-02 | -0.040200 | 4.05e-02 | 8.85e-02 | 7.18e-01 | 5.04e-01 | 5.01e-01 | 1.41e-01 |
| Hedgehog 'off' state | 72 | 5.58e-01 | 8.67e-01 | 0.1070 | -5.87e-02 | 0.044200 | 2.97e-02 | 7.17e-02 | 3.90e-01 | 5.17e-01 | 6.63e-01 | 2.93e-01 |
| Thromboxane signalling through TP receptor | 16 | 9.53e-01 | 9.82e-01 | 0.1060 | -2.53e-02 | 0.021000 | 2.71e-03 | 1.01e-01 | 8.61e-01 | 8.84e-01 | 9.85e-01 | 4.83e-01 |
| Phospholipase C-mediated cascade: FGFR1 | 14 | 9.65e-01 | 9.85e-01 | 0.1060 | 2.57e-02 | 0.015000 | -7.60e-03 | 1.02e-01 | 8.68e-01 | 9.22e-01 | 9.61e-01 | 5.11e-01 |
| Degradation of GLI2 by the proteasome | 39 | 7.42e-01 | 9.07e-01 | 0.1060 | -1.00e-01 | 0.034500 | 1.58e-03 | -4.67e-03 | 2.79e-01 | 7.10e-01 | 9.86e-01 | 9.60e-01 |
| PI Metabolism | 72 | 7.18e-01 | 9.06e-01 | 0.1060 | 6.56e-02 | 0.043500 | 7.04e-02 | 7.45e-03 | 3.36e-01 | 5.24e-01 | 3.02e-01 | 9.13e-01 |
| VEGFA-VEGFR2 Pathway | 83 | 5.59e-01 | 8.67e-01 | 0.1060 | 6.60e-02 | -0.036700 | -4.87e-02 | -5.59e-02 | 2.99e-01 | 5.64e-01 | 4.43e-01 | 3.79e-01 |
| Triglyceride metabolism | 28 | 8.32e-01 | 9.39e-01 | 0.1050 | 1.56e-02 | 0.052400 | -8.75e-02 | 1.96e-02 | 8.86e-01 | 6.32e-01 | 4.23e-01 | 8.57e-01 |
| Synthesis of DNA | 85 | 4.44e-01 | 8.13e-01 | 0.1050 | -1.31e-02 | -0.017800 | 1.42e-02 | -1.02e-01 | 8.35e-01 | 7.77e-01 | 8.21e-01 | 1.06e-01 |
| COPI-mediated anterograde transport | 66 | 7.20e-01 | 9.06e-01 | 0.1050 | -5.04e-02 | -0.019100 | -8.60e-02 | -2.53e-02 | 4.79e-01 | 7.88e-01 | 2.27e-01 | 7.23e-01 |
| Class I MHC mediated antigen processing & presentation | 264 | 1.20e-01 | 6.22e-01 | 0.1050 | 4.39e-02 | 0.082700 | -2.30e-02 | -4.05e-02 | 2.22e-01 | 2.11e-02 | 5.21e-01 | 2.59e-01 |
| Signaling by NTRKs | 110 | 5.58e-01 | 8.67e-01 | 0.1040 | 3.37e-02 | 0.044500 | 8.67e-02 | 1.65e-02 | 5.42e-01 | 4.20e-01 | 1.17e-01 | 7.65e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 224 | 1.34e-01 | 6.41e-01 | 0.1040 | 2.04e-02 | 0.093900 | 2.13e-02 | -3.44e-02 | 5.99e-01 | 1.58e-02 | 5.85e-01 | 3.77e-01 |
| SHC-mediated cascade:FGFR1 | 17 | 9.10e-01 | 9.66e-01 | 0.1040 | -4.88e-02 | 0.083200 | -3.83e-02 | -9.90e-03 | 7.27e-01 | 5.53e-01 | 7.84e-01 | 9.44e-01 |
| Rab regulation of trafficking | 90 | 3.28e-01 | 7.66e-01 | 0.1040 | -2.87e-02 | -0.053200 | 7.40e-02 | -4.08e-02 | 6.39e-01 | 3.83e-01 | 2.26e-01 | 5.04e-01 |
| Negative regulation of the PI3K/AKT network | 90 | 5.48e-01 | 8.61e-01 | 0.1030 | 3.30e-02 | 0.094700 | -2.36e-02 | -1.66e-03 | 5.89e-01 | 1.21e-01 | 6.99e-01 | 9.78e-01 |
| Prostacyclin signalling through prostacyclin receptor | 13 | 9.68e-01 | 9.85e-01 | 0.1030 | -5.26e-02 | -0.027700 | 7.87e-02 | -2.89e-02 | 7.43e-01 | 8.63e-01 | 6.23e-01 | 8.57e-01 |
| Ephrin signaling | 17 | 9.76e-01 | 9.88e-01 | 0.1030 | -1.37e-03 | 0.051500 | 3.97e-02 | 7.95e-02 | 9.92e-01 | 7.13e-01 | 7.77e-01 | 5.70e-01 |
| GLI3 is processed to GLI3R by the proteasome | 38 | 7.73e-01 | 9.26e-01 | 0.1020 | -9.15e-02 | 0.038600 | -6.62e-04 | -2.38e-02 | 3.29e-01 | 6.81e-01 | 9.94e-01 | 7.99e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 33 | 8.19e-01 | 9.36e-01 | 0.1020 | -4.14e-02 | -0.041800 | 5.57e-02 | -6.16e-02 | 6.81e-01 | 6.78e-01 | 5.80e-01 | 5.40e-01 |
| Signaling by RAS mutants | 33 | 8.19e-01 | 9.36e-01 | 0.1020 | -4.14e-02 | -0.041800 | 5.57e-02 | -6.16e-02 | 6.81e-01 | 6.78e-01 | 5.80e-01 | 5.40e-01 |
| Signaling by moderate kinase activity BRAF mutants | 33 | 8.19e-01 | 9.36e-01 | 0.1020 | -4.14e-02 | -0.041800 | 5.57e-02 | -6.16e-02 | 6.81e-01 | 6.78e-01 | 5.80e-01 | 5.40e-01 |
| Signaling downstream of RAS mutants | 33 | 8.19e-01 | 9.36e-01 | 0.1020 | -4.14e-02 | -0.041800 | 5.57e-02 | -6.16e-02 | 6.81e-01 | 6.78e-01 | 5.80e-01 | 5.40e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 27 | 9.08e-01 | 9.64e-01 | 0.1010 | -9.94e-02 | 0.006240 | 1.56e-02 | -8.99e-03 | 3.71e-01 | 9.55e-01 | 8.89e-01 | 9.36e-01 |
| RNA Polymerase III Transcription | 27 | 9.08e-01 | 9.64e-01 | 0.1010 | -9.94e-02 | 0.006240 | 1.56e-02 | -8.99e-03 | 3.71e-01 | 9.55e-01 | 8.89e-01 | 9.36e-01 |
| Nucleotide Excision Repair | 75 | 7.67e-01 | 9.21e-01 | 0.1010 | -4.53e-02 | 0.011900 | 6.63e-02 | 6.03e-02 | 4.98e-01 | 8.59e-01 | 3.22e-01 | 3.67e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 57 | 6.36e-01 | 8.80e-01 | 0.1010 | -5.07e-02 | -0.014100 | 6.80e-02 | -5.26e-02 | 5.08e-01 | 8.54e-01 | 3.75e-01 | 4.93e-01 |
| Oncogenic MAPK signaling | 60 | 5.98e-01 | 8.75e-01 | 0.1000 | 4.60e-03 | 0.000287 | 3.70e-02 | -9.29e-02 | 9.51e-01 | 9.97e-01 | 6.21e-01 | 2.14e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 18 | 9.65e-01 | 9.85e-01 | 0.0996 | 4.99e-02 | -0.000220 | -1.28e-02 | -8.52e-02 | 7.14e-01 | 9.99e-01 | 9.25e-01 | 5.32e-01 |
| Downstream TCR signaling | 64 | 6.08e-01 | 8.75e-01 | 0.0993 | -4.95e-02 | 0.048600 | 3.33e-02 | -6.27e-02 | 4.94e-01 | 5.02e-01 | 6.45e-01 | 3.86e-01 |
| Signaling by Receptor Tyrosine Kinases | 384 | 3.80e-02 | 4.32e-01 | 0.0990 | 8.44e-02 | 0.029300 | -4.64e-03 | -4.23e-02 | 4.73e-03 | 3.26e-01 | 8.77e-01 | 1.57e-01 |
| Cyclin E associated events during G1/S transition | 56 | 6.97e-01 | 9.01e-01 | 0.0990 | -4.94e-02 | 0.051500 | 6.24e-02 | -2.85e-02 | 5.23e-01 | 5.05e-01 | 4.20e-01 | 7.12e-01 |
| Influenza Viral RNA Transcription and Replication | 61 | 6.70e-01 | 8.94e-01 | 0.0986 | -6.72e-02 | 0.023900 | 6.23e-02 | -2.76e-02 | 3.65e-01 | 7.48e-01 | 4.00e-01 | 7.09e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 76 | 4.79e-01 | 8.26e-01 | 0.0981 | 2.44e-02 | -0.072800 | 6.73e-03 | -6.07e-02 | 7.13e-01 | 2.73e-01 | 9.19e-01 | 3.60e-01 |
| Signaling by high-kinase activity BRAF mutants | 26 | 8.51e-01 | 9.45e-01 | 0.0981 | -2.26e-03 | -0.021200 | 7.09e-02 | -6.44e-02 | 9.84e-01 | 8.52e-01 | 5.32e-01 | 5.70e-01 |
| Death Receptor Signalling | 113 | 5.74e-01 | 8.67e-01 | 0.0979 | 7.70e-02 | 0.011800 | -3.76e-02 | -4.60e-02 | 1.58e-01 | 8.29e-01 | 4.91e-01 | 3.99e-01 |
| FCGR3A-mediated phagocytosis | 55 | 6.37e-01 | 8.80e-01 | 0.0977 | 4.29e-02 | 0.005150 | 7.56e-02 | -4.44e-02 | 5.83e-01 | 9.47e-01 | 3.33e-01 | 5.70e-01 |
| Leishmania phagocytosis | 55 | 6.37e-01 | 8.80e-01 | 0.0977 | 4.29e-02 | 0.005150 | 7.56e-02 | -4.44e-02 | 5.83e-01 | 9.47e-01 | 3.33e-01 | 5.70e-01 |
| Parasite infection | 55 | 6.37e-01 | 8.80e-01 | 0.0977 | 4.29e-02 | 0.005150 | 7.56e-02 | -4.44e-02 | 5.83e-01 | 9.47e-01 | 3.33e-01 | 5.70e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 37 | 8.78e-01 | 9.53e-01 | 0.0976 | -7.05e-02 | -0.018900 | 1.42e-02 | -6.32e-02 | 4.58e-01 | 8.43e-01 | 8.81e-01 | 5.06e-01 |
| Integrin signaling | 23 | 9.71e-01 | 9.87e-01 | 0.0971 | -5.86e-02 | -0.073900 | 1.99e-02 | 1.22e-02 | 6.27e-01 | 5.40e-01 | 8.69e-01 | 9.19e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 21 | 8.87e-01 | 9.60e-01 | 0.0966 | 5.04e-02 | -0.072400 | 2.86e-02 | -2.73e-02 | 6.90e-01 | 5.66e-01 | 8.20e-01 | 8.29e-01 |
| Neuronal System | 303 | 4.68e-02 | 4.38e-01 | 0.0964 | 5.24e-02 | 0.062600 | -3.90e-02 | 3.33e-02 | 1.18e-01 | 6.21e-02 | 2.45e-01 | 3.21e-01 |
| EPH-Ephrin signaling | 73 | 7.18e-01 | 9.06e-01 | 0.0959 | 1.41e-02 | -0.065700 | -3.40e-02 | -5.94e-02 | 8.35e-01 | 3.32e-01 | 6.16e-01 | 3.80e-01 |
| Signaling by Insulin receptor | 58 | 6.26e-01 | 8.78e-01 | 0.0954 | -8.26e-02 | 0.021300 | -3.58e-02 | 2.34e-02 | 2.77e-01 | 7.79e-01 | 6.38e-01 | 7.58e-01 |
| Signaling by FGFR in disease | 45 | 8.44e-01 | 9.44e-01 | 0.0951 | 2.21e-02 | 0.043200 | 1.45e-03 | 8.17e-02 | 7.98e-01 | 6.17e-01 | 9.87e-01 | 3.43e-01 |
| Mitochondrial biogenesis | 61 | 7.11e-01 | 9.05e-01 | 0.0947 | -6.10e-02 | -0.025700 | 5.18e-02 | -4.37e-02 | 4.10e-01 | 7.29e-01 | 4.84e-01 | 5.56e-01 |
| Interleukin-4 and Interleukin-13 signaling | 81 | 8.18e-01 | 9.36e-01 | 0.0946 | -5.12e-02 | -0.037700 | -5.81e-02 | -3.92e-02 | 4.26e-01 | 5.58e-01 | 3.66e-01 | 5.43e-01 |
| Cellular response to heat stress | 67 | 8.07e-01 | 9.36e-01 | 0.0945 | -1.89e-04 | 0.039800 | 8.45e-02 | 1.43e-02 | 9.98e-01 | 5.74e-01 | 2.32e-01 | 8.40e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 13 | 9.78e-01 | 9.88e-01 | 0.0944 | -3.65e-02 | -0.066900 | 3.23e-02 | -4.54e-02 | 8.20e-01 | 6.76e-01 | 8.40e-01 | 7.77e-01 |
| B-WICH complex positively regulates rRNA expression | 21 | 9.43e-01 | 9.79e-01 | 0.0940 | 6.30e-02 | -0.032800 | -1.17e-02 | -6.05e-02 | 6.17e-01 | 7.95e-01 | 9.26e-01 | 6.32e-01 |
| Signaling by WNT | 204 | 1.89e-01 | 6.71e-01 | 0.0939 | -3.93e-02 | 0.024100 | 1.86e-02 | 7.97e-02 | 3.35e-01 | 5.54e-01 | 6.48e-01 | 5.04e-02 |
| Cellular response to hypoxia | 51 | 7.83e-01 | 9.30e-01 | 0.0939 | -4.33e-02 | 0.066800 | 4.95e-02 | -5.69e-03 | 5.93e-01 | 4.09e-01 | 5.41e-01 | 9.44e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 98 | 7.76e-01 | 9.28e-01 | 0.0938 | 4.66e-02 | 0.070600 | 3.20e-02 | 2.47e-02 | 4.26e-01 | 2.28e-01 | 5.85e-01 | 6.73e-01 |
| HCMV Late Events | 37 | 8.47e-01 | 9.44e-01 | 0.0936 | -4.83e-02 | -0.022100 | 6.56e-02 | -4.05e-02 | 6.11e-01 | 8.17e-01 | 4.90e-01 | 6.70e-01 |
| Asymmetric localization of PCP proteins | 46 | 9.23e-01 | 9.73e-01 | 0.0919 | -7.80e-02 | -0.048300 | 6.07e-03 | -2.95e-03 | 3.61e-01 | 5.71e-01 | 9.43e-01 | 9.72e-01 |
| Diseases of metabolism | 191 | 2.76e-01 | 7.32e-01 | 0.0918 | 2.80e-02 | -0.058300 | -6.49e-02 | -6.04e-03 | 5.06e-01 | 1.66e-01 | 1.23e-01 | 8.86e-01 |
| MAPK6/MAPK4 signaling | 63 | 8.00e-01 | 9.36e-01 | 0.0912 | -5.62e-02 | -0.025100 | 6.72e-02 | 3.46e-03 | 4.41e-01 | 7.31e-01 | 3.57e-01 | 9.62e-01 |
| Clathrin-mediated endocytosis | 106 | 6.36e-01 | 8.80e-01 | 0.0910 | 4.46e-02 | 0.026600 | -7.00e-03 | -7.45e-02 | 4.29e-01 | 6.37e-01 | 9.01e-01 | 1.86e-01 |
| tRNA processing | 76 | 4.91e-01 | 8.27e-01 | 0.0907 | -4.85e-03 | -0.033900 | 6.69e-02 | -5.08e-02 | 9.42e-01 | 6.10e-01 | 3.14e-01 | 4.45e-01 |
| Adaptive Immune System | 516 | 4.29e-02 | 4.38e-01 | 0.0905 | 4.94e-02 | 0.050900 | -1.27e-02 | -5.47e-02 | 5.66e-02 | 4.95e-02 | 6.23e-01 | 3.48e-02 |
| Toll-like Receptor Cascades | 113 | 7.36e-01 | 9.06e-01 | 0.0904 | 5.40e-02 | 0.071800 | 9.93e-03 | -5.18e-04 | 3.22e-01 | 1.88e-01 | 8.56e-01 | 9.92e-01 |
| DNA Replication | 92 | 4.69e-01 | 8.26e-01 | 0.0904 | -4.17e-03 | -0.016700 | 3.28e-02 | -8.25e-02 | 9.45e-01 | 7.82e-01 | 5.87e-01 | 1.72e-01 |
| Platelet calcium homeostasis | 22 | 9.20e-01 | 9.71e-01 | 0.0901 | -4.45e-02 | 0.037600 | -6.87e-02 | -8.32e-04 | 7.18e-01 | 7.60e-01 | 5.77e-01 | 9.95e-01 |
| Signaling by Interleukins | 318 | 1.95e-01 | 6.71e-01 | 0.0899 | -5.33e-02 | -0.009870 | 4.75e-02 | 5.37e-02 | 1.04e-01 | 7.63e-01 | 1.47e-01 | 1.01e-01 |
| EPH-ephrin mediated repulsion of cells | 39 | 9.31e-01 | 9.73e-01 | 0.0893 | -4.84e-03 | -0.074600 | -3.56e-02 | -3.34e-02 | 9.58e-01 | 4.21e-01 | 7.01e-01 | 7.18e-01 |
| PTEN Regulation | 104 | 3.22e-01 | 7.57e-01 | 0.0892 | 7.40e-03 | -0.040700 | 6.94e-02 | -3.79e-02 | 8.96e-01 | 4.74e-01 | 2.22e-01 | 5.05e-01 |
| SUMOylation of transcription cofactors | 32 | 9.33e-01 | 9.74e-01 | 0.0887 | 4.49e-02 | -0.037300 | -3.31e-02 | -5.80e-02 | 6.61e-01 | 7.15e-01 | 7.46e-01 | 5.70e-01 |
| Transmission across Chemical Synapses | 191 | 7.94e-02 | 5.61e-01 | 0.0885 | -5.50e-03 | 0.056100 | -5.52e-02 | 4.01e-02 | 8.96e-01 | 1.83e-01 | 1.90e-01 | 3.40e-01 |
| Axon guidance | 382 | 1.25e-01 | 6.24e-01 | 0.0884 | 7.92e-02 | 0.038500 | -7.37e-03 | 2.49e-03 | 8.24e-03 | 1.99e-01 | 8.06e-01 | 9.34e-01 |
| Elastic fibre formation | 33 | 9.49e-01 | 9.82e-01 | 0.0883 | -2.77e-02 | -0.066700 | -1.00e-02 | 4.99e-02 | 7.83e-01 | 5.08e-01 | 9.21e-01 | 6.20e-01 |
| Metabolism of RNA | 432 | 1.10e-02 | 2.73e-01 | 0.0883 | -2.74e-02 | 0.041100 | 6.55e-02 | -3.25e-02 | 3.32e-01 | 1.45e-01 | 2.02e-02 | 2.50e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 62 | 8.06e-01 | 9.36e-01 | 0.0878 | 4.50e-02 | 0.060700 | -4.28e-02 | 1.31e-02 | 5.41e-01 | 4.09e-01 | 5.61e-01 | 8.59e-01 |
| HCMV Infection | 59 | 7.63e-01 | 9.17e-01 | 0.0865 | -6.07e-03 | 0.032000 | 3.63e-02 | -7.15e-02 | 9.36e-01 | 6.71e-01 | 6.30e-01 | 3.43e-01 |
| Nervous system development | 403 | 1.48e-01 | 6.51e-01 | 0.0855 | 7.45e-02 | 0.041800 | -3.01e-03 | -2.05e-03 | 1.07e-02 | 1.53e-01 | 9.18e-01 | 9.44e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 58 | 7.62e-01 | 9.17e-01 | 0.0855 | -4.19e-02 | 0.019400 | 5.31e-02 | -4.86e-02 | 5.81e-01 | 7.99e-01 | 4.85e-01 | 5.23e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 31 | 9.74e-01 | 9.88e-01 | 0.0854 | 2.87e-02 | 0.064700 | 3.47e-02 | 3.28e-02 | 7.82e-01 | 5.33e-01 | 7.38e-01 | 7.52e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 106 | 4.51e-01 | 8.19e-01 | 0.0844 | -1.44e-02 | 0.079500 | -1.74e-02 | 1.71e-02 | 7.99e-01 | 1.58e-01 | 7.58e-01 | 7.61e-01 |
| Interleukin-1 family signaling | 97 | 5.98e-01 | 8.75e-01 | 0.0836 | -3.16e-02 | 0.059800 | 3.71e-02 | -3.23e-02 | 5.92e-01 | 3.09e-01 | 5.29e-01 | 5.83e-01 |
| UCH proteinases | 60 | 8.76e-01 | 9.53e-01 | 0.0829 | 2.53e-02 | -0.019900 | 5.36e-02 | 5.44e-02 | 7.35e-01 | 7.90e-01 | 4.73e-01 | 4.66e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 53 | 8.32e-01 | 9.39e-01 | 0.0828 | -6.12e-02 | 0.007950 | 3.61e-02 | -4.17e-02 | 4.41e-01 | 9.20e-01 | 6.49e-01 | 6.00e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 64 | 6.97e-01 | 9.01e-01 | 0.0823 | 1.76e-02 | -0.027300 | 7.47e-02 | -1.16e-02 | 8.07e-01 | 7.06e-01 | 3.02e-01 | 8.73e-01 |
| Peptide ligand-binding receptors | 147 | 4.17e-01 | 7.90e-01 | 0.0820 | -2.71e-02 | 0.055900 | -1.88e-02 | -5.02e-02 | 5.71e-01 | 2.43e-01 | 6.94e-01 | 2.95e-01 |
| Bile acid and bile salt metabolism | 32 | 9.80e-01 | 9.88e-01 | 0.0819 | 1.45e-02 | 0.038800 | 5.76e-02 | 4.10e-02 | 8.87e-01 | 7.04e-01 | 5.73e-01 | 6.88e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 86 | 6.86e-01 | 8.99e-01 | 0.0818 | 1.29e-02 | 0.075300 | -2.90e-02 | 2.23e-03 | 8.36e-01 | 2.28e-01 | 6.43e-01 | 9.72e-01 |
| GPVI-mediated activation cascade | 25 | 9.78e-01 | 9.88e-01 | 0.0817 | 3.96e-02 | 0.054300 | 3.63e-02 | -2.90e-02 | 7.32e-01 | 6.38e-01 | 7.53e-01 | 8.02e-01 |
| Transcriptional Regulation by VENTX | 31 | 8.96e-01 | 9.63e-01 | 0.0814 | 6.17e-02 | -0.027600 | 4.46e-02 | -8.43e-03 | 5.52e-01 | 7.91e-01 | 6.68e-01 | 9.35e-01 |
| Metabolism of water-soluble vitamins and cofactors | 87 | 8.68e-01 | 9.50e-01 | 0.0812 | -3.16e-02 | -0.064600 | -3.74e-02 | -5.02e-03 | 6.10e-01 | 2.98e-01 | 5.47e-01 | 9.36e-01 |
| Dual incision in TC-NER | 43 | 8.80e-01 | 9.55e-01 | 0.0812 | -4.05e-02 | -0.033900 | 4.15e-02 | -4.56e-02 | 6.46e-01 | 7.01e-01 | 6.38e-01 | 6.05e-01 |
| Metabolism of carbohydrates | 220 | 4.60e-01 | 8.25e-01 | 0.0809 | -1.62e-02 | -0.064600 | -4.59e-02 | 1.94e-03 | 6.80e-01 | 9.96e-02 | 2.42e-01 | 9.61e-01 |
| L1CAM interactions | 83 | 8.26e-01 | 9.37e-01 | 0.0806 | 7.32e-02 | 0.020900 | 1.00e-02 | 2.45e-02 | 2.50e-01 | 7.42e-01 | 8.75e-01 | 7.00e-01 |
| MTOR signalling | 31 | 9.57e-01 | 9.83e-01 | 0.0798 | -6.03e-02 | 0.009470 | 5.11e-02 | 5.50e-03 | 5.61e-01 | 9.27e-01 | 6.22e-01 | 9.58e-01 |
| Platelet homeostasis | 71 | 8.97e-01 | 9.63e-01 | 0.0796 | -3.79e-02 | -0.015600 | -5.68e-02 | -3.79e-02 | 5.81e-01 | 8.20e-01 | 4.09e-01 | 5.81e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 27 | 9.77e-01 | 9.88e-01 | 0.0792 | -7.81e-03 | 0.025100 | -5.08e-02 | -5.49e-02 | 9.44e-01 | 8.22e-01 | 6.48e-01 | 6.22e-01 |
| ER to Golgi Anterograde Transport | 104 | 7.89e-01 | 9.32e-01 | 0.0790 | 8.00e-03 | -0.007950 | -7.36e-02 | -2.64e-02 | 8.88e-01 | 8.89e-01 | 1.95e-01 | 6.42e-01 |
| Oxidative Stress Induced Senescence | 53 | 9.31e-01 | 9.73e-01 | 0.0790 | 5.01e-02 | 0.019800 | -2.04e-02 | -5.41e-02 | 5.28e-01 | 8.03e-01 | 7.97e-01 | 4.96e-01 |
| DNA Repair | 196 | 1.52e-01 | 6.51e-01 | 0.0787 | 2.79e-03 | -0.049900 | 4.66e-02 | -3.91e-02 | 9.46e-01 | 2.30e-01 | 2.61e-01 | 3.47e-01 |
| FGFR1 ligand binding and activation | 13 | 9.87e-01 | 9.94e-01 | 0.0785 | 4.11e-03 | -0.030800 | -3.38e-02 | 6.36e-02 | 9.80e-01 | 8.47e-01 | 8.33e-01 | 6.91e-01 |
| Asparagine N-linked glycosylation | 213 | 3.19e-01 | 7.55e-01 | 0.0784 | 1.95e-02 | -0.066700 | -3.56e-02 | 6.80e-03 | 6.24e-01 | 9.44e-02 | 3.73e-01 | 8.65e-01 |
| Cardiac conduction | 113 | 8.13e-01 | 9.36e-01 | 0.0780 | 1.18e-02 | 0.044300 | 3.54e-02 | 5.22e-02 | 8.29e-01 | 4.17e-01 | 5.17e-01 | 3.38e-01 |
| Phospholipid metabolism | 163 | 4.23e-01 | 7.93e-01 | 0.0778 | 1.44e-03 | -0.055300 | 4.92e-02 | 2.40e-02 | 9.75e-01 | 2.24e-01 | 2.80e-01 | 5.98e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 62 | 8.93e-01 | 9.63e-01 | 0.0778 | -3.93e-02 | -0.040400 | -1.50e-02 | 5.16e-02 | 5.93e-01 | 5.83e-01 | 8.39e-01 | 4.83e-01 |
| Metabolism of vitamins and cofactors | 135 | 7.91e-01 | 9.32e-01 | 0.0778 | -2.56e-02 | -0.057000 | -3.99e-02 | -2.36e-02 | 6.08e-01 | 2.54e-01 | 4.24e-01 | 6.37e-01 |
| Signaling by BRAF and RAF fusions | 48 | 8.88e-01 | 9.60e-01 | 0.0775 | 3.88e-02 | 0.011700 | 1.82e-02 | -6.35e-02 | 6.42e-01 | 8.88e-01 | 8.27e-01 | 4.47e-01 |
| COPII-mediated vesicle transport | 50 | 8.74e-01 | 9.52e-01 | 0.0770 | 6.20e-02 | -0.020600 | 2.79e-02 | 2.98e-02 | 4.49e-01 | 8.02e-01 | 7.33e-01 | 7.16e-01 |
| Neddylation | 165 | 3.32e-01 | 7.66e-01 | 0.0770 | -4.30e-02 | 0.043700 | -3.85e-02 | -2.61e-02 | 3.42e-01 | 3.34e-01 | 3.94e-01 | 5.64e-01 |
| Glycolysis | 55 | 9.04e-01 | 9.63e-01 | 0.0756 | -4.32e-02 | -0.050000 | 3.05e-02 | -2.03e-02 | 5.80e-01 | 5.21e-01 | 6.96e-01 | 7.95e-01 |
| Hemostasis | 460 | 8.81e-02 | 5.78e-01 | 0.0754 | 1.22e-03 | -0.001440 | -9.85e-03 | -7.47e-02 | 9.65e-01 | 9.58e-01 | 7.19e-01 | 6.34e-03 |
| G alpha (q) signalling events | 166 | 5.24e-01 | 8.49e-01 | 0.0749 | 3.46e-02 | 0.055700 | -2.24e-02 | 2.84e-02 | 4.43e-01 | 2.17e-01 | 6.19e-01 | 5.29e-01 |
| Collagen degradation | 33 | 9.40e-01 | 9.78e-01 | 0.0745 | 3.30e-02 | -0.021900 | -5.24e-02 | 3.51e-02 | 7.43e-01 | 8.28e-01 | 6.02e-01 | 7.27e-01 |
| Ion transport by P-type ATPases | 42 | 9.33e-01 | 9.74e-01 | 0.0735 | 2.23e-02 | 0.037700 | -7.71e-03 | 5.85e-02 | 8.03e-01 | 6.72e-01 | 9.31e-01 | 5.12e-01 |
| Fatty acid metabolism | 132 | 6.47e-01 | 8.84e-01 | 0.0733 | -1.32e-02 | -0.038300 | 5.85e-02 | 1.76e-02 | 7.94e-01 | 4.48e-01 | 2.47e-01 | 7.27e-01 |
| Transport to the Golgi and subsequent modification | 127 | 6.83e-01 | 8.99e-01 | 0.0731 | 2.85e-02 | 0.001800 | -6.73e-02 | -2.75e-03 | 5.80e-01 | 9.72e-01 | 1.91e-01 | 9.57e-01 |
| Interleukin-10 signaling | 33 | 9.75e-01 | 9.88e-01 | 0.0728 | 2.03e-02 | 0.067300 | 1.20e-02 | 1.44e-02 | 8.40e-01 | 5.03e-01 | 9.05e-01 | 8.86e-01 |
| Signaling by Rho GTPases | 299 | 8.97e-02 | 5.78e-01 | 0.0722 | -9.63e-04 | -0.031900 | 6.12e-02 | -2.13e-02 | 9.77e-01 | 3.45e-01 | 7.00e-02 | 5.27e-01 |
| Developmental Biology | 701 | 3.04e-02 | 4.13e-01 | 0.0719 | 7.06e-02 | 0.011400 | -3.38e-03 | -7.39e-03 | 1.63e-03 | 6.10e-01 | 8.80e-01 | 7.41e-01 |
| Muscle contraction | 169 | 7.18e-01 | 9.06e-01 | 0.0719 | -1.35e-02 | 0.012100 | 3.45e-02 | 6.04e-02 | 7.63e-01 | 7.86e-01 | 4.40e-01 | 1.76e-01 |
| Cilium Assembly | 146 | 7.31e-01 | 9.06e-01 | 0.0718 | 5.31e-02 | 0.028100 | 1.56e-03 | -3.92e-02 | 2.69e-01 | 5.58e-01 | 9.74e-01 | 4.14e-01 |
| Membrane Trafficking | 461 | 1.06e-01 | 6.04e-01 | 0.0710 | 3.25e-02 | 0.000350 | -6.05e-03 | -6.29e-02 | 2.35e-01 | 9.90e-01 | 8.25e-01 | 2.15e-02 |
| Signal Transduction | 1912 | 7.61e-04 | 5.58e-02 | 0.0709 | 5.05e-02 | 0.049100 | -4.98e-03 | 5.91e-03 | 3.90e-04 | 5.61e-04 | 7.27e-01 | 6.78e-01 |
| Vesicle-mediated transport | 491 | 1.01e-01 | 5.99e-01 | 0.0709 | 2.71e-02 | -0.014200 | -1.61e-02 | -6.19e-02 | 3.08e-01 | 5.92e-01 | 5.45e-01 | 1.97e-02 |
| Cargo trafficking to the periciliary membrane | 37 | 9.83e-01 | 9.90e-01 | 0.0688 | 4.60e-02 | 0.041700 | -9.63e-03 | -2.79e-02 | 6.28e-01 | 6.61e-01 | 9.19e-01 | 7.69e-01 |
| RNA Polymerase II Transcription | 807 | 5.21e-02 | 4.71e-01 | 0.0681 | 4.35e-02 | 0.039000 | 2.57e-02 | -2.39e-02 | 3.79e-02 | 6.27e-02 | 2.20e-01 | 2.54e-01 |
| Transport of small molecules | 553 | 2.07e-01 | 6.78e-01 | 0.0674 | -5.19e-02 | -0.026400 | 2.82e-02 | 1.86e-02 | 3.83e-02 | 2.91e-01 | 2.61e-01 | 4.58e-01 |
| VEGFR2 mediated cell proliferation | 18 | 9.83e-01 | 9.90e-01 | 0.0672 | -2.46e-02 | 0.049800 | -1.09e-03 | 3.78e-02 | 8.57e-01 | 7.15e-01 | 9.94e-01 | 7.81e-01 |
| Cellular responses to stress | 331 | 2.33e-01 | 6.96e-01 | 0.0671 | -1.20e-04 | 0.031600 | 5.32e-02 | -2.61e-02 | 9.97e-01 | 3.26e-01 | 9.80e-02 | 4.16e-01 |
| Innate Immune System | 732 | 2.94e-02 | 4.13e-01 | 0.0670 | -3.31e-02 | -0.019300 | 5.56e-03 | -5.47e-02 | 1.32e-01 | 3.78e-01 | 8.00e-01 | 1.26e-02 |
| Metabolism | 1511 | 5.02e-03 | 1.82e-01 | 0.0670 | -5.49e-02 | -0.036300 | 9.03e-03 | -9.03e-03 | 4.96e-04 | 2.11e-02 | 5.66e-01 | 5.66e-01 |
| Rho GTPase cycle | 116 | 7.35e-01 | 9.06e-01 | 0.0654 | 2.09e-02 | -0.047300 | 1.00e-04 | 4.01e-02 | 6.98e-01 | 3.80e-01 | 9.99e-01 | 4.56e-01 |
| Cellular responses to external stimuli | 338 | 2.09e-01 | 6.82e-01 | 0.0644 | -9.27e-03 | 0.023500 | 4.89e-02 | -3.35e-02 | 7.71e-01 | 4.59e-01 | 1.24e-01 | 2.93e-01 |
| Neurotransmitter release cycle | 35 | 9.35e-01 | 9.75e-01 | 0.0633 | -2.59e-02 | 0.034800 | -4.41e-02 | 1.32e-02 | 7.91e-01 | 7.22e-01 | 6.51e-01 | 8.93e-01 |
| Degradation of beta-catenin by the destruction complex | 60 | 9.49e-01 | 9.82e-01 | 0.0631 | -4.71e-02 | 0.007200 | 2.66e-02 | 3.15e-02 | 5.28e-01 | 9.23e-01 | 7.22e-01 | 6.73e-01 |
| Gene expression (Transcription) | 905 | 5.54e-02 | 4.75e-01 | 0.0624 | 4.54e-02 | 0.029000 | 2.67e-02 | -1.67e-02 | 2.21e-02 | 1.44e-01 | 1.79e-01 | 4.02e-01 |
| Cytosolic sensors of pathogen-associated DNA | 46 | 9.17e-01 | 9.69e-01 | 0.0623 | 7.51e-03 | -0.022100 | 5.53e-02 | -1.67e-02 | 9.30e-01 | 7.96e-01 | 5.16e-01 | 8.45e-01 |
| Platelet degranulation | 99 | 7.06e-01 | 9.05e-01 | 0.0619 | 3.27e-02 | -0.022400 | 4.45e-02 | -1.66e-02 | 5.74e-01 | 7.00e-01 | 4.44e-01 | 7.76e-01 |
| Molecules associated with elastic fibres | 28 | 9.88e-01 | 9.94e-01 | 0.0617 | 4.25e-02 | 0.002280 | -4.40e-02 | -7.86e-03 | 6.97e-01 | 9.83e-01 | 6.87e-01 | 9.43e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 138 | 6.08e-01 | 8.75e-01 | 0.0617 | -3.91e-02 | 0.038200 | -2.57e-02 | -1.27e-02 | 4.29e-01 | 4.40e-01 | 6.03e-01 | 7.97e-01 |
| Leishmania parasite growth and survival | 138 | 6.08e-01 | 8.75e-01 | 0.0617 | -3.91e-02 | 0.038200 | -2.57e-02 | -1.27e-02 | 4.29e-01 | 4.40e-01 | 6.03e-01 | 7.97e-01 |
| Nucleobase catabolism | 27 | 9.93e-01 | 9.96e-01 | 0.0596 | 9.74e-03 | 0.023200 | -3.99e-02 | -3.65e-02 | 9.30e-01 | 8.35e-01 | 7.20e-01 | 7.43e-01 |
| Class A/1 (Rhodopsin-like receptors) | 248 | 5.04e-01 | 8.34e-01 | 0.0587 | 8.10e-03 | 0.024000 | -5.27e-02 | -5.21e-03 | 8.27e-01 | 5.17e-01 | 1.54e-01 | 8.88e-01 |
| Signaling by Nuclear Receptors | 191 | 6.97e-01 | 9.01e-01 | 0.0585 | -7.93e-03 | -0.002970 | -2.53e-03 | -5.78e-02 | 8.50e-01 | 9.44e-01 | 9.52e-01 | 1.69e-01 |
| Ion channel transport | 130 | 7.67e-01 | 9.21e-01 | 0.0574 | -7.74e-03 | 0.056700 | -1.72e-03 | 4.74e-03 | 8.79e-01 | 2.65e-01 | 9.73e-01 | 9.26e-01 |
| Cytokine Signaling in Immune system | 611 | 1.21e-01 | 6.22e-01 | 0.0573 | -1.55e-02 | 0.006830 | 5.42e-02 | -7.74e-03 | 5.16e-01 | 7.75e-01 | 2.34e-02 | 7.46e-01 |
| Disorders of transmembrane transporters | 131 | 8.99e-01 | 9.63e-01 | 0.0571 | -3.92e-02 | -0.037000 | 3.38e-03 | -1.84e-02 | 4.40e-01 | 4.65e-01 | 9.47e-01 | 7.16e-01 |
| Response to elevated platelet cytosolic Ca2+ | 103 | 7.57e-01 | 9.15e-01 | 0.0570 | 1.64e-02 | -0.046500 | 2.64e-02 | -1.12e-02 | 7.74e-01 | 4.16e-01 | 6.43e-01 | 8.44e-01 |
| Transcriptional regulation by RUNX3 | 75 | 8.71e-01 | 9.51e-01 | 0.0544 | 3.56e-02 | -0.028400 | 1.33e-02 | -2.67e-02 | 5.94e-01 | 6.71e-01 | 8.42e-01 | 6.90e-01 |
| Infectious disease | 508 | 2.12e-01 | 6.82e-01 | 0.0537 | -2.91e-03 | 0.008570 | 1.38e-02 | -5.11e-02 | 9.11e-01 | 7.43e-01 | 5.98e-01 | 5.04e-02 |
| Scavenging by Class A Receptors | 13 | 9.95e-01 | 9.97e-01 | 0.0532 | 2.82e-02 | -0.032900 | 8.80e-03 | -2.96e-02 | 8.60e-01 | 8.37e-01 | 9.56e-01 | 8.53e-01 |
| PI3K/AKT Signaling in Cancer | 84 | 9.40e-01 | 9.78e-01 | 0.0527 | 2.14e-02 | 0.042700 | -2.21e-02 | 3.40e-03 | 7.35e-01 | 4.99e-01 | 7.26e-01 | 9.57e-01 |
| Intracellular signaling by second messengers | 239 | 8.52e-01 | 9.45e-01 | 0.0524 | 1.48e-02 | 0.036300 | 3.08e-02 | 1.61e-02 | 6.94e-01 | 3.36e-01 | 4.14e-01 | 6.69e-01 |
| Signaling by Hedgehog | 98 | 8.40e-01 | 9.43e-01 | 0.0522 | 1.83e-03 | 0.031900 | -2.70e-02 | 3.12e-02 | 9.75e-01 | 5.86e-01 | 6.45e-01 | 5.94e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 21 | 9.96e-01 | 9.97e-01 | 0.0521 | 2.64e-02 | -0.009110 | -1.16e-02 | -4.24e-02 | 8.34e-01 | 9.42e-01 | 9.27e-01 | 7.36e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 286 | 7.42e-01 | 9.07e-01 | 0.0511 | 4.77e-02 | 0.016900 | 1.30e-03 | -6.66e-03 | 1.67e-01 | 6.24e-01 | 9.70e-01 | 8.47e-01 |
| Glycosaminoglycan metabolism | 93 | 9.67e-01 | 9.85e-01 | 0.0503 | 2.55e-02 | 0.037200 | -7.82e-03 | -2.08e-02 | 6.71e-01 | 5.36e-01 | 8.96e-01 | 7.29e-01 |
| Organelle biogenesis and maintenance | 207 | 7.34e-01 | 9.06e-01 | 0.0497 | 1.94e-02 | 0.012300 | 1.65e-02 | -4.08e-02 | 6.31e-01 | 7.61e-01 | 6.83e-01 | 3.13e-01 |
| GPCR ligand binding | 332 | 3.49e-01 | 7.67e-01 | 0.0491 | -2.41e-02 | 0.036700 | -1.12e-02 | 1.88e-02 | 4.53e-01 | 2.52e-01 | 7.26e-01 | 5.58e-01 |
| PIP3 activates AKT signaling | 206 | 8.60e-01 | 9.46e-01 | 0.0460 | 1.78e-02 | 0.025000 | 3.23e-02 | -1.15e-02 | 6.60e-01 | 5.37e-01 | 4.26e-01 | 7.76e-01 |
| Metabolism of steroids | 117 | 9.64e-01 | 9.85e-01 | 0.0449 | -8.76e-03 | -0.018600 | -1.56e-02 | -3.67e-02 | 8.70e-01 | 7.29e-01 | 7.71e-01 | 4.93e-01 |
| Generic Transcription Pathway | 724 | 4.27e-01 | 7.93e-01 | 0.0438 | 3.50e-02 | 0.017300 | 1.57e-02 | -1.24e-02 | 1.13e-01 | 4.32e-01 | 4.77e-01 | 5.73e-01 |
| Metabolism of lipids | 553 | 3.80e-01 | 7.68e-01 | 0.0402 | -1.03e-02 | -0.018100 | 2.15e-02 | -2.68e-02 | 6.81e-01 | 4.71e-01 | 3.92e-01 | 2.84e-01 |
| Transcriptional regulation by RUNX1 | 135 | 9.28e-01 | 9.73e-01 | 0.0393 | 2.46e-02 | -0.023800 | -1.09e-02 | -1.60e-02 | 6.23e-01 | 6.33e-01 | 8.27e-01 | 7.49e-01 |
| SLC transporter disorders | 79 | 9.68e-01 | 9.85e-01 | 0.0383 | -2.55e-03 | -0.032500 | 1.78e-02 | -9.35e-03 | 9.69e-01 | 6.18e-01 | 7.85e-01 | 8.86e-01 |
| Immune System | 1469 | 7.87e-02 | 5.61e-01 | 0.0365 | -6.95e-03 | -0.012100 | 1.53e-02 | -3.01e-02 | 6.63e-01 | 4.49e-01 | 3.39e-01 | 5.95e-02 |
| MAPK family signaling cascades | 234 | 9.53e-01 | 9.82e-01 | 0.0343 | -2.23e-02 | -0.007160 | 1.13e-02 | 2.23e-02 | 5.57e-01 | 8.51e-01 | 7.66e-01 | 5.57e-01 |
| G alpha (i) signalling events | 288 | 8.06e-01 | 9.36e-01 | 0.0342 | -1.88e-04 | -0.000794 | -1.76e-02 | 2.93e-02 | 9.96e-01 | 9.82e-01 | 6.08e-01 | 3.94e-01 |
| Leishmania infection | 203 | 9.77e-01 | 9.88e-01 | 0.0296 | 1.98e-02 | 0.001160 | -1.29e-02 | -1.78e-02 | 6.27e-01 | 9.77e-01 | 7.53e-01 | 6.64e-01 |
| Disease | 1068 | 3.76e-01 | 7.68e-01 | 0.0295 | 1.95e-02 | -0.008650 | 5.21e-03 | -1.98e-02 | 2.89e-01 | 6.38e-01 | 7.77e-01 | 2.83e-01 |
| Post-translational protein modification | 978 | 6.88e-01 | 8.99e-01 | 0.0253 | 2.22e-02 | -0.002680 | -8.69e-04 | -1.17e-02 | 2.46e-01 | 8.89e-01 | 9.64e-01 | 5.42e-01 |
| MAPK1/MAPK3 signaling | 204 | 9.90e-01 | 9.95e-01 | 0.0228 | -1.90e-02 | -0.009170 | -6.01e-03 | 6.39e-03 | 6.41e-01 | 8.22e-01 | 8.83e-01 | 8.75e-01 |
| RAF/MAP kinase cascade | 199 | 9.94e-01 | 9.96e-01 | 0.0196 | -1.60e-02 | -0.003670 | -1.01e-02 | -3.43e-03 | 6.98e-01 | 9.29e-01 | 8.07e-01 | 9.34e-01 |
| Platelet activation, signaling and aggregation | 201 | 9.91e-01 | 9.95e-01 | 0.0158 | 4.96e-03 | -0.002790 | 1.14e-02 | -9.29e-03 | 9.04e-01 | 9.46e-01 | 7.80e-01 | 8.21e-01 |
| Metabolism of proteins | 1339 | 8.88e-01 | 9.60e-01 | 0.0140 | 5.42e-05 | -0.011700 | 7.68e-03 | -9.66e-04 | 9.97e-01 | 4.83e-01 | 6.44e-01 | 9.54e-01 |
| FLT3 Signaling | 212 | 9.97e-01 | 9.97e-01 | 0.0135 | -1.12e-03 | 0.001760 | -1.34e-02 | 1.97e-05 | 9.78e-01 | 9.65e-01 | 7.38e-01 | 1.00e+00 |
Detailed Gene set reports
TRAF6 mediated IRF7 activation
| metric | value |
|---|---|
| setSize | 27 |
| pMANOVA | 1.29e-20 |
| p.adjustMANOVA | 8.51e-18 |
| s.dist | 1.07 |
| s.heart_ctrl_vs_acetate | 0.52 |
| s.heart_ctrl_vs_hifibre | 0.551 |
| s.spleen_ctrl_vs_acetate | 0.526 |
| s.spleen_ctrl_vs_hifibre | -0.534 |
| p.heart_ctrl_vs_acetate | 2.9e-06 |
| p.heart_ctrl_vs_hifibre | 7.2e-07 |
| p.spleen_ctrl_vs_acetate | 2.23e-06 |
| p.spleen_ctrl_vs_hifibre | 1.54e-06 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| IFNA1 | 4743 | -6287 |
| IFNA10 | 4743 | -6287 |
| IFNA14 | 4743 | -6287 |
| IFNA16 | 4743 | -6287 |
| IFNA17 | 4743 | -6287 |
| IFNA2 | 4743 | -6287 |
| IFNA21 | 4743 | -6287 |
| IFNA4 | 4743 | -6287 |
| IFNA5 | 4743 | -6287 |
| IFNA6 | 4743 | -6287 |
| IFNA7 | 4743 | -6287 |
| IFNA8 | 4743 | -6287 |
| IFNB1 | 3901 | -5964 |
| IFIH1 | 2259 | -5129 |
| SIKE1 | 3075 | -3617 |
| TRAF6 | 2512 | -809 |
| CREBBP | 952 | -1434 |
| TRAF2 | 71 | -6788 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CREBBP | 4478 | 952 | 4833 | -1434 |
| DDX58 | -4308 | -6101 | -4708 | -1631 |
| EP300 | 5933 | 1528 | 4514 | 3579 |
| IFIH1 | 6021 | 2259 | 2027 | -5129 |
| IFNA1 | 7041 | 4743 | 6305 | -6287 |
| IFNA10 | 7041 | 4743 | 6305 | -6287 |
| IFNA14 | 7041 | 4743 | 6305 | -6287 |
| IFNA16 | 7041 | 4743 | 6305 | -6287 |
| IFNA17 | 7041 | 4743 | 6305 | -6287 |
| IFNA2 | 7041 | 4743 | 6305 | -6287 |
| IFNA21 | 7041 | 4743 | 6305 | -6287 |
| IFNA4 | 7041 | 4743 | 6305 | -6287 |
| IFNA5 | 7041 | 4743 | 6305 | -6287 |
| IFNA6 | 7041 | 4743 | 6305 | -6287 |
| IFNA7 | 7041 | 4743 | 6305 | -6287 |
| IFNA8 | 7041 | 4743 | 6305 | -6287 |
| IFNB1 | 886 | 3901 | -5835 | -5964 |
| IKBKE | -158 | -6360 | -2473 | -1146 |
| IRF3 | -4411 | -5704 | 811 | -1016 |
| IRF7 | 4400 | -1601 | 6372 | 5310 |
| MAVS | 1585 | -1596 | 4572 | -5675 |
| RNF135 | -1270 | -1662 | 1149 | 1338 |
| SIKE1 | 5088 | 3075 | 5486 | -3617 |
| TANK | 5834 | 4410 | 3239 | 1175 |
| TBK1 | -3177 | -5581 | 3609 | -3201 |
| TRAF2 | -2689 | 71 | -232 | -6788 |
| TRAF6 | 3819 | 2512 | -409 | -809 |
Regulation of IFNA signaling
| metric | value |
|---|---|
| setSize | 23 |
| pMANOVA | 1.5e-13 |
| p.adjustMANOVA | 4.95e-11 |
| s.dist | 0.968 |
| s.heart_ctrl_vs_acetate | 0.588 |
| s.heart_ctrl_vs_hifibre | 0.469 |
| s.spleen_ctrl_vs_acetate | 0.472 |
| s.spleen_ctrl_vs_hifibre | -0.385 |
| p.heart_ctrl_vs_acetate | 1.07e-06 |
| p.heart_ctrl_vs_hifibre | 9.84e-05 |
| p.spleen_ctrl_vs_acetate | 8.95e-05 |
| p.spleen_ctrl_vs_hifibre | 0.00138 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_acetate |
|---|---|---|
| IFNA1 | 7041.0 | 6305.0 |
| IFNA10 | 7041.0 | 6305.0 |
| IFNA14 | 7041.0 | 6305.0 |
| IFNA16 | 7041.0 | 6305.0 |
| IFNA17 | 7041.0 | 6305.0 |
| IFNA2 | 7041.0 | 6305.0 |
| IFNA21 | 7041.0 | 6305.0 |
| IFNA4 | 7041.0 | 6305.0 |
| IFNA5 | 7041.0 | 6305.0 |
| IFNA6 | 7041.0 | 6305.0 |
| IFNA7 | 7041.0 | 6305.0 |
| IFNA8 | 7041.0 | 6305.0 |
| PTPN1 | 4238.0 | 5283.0 |
| STAT1 | 5675.0 | 1464.0 |
| USP18 | 3112.5 | 1614.5 |
| IFNAR1 | 5118.0 | 571.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| IFNA1 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA10 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA14 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA16 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA17 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA2 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA21 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA4 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA5 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA6 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA7 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNA8 | 7041.0 | 4743.0 | 6305.0 | -6287.0 |
| IFNAR1 | 5118.0 | 703.0 | 571.0 | 5944.0 |
| IFNAR2 | -5540.0 | -4823.0 | 4712.0 | 6140.0 |
| IFNB1 | 886.0 | 3901.0 | -5835.0 | -5964.0 |
| JAK1 | 5110.0 | 1267.0 | -2061.0 | -3259.0 |
| PTPN1 | 4238.0 | -1865.0 | 5283.0 | 4560.0 |
| PTPN11 | 1405.0 | -2226.0 | -2722.0 | 820.0 |
| PTPN6 | 2088.0 | -8213.0 | -6182.0 | -3620.0 |
| SOCS3 | -4723.0 | -6532.0 | 4294.0 | 5550.0 |
| STAT1 | 5675.0 | -1637.0 | 1464.0 | 2044.0 |
| TYK2 | -538.0 | -6255.0 | -1232.0 | 4175.0 |
| USP18 | 3112.5 | -3965.5 | 1614.5 | -3229.5 |
Glucuronidation
| metric | value |
|---|---|
| setSize | 16 |
| pMANOVA | 0.00029 |
| p.adjustMANOVA | 0.0247 |
| s.dist | 0.75 |
| s.heart_ctrl_vs_acetate | 0.372 |
| s.heart_ctrl_vs_hifibre | 0.633 |
| s.spleen_ctrl_vs_acetate | 0.0851 |
| s.spleen_ctrl_vs_hifibre | 0.124 |
| p.heart_ctrl_vs_acetate | 0.00994 |
| p.heart_ctrl_vs_hifibre | 1.17e-05 |
| p.spleen_ctrl_vs_acetate | 0.556 |
| p.spleen_ctrl_vs_hifibre | 0.391 |
| Gene | heart_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| UGT2A1 | 4668.0 | 7029.0 |
| UGT1A10 | 4640.5 | 6352.5 |
| UGT1A7 | 4640.5 | 6352.5 |
| UGT1A8 | 4640.5 | 6352.5 |
| UGT1A9 | 4640.5 | 6352.5 |
| UGP2 | 4227.0 | 6464.0 |
| ABHD10 | 3523.0 | 4233.0 |
| UGT1A6 | 2662.0 | 4684.0 |
| UGT1A3 | 2421.0 | 2416.0 |
| UGT1A4 | 2421.0 | 2416.0 |
| UGT1A5 | 2421.0 | 2416.0 |
| UGT3A1 | 1273.5 | 1828.5 |
| UGT3A2 | 1273.5 | 1828.5 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ABHD10 | 4233.0 | 3523.0 | -6429.0 | -5998.0 |
| SLC35D1 | -4384.0 | 1884.0 | -353.0 | 6047.0 |
| UGDH | -5198.0 | -7460.0 | -3924.0 | -6414.0 |
| UGP2 | 6464.0 | 4227.0 | 6461.0 | 1231.0 |
| UGT1A1 | -2069.0 | -1045.0 | -4479.0 | -4090.0 |
| UGT1A10 | 6352.5 | 4640.5 | 3571.5 | 2316.5 |
| UGT1A3 | 2416.0 | 2421.0 | 2890.0 | 3016.0 |
| UGT1A4 | 2416.0 | 2421.0 | 2890.0 | 3016.0 |
| UGT1A5 | 2416.0 | 2421.0 | 2890.0 | 3016.0 |
| UGT1A6 | 4684.0 | 2662.0 | 5529.0 | 3208.0 |
| UGT1A7 | 6352.5 | 4640.5 | 3571.5 | 2316.5 |
| UGT1A8 | 6352.5 | 4640.5 | 3571.5 | 2316.5 |
| UGT1A9 | 6352.5 | 4640.5 | 3571.5 | 2316.5 |
| UGT2A1 | 7029.0 | 4668.0 | -6735.0 | -6716.0 |
| UGT3A1 | 1828.5 | 1273.5 | -1281.5 | 3267.5 |
| UGT3A2 | 1828.5 | 1273.5 | -1281.5 | 3267.5 |
Glutathione synthesis and recycling
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0358 |
| p.adjustMANOVA | 0.422 |
| s.dist | 0.671 |
| s.heart_ctrl_vs_acetate | -0.345 |
| s.heart_ctrl_vs_hifibre | -0.414 |
| s.spleen_ctrl_vs_acetate | -0.248 |
| s.spleen_ctrl_vs_hifibre | -0.314 |
| p.heart_ctrl_vs_acetate | 0.0476 |
| p.heart_ctrl_vs_hifibre | 0.0173 |
| p.spleen_ctrl_vs_acetate | 0.155 |
| p.spleen_ctrl_vs_hifibre | 0.0716 |
| Gene | heart_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| GGT6 | -8350 | -5833 |
| CHAC1 | -6723 | -4374 |
| GGCT | -3285 | -5506 |
| GGT1 | -8393 | -1982 |
| GGT5 | -6813 | -2039 |
| OPLAH | -8650 | -1413 |
| GGT7 | -6817 | -1667 |
| GCLC | -290 | -2464 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CHAC1 | -4374 | -6723 | -5565 | -5277 |
| CNDP2 | 2841 | -4044 | -6486 | -5317 |
| GCLC | -2464 | -290 | 5571 | 5695 |
| GCLM | 378 | 856 | 1954 | -476 |
| GGCT | -5506 | -3285 | -3590 | -6536 |
| GGT1 | -1982 | -8393 | -4421 | -3426 |
| GGT5 | -2039 | -6813 | -3002 | -3932 |
| GGT6 | -5833 | -8350 | 3504 | 2068 |
| GGT7 | -1667 | -6817 | -304 | -1848 |
| GSS | 706 | -596 | -2681 | -5261 |
| OPLAH | -1413 | -8650 | -2718 | -138 |
Regulation of TLR by endogenous ligand
| metric | value |
|---|---|
| setSize | 13 |
| pMANOVA | 0.0102 |
| p.adjustMANOVA | 0.263 |
| s.dist | 0.661 |
| s.heart_ctrl_vs_acetate | 0.343 |
| s.heart_ctrl_vs_hifibre | 0.343 |
| s.spleen_ctrl_vs_acetate | -0.262 |
| s.spleen_ctrl_vs_hifibre | -0.364 |
| p.heart_ctrl_vs_acetate | 0.0323 |
| p.heart_ctrl_vs_hifibre | 0.0323 |
| p.spleen_ctrl_vs_acetate | 0.102 |
| p.spleen_ctrl_vs_hifibre | 0.0231 |
| Gene | spleen_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| TLR1 | -5771 | 2477 |
| HMGB1 | -3133 | 4519 |
| FGA | -2232 | 5992 |
| LY96 | -4069 | 1387 |
| LBP | -1142 | 3323 |
| S100A8 | -6276 | 502 |
| CD14 | -3965 | 202 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| APOB | 4655 | 609 | -2392 | 1045 |
| CD14 | 202 | 198 | -1814 | -3965 |
| CD36 | -321 | 4587 | -2307 | -6464 |
| FGA | 5992 | 3727 | -2962 | -2232 |
| FGB | 5717 | 2634 | -2003 | 1613 |
| FGG | -2760 | -2775 | 1587 | -5737 |
| HMGB1 | 4519 | -1286 | 5213 | -3133 |
| LBP | 3323 | -3036 | -3398 | -1142 |
| LY96 | 1387 | 3013 | -5782 | -4069 |
| S100A8 | 502 | 2727 | 3075 | -6276 |
| TLR1 | 2477 | -1564 | -1533 | -5771 |
| TLR2 | 4499 | -832 | -5488 | 1538 |
| TLR6 | 5471 | -3727 | -4430 | 1274 |
SHC1 events in EGFR signaling
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.018 |
| p.adjustMANOVA | 0.348 |
| s.dist | 0.629 |
| s.heart_ctrl_vs_acetate | 0.0746 |
| s.heart_ctrl_vs_hifibre | 0.446 |
| s.spleen_ctrl_vs_acetate | -0.178 |
| s.spleen_ctrl_vs_hifibre | -0.4 |
| p.heart_ctrl_vs_acetate | 0.683 |
| p.heart_ctrl_vs_hifibre | 0.0147 |
| p.spleen_ctrl_vs_acetate | 0.33 |
| p.spleen_ctrl_vs_hifibre | 0.0284 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| EGFR | 3848 | -3626 |
| EGF | 1525 | -6806 |
| EPGN | 1404 | -5130 |
| HRAS | 181 | -6119 |
| TGFA | 1140 | -588 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AREG | 6993.5 | -213.5 | -5949.5 | 918.5 |
| EGF | 4348.0 | 1525.0 | 5969.0 | -6806.0 |
| EGFR | 17.0 | 3848.0 | 944.0 | -3626.0 |
| EPGN | 2464.0 | 1404.0 | -4355.0 | -5130.0 |
| GRB2 | -5578.0 | 1873.0 | 2524.0 | 956.0 |
| HBEGF | -1952.0 | -1746.0 | -4004.0 | -5759.0 |
| HRAS | -3746.0 | 181.0 | -4860.0 | -6119.0 |
| KRAS | 2066.0 | 3576.0 | 5421.0 | 3808.0 |
| SHC1 | 2874.0 | -1303.0 | -4227.0 | -5767.0 |
| TGFA | 1676.0 | 1140.0 | -2828.0 | -588.0 |
TP53 Regulates Transcription of Death Receptors and Ligands
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.00319 |
| p.adjustMANOVA | 0.162 |
| s.dist | 0.61 |
| s.heart_ctrl_vs_acetate | -0.188 |
| s.heart_ctrl_vs_hifibre | 0.289 |
| s.spleen_ctrl_vs_acetate | 0.323 |
| s.spleen_ctrl_vs_hifibre | -0.385 |
| p.heart_ctrl_vs_acetate | 0.304 |
| p.heart_ctrl_vs_hifibre | 0.113 |
| p.spleen_ctrl_vs_acetate | 0.0769 |
| p.spleen_ctrl_vs_hifibre | 0.0349 |
| Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
|---|---|---|
| TNFRSF10A | -6768.5 | 3375.5 |
| TNFRSF10B | -6768.5 | 3375.5 |
| TNFRSF10C | -6768.5 | 3375.5 |
| TNFRSF10D | -6768.5 | 3375.5 |
| PPP1R13B | -3903.0 | 2532.0 |
| TP73 | -3588.0 | 362.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| IGFBP3 | 6280.0 | 4511.0 | 6409.0 | 6634.0 |
| PPP1R13B | 5189.0 | 2772.0 | 2532.0 | -3903.0 |
| TMEM219 | -6301.0 | -7042.0 | -5712.0 | -5608.0 |
| TNFRSF10A | -4416.5 | 2639.5 | 3375.5 | -6768.5 |
| TNFRSF10B | -4416.5 | 2639.5 | 3375.5 | -6768.5 |
| TNFRSF10C | -4416.5 | 2639.5 | 3375.5 | -6768.5 |
| TNFRSF10D | -4416.5 | 2639.5 | 3375.5 | -6768.5 |
| TP53 | 3315.0 | -8071.0 | 337.0 | 169.0 |
| TP63 | 2008.0 | 2735.0 | 5322.0 | 6276.0 |
| TP73 | -1538.0 | -5827.0 | 362.0 | -3588.0 |
Nucleotide-like (purinergic) receptors
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0074 |
| p.adjustMANOVA | 0.212 |
| s.dist | 0.598 |
| s.heart_ctrl_vs_acetate | 0.446 |
| s.heart_ctrl_vs_hifibre | 0.148 |
| s.spleen_ctrl_vs_acetate | -0.32 |
| s.spleen_ctrl_vs_hifibre | 0.186 |
| p.heart_ctrl_vs_acetate | 0.0105 |
| p.heart_ctrl_vs_hifibre | 0.395 |
| p.spleen_ctrl_vs_acetate | 0.066 |
| p.spleen_ctrl_vs_hifibre | 0.284 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_acetate |
|---|---|---|
| ADORA2A | 6730 | -5541 |
| ADORA2B | 3957 | -6637 |
| GPR17 | 5041 | -4352 |
| P2RY12 | 4307 | -4868 |
| P2RY13 | 4174 | -4250 |
| P2RY4 | 6067 | -2543 |
| P2RY1 | 4008 | -3449 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ADORA1 | 3908 | -195 | 6835 | 5885 |
| ADORA2A | 6730 | 2596 | -5541 | -1915 |
| ADORA2B | 3957 | -3873 | -6637 | -5738 |
| GPR17 | 5041 | -5691 | -4352 | 4771 |
| P2RY1 | 4008 | 1444 | -3449 | 6063 |
| P2RY12 | 4307 | -2479 | -4868 | 2279 |
| P2RY13 | 4174 | 743 | -4250 | 4645 |
| P2RY14 | 2143 | 357 | 2416 | -2230 |
| P2RY2 | -1249 | -918 | 4251 | -692 |
| P2RY4 | 6067 | -1661 | -2543 | 4438 |
| P2RY6 | -1220 | -1295 | -5016 | -4485 |
HIV elongation arrest and recovery
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.00705 |
| p.adjustMANOVA | 0.207 |
| s.dist | 0.596 |
| s.heart_ctrl_vs_acetate | -0.141 |
| s.heart_ctrl_vs_hifibre | -0.443 |
| s.spleen_ctrl_vs_acetate | -0.161 |
| s.spleen_ctrl_vs_hifibre | -0.337 |
| p.heart_ctrl_vs_acetate | 0.345 |
| p.heart_ctrl_vs_hifibre | 0.00296 |
| p.spleen_ctrl_vs_acetate | 0.281 |
| p.spleen_ctrl_vs_hifibre | 0.0239 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| CDK9 | -8260 | -6058 |
| POLR2A | -7171 | -6747 |
| POLR2E | -6710 | -4639 |
| SSRP1 | -6313 | -4367 |
| GTF2F1 | -4377 | -5948 |
| CCNT1 | -6719 | -3151 |
| SUPT5H | -2242 | -5839 |
| POLR2B | -5327 | -2151 |
| ELL | -2223 | -4810 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CCNT1 | -3665 | -6719 | -3269 | -3151 |
| CDK9 | 403 | -8260 | -4137 | -6058 |
| CTDP1 | -46 | 1127 | -1019 | -4988 |
| ELL | -1924 | -2223 | -15 | -4810 |
| GTF2F1 | -6350 | -4377 | 1838 | -5948 |
| NELFB | -5182 | -4712 | 6855 | 6412 |
| NELFCD | -566 | -8537 | -748 | 334 |
| NELFE | -3479 | -7291 | -1555 | 1465 |
| POLR2A | 3311 | -7171 | 552 | -6747 |
| POLR2B | -484 | -5327 | -2939 | -2151 |
| POLR2C | 2604 | -1814 | -1628 | 418 |
| POLR2E | -250 | -6710 | -4002 | -4639 |
| SSRP1 | 6316 | -6313 | -6325 | -4367 |
| SUPT4H1 | -2548 | -4779 | 1714 | 4382 |
| SUPT5H | 3606 | -2242 | -603 | -5839 |
Pausing and recovery of HIV elongation
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.00705 |
| p.adjustMANOVA | 0.207 |
| s.dist | 0.596 |
| s.heart_ctrl_vs_acetate | -0.141 |
| s.heart_ctrl_vs_hifibre | -0.443 |
| s.spleen_ctrl_vs_acetate | -0.161 |
| s.spleen_ctrl_vs_hifibre | -0.337 |
| p.heart_ctrl_vs_acetate | 0.345 |
| p.heart_ctrl_vs_hifibre | 0.00296 |
| p.spleen_ctrl_vs_acetate | 0.281 |
| p.spleen_ctrl_vs_hifibre | 0.0239 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| CDK9 | -8260 | -6058 |
| POLR2A | -7171 | -6747 |
| POLR2E | -6710 | -4639 |
| SSRP1 | -6313 | -4367 |
| GTF2F1 | -4377 | -5948 |
| CCNT1 | -6719 | -3151 |
| SUPT5H | -2242 | -5839 |
| POLR2B | -5327 | -2151 |
| ELL | -2223 | -4810 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CCNT1 | -3665 | -6719 | -3269 | -3151 |
| CDK9 | 403 | -8260 | -4137 | -6058 |
| CTDP1 | -46 | 1127 | -1019 | -4988 |
| ELL | -1924 | -2223 | -15 | -4810 |
| GTF2F1 | -6350 | -4377 | 1838 | -5948 |
| NELFB | -5182 | -4712 | 6855 | 6412 |
| NELFCD | -566 | -8537 | -748 | 334 |
| NELFE | -3479 | -7291 | -1555 | 1465 |
| POLR2A | 3311 | -7171 | 552 | -6747 |
| POLR2B | -484 | -5327 | -2939 | -2151 |
| POLR2C | 2604 | -1814 | -1628 | 418 |
| POLR2E | -250 | -6710 | -4002 | -4639 |
| SSRP1 | 6316 | -6313 | -6325 | -4367 |
| SUPT4H1 | -2548 | -4779 | 1714 | 4382 |
| SUPT5H | 3606 | -2242 | -603 | -5839 |
Pausing and recovery of Tat-mediated HIV elongation
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.00705 |
| p.adjustMANOVA | 0.207 |
| s.dist | 0.596 |
| s.heart_ctrl_vs_acetate | -0.141 |
| s.heart_ctrl_vs_hifibre | -0.443 |
| s.spleen_ctrl_vs_acetate | -0.161 |
| s.spleen_ctrl_vs_hifibre | -0.337 |
| p.heart_ctrl_vs_acetate | 0.345 |
| p.heart_ctrl_vs_hifibre | 0.00296 |
| p.spleen_ctrl_vs_acetate | 0.281 |
| p.spleen_ctrl_vs_hifibre | 0.0239 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| CDK9 | -8260 | -6058 |
| POLR2A | -7171 | -6747 |
| POLR2E | -6710 | -4639 |
| SSRP1 | -6313 | -4367 |
| GTF2F1 | -4377 | -5948 |
| CCNT1 | -6719 | -3151 |
| SUPT5H | -2242 | -5839 |
| POLR2B | -5327 | -2151 |
| ELL | -2223 | -4810 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CCNT1 | -3665 | -6719 | -3269 | -3151 |
| CDK9 | 403 | -8260 | -4137 | -6058 |
| CTDP1 | -46 | 1127 | -1019 | -4988 |
| ELL | -1924 | -2223 | -15 | -4810 |
| GTF2F1 | -6350 | -4377 | 1838 | -5948 |
| NELFB | -5182 | -4712 | 6855 | 6412 |
| NELFCD | -566 | -8537 | -748 | 334 |
| NELFE | -3479 | -7291 | -1555 | 1465 |
| POLR2A | 3311 | -7171 | 552 | -6747 |
| POLR2B | -484 | -5327 | -2939 | -2151 |
| POLR2C | 2604 | -1814 | -1628 | 418 |
| POLR2E | -250 | -6710 | -4002 | -4639 |
| SSRP1 | 6316 | -6313 | -6325 | -4367 |
| SUPT4H1 | -2548 | -4779 | 1714 | 4382 |
| SUPT5H | 3606 | -2242 | -603 | -5839 |
Tat-mediated HIV elongation arrest and recovery
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.00705 |
| p.adjustMANOVA | 0.207 |
| s.dist | 0.596 |
| s.heart_ctrl_vs_acetate | -0.141 |
| s.heart_ctrl_vs_hifibre | -0.443 |
| s.spleen_ctrl_vs_acetate | -0.161 |
| s.spleen_ctrl_vs_hifibre | -0.337 |
| p.heart_ctrl_vs_acetate | 0.345 |
| p.heart_ctrl_vs_hifibre | 0.00296 |
| p.spleen_ctrl_vs_acetate | 0.281 |
| p.spleen_ctrl_vs_hifibre | 0.0239 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| CDK9 | -8260 | -6058 |
| POLR2A | -7171 | -6747 |
| POLR2E | -6710 | -4639 |
| SSRP1 | -6313 | -4367 |
| GTF2F1 | -4377 | -5948 |
| CCNT1 | -6719 | -3151 |
| SUPT5H | -2242 | -5839 |
| POLR2B | -5327 | -2151 |
| ELL | -2223 | -4810 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CCNT1 | -3665 | -6719 | -3269 | -3151 |
| CDK9 | 403 | -8260 | -4137 | -6058 |
| CTDP1 | -46 | 1127 | -1019 | -4988 |
| ELL | -1924 | -2223 | -15 | -4810 |
| GTF2F1 | -6350 | -4377 | 1838 | -5948 |
| NELFB | -5182 | -4712 | 6855 | 6412 |
| NELFCD | -566 | -8537 | -748 | 334 |
| NELFE | -3479 | -7291 | -1555 | 1465 |
| POLR2A | 3311 | -7171 | 552 | -6747 |
| POLR2B | -484 | -5327 | -2939 | -2151 |
| POLR2C | 2604 | -1814 | -1628 | 418 |
| POLR2E | -250 | -6710 | -4002 | -4639 |
| SSRP1 | 6316 | -6313 | -6325 | -4367 |
| SUPT4H1 | -2548 | -4779 | 1714 | 4382 |
| SUPT5H | 3606 | -2242 | -603 | -5839 |
Olfactory Signaling Pathway
| metric | value |
|---|---|
| setSize | 142 |
| pMANOVA | 2.23e-27 |
| p.adjustMANOVA | 2.95e-24 |
| s.dist | 0.596 |
| s.heart_ctrl_vs_acetate | 0.293 |
| s.heart_ctrl_vs_hifibre | 0.515 |
| s.spleen_ctrl_vs_acetate | -0.0523 |
| s.spleen_ctrl_vs_hifibre | 0.0287 |
| p.heart_ctrl_vs_acetate | 1.66e-09 |
| p.heart_ctrl_vs_hifibre | 3.13e-26 |
| p.spleen_ctrl_vs_acetate | 0.283 |
| p.spleen_ctrl_vs_hifibre | 0.555 |
| Gene | heart_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| OR5P2 | 4808.0 | 7222.0 |
| OR4C15 | 4782.0 | 7220.0 |
| OR2AG1 | 4780.5 | 7218.5 |
| OR2AG2 | 4780.5 | 7218.5 |
| OR1E1 | 4778.5 | 7189.5 |
| OR1E2 | 4778.5 | 7189.5 |
| OR5B3 | 4777.0 | 7161.0 |
| OR14A2 | 4734.0 | 7172.0 |
| OR7E24 | 4726.0 | 7173.0 |
| OR8H1 | 4717.0 | 7135.0 |
| OR8H2 | 4717.0 | 7135.0 |
| OR8H3 | 4717.0 | 7135.0 |
| OR52R1 | 4690.0 | 7170.0 |
| OR5T2 | 4704.0 | 7074.0 |
| OR4A16 | 4770.5 | 6971.5 |
| OR4A5 | 4770.5 | 6971.5 |
| OR2F1 | 4660.5 | 7092.5 |
| OR2F2 | 4660.5 | 7092.5 |
| OR4B1 | 4648.0 | 7089.0 |
| OR5AK2 | 4585.0 | 7012.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| GNAL | 3442.0 | -2499.0 | -4579.0 | -753.0 |
| GNB1 | -3642.0 | 577.0 | 4567.0 | -2559.0 |
| GNGT1 | 5984.0 | 3847.0 | -4531.0 | 4332.0 |
| OR10A3 | 2722.5 | 4719.5 | 3857.5 | 3827.5 |
| OR10A4 | -1963.0 | 1627.0 | 2476.0 | 1400.0 |
| OR10A6 | 2722.5 | 4719.5 | 3857.5 | 3827.5 |
| OR10AD1 | -1767.0 | -5145.0 | 1309.0 | 5712.0 |
| OR10C1 | 6504.0 | 1357.0 | -2394.0 | -3288.0 |
| OR10D3 | 7151.0 | 3685.0 | -4291.0 | -5232.0 |
| OR10G2 | 2540.0 | 3589.0 | -3995.0 | -5156.0 |
| OR10G3 | -6031.0 | -8336.0 | 6223.0 | 6618.0 |
| OR10G4 | 1465.5 | 3960.5 | 6594.5 | 2403.5 |
| OR10G7 | 1465.5 | 3960.5 | 6594.5 | 2403.5 |
| OR10G8 | 1465.5 | 3960.5 | 6594.5 | 2403.5 |
| OR10G9 | 1465.5 | 3960.5 | 6594.5 | 2403.5 |
| OR10H3 | 5389.5 | 1230.5 | -2792.5 | -5790.5 |
| OR10H4 | 5389.5 | 1230.5 | -2792.5 | -5790.5 |
| OR10J3 | 3460.5 | 4631.5 | -1801.5 | 3122.5 |
| OR10J4 | 3460.5 | 4631.5 | -1801.5 | 3122.5 |
| OR10K2 | -1704.0 | 1233.0 | -5084.0 | 3868.0 |
| OR10P1 | 6382.0 | 3440.0 | -3191.0 | -1963.0 |
| OR10Q1 | 2864.0 | 4204.0 | -5529.0 | -244.0 |
| OR10S1 | 456.0 | -2816.0 | 2769.0 | 3520.0 |
| OR10V1 | 6690.0 | 2428.0 | 6550.0 | 3536.0 |
| OR10W1 | 1564.0 | 2720.0 | 1369.0 | 3941.0 |
| OR10X1 | -718.0 | 4397.0 | 6148.0 | 4187.0 |
| OR10Z1 | -6078.0 | 1196.0 | 3968.0 | -1833.0 |
| OR11L1 | -4361.0 | -6547.0 | -6274.0 | -3488.0 |
| OR12D2 | 5531.5 | 4283.5 | 1512.5 | 326.5 |
| OR12D3 | -1438.0 | 2159.0 | -3818.0 | -1036.0 |
| OR13A1 | 6458.0 | 3637.0 | -5898.0 | -5127.0 |
| OR13C3 | -3595.0 | 1124.0 | 2667.0 | 5664.0 |
| OR13C8 | 5799.0 | 3365.0 | -5547.0 | -1760.0 |
| OR13D1 | 2839.0 | 1673.0 | -5374.0 | -6235.0 |
| OR13G1 | 6745.0 | 4625.0 | -6407.0 | -6612.0 |
| OR13J1 | -1930.0 | -5980.0 | -2679.0 | 2933.0 |
| OR14A2 | 7172.0 | 4734.0 | 2290.0 | 1584.0 |
| OR1E1 | 7189.5 | 4778.5 | 3277.5 | 2300.5 |
| OR1E2 | 7189.5 | 4778.5 | 3277.5 | 2300.5 |
| OR2A25 | -568.0 | 2522.0 | -2356.0 | 5269.0 |
| OR2A4 | 2206.5 | 2605.5 | -682.5 | -2935.5 |
| OR2A7 | 2206.5 | 2605.5 | -682.5 | -2935.5 |
| OR2AG1 | 7218.5 | 4780.5 | -2043.5 | -1626.5 |
| OR2AG2 | 7218.5 | 4780.5 | -2043.5 | -1626.5 |
| OR2AP1 | 6984.0 | 4412.0 | 4790.0 | 3407.0 |
| OR2AT4 | 2011.0 | -4157.0 | -2361.0 | 3931.0 |
| OR2B11 | 5200.0 | -3216.0 | 3803.0 | 4323.0 |
| OR2B6 | -4220.0 | -2241.0 | -1713.0 | -526.0 |
| OR2C1 | 2219.0 | 208.0 | 2581.0 | 1756.0 |
| OR2F1 | 7092.5 | 4660.5 | -6736.5 | 5113.5 |
| OR2F2 | 7092.5 | 4660.5 | -6736.5 | 5113.5 |
| OR2L2 | 5777.5 | 3026.5 | 6284.5 | 4408.5 |
| OR2L3 | 5777.5 | 3026.5 | 6284.5 | 4408.5 |
| OR2L5 | 5777.5 | 3026.5 | 6284.5 | 4408.5 |
| OR2L8 | 5777.5 | 3026.5 | 6284.5 | 4408.5 |
| OR2T1 | 1377.0 | -89.0 | -862.0 | 2859.0 |
| OR2T12 | -3633.0 | -5633.0 | 6034.0 | 5866.0 |
| OR2T2 | -1330.5 | 4287.5 | -3088.5 | 3161.5 |
| OR2T29 | 1251.0 | 4657.0 | -275.0 | -6733.0 |
| OR2T33 | -3633.0 | -5633.0 | 6034.0 | 5866.0 |
| OR2T35 | -1330.5 | 4287.5 | -3088.5 | 3161.5 |
| OR2T4 | 1251.0 | 4657.0 | -275.0 | -6733.0 |
| OR2T5 | 1251.0 | 4657.0 | -275.0 | -6733.0 |
| OR2T6 | -6235.0 | 2409.0 | -4728.0 | -6488.0 |
| OR2T8 | -3633.0 | -5633.0 | 6034.0 | 5866.0 |
| OR2W3 | 4505.0 | -7635.0 | 5937.0 | 1635.0 |
| OR3A1 | 5990.0 | 4496.0 | 2276.0 | 6706.0 |
| OR4A15 | 2005.0 | 2149.0 | 5340.0 | 3615.0 |
| OR4A16 | 6971.5 | 4770.5 | 506.5 | 245.5 |
| OR4A5 | 6971.5 | 4770.5 | 506.5 | 245.5 |
| OR4B1 | 7089.0 | 4648.0 | 6820.0 | 163.0 |
| OR4C15 | 7220.0 | 4782.0 | -1128.0 | 4786.0 |
| OR4C3 | -972.0 | -257.0 | -1361.0 | -6651.0 |
| OR4C5 | 2908.0 | 4136.0 | 6007.0 | -2689.0 |
| OR4D1 | -5335.0 | -3435.0 | 1668.0 | 4856.0 |
| OR4D11 | 4840.0 | 2879.0 | -4274.0 | -1315.0 |
| OR4D2 | -4885.0 | -8388.0 | 3695.0 | 5926.0 |
| OR4D6 | -2075.0 | 968.0 | 1914.0 | 6144.0 |
| OR4E2 | -1950.0 | -1319.0 | 827.0 | -551.0 |
| OR4K1 | 6189.0 | 4279.0 | 3693.0 | 769.0 |
| OR4M1 | 6444.5 | 2184.5 | -6552.5 | -4823.5 |
| OR4M2 | 6444.5 | 2184.5 | -6552.5 | -4823.5 |
| OR51F1 | 2736.0 | 4282.0 | -2701.0 | -1486.0 |
| OR51F2 | 3393.0 | 3280.0 | -3497.0 | 2126.0 |
| OR51G1 | 1632.0 | 1812.0 | -6202.0 | -4835.0 |
| OR51I1 | 2222.0 | 1768.0 | 4325.0 | -6481.0 |
| OR51I2 | 2438.0 | 2738.0 | -4336.0 | 2518.0 |
| OR51M1 | -1694.0 | 415.0 | -6695.0 | -6738.0 |
| OR51Q1 | -329.0 | 4121.0 | -1523.0 | 1331.0 |
| OR51S1 | 4212.0 | 2402.0 | 1500.0 | -3864.0 |
| OR51T1 | -848.0 | 1937.0 | 2169.0 | -1188.0 |
| OR52B2 | 1713.0 | -1533.0 | -3562.0 | -3316.0 |
| OR52D1 | -6323.0 | -6198.0 | -5640.0 | -844.0 |
| OR52E2 | 5575.0 | 3093.0 | 2507.0 | 2634.0 |
| OR52E4 | 0.0 | 781.0 | 4256.0 | -3295.0 |
| OR52H1 | 4293.0 | -3832.0 | -4521.0 | 4379.0 |
| OR52I1 | 4236.5 | 2877.5 | 1892.5 | -5342.5 |
| OR52I2 | 4236.5 | 2877.5 | 1892.5 | -5342.5 |
| OR52J3 | 4244.0 | 2854.0 | 5824.0 | 5813.0 |
| OR52K2 | -4249.0 | -3582.0 | 2233.0 | -3567.0 |
| OR52M1 | -4955.0 | -640.0 | -3643.0 | 3949.0 |
| OR52N4 | -3387.0 | -5692.0 | -6265.0 | -3977.0 |
| OR52R1 | 7170.0 | 4690.0 | 3169.0 | -2681.0 |
| OR56A4 | 1003.0 | 4508.0 | 360.0 | 849.0 |
| OR56B1 | 4720.0 | 4398.0 | 2449.0 | -3963.0 |
| OR5A1 | 649.0 | -796.0 | 365.0 | 397.0 |
| OR5AK2 | 7012.0 | 4585.0 | -6129.0 | -4526.0 |
| OR5AN1 | 6129.0 | 4725.0 | -2039.0 | -3582.0 |
| OR5AU1 | -3331.0 | -4778.0 | -3571.0 | -634.0 |
| OR5B3 | 7161.0 | 4777.0 | -1296.0 | -2634.0 |
| OR5C1 | 462.0 | -539.0 | -2442.0 | 3613.0 |
| OR5D14 | 6808.0 | 4643.0 | 660.0 | 2727.0 |
| OR5D16 | 158.0 | 4236.0 | 3495.0 | 4769.0 |
| OR5D18 | 5993.0 | 4672.0 | -337.0 | -2223.0 |
| OR5I1 | 1769.0 | 2434.0 | -3132.0 | -6561.0 |
| OR5J2 | 1881.0 | 3036.0 | -4986.0 | -6232.0 |
| OR5P2 | 7222.0 | 4808.0 | -6029.0 | 4388.0 |
| OR5T2 | 7074.0 | 4704.0 | -3678.0 | -4973.0 |
| OR6B1 | 786.0 | 1359.0 | -5879.0 | -4325.0 |
| OR6B2 | 4401.5 | -3563.5 | -4367.5 | -4664.5 |
| OR6B3 | 4401.5 | -3563.5 | -4367.5 | -4664.5 |
| OR6C6 | 5509.0 | 4624.0 | -5061.0 | -6531.0 |
| OR6C74 | 123.0 | 3160.0 | 1849.0 | -4753.0 |
| OR6K2 | 5408.0 | -229.0 | 3983.0 | 5409.0 |
| OR6P1 | 2194.0 | 1049.0 | -1973.0 | -3637.0 |
| OR6S1 | 248.0 | -5828.0 | -4764.0 | -678.0 |
| OR6X1 | 4725.0 | 361.0 | -5837.0 | -3538.0 |
| OR7E24 | 7173.0 | 4726.0 | -6191.0 | -4666.0 |
| OR7G3 | -2919.0 | -3645.0 | 627.0 | 5566.0 |
| OR8H1 | 7135.0 | 4717.0 | -539.0 | 4538.0 |
| OR8H2 | 7135.0 | 4717.0 | -539.0 | 4538.0 |
| OR8H3 | 7135.0 | 4717.0 | -539.0 | 4538.0 |
| OR8J1 | 6883.5 | 4311.5 | 822.5 | -355.5 |
| OR8J3 | 6883.5 | 4311.5 | 822.5 | -355.5 |
| OR8U1 | 2630.0 | 2327.0 | 2048.0 | 974.0 |
| OR9A4 | -1698.0 | 1682.0 | 711.0 | 6541.0 |
| REEP1 | -536.0 | 1871.0 | 2658.0 | -3464.0 |
| REEP2 | -187.0 | -6505.0 | 2681.0 | 2724.0 |
| REEP4 | 1665.0 | -7337.0 | -4499.0 | -769.0 |
| REEP5 | -3249.0 | 2997.0 | 3251.0 | 6450.0 |
| RTP1 | 1907.0 | -4868.0 | -3663.0 | -837.0 |
| RTP2 | -3597.0 | -4978.0 | -5025.0 | -4046.0 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0463 |
| p.adjustMANOVA | 0.438 |
| s.dist | 0.596 |
| s.heart_ctrl_vs_acetate | -0.455 |
| s.heart_ctrl_vs_hifibre | -0.196 |
| s.spleen_ctrl_vs_acetate | 0.272 |
| s.spleen_ctrl_vs_hifibre | 0.188 |
| p.heart_ctrl_vs_acetate | 0.00893 |
| p.heart_ctrl_vs_hifibre | 0.261 |
| p.spleen_ctrl_vs_acetate | 0.119 |
| p.spleen_ctrl_vs_hifibre | 0.281 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_acetate |
|---|---|---|
| SLC29A1 | -6320 | 5437 |
| SLC28A1 | -5344 | 2535 |
| SLC28A3 | -5408 | 2221 |
| ARL2 | -4832 | 2219 |
| SLC29A4 | -1753 | 2813 |
| SLC29A2 | -860 | 4184 |
| SLC29A3 | -5647 | 181 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ARL2 | -4832 | -5465 | 2219 | -3284 |
| ARL2BP | 3588 | 25 | 6378 | 1905 |
| SLC25A4 | -1621 | 758 | -6632 | -2937 |
| SLC25A5 | -5991 | 1255 | -1923 | 2583 |
| SLC28A1 | -5344 | -6465 | 2535 | -5095 |
| SLC28A2 | 4574 | 4510 | 3773 | 3958 |
| SLC28A3 | -5408 | -7840 | 2221 | 3876 |
| SLC29A1 | -6320 | -6526 | 5437 | 2249 |
| SLC29A2 | -860 | -5031 | 4184 | 1864 |
| SLC29A3 | -5647 | -8007 | 181 | 3783 |
| SLC29A4 | -1753 | -3952 | 2813 | 4215 |
Platelet Adhesion to exposed collagen
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0596 |
| p.adjustMANOVA | 0.498 |
| s.dist | 0.585 |
| s.heart_ctrl_vs_acetate | 0.442 |
| s.heart_ctrl_vs_hifibre | 0.199 |
| s.spleen_ctrl_vs_acetate | 0.223 |
| s.spleen_ctrl_vs_hifibre | 0.239 |
| p.heart_ctrl_vs_acetate | 0.0111 |
| p.heart_ctrl_vs_hifibre | 0.253 |
| p.spleen_ctrl_vs_acetate | 0.2 |
| p.spleen_ctrl_vs_hifibre | 0.17 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| ITGA1 | 6501 | 6521 |
| GP1BB | 5438 | 6709 |
| FYN | 5806 | 5564 |
| LYN | 6943 | 4351 |
| ITGB1 | 2890 | 4051 |
| GP1BA | 3390 | 1725 |
| GP5 | 1208 | 2833 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| FYN | 5806 | 792 | 3513 | 5564 |
| GP1BA | 3390 | 3809 | 2701 | 1725 |
| GP1BB | 5438 | -4268 | 4270 | 6709 |
| GP5 | 1208 | 341 | 1133 | 2833 |
| GP9 | 1340 | -5647 | 2391 | -4748 |
| ITGA1 | 6501 | 3293 | 3057 | 6521 |
| ITGA10 | -298 | -7719 | -789 | -1782 |
| ITGA2 | 215 | -387 | -4490 | -4563 |
| ITGB1 | 2890 | 4290 | 4116 | 4051 |
| LYN | 6943 | 4344 | 6532 | 4351 |
| VWF | 4170 | -6011 | -4908 | -3711 |
FOXO-mediated transcription of cell death genes
| metric | value |
|---|---|
| setSize | 13 |
| pMANOVA | 0.0369 |
| p.adjustMANOVA | 0.43 |
| s.dist | 0.585 |
| s.heart_ctrl_vs_acetate | 0.326 |
| s.heart_ctrl_vs_hifibre | 0.157 |
| s.spleen_ctrl_vs_acetate | 0.347 |
| s.spleen_ctrl_vs_hifibre | 0.301 |
| p.heart_ctrl_vs_acetate | 0.042 |
| p.heart_ctrl_vs_hifibre | 0.326 |
| p.spleen_ctrl_vs_acetate | 0.0302 |
| p.spleen_ctrl_vs_hifibre | 0.0605 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
|---|---|---|
| EP300 | 4514 | 5933 |
| CITED2 | 4423 | 5589 |
| CREBBP | 4833 | 4478 |
| NFYA | 2568 | 6975 |
| FOXO3 | 3548 | 4382 |
| NFYB | 2325 | 4460 |
| FOXO4 | 3079 | 2829 |
| BCL2L11 | 1935 | 2954 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| BCL2L11 | 2954 | -1481 | 1935 | 3934 |
| BCL6 | -679 | -5334 | 1422 | 127 |
| CITED2 | 5589 | 4161 | 4423 | 4764 |
| CREBBP | 4478 | 952 | 4833 | -1434 |
| EP300 | 5933 | 1528 | 4514 | 3579 |
| FASLG | 1906 | 2473 | -2621 | 6356 |
| FOXO3 | 4382 | -3490 | 3548 | 5504 |
| FOXO4 | 2829 | -811 | 3079 | -4126 |
| NFYA | 6975 | 1298 | 2568 | 1039 |
| NFYB | 4460 | -4154 | 2325 | -8 |
| NFYC | -1643 | 3850 | 6590 | -486 |
| PINK1 | -2188 | -3667 | -3933 | 4814 |
| STK11 | -863 | -7480 | 3019 | 1438 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
| metric | value |
|---|---|
| setSize | 13 |
| pMANOVA | 0.0308 |
| p.adjustMANOVA | 0.413 |
| s.dist | 0.584 |
| s.heart_ctrl_vs_acetate | -0.117 |
| s.heart_ctrl_vs_hifibre | -0.345 |
| s.spleen_ctrl_vs_acetate | -0.225 |
| s.spleen_ctrl_vs_hifibre | -0.397 |
| p.heart_ctrl_vs_acetate | 0.464 |
| p.heart_ctrl_vs_hifibre | 0.0315 |
| p.spleen_ctrl_vs_acetate | 0.16 |
| p.spleen_ctrl_vs_hifibre | 0.0132 |
| Gene | spleen_ctrl_vs_hifibre | heart_ctrl_vs_hifibre |
|---|---|---|
| CHD4 | -6404 | -5946 |
| H2AFX | -5335 | -5318 |
| MTA2 | -3368 | -7034 |
| MTA1 | -2584 | -8212 |
| CHD3 | -1353 | -8583 |
| TTF1 | -6624 | -1410 |
| MBD3 | -942 | -6615 |
| RBBP7 | -4740 | -1110 |
| GATAD2A | -5892 | -647 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CHD3 | 3733 | -8583 | -2756 | -1353 |
| CHD4 | 1583 | -5946 | -6368 | -6404 |
| EHMT2 | -2441 | -8805 | -2084 | 1107 |
| ERCC6 | 854 | 3017 | 2076 | 2637 |
| GATAD2A | -2113 | -647 | 5605 | -5892 |
| H2AFX | -5473 | -5318 | 3179 | -5335 |
| HDAC2 | 3028 | 1845 | -2969 | -5043 |
| MBD3 | 2050 | -6615 | 411 | -942 |
| MTA1 | 1199 | -8212 | -2157 | -2584 |
| MTA2 | -4105 | -7034 | -1859 | -3368 |
| MTA3 | 1079 | -7763 | 21 | 2273 |
| RBBP7 | -5771 | -1110 | -5716 | -4740 |
| TTF1 | 1287 | -1410 | -6321 | -6624 |
CLEC7A (Dectin-1) induces NFAT activation
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.126 |
| p.adjustMANOVA | 0.624 |
| s.dist | 0.582 |
| s.heart_ctrl_vs_acetate | 0.438 |
| s.heart_ctrl_vs_hifibre | 0.358 |
| s.spleen_ctrl_vs_acetate | 0.129 |
| s.spleen_ctrl_vs_hifibre | 0.0495 |
| p.heart_ctrl_vs_acetate | 0.0164 |
| p.heart_ctrl_vs_hifibre | 0.0501 |
| p.spleen_ctrl_vs_acetate | 0.481 |
| p.spleen_ctrl_vs_hifibre | 0.786 |
| Gene | heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre |
|---|---|---|
| AHCYL1 | 6521 | 3887 |
| PPP3CB | 4814 | 4493 |
| CALM1 | 6597 | 2302 |
| ITPR1 | 3235 | 2924 |
| PPP3CA | 6037 | 1165 |
| NFATC1 | 2842 | 847 |
| NFATC3 | 3153 | 325 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AHCYL1 | 6521 | 3887 | 4141 | 4513 |
| CALM1 | 6597 | 2302 | 1288 | -1301 |
| ITPR1 | 3235 | 2924 | 1170 | -1881 |
| ITPR2 | -3828 | -4002 | 4756 | 1798 |
| ITPR3 | 81 | -3266 | -6557 | 3599 |
| NFATC1 | 2842 | 847 | 1791 | -4871 |
| NFATC2 | 4463 | -4365 | -1660 | 1582 |
| NFATC3 | 3153 | 325 | 377 | -2420 |
| PPP3CA | 6037 | 1165 | -2401 | 822 |
| PPP3CB | 4814 | 4493 | 6618 | 669 |
Regulation of PTEN mRNA translation
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.115 |
| p.adjustMANOVA | 0.622 |
| s.dist | 0.581 |
| s.heart_ctrl_vs_acetate | 0.212 |
| s.heart_ctrl_vs_hifibre | 0.272 |
| s.spleen_ctrl_vs_acetate | 0.378 |
| s.spleen_ctrl_vs_hifibre | 0.276 |
| p.heart_ctrl_vs_acetate | 0.223 |
| p.heart_ctrl_vs_hifibre | 0.118 |
| p.spleen_ctrl_vs_acetate | 0.03 |
| p.spleen_ctrl_vs_hifibre | 0.113 |
| Gene | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| MIR214 | 6425 | 6517 |
| PTEN | 6816 | 4607 |
| CNOT6L | 5930 | 5156 |
| MOV10 | 3661 | 5492 |
| AGO4 | 4321 | 3938 |
| AGO2 | 5496 | 662 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AGO1 | -1627 | -6861 | 1244 | -2809 |
| AGO2 | -4669 | -777 | 5496 | 662 |
| AGO3 | 6681 | 3752 | 1403 | -1930 |
| AGO4 | 5217 | 1118 | 4321 | 3938 |
| CNOT6L | 4626 | 4603 | 5930 | 5156 |
| MIR214 | 2530 | 3311 | 6425 | 6517 |
| MIR26A1 | 5293 | -6190 | -4610 | -3333 |
| MOV10 | -1914 | 2165 | 3661 | 5492 |
| PTEN | 5651 | 3103 | 6816 | 4607 |
| TNRC6B | -1165 | 1692 | 1359 | -1791 |
| TNRC6C | -226 | -7612 | -2913 | 3191 |
Classical antibody-mediated complement activation
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0312 |
| p.adjustMANOVA | 0.413 |
| s.dist | 0.58 |
| s.heart_ctrl_vs_acetate | -0.432 |
| s.heart_ctrl_vs_hifibre | -0.091 |
| s.spleen_ctrl_vs_acetate | -0.0187 |
| s.spleen_ctrl_vs_hifibre | -0.375 |
| p.heart_ctrl_vs_acetate | 0.0179 |
| p.heart_ctrl_vs_hifibre | 0.618 |
| p.spleen_ctrl_vs_acetate | 0.919 |
| p.spleen_ctrl_vs_hifibre | 0.0399 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| IGHG1 | -4644.5 | -6896.5 |
| IGHG2 | -4644.5 | -6896.5 |
| IGHG3 | -4644.5 | -6896.5 |
| IGHG4 | -4644.5 | -6896.5 |
| C1QA | -5925.0 | -3258.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| C1QA | -5925.0 | -6707.0 | -1129.0 | -3258.0 |
| C1QB | 5705.0 | -3985.0 | 5565.0 | 2489.0 |
| C1QC | -3814.0 | -5340.0 | 1866.0 | 2256.0 |
| C1R | -1623.0 | -4196.0 | 4752.0 | 4094.0 |
| C1S | 2325.0 | -3798.0 | -1752.0 | -6603.0 |
| CRP | -3448.0 | 88.0 | 1395.0 | 2186.0 |
| IGHG1 | -4644.5 | -580.5 | -2804.5 | -6896.5 |
| IGHG2 | -4644.5 | -580.5 | -2804.5 | -6896.5 |
| IGHG3 | -4644.5 | -580.5 | -2804.5 | -6896.5 |
| IGHG4 | -4644.5 | -580.5 | -2804.5 | -6896.5 |
eNOS activation
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0856 |
| p.adjustMANOVA | 0.576 |
| s.dist | 0.579 |
| s.heart_ctrl_vs_acetate | 0.0472 |
| s.heart_ctrl_vs_hifibre | 0.0615 |
| s.spleen_ctrl_vs_acetate | -0.263 |
| s.spleen_ctrl_vs_hifibre | -0.51 |
| p.heart_ctrl_vs_acetate | 0.796 |
| p.heart_ctrl_vs_hifibre | 0.737 |
| p.spleen_ctrl_vs_acetate | 0.151 |
| p.spleen_ctrl_vs_hifibre | 0.0052 |
| Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
|---|---|---|
| SPR | -6632 | -6708 |
| DDAH1 | -4437 | -3760 |
| AKT1 | -3263 | -3225 |
| DDAH2 | -3813 | -2391 |
| HSP90AA1 | -4327 | -1219 |
| LYPLA1 | -4765 | -412 |
| NOS3 | -3459 | -550 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AKT1 | -4342 | -6318 | -3225 | -3263 |
| CALM1 | 6597 | 2302 | 1288 | -1301 |
| CAV1 | 2283 | 4045 | -6205 | 1264 |
| DDAH1 | 4062 | 3709 | -3760 | -4437 |
| DDAH2 | 2236 | -6403 | -2391 | -3813 |
| HSP90AA1 | -2713 | -6124 | -1219 | -4327 |
| LYPLA1 | 79 | -3217 | -412 | -4765 |
| NOS3 | 4706 | -6717 | -550 | -3459 |
| SPR | -2935 | -552 | -6708 | -6632 |
| ZDHHC21 | -2681 | 3400 | 6056 | -4878 |
Passive transport by Aquaporins
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.0148 |
| p.adjustMANOVA | 0.325 |
| s.dist | 0.561 |
| s.heart_ctrl_vs_acetate | -0.0866 |
| s.heart_ctrl_vs_hifibre | -0.392 |
| s.spleen_ctrl_vs_acetate | -0.146 |
| s.spleen_ctrl_vs_hifibre | 0.363 |
| p.heart_ctrl_vs_acetate | 0.603 |
| p.heart_ctrl_vs_hifibre | 0.0188 |
| p.spleen_ctrl_vs_acetate | 0.382 |
| p.spleen_ctrl_vs_hifibre | 0.0293 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| AQP6 | -7649.0 | 4503.0 |
| AQP7 | -7578.0 | 3545.0 |
| AQP12A | -6916.5 | 3805.5 |
| AQP11 | -3735.0 | 4928.0 |
| AQP2 | -6144.0 | 2862.0 |
| AQP1 | -2292.0 | 6632.0 |
| AQP8 | -3620.0 | 4062.0 |
| AQP9 | -2417.0 | 5567.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AQP1 | 5973.0 | -2292.0 | -6731.0 | 6632.0 |
| AQP11 | -2925.0 | -3735.0 | -2685.0 | 4928.0 |
| AQP12A | -2861.5 | -6916.5 | 1498.5 | 3805.5 |
| AQP2 | 2716.0 | -6144.0 | -3830.0 | 2862.0 |
| AQP3 | 3055.0 | -6373.0 | -5230.0 | -1111.0 |
| AQP4 | -961.0 | 3330.0 | 3816.0 | -1829.0 |
| AQP5 | -4104.0 | -6585.0 | -107.0 | -2419.0 |
| AQP6 | -2516.0 | -7649.0 | -3819.0 | 4503.0 |
| AQP7 | 2952.0 | -7578.0 | 4394.0 | 3545.0 |
| AQP8 | 2407.0 | -3620.0 | 5747.0 | 4062.0 |
| AQP9 | -2409.0 | -2417.0 | 1616.0 | 5567.0 |
| MIP | -3507.0 | -6108.0 | -5670.0 | -1893.0 |
E2F mediated regulation of DNA replication
| metric | value |
|---|---|
| setSize | 18 |
| pMANOVA | 0.000206 |
| p.adjustMANOVA | 0.0209 |
| s.dist | 0.555 |
| s.heart_ctrl_vs_acetate | 0.2 |
| s.heart_ctrl_vs_hifibre | 0.16 |
| s.spleen_ctrl_vs_acetate | 0.457 |
| s.spleen_ctrl_vs_hifibre | -0.183 |
| p.heart_ctrl_vs_acetate | 0.141 |
| p.heart_ctrl_vs_hifibre | 0.24 |
| p.spleen_ctrl_vs_acetate | 0.000783 |
| p.spleen_ctrl_vs_hifibre | 0.179 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
|---|---|---|
| CDK1 | 5240 | 6933 |
| RB1 | 5151 | 6490 |
| ORC1 | 4904 | 5767 |
| PPP2R1A | 6241 | 3306 |
| ORC4 | 2517 | 6471 |
| ORC3 | 2670 | 5412 |
| POLA1 | 2790 | 4975 |
| TFDP2 | 3503 | 3707 |
| PRIM2 | 1770 | 4595 |
| POLA2 | 3894 | 1708 |
| PPP2CB | 782 | 4429 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CCNB1 | -5306.0 | -2765.0 | 4736.0 | 3596.0 |
| CDK1 | 6933.0 | -3921.0 | 5240.0 | 780.0 |
| E2F1 | -807.0 | -1429.0 | 5399.0 | 345.0 |
| ORC1 | 5767.0 | -1323.0 | 4904.0 | 4176.0 |
| ORC2 | -4246.0 | -336.0 | 6120.0 | -1632.0 |
| ORC3 | 5412.0 | 2947.0 | 2670.0 | -5236.0 |
| ORC4 | 6471.0 | 4636.0 | 2517.0 | -6158.0 |
| POLA1 | 4975.0 | 3630.0 | 2790.0 | -357.0 |
| POLA2 | 1708.0 | -5431.0 | 3894.0 | -3842.0 |
| PPP2CA | -3391.0 | -2174.0 | 4047.0 | -3589.0 |
| PPP2CB | 4429.0 | 1265.0 | 782.0 | -4786.0 |
| PPP2R1A | 3306.0 | 2019.0 | 6241.0 | 2538.0 |
| PPP2R1B | -3173.0 | -5968.0 | 5430.0 | 4913.0 |
| PRIM1 | -5383.0 | -7372.0 | -2457.0 | 2625.0 |
| PRIM2 | 4595.0 | -37.0 | 1770.0 | -4580.0 |
| RB1 | 6490.0 | 3350.0 | 5151.0 | -5157.0 |
| TFDP1 | 383.5 | -5259.5 | -5364.5 | -4092.5 |
| TFDP2 | 3707.0 | 1675.0 | 3503.0 | -3504.0 |
Activation of RAC1
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.126 |
| p.adjustMANOVA | 0.624 |
| s.dist | 0.548 |
| s.heart_ctrl_vs_acetate | 0.209 |
| s.heart_ctrl_vs_hifibre | 0.448 |
| s.spleen_ctrl_vs_acetate | 0.224 |
| s.spleen_ctrl_vs_hifibre | -0.0729 |
| p.heart_ctrl_vs_acetate | 0.252 |
| p.heart_ctrl_vs_hifibre | 0.0142 |
| p.spleen_ctrl_vs_acetate | 0.22 |
| p.spleen_ctrl_vs_hifibre | 0.69 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
|---|---|---|
| NCK1 | 4330 | 5481 |
| ROBO1 | 3155 | 4041 |
| RAC1 | 1836 | 5823 |
| SLIT2 | 4667 | 747 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| NCK1 | 6069 | 4330 | 5481 | -5971 |
| NCK2 | 6299 | 3193 | -5544 | -1401 |
| PAK2 | -6007 | -5516 | 6695 | 5321 |
| PAK3 | 6294 | 4482 | -5558 | -6449 |
| PAK4 | -4129 | -5615 | 1723 | -1139 |
| PAK6 | -2562 | 842 | -2080 | -799 |
| RAC1 | -2849 | 1836 | 5823 | 5505 |
| ROBO1 | 3886 | 3155 | 4041 | 1332 |
| SLIT2 | 5851 | 4667 | 747 | -490 |
| SOS2 | 5462 | -932 | 4691 | -1736 |
Condensation of Prophase Chromosomes
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.04 |
| p.adjustMANOVA | 0.438 |
| s.dist | 0.544 |
| s.heart_ctrl_vs_acetate | 0.179 |
| s.heart_ctrl_vs_hifibre | 0.0635 |
| s.spleen_ctrl_vs_acetate | 0.507 |
| s.spleen_ctrl_vs_hifibre | 0.0572 |
| p.heart_ctrl_vs_acetate | 0.327 |
| p.heart_ctrl_vs_hifibre | 0.728 |
| p.spleen_ctrl_vs_acetate | 0.00552 |
| p.spleen_ctrl_vs_hifibre | 0.754 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
|---|---|---|
| PHF8 | 6608 | 6346 |
| CDK1 | 5240 | 6933 |
| RB1 | 5151 | 6490 |
| MCPH1 | 5840 | 4444 |
| NCAPG2 | 5 | 2835 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CCNB1 | -5306 | -2765 | 4736 | 3596 |
| CDK1 | 6933 | -3921 | 5240 | 780 |
| H2AFX | -5473 | -5318 | 3179 | -5335 |
| MCPH1 | 4444 | 2866 | 5840 | -2728 |
| NCAPG2 | 2835 | -3780 | 5 | 2812 |
| NCAPH2 | 6889 | -8295 | -2526 | 1454 |
| PHF8 | 6346 | 3327 | 6608 | 4501 |
| RB1 | 6490 | 3350 | 5151 | -5157 |
| SET | -3563 | -4668 | 2289 | 6170 |
| SMC4 | -3318 | 3471 | 4740 | -3057 |
Metabolism of nitric oxide: NOS3 activation and regulation
| metric | value |
|---|---|
| setSize | 14 |
| pMANOVA | 0.0234 |
| p.adjustMANOVA | 0.396 |
| s.dist | 0.541 |
| s.heart_ctrl_vs_acetate | 0.137 |
| s.heart_ctrl_vs_hifibre | 0.000451 |
| s.spleen_ctrl_vs_acetate | -0.163 |
| s.spleen_ctrl_vs_hifibre | -0.497 |
| p.heart_ctrl_vs_acetate | 0.374 |
| p.heart_ctrl_vs_hifibre | 0.998 |
| p.spleen_ctrl_vs_acetate | 0.291 |
| p.spleen_ctrl_vs_hifibre | 0.00129 |
| Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
|---|---|---|
| SPR | -6632 | -6708 |
| DDAH1 | -4437 | -3760 |
| AKT1 | -3263 | -3225 |
| DDAH2 | -3813 | -2391 |
| HSP90AA1 | -4327 | -1219 |
| WASL | -6150 | -478 |
| LYPLA1 | -4765 | -412 |
| NOS3 | -3459 | -550 |
| DNM2 | -5255 | -37 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AKT1 | -4342 | -6318 | -3225 | -3263 |
| CALM1 | 6597 | 2302 | 1288 | -1301 |
| CAV1 | 2283 | 4045 | -6205 | 1264 |
| DDAH1 | 4062 | 3709 | -3760 | -4437 |
| DDAH2 | 2236 | -6403 | -2391 | -3813 |
| DNM2 | 3753 | -8144 | -37 | -5255 |
| HSP90AA1 | -2713 | -6124 | -1219 | -4327 |
| LYPLA1 | 79 | -3217 | -412 | -4765 |
| NOS3 | 4706 | -6717 | -550 | -3459 |
| NOSIP | -4069 | -8614 | 591 | -2850 |
| NOSTRIN | 5801 | 2846 | 2558 | 1310 |
| SPR | -2935 | -552 | -6708 | -6632 |
| WASL | 6019 | 1746 | -478 | -6150 |
| ZDHHC21 | -2681 | 3400 | 6056 | -4878 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta
| metric | value |
|---|---|
| setSize | 58 |
| pMANOVA | 5.14e-12 |
| p.adjustMANOVA | 1.36e-09 |
| s.dist | 0.54 |
| s.heart_ctrl_vs_acetate | 0.259 |
| s.heart_ctrl_vs_hifibre | 0.232 |
| s.spleen_ctrl_vs_acetate | 0.204 |
| s.spleen_ctrl_vs_hifibre | -0.36 |
| p.heart_ctrl_vs_acetate | 0.000655 |
| p.heart_ctrl_vs_hifibre | 0.0023 |
| p.spleen_ctrl_vs_acetate | 0.00719 |
| p.spleen_ctrl_vs_hifibre | 2.11e-06 |
| Gene | spleen_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| IFNA1 | -6287 | 7041 |
| IFNA10 | -6287 | 7041 |
| IFNA14 | -6287 | 7041 |
| IFNA16 | -6287 | 7041 |
| IFNA17 | -6287 | 7041 |
| IFNA2 | -6287 | 7041 |
| IFNA21 | -6287 | 7041 |
| IFNA4 | -6287 | 7041 |
| IFNA5 | -6287 | 7041 |
| IFNA6 | -6287 | 7041 |
| IFNA7 | -6287 | 7041 |
| IFNA8 | -6287 | 7041 |
| RIPK1 | -5885 | 6907 |
| TAX1BP1 | -5350 | 6700 |
| IFIH1 | -5129 | 6021 |
| CASP8 | -5290 | 5302 |
| SIKE1 | -3617 | 5088 |
| HMGB1 | -3133 | 4519 |
| S100B | -3575 | 2862 |
| MAVS | -5675 | 1585 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| APP | 2948 | 2127 | 618 | 2020 |
| ATG5 | -3795 | -3406 | -4915 | -247 |
| CASP8 | 5302 | 721 | 4662 | -5290 |
| CHUK | -2840 | 154 | -5126 | -4997 |
| CREBBP | 4478 | 952 | 4833 | -1434 |
| CYLD | 2410 | 3661 | 4608 | -1719 |
| DDX58 | -4308 | -6101 | -4708 | -1631 |
| DHX58 | -4848 | -7242 | 1177 | -716 |
| EP300 | 5933 | 1528 | 4514 | 3579 |
| FADD | 710 | -3032 | 247 | -1471 |
| HMGB1 | 4519 | -1286 | 5213 | -3133 |
| IFIH1 | 6021 | 2259 | 2027 | -5129 |
| IFNA1 | 7041 | 4743 | 6305 | -6287 |
| IFNA10 | 7041 | 4743 | 6305 | -6287 |
| IFNA14 | 7041 | 4743 | 6305 | -6287 |
| IFNA16 | 7041 | 4743 | 6305 | -6287 |
| IFNA17 | 7041 | 4743 | 6305 | -6287 |
| IFNA2 | 7041 | 4743 | 6305 | -6287 |
| IFNA21 | 7041 | 4743 | 6305 | -6287 |
| IFNA4 | 7041 | 4743 | 6305 | -6287 |
| IFNA5 | 7041 | 4743 | 6305 | -6287 |
| IFNA6 | 7041 | 4743 | 6305 | -6287 |
| IFNA7 | 7041 | 4743 | 6305 | -6287 |
| IFNA8 | 7041 | 4743 | 6305 | -6287 |
| IFNB1 | 886 | 3901 | -5835 | -5964 |
| IKBKB | 5254 | -6809 | -4544 | -1072 |
| IKBKE | -158 | -6360 | -2473 | -1146 |
| IKBKG | 2223 | 1533 | -291 | 939 |
| IRF3 | -4411 | -5704 | 811 | -1016 |
| IRF7 | 4400 | -1601 | 6372 | 5310 |
| MAP3K1 | 3685 | -7902 | -1401 | 1385 |
| MAVS | 1585 | -1596 | 4572 | -5675 |
| NFKB1 | 2278 | -2851 | -49 | -3913 |
| NFKB2 | -2824 | -8263 | -2482 | -5965 |
| NFKBIA | -4337 | -586 | 3522 | -3729 |
| NFKBIB | 1795 | -1663 | -941 | 1974 |
| NKIRAS2 | -6330 | -7656 | 5482 | 741 |
| NLRC5 | -2899 | -2809 | -901 | -4048 |
| NLRX1 | -3640 | 1152 | 3417 | -1875 |
| RELA | 3054 | -3513 | -1419 | -1233 |
| RIPK1 | 6907 | -80 | 2377 | -5885 |
| RNF125 | 313 | -5092 | 261 | -6539 |
| RNF135 | -1270 | -1662 | 1149 | 1338 |
| RNF216 | -5531 | -1911 | -4608 | -3744 |
| S100B | 2862 | -1236 | -5760 | -3575 |
| SIKE1 | 5088 | 3075 | 5486 | -3617 |
| TANK | 5834 | 4410 | 3239 | 1175 |
| TAX1BP1 | 6700 | 4363 | 2939 | -5350 |
| TBK1 | -3177 | -5581 | 3609 | -3201 |
| TNFAIP3 | 6894 | 2285 | -1797 | 4359 |
| TRAF2 | -2689 | 71 | -232 | -6788 |
| TRAF3 | -2153 | -7824 | -5668 | 283 |
| TRAF6 | 3819 | 2512 | -409 | -809 |
| UBA52 | 6159 | 1509 | -5902 | 1309 |
| UBA7 | -2494 | -6530 | -3581 | 2305 |
| UBE2D1 | -5029 | -5535 | -305 | 567 |
| UBE2K | 6709 | 1480 | 2424 | 2329 |
| UBE2L6 | -4983 | -5967 | -1162 | -10 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.00915 |
| p.adjustMANOVA | 0.247 |
| s.dist | 0.539 |
| s.heart_ctrl_vs_acetate | -0.203 |
| s.heart_ctrl_vs_hifibre | -0.15 |
| s.spleen_ctrl_vs_acetate | 0.462 |
| s.spleen_ctrl_vs_hifibre | -0.117 |
| p.heart_ctrl_vs_acetate | 0.245 |
| p.heart_ctrl_vs_hifibre | 0.39 |
| p.spleen_ctrl_vs_acetate | 0.00794 |
| p.spleen_ctrl_vs_hifibre | 0.502 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
|---|---|---|
| ROR1 | 6866 | -2608 |
| FZD2 | 3003 | -5572 |
| AP2S1 | 2668 | -5973 |
| CLTB | 2662 | -3504 |
| FZD5 | 2959 | -1188 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AP2A1 | 1606 | -8408 | -1640 | -2436 |
| AP2A2 | 755 | 1861 | 3891 | -5834 |
| AP2M1 | 3027 | -5767 | 5887 | -940 |
| AP2S1 | -5973 | -7762 | 2668 | -1227 |
| CLTA | -3680 | -2737 | -2373 | -6516 |
| CLTB | -3504 | -4437 | 2662 | 877 |
| CLTC | 4493 | 3946 | 6258 | -4217 |
| FZD2 | -5572 | -701 | 3003 | 2415 |
| FZD5 | -1188 | -6309 | 2959 | 5376 |
| ROR1 | -2608 | 3437 | 6866 | 4934 |
| ROR2 | 1953 | -6398 | 5266 | -2136 |
Retrograde neurotrophin signalling
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.00465 |
| p.adjustMANOVA | 0.182 |
| s.dist | 0.533 |
| s.heart_ctrl_vs_acetate | 0.213 |
| s.heart_ctrl_vs_hifibre | -0.0523 |
| s.spleen_ctrl_vs_acetate | 0.0999 |
| s.spleen_ctrl_vs_hifibre | -0.476 |
| p.heart_ctrl_vs_acetate | 0.201 |
| p.heart_ctrl_vs_hifibre | 0.754 |
| p.spleen_ctrl_vs_acetate | 0.549 |
| p.spleen_ctrl_vs_hifibre | 0.00433 |
| Gene | spleen_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| SH3GL2 | -4539 | 4918 |
| DNM2 | -5255 | 3753 |
| CLTC | -4217 | 4493 |
| NGF | -3879 | 4360 |
| DNAL4 | -5842 | 1393 |
| DNM1 | -3710 | 1523 |
| AP2A2 | -5834 | 755 |
| AP2A1 | -2436 | 1606 |
| AP2M1 | -940 | 3027 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| AP2A1 | 1606 | -8408 | -1640 | -2436 |
| AP2A2 | 755 | 1861 | 3891 | -5834 |
| AP2M1 | 3027 | -5767 | 5887 | -940 |
| AP2S1 | -5973 | -7762 | 2668 | -1227 |
| CLTA | -3680 | -2737 | -2373 | -6516 |
| CLTC | 4493 | 3946 | 6258 | -4217 |
| DNAL4 | 1393 | -461 | -6698 | -5842 |
| DNM1 | 1523 | -5916 | 440 | -3710 |
| DNM2 | 3753 | -8144 | -37 | -5255 |
| DNM3 | 6127 | 183 | 899 | 4496 |
| NGF | 4360 | 3455 | 4432 | -3879 |
| SH3GL2 | 4918 | 1407 | -4662 | -4539 |
PINK1-PRKN Mediated Mitophagy
| metric | value |
|---|---|
| setSize | 14 |
| pMANOVA | 0.0257 |
| p.adjustMANOVA | 0.402 |
| s.dist | 0.529 |
| s.heart_ctrl_vs_acetate | -0.409 |
| s.heart_ctrl_vs_hifibre | -0.165 |
| s.spleen_ctrl_vs_acetate | -0.0247 |
| s.spleen_ctrl_vs_hifibre | -0.291 |
| p.heart_ctrl_vs_acetate | 0.00811 |
| p.heart_ctrl_vs_hifibre | 0.284 |
| p.spleen_ctrl_vs_acetate | 0.873 |
| p.spleen_ctrl_vs_hifibre | 0.0596 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| TOMM7 | -6280.0 | -6602.0 |
| MAP1LC3A | -5055.0 | -5610.0 |
| VDAC1 | -4079.0 | -3904.0 |
| TOMM40 | -3808.0 | -4174.0 |
| SQSTM1 | -5693.0 | -1449.0 |
| MFN1 | -1279.0 | -6192.0 |
| TOMM22 | -2356.0 | -2012.0 |
| MAP1LC3B | -2047.5 | -520.5 |
| ATG5 | -3795.0 | -247.0 |
| MFN2 | -3851.0 | -76.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ATG5 | -3795.0 | -3406.0 | -4915.0 | -247.0 |
| MAP1LC3A | -5055.0 | -3470.0 | 2205.0 | -5610.0 |
| MAP1LC3B | -2047.5 | -4317.5 | 2509.5 | -520.5 |
| MFN1 | -1279.0 | 677.0 | 5396.0 | -6192.0 |
| MFN2 | -3851.0 | -5563.0 | -2862.0 | -76.0 |
| PARK2 | 898.0 | 483.0 | 4930.0 | 2230.0 |
| PINK1 | -2188.0 | -3667.0 | -3933.0 | 4814.0 |
| SQSTM1 | -5693.0 | -5587.0 | 6030.0 | -1449.0 |
| TOMM22 | -2356.0 | -2932.0 | -6149.0 | -2012.0 |
| TOMM40 | -3808.0 | -8239.0 | -3090.0 | -4174.0 |
| TOMM5 | 137.0 | 859.0 | -1548.0 | -6487.0 |
| TOMM7 | -6280.0 | -2991.0 | 2432.0 | -6602.0 |
| UBA52 | 6159.0 | 1509.0 | -5902.0 | 1309.0 |
| VDAC1 | -4079.0 | -7189.0 | 3593.0 | -3904.0 |
Presynaptic nicotinic acetylcholine receptors
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0338 |
| p.adjustMANOVA | 0.413 |
| s.dist | 0.524 |
| s.heart_ctrl_vs_acetate | -0.506 |
| s.heart_ctrl_vs_hifibre | -0.0181 |
| s.spleen_ctrl_vs_acetate | -0.0622 |
| s.spleen_ctrl_vs_hifibre | -0.122 |
| p.heart_ctrl_vs_acetate | 0.00369 |
| p.heart_ctrl_vs_hifibre | 0.917 |
| p.spleen_ctrl_vs_acetate | 0.721 |
| p.spleen_ctrl_vs_hifibre | 0.485 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| CHRNA6 | -5865 | -5613 |
| CHRNE | -5282 | -5709 |
| CHRNA2 | -5412 | -4212 |
| CHRNB3 | -5018 | -3318 |
| CHRND | -5240 | -1852 |
| CHRNA1 | -6274 | -693 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CHRNA1 | -6274 | -3449 | -5159 | -693 |
| CHRNA2 | -5412 | -4560 | -3029 | -4212 |
| CHRNA3 | -4162 | 1694 | 6676 | 6658 |
| CHRNA4 | 1503 | -497 | 722 | 887 |
| CHRNA5 | 2950 | 2483 | -475 | -3039 |
| CHRNA6 | -5865 | -2614 | -6283 | -5613 |
| CHRNB2 | 3999 | -919 | -4385 | 308 |
| CHRNB3 | -5018 | 1035 | 2559 | -3318 |
| CHRND | -5240 | -6665 | -2243 | -1852 |
| CHRNE | -5282 | -3751 | 2462 | -5709 |
| CHRNG | -4578 | -6180 | 5324 | 6519 |
Heme degradation
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.0143 |
| p.adjustMANOVA | 0.325 |
| s.dist | 0.523 |
| s.heart_ctrl_vs_acetate | -0.122 |
| s.heart_ctrl_vs_hifibre | 0.198 |
| s.spleen_ctrl_vs_acetate | 0.466 |
| s.spleen_ctrl_vs_hifibre | 0.0433 |
| p.heart_ctrl_vs_acetate | 0.415 |
| p.heart_ctrl_vs_hifibre | 0.185 |
| p.spleen_ctrl_vs_acetate | 0.00176 |
| p.spleen_ctrl_vs_hifibre | 0.771 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_hifibre |
|---|---|---|
| ABCG2 | 6507.0 | 3978.0 |
| SLCO1B1 | 4673.0 | 4499.0 |
| SLCO1B3 | 4673.0 | 4499.0 |
| HMOX2 | 6670.0 | 2904.0 |
| GSTA1 | 5106.5 | 2838.5 |
| ALB | 3600.0 | 3309.0 |
| UGT1A4 | 2890.0 | 2421.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ABCC1 | -3897.0 | -923.0 | 6054.0 | -5058.0 |
| ABCC2 | -311.0 | -5680.0 | 3873.0 | 5304.0 |
| ABCG2 | -5391.0 | 3978.0 | 6507.0 | 5843.0 |
| ALB | 523.0 | 3309.0 | 3600.0 | 3571.0 |
| BLVRA | -5136.0 | -7807.0 | 4636.0 | -5876.0 |
| BLVRB | 1160.0 | -3467.0 | 916.0 | -785.0 |
| FABP1 | 3758.0 | 159.0 | -2484.0 | -3173.0 |
| GSTA1 | -214.5 | 2838.5 | 5106.5 | 6331.5 |
| GUSB | -139.0 | -7318.0 | -1221.0 | 2211.0 |
| HMOX1 | -5804.0 | -5989.0 | -958.0 | 2354.0 |
| HMOX2 | -3548.0 | 2904.0 | 6670.0 | 2608.0 |
| SLCO1B1 | 6652.0 | 4499.0 | 4673.0 | -5733.0 |
| SLCO1B3 | 6652.0 | 4499.0 | 4673.0 | -5733.0 |
| SLCO2B1 | -3023.0 | -3326.0 | 3810.0 | -1746.0 |
| UGT1A4 | 2416.0 | 2421.0 | 2890.0 | 3016.0 |
Mitophagy
| metric | value |
|---|---|
| setSize | 18 |
| pMANOVA | 0.00569 |
| p.adjustMANOVA | 0.192 |
| s.dist | 0.52 |
| s.heart_ctrl_vs_acetate | -0.426 |
| s.heart_ctrl_vs_hifibre | -0.168 |
| s.spleen_ctrl_vs_acetate | 0.0577 |
| s.spleen_ctrl_vs_hifibre | -0.241 |
| p.heart_ctrl_vs_acetate | 0.00177 |
| p.heart_ctrl_vs_hifibre | 0.216 |
| p.spleen_ctrl_vs_acetate | 0.672 |
| p.spleen_ctrl_vs_hifibre | 0.0771 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| TOMM7 | -6280.0 | -6602.0 |
| MAP1LC3A | -5055.0 | -5610.0 |
| FUNDC1 | -4300.0 | -4588.0 |
| VDAC1 | -4079.0 | -3904.0 |
| TOMM40 | -3808.0 | -4174.0 |
| PGAM5 | -3250.0 | -3594.0 |
| SQSTM1 | -5693.0 | -1449.0 |
| MFN1 | -1279.0 | -6192.0 |
| TOMM22 | -2356.0 | -2012.0 |
| MAP1LC3B | -2047.5 | -520.5 |
| ATG5 | -3795.0 | -247.0 |
| MFN2 | -3851.0 | -76.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ATG5 | -3795.0 | -3406.0 | -4915.0 | -247.0 |
| CSNK2A2 | -2086.0 | -1535.0 | 4096.0 | 6022.0 |
| FUNDC1 | -4300.0 | 441.0 | 2203.0 | -4588.0 |
| MAP1LC3A | -5055.0 | -3470.0 | 2205.0 | -5610.0 |
| MAP1LC3B | -2047.5 | -4317.5 | 2509.5 | -520.5 |
| MFN1 | -1279.0 | 677.0 | 5396.0 | -6192.0 |
| MFN2 | -3851.0 | -5563.0 | -2862.0 | -76.0 |
| PARK2 | 898.0 | 483.0 | 4930.0 | 2230.0 |
| PGAM5 | -3250.0 | -4703.0 | 4100.0 | -3594.0 |
| PINK1 | -2188.0 | -3667.0 | -3933.0 | 4814.0 |
| SQSTM1 | -5693.0 | -5587.0 | 6030.0 | -1449.0 |
| SRC | -1934.0 | -7098.0 | -679.0 | 47.0 |
| TOMM22 | -2356.0 | -2932.0 | -6149.0 | -2012.0 |
| TOMM40 | -3808.0 | -8239.0 | -3090.0 | -4174.0 |
| TOMM5 | 137.0 | 859.0 | -1548.0 | -6487.0 |
| TOMM7 | -6280.0 | -2991.0 | 2432.0 | -6602.0 |
| UBA52 | 6159.0 | 1509.0 | -5902.0 | 1309.0 |
| VDAC1 | -4079.0 | -7189.0 | 3593.0 | -3904.0 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0526 |
| p.adjustMANOVA | 0.471 |
| s.dist | 0.518 |
| s.heart_ctrl_vs_acetate | 0.196 |
| s.heart_ctrl_vs_hifibre | 0.438 |
| s.spleen_ctrl_vs_acetate | -0.172 |
| s.spleen_ctrl_vs_hifibre | 0.0912 |
| p.heart_ctrl_vs_acetate | 0.283 |
| p.heart_ctrl_vs_hifibre | 0.0166 |
| p.spleen_ctrl_vs_acetate | 0.345 |
| p.spleen_ctrl_vs_hifibre | 0.617 |
| Gene | heart_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| TAB2 | 4389.0 | 6863.0 |
| TICAM2 | 2455.5 | 6648.5 |
| MAP3K7 | 3634.0 | 4263.0 |
| TRAF6 | 2512.0 | 3819.0 |
| UBA52 | 1509.0 | 6159.0 |
| LY96 | 3013.0 | 1387.0 |
| CD14 | 198.0 | 202.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CD14 | 202.0 | 198.0 | -1814.0 | -3965.0 |
| IRAK2 | -4752.0 | -6250.0 | 4667.0 | 971.0 |
| LY96 | 1387.0 | 3013.0 | -5782.0 | -4069.0 |
| MAP3K7 | 4263.0 | 3634.0 | -5194.0 | -3471.0 |
| TAB1 | -5289.0 | -2289.0 | -1547.0 | 5063.0 |
| TAB2 | 6863.0 | 4389.0 | 5867.0 | 2397.0 |
| TICAM1 | -1862.0 | 564.0 | 3871.0 | 4472.0 |
| TICAM2 | 6648.5 | 2455.5 | -4748.5 | 3455.5 |
| TRAF6 | 3819.0 | 2512.0 | -409.0 | -809.0 |
| UBA52 | 6159.0 | 1509.0 | -5902.0 | 1309.0 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
| metric | value |
|---|---|
| setSize | 19 |
| pMANOVA | 0.0051 |
| p.adjustMANOVA | 0.182 |
| s.dist | 0.512 |
| s.heart_ctrl_vs_acetate | 0.162 |
| s.heart_ctrl_vs_hifibre | -0.132 |
| s.spleen_ctrl_vs_acetate | -0.169 |
| s.spleen_ctrl_vs_hifibre | -0.436 |
| p.heart_ctrl_vs_acetate | 0.222 |
| p.heart_ctrl_vs_hifibre | 0.319 |
| p.spleen_ctrl_vs_acetate | 0.201 |
| p.spleen_ctrl_vs_hifibre | 0.001 |
| Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
|---|---|---|
| RAD51D | -5596 | -5939 |
| RMI1 | -5035 | -4622 |
| ATM | -4994 | -4464 |
| RAD51AP1 | -5746 | -3604 |
| BARD1 | -5793 | -3306 |
| RAD50 | -4040 | -3646 |
| DNA2 | -2086 | -3396 |
| RBBP8 | -1856 | -2854 |
| XRCC2 | -1090 | -4511 |
| TOP3A | -4210 | -948 |
| PALB2 | -985 | -822 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ATM | 2922.0 | -1173.0 | -4464.0 | -4994.0 |
| BARD1 | 6506.0 | 1824.0 | -3306.0 | -5793.0 |
| BRCA1 | -2721.0 | -3732.0 | 5606.0 | -4907.0 |
| DNA2 | -3010.0 | -8455.0 | -3396.0 | -2086.0 |
| EXO1 | 7073.0 | 3858.0 | 2020.0 | -6237.0 |
| KAT5 | -201.0 | -7550.0 | 1385.0 | -1591.0 |
| PALB2 | -5650.0 | -6174.0 | -822.0 | -985.0 |
| RAD50 | 405.0 | -5560.0 | -3646.0 | -4040.0 |
| RAD51 | 2506.0 | -2962.0 | 3799.0 | 1291.0 |
| RAD51AP1 | 4278.0 | -3369.0 | -3604.0 | -5746.0 |
| RAD51B | 6602.0 | -2516.0 | 3863.0 | 3395.0 |
| RAD51D | -5936.0 | -6221.0 | -5939.0 | -5596.0 |
| RBBP8 | 2263.0 | 2454.0 | -2854.0 | -1856.0 |
| RMI1 | 459.0 | -1764.0 | -4622.0 | -5035.0 |
| RMI2 | 4344.0 | 191.0 | -6300.0 | 1351.0 |
| RTEL1 | 3133.5 | 947.5 | 1687.5 | -4497.5 |
| TOP3A | 4728.0 | -4810.0 | -948.0 | -4210.0 |
| XRCC2 | 2906.0 | -3720.0 | -4511.0 | -1090.0 |
| XRCC3 | -1946.0 | -6477.0 | 5576.0 | -5393.0 |
Interleukin-35 Signalling
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.14 |
| p.adjustMANOVA | 0.641 |
| s.dist | 0.508 |
| s.heart_ctrl_vs_acetate | -0.0877 |
| s.heart_ctrl_vs_hifibre | 0.0296 |
| s.spleen_ctrl_vs_acetate | 0.231 |
| s.spleen_ctrl_vs_hifibre | 0.444 |
| p.heart_ctrl_vs_acetate | 0.615 |
| p.heart_ctrl_vs_hifibre | 0.865 |
| p.spleen_ctrl_vs_acetate | 0.186 |
| p.spleen_ctrl_vs_hifibre | 0.0109 |
| Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
|---|---|---|
| IL27RA | 6720 | 5893 |
| CANX | 2635 | 6720 |
| IL12RB2 | 6636 | 2394 |
| STAT4 | 3895 | 3464 |
| EBI3 | 3765 | 2571 |
| IL6ST | 2856 | 1424 |
| STAT1 | 2044 | 1464 |
| STAT3 | 1746 | 213 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CANX | 2078 | 3657 | 6720 | 2635 |
| EBI3 | -764 | -3580 | 2571 | 3765 |
| IL12A | -2938 | 424 | -2760 | 1064 |
| IL12RB2 | 173 | 3719 | 2394 | 6636 |
| IL27RA | -5614 | -7672 | 5893 | 6720 |
| IL6ST | -4423 | -3948 | 1424 | 2856 |
| JAK1 | 5110 | 1267 | -2061 | -3259 |
| STAT1 | 5675 | -1637 | 1464 | 2044 |
| STAT3 | -230 | -8483 | 213 | 1746 |
| STAT4 | -608 | 2657 | 3464 | 3895 |
| TYK2 | -538 | -6255 | -1232 | 4175 |
CD209 (DC-SIGN) signaling
| metric | value |
|---|---|
| setSize | 17 |
| pMANOVA | 0.0545 |
| p.adjustMANOVA | 0.472 |
| s.dist | 0.505 |
| s.heart_ctrl_vs_acetate | 0.293 |
| s.heart_ctrl_vs_hifibre | 0.384 |
| s.spleen_ctrl_vs_acetate | 0.103 |
| s.spleen_ctrl_vs_hifibre | 0.105 |
| p.heart_ctrl_vs_acetate | 0.0365 |
| p.heart_ctrl_vs_hifibre | 0.00607 |
| p.spleen_ctrl_vs_acetate | 0.463 |
| p.spleen_ctrl_vs_hifibre | 0.454 |
| Gene | heart_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| CD209 | 4692.5 | 6938.5 |
| LYN | 4344.0 | 6943.0 |
| PAK3 | 4482.0 | 6294.0 |
| RELB | 3326.0 | 4398.0 |
| EP300 | 1528.0 | 5933.0 |
| KRAS | 3576.0 | 2066.0 |
| RAF1 | 1827.0 | 2744.0 |
| FYN | 792.0 | 5806.0 |
| CREBBP | 952.0 | 4478.0 |
| PRKACA | 262.0 | 2455.0 |
| PRKACB | 2277.0 | 25.0 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CD209 | 6938.5 | 4692.5 | 6658.5 | 4440.5 |
| CREBBP | 4478.0 | 952.0 | 4833.0 | -1434.0 |
| EP300 | 5933.0 | 1528.0 | 4514.0 | 3579.0 |
| FYN | 5806.0 | 792.0 | 3513.0 | 5564.0 |
| HRAS | -3746.0 | 181.0 | -4860.0 | -6119.0 |
| ICAM2 | -696.0 | -4948.0 | -4363.0 | -4645.0 |
| KRAS | 2066.0 | 3576.0 | 5421.0 | 3808.0 |
| LYN | 6943.0 | 4344.0 | 6532.0 | 4351.0 |
| NFKB1 | 2278.0 | -2851.0 | -49.0 | -3913.0 |
| PAK2 | -6007.0 | -5516.0 | 6695.0 | 5321.0 |
| PAK3 | 6294.0 | 4482.0 | -5558.0 | -6449.0 |
| PRKACA | 2455.0 | 262.0 | 5210.0 | 3696.0 |
| PRKACB | 25.0 | 2277.0 | -2791.0 | 4023.0 |
| RAF1 | 2744.0 | 1827.0 | -3338.0 | 1602.0 |
| RELA | 3054.0 | -3513.0 | -1419.0 | -1233.0 |
| RELB | 4398.0 | 3326.0 | -6076.0 | -5580.0 |
| RPS6KA5 | -2116.0 | -1030.0 | -1751.0 | 3664.0 |
Acetylcholine binding and downstream events
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.0447 |
| p.adjustMANOVA | 0.438 |
| s.dist | 0.5 |
| s.heart_ctrl_vs_acetate | -0.47 |
| s.heart_ctrl_vs_hifibre | -0.0451 |
| s.spleen_ctrl_vs_acetate | -0.0868 |
| s.spleen_ctrl_vs_hifibre | -0.138 |
| p.heart_ctrl_vs_acetate | 0.00482 |
| p.heart_ctrl_vs_hifibre | 0.787 |
| p.spleen_ctrl_vs_acetate | 0.603 |
| p.spleen_ctrl_vs_hifibre | 0.408 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| CHRNA6 | -5865 | -5613 |
| CHRNE | -5282 | -5709 |
| CHRNA2 | -5412 | -4212 |
| CHRNB3 | -5018 | -3318 |
| CHRND | -5240 | -1852 |
| CHRNA1 | -6274 | -693 |
| CHRNA9 | -123 | -2250 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CHRNA1 | -6274 | -3449 | -5159 | -693 |
| CHRNA2 | -5412 | -4560 | -3029 | -4212 |
| CHRNA3 | -4162 | 1694 | 6676 | 6658 |
| CHRNA4 | 1503 | -497 | 722 | 887 |
| CHRNA5 | 2950 | 2483 | -475 | -3039 |
| CHRNA6 | -5865 | -2614 | -6283 | -5613 |
| CHRNA9 | -123 | -4333 | -2363 | -2250 |
| CHRNB2 | 3999 | -919 | -4385 | 308 |
| CHRNB3 | -5018 | 1035 | 2559 | -3318 |
| CHRND | -5240 | -6665 | -2243 | -1852 |
| CHRNE | -5282 | -3751 | 2462 | -5709 |
| CHRNG | -4578 | -6180 | 5324 | 6519 |
Postsynaptic nicotinic acetylcholine receptors
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.0447 |
| p.adjustMANOVA | 0.438 |
| s.dist | 0.5 |
| s.heart_ctrl_vs_acetate | -0.47 |
| s.heart_ctrl_vs_hifibre | -0.0451 |
| s.spleen_ctrl_vs_acetate | -0.0868 |
| s.spleen_ctrl_vs_hifibre | -0.138 |
| p.heart_ctrl_vs_acetate | 0.00482 |
| p.heart_ctrl_vs_hifibre | 0.787 |
| p.spleen_ctrl_vs_acetate | 0.603 |
| p.spleen_ctrl_vs_hifibre | 0.408 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| CHRNA6 | -5865 | -5613 |
| CHRNE | -5282 | -5709 |
| CHRNA2 | -5412 | -4212 |
| CHRNB3 | -5018 | -3318 |
| CHRND | -5240 | -1852 |
| CHRNA1 | -6274 | -693 |
| CHRNA9 | -123 | -2250 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CHRNA1 | -6274 | -3449 | -5159 | -693 |
| CHRNA2 | -5412 | -4560 | -3029 | -4212 |
| CHRNA3 | -4162 | 1694 | 6676 | 6658 |
| CHRNA4 | 1503 | -497 | 722 | 887 |
| CHRNA5 | 2950 | 2483 | -475 | -3039 |
| CHRNA6 | -5865 | -2614 | -6283 | -5613 |
| CHRNA9 | -123 | -4333 | -2363 | -2250 |
| CHRNB2 | 3999 | -919 | -4385 | 308 |
| CHRNB3 | -5018 | 1035 | 2559 | -3318 |
| CHRND | -5240 | -6665 | -2243 | -1852 |
| CHRNE | -5282 | -3751 | 2462 | -5709 |
| CHRNG | -4578 | -6180 | 5324 | 6519 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0906 |
| p.adjustMANOVA | 0.578 |
| s.dist | 0.499 |
| s.heart_ctrl_vs_acetate | -0.247 |
| s.heart_ctrl_vs_hifibre | 0.197 |
| s.spleen_ctrl_vs_acetate | 0.348 |
| s.spleen_ctrl_vs_hifibre | 0.169 |
| p.heart_ctrl_vs_acetate | 0.156 |
| p.heart_ctrl_vs_hifibre | 0.259 |
| p.spleen_ctrl_vs_acetate | 0.0457 |
| p.spleen_ctrl_vs_hifibre | 0.333 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
|---|---|---|
| YWHAB | 6459 | -5308 |
| EXOSC3 | 6132 | -5348 |
| EXOSC2 | 6319 | -3454 |
| TNPO1 | 4028 | -2783 |
| DCP1A | 2955 | -2467 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| DCP1A | -2467 | -2019 | 2955 | 2848 |
| DCP2 | 2210 | -916 | 6601 | 6287 |
| DIS3 | -5444 | -2551 | -6537 | -6745 |
| EXOSC2 | -3454 | -6058 | 6319 | 1424 |
| EXOSC3 | -5348 | -3363 | 6132 | 5761 |
| EXOSC7 | -37 | -305 | -3906 | -4670 |
| EXOSC8 | 2854 | -1384 | 3922 | 2435 |
| EXOSC9 | 1461 | 3766 | 5845 | 5889 |
| TNPO1 | -2783 | 3892 | 4028 | -4964 |
| XRN1 | 4317 | -47 | -4933 | -1695 |
| YWHAB | -5308 | 1644 | 6459 | 5120 |
ERBB2 Activates PTK6 Signaling
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.202 |
| p.adjustMANOVA | 0.673 |
| s.dist | 0.493 |
| s.heart_ctrl_vs_acetate | 0.292 |
| s.heart_ctrl_vs_hifibre | 0.263 |
| s.spleen_ctrl_vs_acetate | -0.049 |
| s.spleen_ctrl_vs_hifibre | -0.294 |
| p.heart_ctrl_vs_acetate | 0.11 |
| p.heart_ctrl_vs_hifibre | 0.15 |
| p.spleen_ctrl_vs_acetate | 0.788 |
| p.spleen_ctrl_vs_hifibre | 0.107 |
| Gene | spleen_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| EGF | -6806 | 4348 |
| NRG4 | -2277 | 6874 |
| NRG1 | -2037 | 4945 |
| PTK6 | -6231 | 1326 |
| EGFR | -3626 | 17 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| EGF | 4348 | 1525 | 5969 | -6806 |
| EGFR | 17 | 3848 | 944 | -3626 |
| ERBB2 | 2092 | -6876 | -1188 | 5608 |
| ERBB3 | 3522 | -3277 | 1995 | 1899 |
| HBEGF | -1952 | -1746 | -4004 | -5759 |
| NRG1 | 4945 | 3826 | 372 | -2037 |
| NRG2 | -514 | -998 | -3384 | -3645 |
| NRG3 | 3309 | 3812 | -2985 | 1968 |
| NRG4 | 6874 | 628 | 1276 | -2277 |
| PTK6 | 1326 | -2917 | -1585 | -6231 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
| metric | value |
|---|---|
| setSize | 14 |
| pMANOVA | 0.0642 |
| p.adjustMANOVA | 0.507 |
| s.dist | 0.492 |
| s.heart_ctrl_vs_acetate | 0.19 |
| s.heart_ctrl_vs_hifibre | 0.391 |
| s.spleen_ctrl_vs_acetate | 0.0715 |
| s.spleen_ctrl_vs_hifibre | 0.22 |
| p.heart_ctrl_vs_acetate | 0.218 |
| p.heart_ctrl_vs_hifibre | 0.0114 |
| p.spleen_ctrl_vs_acetate | 0.643 |
| p.spleen_ctrl_vs_hifibre | 0.155 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| MAP2K4 | 3559 | 5306 |
| IRAK1 | 1954 | 5891 |
| TAB2 | 4389 | 2397 |
| MAPK10 | 4087 | 1374 |
| MAPK9 | 1301 | 1679 |
| IKBKG | 1533 | 939 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| IKBKG | 2223 | 1533 | -291 | 939 |
| IRAK1 | 3664 | 1954 | -2068 | 5891 |
| IRAK2 | -4752 | -6250 | 4667 | 971 |
| MAP2K4 | 5301 | 3559 | 5976 | 5306 |
| MAP2K7 | 1163 | -7174 | -2547 | 2775 |
| MAP3K7 | 4263 | 3634 | -5194 | -3471 |
| MAPK10 | 4535 | 4087 | -1738 | 1374 |
| MAPK8 | 4261 | 4515 | 4735 | -1594 |
| MAPK9 | 4846 | 1301 | -183 | 1679 |
| NOD2 | -4635 | -2428 | -6090 | -3403 |
| TAB1 | -5289 | -2289 | -1547 | 5063 |
| TAB2 | 6863 | 4389 | 5867 | 2397 |
| TRAF6 | 3819 | 2512 | -409 | -809 |
| UBE2N | -2431 | -204 | 6687 | 2612 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.0595 |
| p.adjustMANOVA | 0.498 |
| s.dist | 0.491 |
| s.heart_ctrl_vs_acetate | 0.262 |
| s.heart_ctrl_vs_hifibre | 0.255 |
| s.spleen_ctrl_vs_acetate | 0.224 |
| s.spleen_ctrl_vs_hifibre | -0.24 |
| p.heart_ctrl_vs_acetate | 0.117 |
| p.heart_ctrl_vs_hifibre | 0.126 |
| p.spleen_ctrl_vs_acetate | 0.179 |
| p.spleen_ctrl_vs_hifibre | 0.149 |
| Gene | heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre |
|---|---|---|
| SNW1 | 6274 | 3546 |
| ONECUT1 | 5436 | 3754 |
| MAML2 | 5458 | 1668 |
| EP300 | 5933 | 1528 |
| MAML1 | 2330 | 3665 |
| CREBBP | 4478 | 952 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CREBBP | 4478 | 952 | 4833 | -1434 |
| EP300 | 5933 | 1528 | 4514 | 3579 |
| HES1 | -2934 | 3234 | -546 | 3794 |
| KAT2A | -5008 | -5991 | 2514 | -1118 |
| KAT2B | -2547 | -1082 | 2777 | -1211 |
| MAML1 | 2330 | 3665 | 4307 | -5721 |
| MAML2 | 5458 | 1668 | 2285 | -4284 |
| MAML3 | 3274 | -4438 | 5044 | 2322 |
| NOTCH1 | 4892 | -7392 | -2818 | -1461 |
| ONECUT1 | 5436 | 3754 | 5648 | -2630 |
| RBPJ | -1320 | -2680 | -6397 | -6473 |
| SNW1 | 6274 | 3546 | -2955 | -6042 |
GRB2 events in ERBB2 signaling
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0951 |
| p.adjustMANOVA | 0.593 |
| s.dist | 0.49 |
| s.heart_ctrl_vs_acetate | 0.0984 |
| s.heart_ctrl_vs_hifibre | 0.423 |
| s.spleen_ctrl_vs_acetate | -0.00988 |
| s.spleen_ctrl_vs_hifibre | -0.227 |
| p.heart_ctrl_vs_acetate | 0.572 |
| p.heart_ctrl_vs_hifibre | 0.015 |
| p.spleen_ctrl_vs_acetate | 0.955 |
| p.spleen_ctrl_vs_hifibre | 0.193 |
| Gene | heart_ctrl_vs_hifibre | spleen_ctrl_vs_hifibre |
|---|---|---|
| EGFR | 3848 | -3626 |
| EGF | 1525 | -6806 |
| NRG1 | 3826 | -2037 |
| NRG4 | 628 | -2277 |
| HRAS | 181 | -6119 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| EGF | 4348 | 1525 | 5969 | -6806 |
| EGFR | 17 | 3848 | 944 | -3626 |
| ERBB2 | 2092 | -6876 | -1188 | 5608 |
| GRB2 | -5578 | 1873 | 2524 | 956 |
| HBEGF | -1952 | -1746 | -4004 | -5759 |
| HRAS | -3746 | 181 | -4860 | -6119 |
| KRAS | 2066 | 3576 | 5421 | 3808 |
| NRG1 | 4945 | 3826 | 372 | -2037 |
| NRG2 | -514 | -998 | -3384 | -3645 |
| NRG3 | 3309 | 3812 | -2985 | 1968 |
| NRG4 | 6874 | 628 | 1276 | -2277 |
Apoptotic cleavage of cell adhesion proteins
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.179 |
| p.adjustMANOVA | 0.671 |
| s.dist | 0.49 |
| s.heart_ctrl_vs_acetate | 0.201 |
| s.heart_ctrl_vs_hifibre | 0.444 |
| s.spleen_ctrl_vs_acetate | 0.0242 |
| s.spleen_ctrl_vs_hifibre | 0.051 |
| p.heart_ctrl_vs_acetate | 0.272 |
| p.heart_ctrl_vs_hifibre | 0.0152 |
| p.spleen_ctrl_vs_acetate | 0.895 |
| p.spleen_ctrl_vs_hifibre | 0.78 |
| Gene | heart_ctrl_vs_hifibre | heart_ctrl_vs_acetate |
|---|---|---|
| DSG1 | 4145 | 6230 |
| TJP1 | 2709 | 6234 |
| DSG3 | 2659 | 3367 |
| OCLN | 3128 | 1955 |
| CTNNB1 | 1000 | 5792 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| CDH1 | -2374 | -1214 | 6456 | 4604 |
| CTNNB1 | 5792 | 1000 | -1901 | 329 |
| DSG1 | 6230 | 4145 | -2900 | -2227 |
| DSG2 | -4958 | 1590 | 1465 | -4027 |
| DSG3 | 3367 | 2659 | -6583 | -4054 |
| DSP | 3109 | -2368 | -1157 | -3830 |
| OCLN | 1955 | 3128 | 5473 | 2075 |
| PKP1 | 2145 | -254 | 3740 | 4015 |
| TJP1 | 6234 | 2709 | -1039 | 5027 |
| TJP2 | -3747 | -1254 | -1156 | 703 |
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.141 |
| p.adjustMANOVA | 0.641 |
| s.dist | 0.49 |
| s.heart_ctrl_vs_acetate | -0.388 |
| s.heart_ctrl_vs_hifibre | -0.22 |
| s.spleen_ctrl_vs_acetate | -0.198 |
| s.spleen_ctrl_vs_hifibre | -0.0447 |
| p.heart_ctrl_vs_acetate | 0.0199 |
| p.heart_ctrl_vs_hifibre | 0.188 |
| p.spleen_ctrl_vs_acetate | 0.235 |
| p.spleen_ctrl_vs_hifibre | 0.789 |
| Gene | heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre |
|---|---|---|
| MUC17 | -5538 | -8162 |
| MUC1 | -6178 | -6981 |
| MUC6 | -4936 | -6091 |
| MUC3A | -3477 | -5774 |
| MUC4 | -1600 | -5189 |
| MUC2 | -559 | -7967 |
| MUC20 | -1201 | -2761 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| C1GALT1 | -4376 | 587 | -3206 | -1411 |
| C1GALT1C1 | -6239 | 275 | 895 | 1179 |
| MUC1 | -6178 | -6981 | 5651 | -2940 |
| MUC15 | 533 | 3525 | -1489 | -1400 |
| MUC17 | -5538 | -8162 | -4524 | -4876 |
| MUC19 | 5937 | -2264 | -6060 | -4242 |
| MUC2 | -559 | -7967 | -1328 | -993 |
| MUC20 | -1201 | -2761 | 5042 | 5056 |
| MUC3A | -3477 | -5774 | -634 | -661 |
| MUC4 | -1600 | -5189 | -930 | 5297 |
| MUC5B | 818 | -1208 | -3511 | 1945 |
| MUC6 | -4936 | -6091 | -5190 | -1636 |
Class I peroxisomal membrane protein import
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.176 |
| p.adjustMANOVA | 0.671 |
| s.dist | 0.487 |
| s.heart_ctrl_vs_acetate | 0.309 |
| s.heart_ctrl_vs_hifibre | 0.186 |
| s.spleen_ctrl_vs_acetate | -0.121 |
| s.spleen_ctrl_vs_hifibre | -0.304 |
| p.heart_ctrl_vs_acetate | 0.0764 |
| p.heart_ctrl_vs_hifibre | 0.286 |
| p.spleen_ctrl_vs_acetate | 0.487 |
| p.spleen_ctrl_vs_hifibre | 0.081 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_hifibre |
|---|---|---|
| PXMP4 | 5751 | -6478 |
| GDAP1 | 5478 | -4584 |
| ABCD2 | 4480 | -5282 |
| ABCD3 | 6841 | -2413 |
| PEX11B | 3002 | -4663 |
| ALDH3A2 | 2329 | -1662 |
| PEX19 | 1215 | -1679 |
| PEX3 | 488 | -2299 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ABCD2 | 4480 | 2757 | 4239 | -5282 |
| ABCD3 | 6841 | -56 | -3560 | -2413 |
| ALDH3A2 | 2329 | -4620 | -582 | -1662 |
| FIS1 | 624 | -3955 | 1844 | 5783 |
| GDAP1 | 5478 | 4238 | 2556 | -4584 |
| PEX11B | 3002 | -1202 | -6495 | -4663 |
| PEX14 | -3833 | -5267 | -3509 | -6659 |
| PEX19 | 1215 | -3812 | -2556 | -1679 |
| PEX26 | 1227 | 562 | 3779 | 6228 |
| PEX3 | 488 | 2365 | -1316 | -2299 |
| PXMP4 | 5751 | 837 | -2636 | -6478 |
Insulin receptor recycling
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.0338 |
| p.adjustMANOVA | 0.413 |
| s.dist | 0.484 |
| s.heart_ctrl_vs_acetate | -0.386 |
| s.heart_ctrl_vs_hifibre | -0.0677 |
| s.spleen_ctrl_vs_acetate | 0.281 |
| s.spleen_ctrl_vs_hifibre | 0.0487 |
| p.heart_ctrl_vs_acetate | 0.00973 |
| p.heart_ctrl_vs_hifibre | 0.65 |
| p.spleen_ctrl_vs_acetate | 0.0595 |
| p.spleen_ctrl_vs_hifibre | 0.744 |
| Gene | heart_ctrl_vs_acetate | spleen_ctrl_vs_acetate |
|---|---|---|
| ATP6V1C2 | -6096 | 5662 |
| ATP6V1B1 | -4346 | 6143 |
| INSR | -5843 | 3189 |
| ATP6V0A2 | -3608 | 4737 |
| ATP6V1C1 | -3791 | 3613 |
| INS | -2218 | 4697 |
| ATP6V1G2 | -2591 | 2261 |
| TCIRG1 | -4006 | 807 |
| ATP6V0D1 | -945 | 1562 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ATP6V0A1 | -5553 | -6050 | -2004 | -5185 |
| ATP6V0A2 | -3608 | -2327 | 4737 | 3556 |
| ATP6V0A4 | -3188 | -7165 | -4831 | -4536 |
| ATP6V0D1 | -945 | -2615 | 1562 | -2690 |
| ATP6V0D2 | 4054 | 4043 | 5546 | 2419 |
| ATP6V1B1 | -4346 | 1907 | 6143 | 6546 |
| ATP6V1B2 | 398 | -2974 | 4260 | 434 |
| ATP6V1C1 | -3791 | 2927 | 3613 | 5085 |
| ATP6V1C2 | -6096 | -6188 | 5662 | 6427 |
| ATP6V1E1 | 1192 | 1077 | 821 | -4074 |
| ATP6V1E2 | 3288 | -6989 | -6642 | -6431 |
| ATP6V1G2 | -2591 | -6888 | 2261 | -4512 |
| INS | -2218 | 4190 | 4697 | 2636 |
| INSR | -5843 | -1650 | 3189 | 1765 |
| TCIRG1 | -4006 | -8299 | 807 | 2243 |
ERBB2 Regulates Cell Motility
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.216 |
| p.adjustMANOVA | 0.684 |
| s.dist | 0.481 |
| s.heart_ctrl_vs_acetate | 0.313 |
| s.heart_ctrl_vs_hifibre | 0.3 |
| s.spleen_ctrl_vs_acetate | -0.0633 |
| s.spleen_ctrl_vs_hifibre | -0.198 |
| p.heart_ctrl_vs_acetate | 0.0727 |
| p.heart_ctrl_vs_hifibre | 0.0851 |
| p.spleen_ctrl_vs_acetate | 0.716 |
| p.spleen_ctrl_vs_hifibre | 0.254 |
| Gene | heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre |
|---|---|---|
| NRG1 | 4945 | 3826 |
| DIAPH1 | 6647 | 2125 |
| NRG3 | 3309 | 3812 |
| EGF | 4348 | 1525 |
| NRG4 | 6874 | 628 |
| EGFR | 17 | 3848 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| DIAPH1 | 6647 | 2125 | -5223 | 2755 |
| EGF | 4348 | 1525 | 5969 | -6806 |
| EGFR | 17 | 3848 | 944 | -3626 |
| ERBB2 | 2092 | -6876 | -1188 | 5608 |
| ERBB3 | 3522 | -3277 | 1995 | 1899 |
| HBEGF | -1952 | -1746 | -4004 | -5759 |
| MEMO1 | -1391 | -2472 | 2311 | -3893 |
| NRG1 | 4945 | 3826 | 372 | -2037 |
| NRG2 | -514 | -998 | -3384 | -3645 |
| NRG3 | 3309 | 3812 | -2985 | 1968 |
| NRG4 | 6874 | 628 | 1276 | -2277 |
NOTCH2 Activation and Transmission of Signal to the Nucleus
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.083 |
| p.adjustMANOVA | 0.567 |
| s.dist | 0.478 |
| s.heart_ctrl_vs_acetate | 0.155 |
| s.heart_ctrl_vs_hifibre | -0.143 |
| s.spleen_ctrl_vs_acetate | -0.424 |
| s.spleen_ctrl_vs_hifibre | -0.0635 |
| p.heart_ctrl_vs_acetate | 0.353 |
| p.heart_ctrl_vs_hifibre | 0.392 |
| p.spleen_ctrl_vs_acetate | 0.011 |
| p.spleen_ctrl_vs_hifibre | 0.703 |
| Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
|---|---|---|
| CNTN1 | -6307 | 6986 |
| UBA52 | -5902 | 6159 |
| DLL1 | -3755 | 4596 |
| NCSTN | -4750 | 3075 |
| JAG1 | -5492 | 2446 |
| ADAM10 | -618 | 6151 |
Click HERE to show all gene set members
| heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
|---|---|---|---|---|
| ADAM10 | 6151 | 3686 | -618 | 2485 |
| APH1A | -3282 | -5918 | 2930 | 6139 |
| CNTN1 | 6986 | 3284 | -6307 | -721 |
| DLL1 | 4596 | -6117 | -3755 | 139 |
| DLL4 | -1509 | -1869 | -4174 | -3713 |
| JAG1 | 2446 | -1239 | -5492 | -4227 |
| JAG2 | 1499 | -4566 | 2982 | -4252 |
| MIB2 | -2996 | -8655 | -1716 | -2525 |
| NCSTN | 3075 | -7183 | -4750 | -557 |
| PSEN1 | -1252 | -264 | -3349 | -2323 |
| PSEN2 | -4318 | -8410 | -3605 | 2023 |
| UBA52 | 6159 | 1509 | -5902 | 1309 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] stats4 parallel stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.1.0 GGally_2.0.0
## [3] beeswarm_0.2.3 gtools_3.8.2
## [5] echarts4r_0.3.2 mitch_1.0.6
## [7] fgsea_1.14.0 gplots_3.0.3
## [9] DESeq2_1.28.1 SummarizedExperiment_1.18.1
## [11] DelayedArray_0.14.0 matrixStats_0.56.0
## [13] Biobase_2.48.0 GenomicRanges_1.40.0
## [15] GenomeInfoDb_1.24.2 IRanges_2.22.2
## [17] S4Vectors_0.26.1 BiocGenerics_0.34.0
## [19] reshape2_1.4.4 forcats_0.5.0
## [21] stringr_1.4.0 dplyr_1.0.0
## [23] purrr_0.3.4 readr_1.3.1
## [25] tidyr_1.1.0 tibble_3.0.1
## [27] ggplot2_3.3.2 tidyverse_1.3.0
## [29] locfit_1.5-9.4 statmod_1.4.34
## [31] plyr_1.8.6
##
## loaded via a namespace (and not attached):
## [1] colorspace_1.4-1 ellipsis_0.3.1 rprojroot_1.3-2
## [4] XVector_0.28.0 fs_1.4.2 rstudioapi_0.11
## [7] farver_2.0.3 bit64_0.9-7 AnnotationDbi_1.50.1
## [10] fansi_0.4.1 lubridate_1.7.9 xml2_1.3.2
## [13] splines_4.0.2 geneplotter_1.66.0 knitr_1.29
## [16] jsonlite_1.7.0 broom_0.5.6 annotate_1.66.0
## [19] dbplyr_1.4.4 shiny_1.5.0 compiler_4.0.2
## [22] httr_1.4.1 backports_1.1.8 assertthat_0.2.1
## [25] Matrix_1.2-18 fastmap_1.0.1 cli_2.0.2
## [28] later_1.1.0.1 prettyunits_1.1.1 htmltools_0.5.0
## [31] tools_4.0.2 gtable_0.3.0 glue_1.4.1
## [34] GenomeInfoDbData_1.2.3 fastmatch_1.1-0 Rcpp_1.0.4.6
## [37] cellranger_1.1.0 vctrs_0.3.1 gdata_2.18.0
## [40] nlme_3.1-148 xfun_0.15 testthat_2.3.2
## [43] rvest_0.3.5 mime_0.9 lifecycle_0.2.0
## [46] XML_3.99-0.3 zlibbioc_1.34.0 MASS_7.3-51.6
## [49] scales_1.1.1 hms_0.5.3 promises_1.1.1
## [52] RColorBrewer_1.1-2 yaml_2.2.1 memoise_1.1.0
## [55] gridExtra_2.3 reshape_0.8.8 stringi_1.4.6
## [58] RSQLite_2.2.0 highr_0.8 genefilter_1.70.0
## [61] desc_1.2.0 caTools_1.18.0 BiocParallel_1.22.0
## [64] rlang_0.4.6 pkgconfig_2.0.3 bitops_1.0-6
## [67] evaluate_0.14 lattice_0.20-41 labeling_0.3
## [70] htmlwidgets_1.5.1 bit_1.1-15.2 tidyselect_1.1.0
## [73] magrittr_1.5 R6_2.4.1 generics_0.0.2
## [76] DBI_1.1.0 pillar_1.4.4 haven_2.3.1
## [79] withr_2.2.0 survival_3.2-3 RCurl_1.98-1.2
## [82] modelr_0.1.8 crayon_1.3.4 KernSmooth_2.23-17
## [85] rmarkdown_2.3 progress_1.2.2 grid_4.0.2
## [88] readxl_1.3.1 data.table_1.12.8 blob_1.2.1
## [91] reprex_0.3.0 digest_0.6.25 pbmcapply_1.5.0
## [94] xtable_1.8-4 httpuv_1.5.4 munsell_0.5.0END of report